

# YUCHEN LI

Cancer Centre of Southeastern Ontario  
25 King St. W  
Kingston, ON, K7L 5P9

Phone: (416) 417-6061  
Email: yuchen.li@kingstonHSC.ca

## EDUCATION

---

<b>Master of Public Health</b> , Johns Hopkins Bloomberg School of Public Health Concentration in Health System and Policy Quality, Patient Safety and Outcomes Research Certificate Program	2022 – 2025
<b>Doctor of Medicine</b> , University of Toronto	2014 – 18
<b>Bachelor of Medical Science (Candidate)</b> , Western University Honors in Specialization in Pathology and Toxicology	2011 – 14

## POSTGRADUATE TRAINING

---

<b>Clinical Research Fellowship in Thoracic Oncology</b> Princess Margaret Cancer Centre, University of Toronto	2023 – 2024
<b>Medical Oncology Residency Training</b> , McMaster University Chief resident (2022 – 2023)	2021 – 2023
<b>Core Internal Medicine Residency Training</b> , University of Toronto	2018 – 2021

## PROFESSIONAL APPOINTMENTS

---

<b>Director of Quality</b> Department of Oncology, Queen's University	2025 – Present
<b>Staff Medical Oncologist, Assistant Professor</b> Cancer Centre of Southeastern Ontario, Queen's University, Kingston	2024 – Present
<b>Canadian Cancer Trials Group (CCTG) Lung Disease Site Group Member</b>	2024 – Present
<b>Locum Medical Oncologist</b> , St. Joseph's Health Centre, Toronto	2023 – 2024
<b>Locum Medical Oncologist</b> , Brightshores Cancer Centre, Grey Bruce Health Services, Owen Sound	2023 – 2024

<b>Acute Care Hospitalist</b> , General Internal Medicine, Trillium Health Partners, Mississauga	2022 – 2024
---	-------------

<b>Nocturnist</b> , General Internal Medicine, Hamilton Health Sciences	2022 – 2024
---	-------------

#### COMMITTEE MEMBERSHIPS

---

<b>Executive Committee</b> Department of Oncology, Queen’s University	2025 – Present
--	----------------

<b>Oncological Clinical Informatics Committee</b> Cancer of Southeastern Ontario	2025 – Present
---	----------------

<b>Clinical Trial Executive Committee</b> Cancer of Southeastern Ontario	2024 – Present
---	----------------

<b>Kingston Health Sciences Centre (KHSC) Physician Quality Committee</b>	2024 – Present
---	----------------

<b>Department of Oncology and Cancer Program Quality and Safety Committee</b> Cancer of Southeastern Ontario	2024 – Present
---	----------------

<b>Morbidity and Mortality Committee</b> Kingston Health Sciences Centre	2024 – Present
---	----------------

<b>Quality Improvement and Patient Safety Executive Resident Committee Member</b> McMaster Postgraduate Medical Education	2021 – 3
--	----------

#### LICENSURE

---

<b>Medical Oncology Fellow of The Royal College of Physicians of Canada</b>	2023
---	------

<b>Internal Medicine Fellow of The Royal College of Physicians of Canada</b>	2022
--	------

<b>Licentiate of the Medical Council of Canada</b>	2019
--	------

#### CERTIFICATIONS

---

<b>Fundamentals of Machine Learning for Healthcare (online)</b> , Stanford University	2023
---	------

<b>Evaluation of AI Applications in Healthcare (online)</b> , Stanford University	2023
---	------

<b>Health Canada Division 5 – Drugs for Clinical Trials Involving Human Subjects</b>	2023
--	------

<b>Good Clinical Practice – Canada</b>	2023
--	------

**HONORS AND AWARDS**

---

<b>Hold'em for Life Oncology Fellowship Grant</b> , University of Toronto A total value of \$50,000 as fellowship grant Project: A-IMPROVE (Artificial Intelligent Modeling for Predicting and Reducing Overutilization of Visits to the Emergency Department)	2024 – 2025
<b>Apobiologix Canadian Fellows Award at ASCO</b> A total value of \$3,000 for five recipients.	2023
<b>AstraZeneca Educational Research Grant</b> A total value of \$20,000 in research grant	2022
<b>Fall 2021 SSHRC (Social Sciences and Humanities Research Council) Explore – Standard Research and Research Creation Grant</b> , McMaster University A total value of \$4,000 in research grant	2021
<b>2021 PARO Trust Fund's Resident Teaching Award Nominee</b> , University of Toronto	2021
<b>Odette Cancer Centre Medical Oncology Resident Award</b> , University of Toronto	2020
<b>William V. Hull Scholarship</b> , Faculty of Medicine, University of Toronto Awarded to one student who brought honour to institution through an outstanding act or accomplishment.	2018
<b>The Golden Stethoscope Award</b> , Faculty of Medicine, University of Toronto Recognized as one of the top medical students during clerkship who demonstrated excellence in academic achievement, attributes of compassionate and altruistic clinician, and contribution to betterment of institution.	2017
<b>Mach-Gaensslen Foundation Research Grant</b> , Faculty of Medicine, University of Toronto A total value of \$25,000 for nine recipients.	2016
<b>Natural Sciences and Engineering Research of Canada Undergraduate Student Research Award</b> , Faculty of Science, Western University A value of \$5,600 granted for undergraduate summer research.	2013
<b>Western Continuing Scholarship</b> , Western University A value of \$10,000 awarded for final admission average of 95+%.	2011 – 13
<b>Dean's Honour List</b> , Western University	2011 – 13
<b>Gibson Award for Mathematics</b> , Toronto	2011

## RESEARCH FUNDING

---

Funded as Principal Investigator:

**Queen's University Improving Cancer Care (QUICC)**

2025

A total value of \$20,000 annually funded as support for quality improvement initiatives to optimize cancer care locally

Funded as Co-Investigator:

**The Collaborative Approach to Resource Optimization in Cancer Care Workforce**

2025

A total value of \$30,000 funded by CIHR as support for quality improvement initiative to optimize workforce at Cancer Centre of Southeastern Ontario

## PUBLICATIONS AND PRESENTATIONS

---

### *Peer-Reviewed Journal Publications*

Jimenez Munarriz, B., Khan, S., Li, Y., Ghazali, N., Liu, G. Update advances in ALK-positive NSCLC treatment. *Cancer* [accepted] CNCR-24-2780.R1

Li, Y., Law, J., Le, L., Pettengell, C., Demarco, P., Duong, M., Merritt, D., Davidson, S., Sung, M., Li, Q., Lau, S., Sacher, A., Zahir, S., Chu, R., Ryan, M., Karim, K., Morganstein, J., Leighl, N. Assessing the Feasibility and External Validity of Natural Language Processing-Extracted Data for Advanced Lung Cancer Patients (2025). *Lung Cancer*. <https://doi.org/10.1016/j.lungcan.2025.108080>

Li, Y. Wong, M., Zhan, L., Corke, L., Brown M., Cheng, S., Khan K., Blatnaram., Chowdhury, N., Sabouhanian, A., Herrman, J., Walia P., Strom, E., Patel, D., Garcia-Pardo, M., Schmid, S., Eng, L., Sacher, A., Leighl, N., Bradbury, P., Shepherd, F., Shultz, D., Liu, G. (2024). Single organ metastatic sites in non-small cell lung cancer: patient characteristics, treatment patterns and outcomes from a large retrospective Canadian database. *Lung Cancer*. <https://doi.org/10.1016/j.lungcan.2024.107823>

Crossnohere, N., Anderson, N., Baumhauer, J., Calvert, M., Esparza, R., Gulbransen, S., Haverman, L., Li, Y., Peterson, C., et. al (2024). A Framework for Implementing Patient-Reported Outcomes in Clinical Care: The PROTEUS-Practice Guideline. *Nature Medicine*. <https://doi.org/10.1038/s41591-024-02909-8>

Li, Y., Pond, G., Osch V.A., Reed, R., Ung, Y., Cheng, S., Menjak, I., Doherty, M., Moglica E., Taggar, A. (2024) Enhancing Nutrition Support for Esophageal Cancer Patients: Understanding Factors Influencing Feeding Tube Utilization, *Nutrition and Cancer*, doi: 10.1080/01635581.2024.2301796

Li, Y., Pond, G., McWhirter, E. (2024). Multisystem Immune-Related Adverse Events from Dual Agent Immunotherapy Use. *Current Oncology*. doi: <https://doi.org/10.3390/curroncol31010028>

Li, Y., Juergens, R., Finley, C., Swaminath, A. (2023). Current and Future Treatment Options in the Management of Stage III NSCLC. *Journal of Thoracic Oncology*. doi: 10.1016/j.jtho.2023.08.011

Li, Y., Stewart, L., Tang, S., McWhirter, E. (2023). Pembrolizumab-induced immune-related sclerosing cholangitis. *BMJ Case Reports* 16;11. doi: 10.1136/bcr-2023-256125

Jiang M., Zhang X., Liu, H., LeBron J., Alexandris, A., Peng, Q., Gu, H., Yang, F., Li, Y., Wang, R., Hou, Z., Arbez N., et al. (2020). Nemo-like Kinase Reduces Mutant Huntingtin Levels and Mitigates Huntington's Disease. *Human Molecular Genetics*, 28;29(8), 1340-1352. doi:10.1093/hmg/ddaa061.

Li, Y., Brown, M. C., Estey, K., Gill, G., Liang, M., Perez, A. et al. (2017). Feasibility of collecting routine information for clinical and research purposes via electronic format questionnaire. *Journal of Clinical Oncology*, 35(8\_suppl), 167-167. doi:10.1200/jco.2017.35.8\_suppl.167.

Shani, K., Borean, M., Chen, J., Li, Y., Brown, M. C., Vennettilli, A., et al. (2017). Feasibility and acceptability of implementing an electronic patient reported outcome (e-PRO) dysphagia screening tool for routine multidisciplinary care. *Journal of Clinical Oncology*, 35(4\_suppl), 155-155. doi:10.1200/jco.2017.35.4\_suppl.155.

Tam, E., Chen, J., Zhang, Q., Zheng, D., Tam, V., Li, Y., et al. (2017). Routine physical function assessment through a Branching Logic Electronic Symptom Survey (BLESS) vs. the 32-combined item HAQ-DI WHODAS (HW) survey: A quality improvement controlled trial. *Journal of Clinical Oncology*, 35(8\_suppl), 136-136. doi:10.1200/jco.2017.35.8\_suppl.136.

Guo, H., Ahmed, M., Zhang, F., Yao, C., Li, SiDe., Liang, Y., Hua, J., Soares, F., Sun, Y., Langstein, J., Li, Y., Poon, C., et al. (2016). Modulation of Long Noncoding RNAs by Risk SNPS Underlying Genetic Predisposition to Prostate Cancer. *Nature Genetics*. 48, 1142-50.

Li, Y., Arthur J. (2016). Quality Improvement Project with Circle of Care. *University of Toronto Medical Journal (UTMJ)*. 93, 3.

#### ***Publications Under Review/Revisions Submitted***

Noormohammadpour, P., Hueniken, K., Pienkowski, M., Liu, G, Li, Y. The Predictive Performance of Systemic Inflammation Biomarkers in the Survival of Patients with Head and Neck Squamous Cell Carcinoma. [submitted]

Li, Y., Sheharyar. R., Piliotis, E., Hsieh, E., Giudice, L., Cohen, L., Spiegle, G., Spontaneous Tumor Lysis Syndrome in patient with Metastatic Gastric Adenocarcinoma [submitted]

Li, Y., Al Maqrashi, Z., Siddiqui, Z., Jin, E., Ellis, P. Use of Antibiotics and Outcomes of Patients Presenting to Emergency Department with Non-Neutropenic Fever and/or Suspected Infection. Supportive Care in Cancer. [submitted]

Yuan, B., Kabir, M., He, J.C., Li, Y., Grant, B., Narine, S., Welch, M., Podolsky, S., Khan, M., Liu, N., Ajaj, Zhan, L. J., Kryzanowska, M., Liu, G., Grant, R. Machine Learning Predicts Symptom Dynamics During Cancer Treatment (2024). *The Lancet Digital Health* [submitted]

### ***Invited Guest Presentation***

Bispecific T-cell engager (BiTE) therapy update. 2024. Invited speaker at Thoracic Oncology Meeting, Kingston, Ontario

Navigating Lung Cancer: Treatment Options and Managing Treatment-Related Toxicities. 2024. Invited speaker at the St. Joseph's Health Centre Grand Rounds, Toronto, Ontario.

COMET Post-ASCO Talk: Lung Cancer Updates. 2024. Invited Speaker.

### ***Conference Oral and Poster Presentations:***

He, J. C., Hirsch, I., Li, Y., Yuan, B., Kabir, M., Grant, B., Narine, S., Welch, M., Xu, W., Krzyzanowska, M. K., Powis, M. L., Liu, G., Truong, T., Grant, R. C. Impact of applying machine learning to the electronic medical record on prediction of cancer-associated thrombosis. *JCO Oncol Pract* 20, 2024 (suppl 10; abstr 409). doi: 10.1200/OP.2024.20.10\_suppl.409.

- ASCO Quality Care Symposium, October 2024 (poster)

Kabir, M., He, J. C., Yuan, B., Tran, V., Sue, K., Patel, T., Grant, B., Li, Y., Narine, S., Welch, M., Krzyzanowska, M., Truong, T., Liu, G., Grant, R. Prospective silent deployment and evaluation of an intelligent machine learning model for prediction of emergency department visits during cancer treatment. *JCO Oncol Pract* 20, 2024 (suppl 10; abstr 407). doi: 10.1200/OP.2024.20.10\_suppl.407.

- ASCO Quality Care Symposium, October 2024 (poster)

Li, Y. Wong, M., Zhan, L., Corke, L., Brown M., Cheng, S., Khan K., Blatnaram., Chowdhury, N., Sabouhanian, A., Herrman, J., Walia P., Strom, E., Patel, D., Garcia-Pardo, M., Schmid, S., Eng, L., Sacher, A., Leighl, N., Bradbury, P., Shepherd, F., Shultz, D., Liu, G. Single organ metastatic sites in NSCLC: patient characteristics, treatment patterns and outcomes from a large retrospective Canadian database.

- Princess Margaret Cancer Centre 4<sup>th</sup> Annual Lung Oncology Research Day, November 2023 (**oral**)

Li, Y., Fitch, M., Siddiqui, Z., Longo, C. Validation and Reliability Study of Patient-Administered Financial Effects (P-SAFE) Questionnaire in Common Cancers.

- McMaster University Department of Oncology Student Research Day, June 2023 (poster)

Li, Y., Pond, G., Reed, R., Ung, Y., Cheng, S., Menjak, I., Doherty, M., Moglica, E., Taggar, A. Use of Prophylactic and Reactive Feeding Tubes in Patient with Esophageal Cancer: A Single-Centre Cohort Study

- 16<sup>th</sup> Annual Ontario Thoracic Cancer Conference, April 2023 (**oral**)

**Li, Y.** Pond, G., Shargall, Y., Begum, H., Juergens, R. Rates of Surgery and Adjuvant Chemotherapy Use in Stage IB-IIIA Non-Small Cell Lung Cancer Patients: An Ontario Population-Based Study

- Canadian Association of Medical Oncologist (CAMO) Annual Scientific Meeting, April 2023 (**oral**)
- 16<sup>th</sup> Annual Ontario Thoracic Cancer Conference, April 2023 (**oral**)
- ASCO Quality Care Symposium, October 2023 (poster)

**Li, Y.**, Pond, G., McWhirter, E. Multisystem Immune-Related Adverse Events from Dual Agent Immunotherapy Use

- Canadian Association of Medical Oncologist (CAMO) Annual Scientific Meeting, April 2023 (poster)
- American Society of Clinical Oncology (ASCO) Annual Meeting, June 2023 (poster)

**Li, Y.**, Crossnohere, N., Snyder, C., Brundage, M. Tools to improve the use of patient-reported outcomes in clinical practice.

- Quality Improvement and Safety Symposium, October 2022 (poster)

**Li, Y.**, Stewart, L., Tang, S., McWhirter, E. A Rare Case of Immune-Related Sclerosing Cholangitis.

- McMaster University Medicine Research Day, May 2022 (poster)
- Department of Oncology 17<sup>th</sup> Annual Student Research Day, June 2022 (poster)

**Li, Y.**, Rebello, R., Cutz, Jean-Claude., Juergens, R. Multiple Sclerosis or Lung Cancer? Case of a Patient with Mysterious Brain Lesions.

- 15<sup>th</sup> Annual Ontario Thoracic Cancer Conference, April 2022 (poster)

**Li, Y.**, Juergens, R. Real World Efficacy of Docetaxel in Advanced Non-Small Cell Lung Cancer – A Single Institution Study at Juravinski Cancer Centre. April 2022.

- 15<sup>th</sup> Annual Ontario Thoracic Cancer Conference, April 2022 (poster)
- Department of Oncology 17<sup>th</sup> Annual Student Research Day, June 2022 (poster)

**Li Y.** Piliotis E, Hsieh E, Del Giudice L, Cohen L, Gorab Z, Spiegle G. Spontaneous Tumour Lysis in Metastatic Gastric Adenocarcinoma.

- Ted Giles Clinical Vignettes Session, Canadian Society of Internal Medicine Conference, August 2020 (poster)

**Li, Y.**, Brown, C., et al. Feasibility of Collecting Routine Information for Clinical and Research Purposes via Electronic Format Questionnaire.

- American Society of Clinical Oncology (ASCO) Quality Care Symposium, Miami, FL. March 2017 (poster).
- Personalized Cancer Medicine Conference Harnessing the Cross Disciplinary Approach, Toronto, ON. Feb 2017 (poster)

### **Book Chapter**

**Li, Y.** (2018). Big Idea 2 Ahmed: A Nation with a Drug Problem. In Martin, D. (Ed.), *Better now: Six big ideas to improve health care for all Canadians* (pp. 87-118). Toronto, Ontario: Penguin Canada.

### Articles

Bastedo, S., Li, Y., Hawrylyshyn, K., et al. 2016. An Interprofessional Approach to Strengthen Home and Community Care. Interprofessional Healthcare Students Association Position Paper.

---

### TEACHING EXPERIENCE

---

<b>Mentor</b> , Resident Student Mentorship Program, McMaster University	2021 – 2022
<b>Resident Mentor</b> , Longitudinal Academic Mentorship Program University of Toronto	2019 – 2021
<b>Alumni Mentor</b> , Faculty of Medicine Alumni Mentorship Program, University of Toronto	2018 – 2021
<b>Mentor</b> , Neer-Peer Mentorship Program University of Toronto	2019 – 2021
<b>Clinical Skills Preceptor</b> , Undergraduate Medical Education University of Toronto	2018 – 2021

---

### PROFESSIONAL AFFILIATIONS

---

Canadian Association of Medical Oncologists	2017 – Present
American Society of Clinical Oncology	2016 – Present
Canadian Society of Internal Medicine	2015 – 2021

---

### LANGUAGES

---

**Mandarin:** fluent speaker; able to communicate and take full medical history



# ANDREW ROBINSON

## CURRICULUM VITAE

### IDENTIFICATION

---

**Full Name:** Andrew George Robinson

**Professional Title:** Medical Oncologist, FRCPC

**Academic Title:** Associate Professor Department of Oncology Queen's University Kingston, Ontario K7L 3N6

**Work Address:** Department of Oncology, Queen's University  
Cancer Centre at Kingston General Hospital  
25 King St. West Kingston ON K7L 5P9

**Tel.:** (613) 544-2631 **Email:** [andrew.robinson@kingstonhsc.ca](mailto:andrew.robinson@kingstonhsc.ca)

### SUMMARY OF QUALIFICATIONS

---

**Fellow of the Royal College of Physicians and Surgeons– Medical Oncology -**  
September 2005

**Fellow of the Royal College of Physicians and Surgeons – Internal Medicine**  
September 2004

**Licentiate of the Medical Council of Canada (LMCC) Parts I and II**

## EDUCATION

---

### **Masters of Biotechnology**

Johns Hopkins University, Advanced Academic Programs

2007 to 2014 – Course masters including advanced level courses on cancer biology, clinical trials design, development of novel therapeutics, relational databases, epidemiology, and nanobiotechnology

### **Medical Oncology Residency**

British Columbia Cancer Agency (BCCA)

University of British Columbia, Vancouver BC

January 2004 – July 2005 – Completed a two-year subspecialty residency.

### **Internal Medicine Residency**

St. Pauls Hospital, Vancouver General Hospital

University of British Columbia, Vancouver BC

January 2001 – Dec 2003 – Completed a three-year specialty residency and Chief residency position.

### **Doctor of Medicine**

University of Manitoba, Winnipeg, MB 1996-2000

### **Bachelor of Science – Honors**

University of Toronto, Toronto ON 1990-1996 (with cooperative year)

## CURRENT PROFESSIONAL APPOINTMENTS

---

### **Associate Professor, Department of Oncology and Medicine, Queen's University –**

Full Time Medical Oncologist at the Cancer Centre of Southeastern Ontario with full appointments at the Kingston General Hospital and Hotel Dieu Hospitals – 2013 to current

## CURRENT ADMINISTRATIVE RESPONSIBILITIES

---

**Kingston General Hospital – Cancer Centre of Southeastern Ontario (CCSEO)**

Chair – Division of Medical Oncology – June 2024 to present.

Lead Oncology Clinical Trials Unit -2013-present

Member Medical Oncology Training Program Committee -2013- present

Chair – Competency Committee Residency Program – 2019 – present

Member – Medical Assistance in Dying Provider Group

Director – Medical Oncology Fellowship Program 2020- present

Clinician Subject Matter Expert/Lead Oncology/”Champion” Information Systems Transition (“LUMEO”)

**Cancer Care Ontario – Provincial/Federal**

Lung Cancer Disease Site Co-Chair 2022 -present

Pan Canadian Oncology Drug Review – content/disease site expert – 2015- present;  
Clinical Guidance Panel lead for various lung cancer indications and breast cancer indications

CCO Lung Cancer Drug Advisory Council 2017-present

**External to Queen’s University**

Royal College Physicians and Surgeons of Canada – Medical Oncology Examination Committee. 2015- present. Current Chair. (2021-present)

Royal College International – Medical Oncology Examination Co-Chair 2023 – present

CCTG IND representative

## **CURRENT RESEARCH & GRANTS**

1. National Chair — INSIGNA trial (A Randomized Phase III Study of First- line Immunotherapy Alone or in combination with chemotherapy in Induction Maintenance or Post Progression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis).
2. Principal Applicant for funding from Canadian Cancer Clinical Trials Network (\$50 000) plus incentives ongoing grant.
3. Principal Investigator for Multiple Site Clinical Trials in Lung Cancer, Gynecologic cancer
4. Co-Investigator for Multiple Clinical Trials (Gyne, Breast, Melanoma, IND, GU)

## **RECENT POSTER/ORAL RESEARCH PRESENTATIONS**

1. Jabbour SK, Houghton B, Robinson AG et al. Keynote 867 – A Phase III randomized, placebo controlled trial of SBRT with or without pembrolizumab in patients with unresected stage I or II NSCLC. Int JROBP (Red Journal). ASTRO annual. meeting 2022.
2. Novello S, Kowalski DM, Luft A, Gumus M, Baz DV, Mazieres J, ..Robinson AG..., 5-Year Update from Keynote 407: Pembrolizumab plus chemotherapy in squamous non-small cell lung cancer (NSCLC). Annals of Oncology 22, S993-994. ESMO mini-oral presentation.
3. Rodriguez-Abreu A, Wu Y, Boyer M, Garassino M.C., Mok T, Cheng Y, Hui R, Kowalski DM, Robinson AG et al. Pooled analysis of Outcomes with second-course pembrolizumab across 5 phase III studies of NSCLC. Journal of Thoracic Oncology, volume 17, issue 9 Supplement, 2022. Pg S42-43. Oral Abstract World Lung Cancer Conference.
4. Dehar N, Meem M, Aggarwal I, Hopman W, Gaudreau PO, Robinson AG, Fung AS. Real-world eligibility for clinical trials in extensive stage small cell lung cancer patients. Journal of Thoracic Oncology, volum 17, issue 9 Supplement, 2022. Pg S547. World Lung Cancer Conference.
5. SK Jabbour, B Houghton, AG Robinson, X Quantin. Phase 3, randomized, placebo-controlled study of stereotactic body radiotherapy (SBRT) with or without

- pembrolizumab in patients with unresected stage I or II non–small cell lung cancer (NSCLC): KEYNOTE-867. *Journal of Clinical Oncology*. 2022; 40(16): TPS8597-TPS8597
6. Mansfield AS, Herbst RS, Castro G et al. Outcomes with pembrolizumab (pembro) monotherapy in patients (pts) with PD-L1-positive NSCLC with brain metastases: Pooled analysis of KEYNOTE-001,-010,-024, and-042. *Annals of Oncology*. 2019(30)604-606. ESMO Annual Meeting.
  7. M Reck, D Rodríguez-Abreu, AG Robinson, OA14. 01 KEYNOTE-024 3-Year Survival Update: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer. *Journal of Thoracic Oncology* 2019 14(10). S243. WCLC Barcelona.
  8. Hao D, Ellis PM, Laurie SA et al. Pharmacokinetic (PK) and updated survival data from the Canadian cancer trials group IND.226 study of durvalumab ± tremelimumab in combination with platinum-doublet chemotherapy. *Annals of Oncology*. 2019(30). ESMO Annual Meeting.
  9. L Paz-Ares, D Vicente, A Tafreshi, A Robinson, et al. Pembrolizumab (pembro) + chemotherapy (chemo) in metastatic squamous NSCLC: Final analysis and progression after the next line of therapy (PFS2) in KEYNOTE-407. *Annals of Oncology*. 2019(30). ESMO annual meeting. LBA2.
  10. Clemons M, Ong M, Stober C et al. A randomized trial comparing four-weekly versus 12 weekly administration of bone-targeted agents in patients with bone metastases from prostate cancer or breast cancer. *Journal of Clinical Oncology* 37 (15\_suppl)11501. LBA.
  11. Booth C, Raphael MJ, Wei X. et al. Delivery of bleomycin among patients with testicular cancer. A population based study of pulmonary monitoring and toxicity. *Journal of Clinical Oncology* 37 (15\_suppl) e16056
  12. Stewart DJ, Bosse D, Robinson AG et al. Population kinetics of Progression Free Survival (PFS). *Journal of Clinical Oncology* 37 (15\_suppl) e18251 (ASCO)
  13. Awan AA, Basulaiman B, Robinson A et al. A prospective, multicenter, randomized trial comparing vascular access strategies for patients receiving non-trastuzumab containing chemotherapy for early stage breast cancer. *Annals of Oncology* 30 (Supplement\_3), mdz101 (European Breast Conference)
  14. Kato T, Lee S, Cheng Y et al. Carboplatin-paclitaxel/nab paclitaxel with or without pembrolizumab in first-line metastatic squamous NSCLC: Results of the Keynote-407 east Asia Subgroup: 491O. ESMO Asia. *Annals of Oncology*.

15. Linford G, Robinson D, Wakeham S, Stone C, Coderre-Ball A, Dalgarno N, Egan R, Robinson A, Digby GC. Patient, Caregiver, and Provider Perceptions of Care Before and After Implementation of a Multidisciplinary Lung Cancer Clinic. International Forum on Quality and Safety in Healthcare. Amsterdam 2019.
16. Virik K, Bassalumain B, Robinson AG, Hopman W. Immune Checkpoint Inhibitors (ICIs) in NSCLC: Immune Related Adverse Events (irAEs) and Outcomes. A Canadian Single Institution Experience. World Lung Toronto. Journal of Thoracic Oncology , Volume 13 , Issue 10 , S868
17. Treatment switching—adjusted overall survival (OS) in KEYNOTE-024: First-line pembrolizumab versus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). European Lung Cancer Conference. Geneva, Switzerland. Reck, M et al. Journal of Thoracic Oncology , Volume 13 , Issue 4 , S112 - S113
18. Halmos B, Luft A, Majem M, Corre, R, Gumus M, Laktionov K, Hermes B, Cicin I, Robinson AG, et al. Choice of taxane and outcomes in the KEYNOTE-407 study of pembrolizumab plus chemotherapy alone for metastatic squamous NSCLC. World Lung Cancer Conference. Toronto, Ontario. September 2018. Journal of Thoracic Oncology , Volume 13 , Issue 10 , S391
19. Brahmer J, Rodriguez-Abreu D, Robinson AG et al. KEYNOTE-024 update: pembrolizumab vs platinum-based chemotherapy for advanced NSCLC with PD-L1 tumor proportion score  $\geq 50\%$ . Australian Lung Cancer Conference. Latin American Lung cancer Conference. 2018.
20. Kato T, Lee S, Cheng Y, Lee GW, Lee K, Luffe A, Trigo J, Hui R, Balinta B, Robinson A et al. Carboplatin-paclitaxel/nab-paclitaxel with or without pembrolizumab in first-line metastatic squamous NSCLC: results from the KEYNOTE-407 East Asia subgroup. ESMO Asia meeting. October 2018.
21. O'Donnell, Robinson AG, Booth CM et al. Imaging progression free survival: How much does it matter to patients? ASCO Quality Symposium. JCO 2018.36.30\_suppl.99. October 2018.
22. Tahir A, Hopman W, Robinson A. Neutrophil to Lymphocyte Ratio (NLR) is a Useful Prognostic Marker for Survival in Patients with Locally Advanced (Stage III) Non-Small Cell Lung Cancer. CAMO poster 2018. ASCO abstract 2018. JCO 2018 36:15\_suppl, e20511-e20511
23. Juergens R, Hao D, Laurie S, Ellis P, Mates M, Bradbury P, Tehfe M, Kollmannsberger C, ... Robinson AG, ...Seymour L. Durvalumab -/+ Tremelimumab with platinum doublets in Non-Small Cell Lung Cancer: Canadian Cancer Trials Group Study IND.226. IASLC World Lung Cancer Conference. Yokohoma Japan. Abstract 10-01

24. Daaboul, N., et al., *Immune related adverse events (irAE) with platinum chemotherapy (CT) with durvalumab (D) ± tremelimumab (T): CCTG IND226*. Journal of Clinical Oncology, 2017. **35**(15\_suppl): p. 3058-3058.  
ASCO 2017 poster presentation. Chicago, Illinois.
25. Brahmer J, Rodriguez-Abreu D, Robinson AG. Et al. Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024. Abstract 9000. ASCO 2017 Oral Presentation. J Clin Oncol 35, 2017 (suppl; abstr 9000)
26. Brahmer JR, Rodríguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: pembrolizumab vs platinum-based chemotherapy for advanced NSCLC with PD-L1 TPS ≥50%. Presented at: the IASLC 18th World Conference on Lung Cancer; Oral Presentation. October 15-18; Yokohama, Japan. Abstract OA 17.06 (ID 9582).
27. Robinson A, Stober S, Bedard D, et al. Using Randomized Pragmatic Studies to Compare Intravenous Access Strategies for Patients Receiving Chemotherapy for Breast Cancer not receiving trastuzumab. (REACT-VA Her2 negative) and receiving trastuzumab. (REACT-VA trastuzumab). May 2017, Toronto.
28. LeVasseur N, ...Robinson AG et al. Optimising vascular access for patients receiving intravenous systemic therapy for early stage breast cancer – A survey of oncology nurses and physicians. Applied Research in Cancer Control Symposium Poster Presentation. May 2017, Toronto.
29. LeVasseur N, ...Robinson AG et al. Perceptions around vascular access for intravenous systemic therapy and risk factors for lymphedema in early stage breast cancer – A patient survey. Applied Research in Cancer Control Symposium Poster Presentation. May 2017, Toronto.
30. Mazzarello S, ... Robinson AG et al. Feasibility of using an Integrated Consent Model (ICM) to Compare Standard of Care Administration Schedules of G-CSF (filgrastim) for primary prophylaxis of Chemotherapy-Induced Febrile Neutropenia in Early Stage Breast Cancer. Applied Research in Cancer Control Symposium Oral Presentation. May 2017, Toronto.
31. Digby G, Robinson AG. Optimizing the Management of Chronic Obstructive Pulmonary Disease in Patients with Lung Cancer: A Study of Quality Improvement Initiatives. Poster Presentation, American Thoracic Society International Conference. May 2017. Washington D.C.
32. Digby G, Vaid H, Selvam R, Bhardwaj N, Sandhu S, Edmunds S, Brown E, Robinson AG. An Interdisciplinary Lung Cancer Clinic: A Quality Improvement Pilot Project to Decrease Time to Assessment and Treatment Following a New

- Diagnosis of Lung Cancer. Canadian Partnership Against Cancer (CPAC). April 2017.
33. Reck M, Rodriguez-Abreu D, Robinson AG et al. Keynote 024 : Pembrolizumab vs Platinum based chemotherapy as first line therapy for advanced NSCLC with a PD-L1 tumour proportion score >50%. European Society of Medical Oncology Annual Meeting 2016. Copenhagen. Late Breaking Abstract, Presidents Symposium.
  34. Brahmer JR, Rodrigues-Abreu D, Robinson AG et al. Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS > 50%. Data from Keynote-024, 12-2016. World Conference on Lung Cancer, Vienna.
  35. Edward Garon, Martin Reck, Delvys Rodríguez-Abreu, Andrew Robinson et al. Use of a 200-Mg Fixed Dose of Pembrolizumab for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC). Poster Presentation, World Lung Cancer. Published 2017/01/31 Journal of Thoracic Oncology Volume 12(1) S1290-1291.
  36. Robinson AG, et al. Utilization of palliative chemotherapy for advanced bladder cancer: Patterns of care in routine clinical practice. Presented at American Society of Clinical Oncology Annual Meeting, June 2015.
  37. Garth Andrew Nicholas, John R. Goffin, Scott Andrew Laurie, Andrew George Robinson, Glenwood D. Goss, et al. A phase 1B study of selumetinib in patients (pts) with previously untreated metastatic Non-Small Cell Lung Cancer (NSCLC) receiving standard chemotherapy: NCIC Clinical Trials Group IND.215. Presented at American Society of Clinical Oncology Annual Meeting, June 2015.
  38. Digby G, Robinson AG. Management of Obstructive Lung Disease in patients with lung cancer at the Southeastern Ontario Cancer Centre – a quality audit identifying areas for improvement. Presented at Queen’s Internal Medicine Resident Research Day, May 2015.
  39. Breadner D, Robinson AG. Inflammatory (T4D) and non-inflammatory (T4a,b,c) presentation of breast cancer in a predominantly rural setting in Northern Ontario. Timelines, patient characteristics, and outcomes. Presented at Canadian Association of Medical Oncologists (CAMO) annual meeting, April 2015.
  40. Young K, Balchin K, Robinson AG. Febrile Neutropenia and hospital admissions for patients treated with radical therapy for stage III NSCLC. Presented at Ontario Thoracic Cancer Conference. April 2015.



1. Thibodeau S, Nguyen P, Robinson A et al. Health care system factors associated with receipt of treatment and treatment intent in stage III non-small cell lung cancer: A population-based study in Ontario. *Clinical and Translational Radiation Oncology*. Volume 50. Jan 2025.
2. Mueller CR, Parr K, Mates M et al. Frequent monitoring of NSCLC immunotherapy using an mDETECT liquid biopsy reveals unexpected complexity and opportunities. *Clinical Cancer Research* 30 21\_supplement.
3. Di Pastena F, Pond G, Tsakiridis EE et al. Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected Locally Advanced Non-Small Cell Lung Cancer treated with chemo- radiotherapy. *Radiation Oncology*. 19(155), 2024.
4. Gupta A, Brundage MD, Galica J et al. Patients' considerations of time toxicity when assessing cancer treatments with marginal benefit. *The Oncologist* 29 (11) 978-985.
5. AlGhamdi S, Ahimsadasan N, Kong W et al., Factors Influencing the Timeliness and Completeness of Appropriate Staging Investigations for Patients with Stage I-III Lung Cancer in Southeastern Ontario. *Current Oncology* 31 (10) 6073/6084.
6. Drew, S Lheureux, E Chen, E Tsang, A Robinson, M Rushton, S Welch, G Martos, N Dhani, A Tinker, I King, A Smrke, T Unger, J Sederias, W Tu, L Seymour 235 (PB223): IND. 243: a multiple expansion cohort, signal seeking and dose confirmation phase 2 trial of the PKMYT1 inhibitor lunresertib. *European Journal of Cancer* 211, 114753
7. Spicer J, Blais N, Owen S, Robinson AG et al. A Phase II Study of Neoadjuvant Opnurasib KRAS G12C Inhibitor in Patients With Surgically Resectable Non-Small Cell Lung Cancer (CCTG IND.242A): A Substudy of the IND.242 Platform Master Protocol. *Clin Lung Cancer*. 2024 Sep (online)
8. Seo S, Calderon B, Chou HH et al. Association of biomarkers with response to first-line (1L) vibostolimab (anti-TIGIT) coformulated with pembrolizumab (vibo/pembro) in advanced head and neck squamous cell carcinoma (HNSCC): Results from KEYVIBE-005. *ESMO Annals of Oncology*. Volume 35, Supplement 2, S617-S618.
9. Toullec C, Seo S, Robinson AG et al. Safety and efficacy of vibostolimab (anti-TIGIT) coformulated with pembrolizumab (vibo/pembro) in previously untreated advanced head and neck squamous cell carcinoma (HNSCC): Results from the

- phase II KEYVIBE-005 study. ESMO Annals of Oncology. Volume 35, Supplement 2, S617-S618.
10. Dehar N, Meem M, Aggarwal I, et al. Brief Report: Real-world eligibility for clinical trials in extensive stage small cell lung cancer (ES-SCLC) patients at a tertiary care center. JTO Clinical and Research Reports. 5;7. 2024.
  11. Felip E, Ponce Aix S, Bar J, et al. Association of RNA-sequencing signatures with clinical outcomes of pembrolizumab + chemotherapy in patients with metastatic nonsquamous non-small cell lung cancer (NSCLC) enrolled in the phase 2 KEYNOTE-782 trial. JCO 42 (16\_Suppl), 5502.
  12. Rojas C, Eskens F, Ghiringhelli F, et al. ViBar J, Esteban E, Rodriguez-Abreu et al. Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair-deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study. JCO 42 (16\_Suppl), 5502.
  13. Association of circulating free DNA (cfDNA) maximum variant allele frequency (mVAF) levels with clinical outcomes in patients with metastatic non-squamous lung cancer treated with pembrolizumab and chemotherapy. Cancer Research 84 (7\_Supplement), LB107.
  14. Gupta A, Nguyen P, Kain D, Robinson AG et al. Trajectories of Health Care Contact Days for Patients with Stage IV Non-Small Cell Lung Cancer. JAMA Netw Open. April 1:7(4) 2024
  15. Bar J, Esteban E, Rodríguez-Abreu D, Aix SP, Szalai Z, Felip E, Gottfried M, Provencio M, Robinson A, et al. Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer: KEYNOTE-782. Lung Cancer. 2024 Apr;

#### **PEER-REVIEWED FULL PUBLICATIONS 2023 and Earlier**

16. Novello S, Kowalski DM, Luft A, Gümüş M, Vicente D, Mazières J, Rodríguez-Cid J, Tafreshi A, Cheng Y, Lee KH, Golf A, Sugawara S, Robinson AG, Halmos B, Jensen E, Schwarzenberger P, Pietanza MC, Paz-Ares L. Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. J Clin Oncol. 2023; 31(11):1999-2006
17. Iams WT, Balbach ML, Phillips S, Sacher A, Bestvina C, Velcheti V, Wang X, Marmarelis ME, Sethakorn N, Leal T, Sackstein PE, Kim C, Robinson MA, Mehta K, Hsu R, Nieva J, Patil T, Camidge DR. A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer Clin Lung Cancer. 2023 May;24(3):228-234

18. Owen DH, Singh N, Ismaila N, Masters G, Riely GJ, Robinson AG, Schneider BJ, Jaiyesimi IA. Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.2. *J Clin Oncol*. 2023 Feb 10;41(5):e1-e9.
19. Owen DH, Singh N, Ismaila N, Blanchard E, Celano P, Florez N, Jain D, Leighl NB, Mamdani H, Masters G, Moffitt PR, Naidoo J, Phillips T, Riely GJ, Robinson AG, Schenk E, Schneider BJ, Sequist L, Spigel DR, Jaiyesimi IA. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2. *J Clin Oncol*. 2023 Feb 10;41(5):e10-e20.
20. Thibodeau S, Meem M, Hopman W, Sandhu S, Zalay O, Fung AS, Kartolo A, Digby GC, Al-Ghamdi S, Robinson A, Ashworth A, Owen T, Mahmud A, Tam K, Olding T, de Moraes FY. Survival outcomes and predicting intracranial metastasis in stage III non-small cell lung cancer treated with definitive chemoradiation: Real-world data from a tertiary cancer center. *Cancer Treat Res Commun*. 2023;36
21. Kartolo A, Robinson A, Vera Badillo FE. Can Oncogenic Driver Alterations be Responsible for the Lack of Immunotherapy Efficacy in First-line Advanced Urothelial Carcinoma? *Eur Urol*. 2023 Jan;83(1):1-2.
22. Moffat GT, Wang T, Robinson AG. Small Cell Lung Cancer in Light/Never Smokers - A Role for Molecular Testing? *J Natl Compr Canc Netw*. 2023 Feb 15;21(4):336-339
23. Brundage MD, Booth CM, Eisenhauer EA, Galica J, Kankesan J, Karim S, Koven R, McDonald V, Ng T, O'Donnell J, Ten Hove J, Robinson A. Patients' attitudes and preferences toward delayed disease progression in the absence of improved survival. *J Natl Cancer Inst*. 2023 Dec 6;115(12):1526-1534
24. Robinson AG, Nguyen P, Goldie CL, Jalink M, Hanna TP. Is cancer stage data missing completely at random? A report from a large population-based cohort of non-small cell lung cancer. *Front Oncol*. 2023 Apr 4;13:1146053

2022

25. Singh N, Temin S, Baker S, Blanchard E, Brahmer JR, Celano P, Duma N, Ellis PM, Elkins IB, Haddad RY, Hesketh PJ, Jain D, Johnson DH, Leighl NB, Mamdani H, Masters G, Moffitt PR, Phillips T, Riely GJ, Robinson AG, Rosell R, Schiller JH, Schneider BJ, Spigel DR, Jaiyesimi IA. Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO living guideline. *Journal of Clinical Oncology*. 40 (28), 3323-3343

26. Singh N, Temin S, Baker S, Blanchard E, Brahmer JR, Celano P, Duma N, Ellis PM, Elkins IB, Haddad RY, Hesketh PJ, Jain D, Johnson DH, Leighl NB, Mamdani H, Masters G, Moffitt PR, Phillips T, Riely GJ, Robinson AG, Rosell R, Schiller JH, Schneider BJ, Spigel DR, Jaiyesimi IA. Therapy for stage IV non–small-cell lung cancer with driver alterations: ASCO living guideline. *Journal of Clinical Oncology*. 40 (28), 3310-3322
27. A Kartolo, A Robinson, AS Fung. Optimal first-line immune checkpoint inhibitor treatment in lung cancer: how to choose? *Future Oncology*. 2022; 18(6):635-638.
28. B Gyawali, R Griffiths, AG Robinson, MDF McInnes, PL Bedard, CM Booth. Use of imaging for active surveillance in testicular cancer: Is real-world practice concordant with guidelines? *Canadian Urological Association Journal*. 2022; 16(2):26.
29. A Robinson, A Mazurek, M Xu, Y Gong. Quantitative Analysis of SARS-CoV-2 antibody status between patients with cancer and healthy individuals with extended vaccination dosing intervals in Canada. *Current Oncology*. 2022; 29(1):68-76.
30. Krzyzanowska MK, Julian JA, Gu C-S, Powis M, Li, Q, Enright K, Howell D, Earle CC, Gandhi S, Rask S, Brezden-Masley C, Dent S, Hajra L, Freeman O, Spadafora S, Hamm C, Califaretti N, Trudeau M, Levine MN, Amir E, Bordeleau L, Chiarotto JA, Elser C, Husain J, Laferriere N, Rahim Y, Robinson AG, Vandenberg T, Grunfeld E. Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial. *BMJ*. 2022; 375:e066588

2021:

31. Beca, JM, Walsh S, Raza K, Hubay S, Robinson A, Mow E, Keech J, Chan, KW. Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada. *BMC Cancer* 21, 1162 (2021). <https://doi.org/10.1186/s12885-021-08746-z>
32. Mansfield AS, Herbst RS, de Castro G Jr, Hui R, Pelen N, Kim DW, Novello S, Satouchi M, Wu YL, Garon EB, Reck M, **Robinson AG** et al. Outcomes with Programmed Death-Ligand 1 Positive NSCLC with Brain Metastases: A pooled analysis of Keynote 001, 010, 024, and 042. *JTO Clin Res Rep*. 2021; 2(8):100205
33. Gyawali B, Griffiths R, **Robinson AG** et al. Utilization of imaging for active surveillance in testicular cancer: Is real-world practice concordant with guidelines? *Can Urol Assoc J*. 2021; Sep. Online ahead of Print.
34. Goldie, C.L.; Nguyen, P.; **Robinson, A.G.**; Goldie, C.E.; Kircher, C.E.; Hanna, T.P. (accepted Aug 23<sup>rd</sup> 2021). Quality of End-of-Life Care for People with

- Advanced Non-Small Cell Lung Cancer in Ontario: A Population-Based Study. *Curr. Oncol.* **2021**, 28, x. Manuscript ID: curroncol-1292912
35. **Robinson AG**, O'Donnell J, Booth CM, Koven R, Eisenhauer E, Brundage B. Patient Perspectives of Value of Delayed Disease Progression on Imaging (imaging PFS). A Treatment Trade-Off Experiment. *J Cancer Policy*. Sept 2021. IN press.
  36. Hanna NH, **Robinson AG**, Temin S et al. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guidance Update. *J Clin Oncol.* 2021; Feb 16. Co-First Author.
  37. Raphael MJ, Gupta S, Wei X, Soares CN, Bedard PL, Siemens DR, **Robinson AG**, Booth CM. Long-Term Mental Health Service Utilization among survivors of testicular cancer: A population based cohort study. *J Clin Oncol* 2021; Mar 39 (7):779-86. Contributing Author.
  38. Kartolo A, Feilotter H, Hopman W, Fung AS, **Robinson A**. A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors. *Cancer Treat Res Commun.* 2021 Feb 6. Senior Author.
  39. Khalid S, Basulaiman B, Emack J, Booth C, Duran I, **Robinson AG** et al. Fibroblast Growth Factor Receptor 3 Mutation as a Prognostic Indicator in Patients with Urothelial Carcinoma: A systematic review and meta-analysis. *Eur Urol Open Sci.* 2020; 21:61-68. Contributing Author.
  40. Ethier JL, Desautels D, **Robinson A**, et al. Practice Patterns and Outcomes of Novel Targeted Agents for the Treatment of ERBB2-Positive Metastatic Breast Cancer. *JAMA Oncol.* 2021; Jul 8 (Online ahead of Print). Contributing Author.
  41. Tsakiridis T, Pond GR, Wright J, Ellis PM, Ahmen N, Abdulkarim B, Roa W, **Robinson A** et al. Metformin in combination with Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer: The OCOG-ALMERA Randomized Clinical Trial. *JAMA ONcol.* 2021 Jul 29. (Online ahead of print). Contributing Author.
  42. Yan M, Sigurdson S, Greifer N, Kennedy TAC, Toh TS, Lindsay PE, Weiss J, Hueniken K, Yeung C, Sugumar V, Sun A, Bezjak A, Cho BCJ, Raman S, Hope AJ, Giuliani ME, Stuart EA, Owen T, Ashworth A, **Robinson A**, et al. A comparison of hypofractionated and Twice-Daily Thoracic Irradiation in Limited Stage Small Cell Lung Cancer: An Overlap-Weighted Analysis. *Cancers.* 2021 Jun 9 (Online ahead of Print). Contributing Author.
  43. Stone C JL, Johnson AP, Robinson D, Katyukha A, Egan R, Linton S, Parker C, **Robinson A**, Digby GC. Health Resource and Cost Savings Achieved in a Multidisciplinary Lung Cancer Clinic. *Curr Oncol* 2021; 28(3):1681-1695. Contributing Author.

44. Reck M, Rodriguez-Abreu, **Robinson AG**, et al. Five-Year Outcomes with Pembrolizumab versus Chemotherapy for Metastatic Non-Small Cell Lung Cancer with PD-L1 Tumor Proportion Score  $\geq 50$ . *J Clin Oncol*. 2021 39(21):2339-2349. Contributing Author.
45. **Robinson AG**, Izard JP Vera-Badillo FE. Treatment and patient selection for Patients with Metastatic Castration-resistant Prostate after Progression on Docetaxel and Abiraterone/Enzalutamide: When to play your CARD and When to do your PARP. *Eur Urol*. 2021; 80(2):123-126. (First Author)

2020

46. Robinson AG, Snow S, Brade A et al. Applicability of the Pacific trial results in patients not eligible for the Pacific trial: Canadian rapid consensus statement and recommendations. *Cancer Treat Res Commun*. 2020. Epub Dec 4.
47. Clemons M, Ong M, Stober C et al. A randomized trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer. *Eur J Cancer*. 2021. 142: 142-132.
48. Clemons M, Dranitsaris G, Sienkiewicz M et al. A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting. *Breast*. 2020; 54:278-285.
49. Raphael MJ, Loughheed MD, Wei X et al. A population-based study of pulmonary monitoring and toxicity for patients with testicular cancer treated with bleomycin. *Curr Oncol*. 2020. 27(6)291-298.
50. Paz-Ares L, Vicente D, Tafreshi A, Robinson A et al. A Randomized Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients with Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of Keynote 407. *J Thorac Oncol*. 2020 Oct 15 (10): 1657-1669.
51. Kartolo A, Holstead R, Khalid S et al. Serum neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in prognosticating immunotherapy efficacy. *Immunotherapy* 2020; 22(785-798)
52. Stewart DJ, Bosse D, Robinson A et al. Potential insights from population kinetic assessment of progression-free survival curves. *Crit Rev Oncol Hematol*. 2020 (153)
53. Robinson AG, Gyawali B, Booth CM. Risk of COVID-19 in patients with cancer. *JAMA Oncol*. 2020 Jul 2, Epub.

54. Robinson AG, Gyawali B, Evans F. COVID-19 and cancer: do we really know what we think we know? *Nat Rev Clin Oncol*. 2020 17(7):386-388.
55. Holstead RG, Robinson AG. Discussing serious news remotely: Navigating Difficult Conversations During a Pandemic. *JCO Oncology Practice*. 2020 16 (7):363-368 (Senior Author)
56. Robinson AG, Wei X, Karim S et al. Venous thromboembolism during chemotherapy for testicular cancer: a population based study. *Clin Oncol (R Coll Radiol)* 2020 Oct 32(10). E188-e193
57. Clemons M, Fergusson D, Simos D et al. A multicentre, randomized trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer. *Ann Oncol*. 2020. 8:951-957
58. Linford G, Egarn R, Doderre-Ball A et al. Patient and physician perceptions of lung cancer care in a multidisciplinary clinic model. *Current Oncology* 2020. 27 (1) e9-e19
59. Juergens RA, Hao D, Ellis PM et al. A phase 1B study of durvalumab with or without tremelimumab and platinum doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226. *Lung Cancer* 2020; 143:1-11.
60. Clemons M, Stober C, Kehoe A et al. A randomized trial comparing vascular access strategies for patients receiving chemotherapy with trastuzumab for early stage breast cancer. *Supp Care Cancer*. 2020 ;28(10):4891-4899
61. Hanna NH, Schneider BJ, Temin S et al. Therapy for stage IV Non-Small-Cell Lung Cancer Without driver Alterations: ASCO and OH (CCO) Joint Guideline Update. *Journal of Clinical Oncology*. 2020 38(14): 1608-1632
62. Vera-Badillo FE, Robinson AJ, Berman DM, Booth CM. Value of biomarker expression for RCT design: One (more) missed opportunity. *J CLin Oncol* 2020. 38(6);649-651

#### PREVIOUS YEARS

63. Malone ER, Saleh RR, Yu C, Ahmed L et al. OCTANE: a platform for intraprovincial, national, and international data-sharing. *Curr Oncol*. 2019 26 (5)
64. Robinson A, Stober C, Fergusson D et al. A multicentre, randomized pilot trial comparing vascular access strategies for early stage breast cancer patients receiving non-trastuzumab containing chemotherapy. *Breast Cancer Research and Treatment*. 2019. 178 (2): 337-345.

65. Stone CJL, Robinson A, Brown E, et al. Improving timeliness of oncology assessment and cancer treatment through implementation of a multidisciplinary lung clinic. *J Oncol Prac* 2019; 15(2):e169-e177
66. Baulaiman B, Awan AA, Fergusson D et al. Creating a pragmatic trials program for breast cancer patients. *Rethinking Clinical Trials (REaCT) Breast Cancer Res Treat.* 2019; 177(1) 93-101
67. McGee S, Clemons M, Joy AA, Hilton J, Jeong A, Robinson A. Why Reply all can push all the wrong buttons. *Oncologist* 2019 24(8):e643-e645.
68. Swaminath A, Vella ET, Ramchander K, et al. Surgery after chemoradiotherapy in patients with stage III non-small cell lung cancer: a systematic review. *Curr Oncol* 2019 26(3) e398-e404
69. Raphael MJ, Robinson A, et al. The value of progression free survival as a treatment endpoint among patients with advanced cancer: a systematic review and qualitative assessment of the literature. *JAMA Oncol* 2019.
70. Vijaykumar DK, Arun S, Abraham AG et al. Breast Cancer Care in South India: Is Practice concordant with national guidelines? *J Glob Oncol.* 2019 Jul 5 (1-7)
71. Raphael MJ, Wei X, Karim S et al. Neurotoxicity among survivors of testicular cancer: a population based study. *Clin Oncol*; 2019: 31 (9) 653-658.
72. Reck M, Rodriguez-Abreu D, Robinson AG et al. Updated analysis of keynote-024: Pembrolizumab versus platinum-based chemotherapy for advanced non-small cell lung cancer with PD-L1 tumor proportion score of 50% or greater. *J Clin Oncol.* 2019 37(7):537-546.
73. Karim S, Wei X, Leveridge MJ et al. Delivery of chemotherapy for testicular cancer in routine practice: a population based study. *Urol Oncol* 2019; 37(3):e17-24
74. Goffin JR, Nicholas G, Mates M et al. Canadian cancer trials group (CCTG) IND215: A phase Ib study of selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens. *Invest New Drugs* 2019; 37(3):498-506
75. LeVasseur N, Stober C, Ibrahim M, Gertler S, Hilton J, Robinson A, McDiarmid S, Fergusson D, Mazzarello S, Hutton B, Joy AA, McInnes M, Clemons M. *Perceptions of vascular access for intravenous systemic therapy and risk factors for lymphedema in early-stage breast cancer-a patient survey.* *Curr Oncol.* 2018 Aug;25(4):e305-e310.
76. LeVasseur N, Stober C, Daigle K, Robinson A, McDiarmid S, Mazzarello S, Hutton B, Joy A, Fergusson D, Hilton J, McInnes M, Clemons M. *Optimizing vascular access for patients receiving intravenous systemic therapy for early-stage breast cancer-a survey of oncology nurses and physicians.* *Curr Oncol.* 2018 Aug;25(4):e298-e304.



77. Ghaffari A, Peterson N, Khalaj K, Vitkin N, Robinson A, Francis JA, Koti M. Ghaffari, A., et al., STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer. *Br J Cancer*, 2018.
78. Ibrahim MK, Hilton J, Mazzarello S, Fergusson D, Hutton B, Robinson A et al. A multi-center pragmatic, randomized, feasibility trial comparing standard of care schedules of filgrastim administration for primary febrile neutropenia prophylaxis in early-stage breast cancer. 2018. **168**(2): p. 371-379.
79. Kartolo, A. and A. Robinson, Correlation between different carboplatin dosing patterns and its toxicity analysis in patients with advanced lung cancers: A retrospective study. *J Oncol Pharm Pract*, 2018.
80. Turner D, Kondic AG, Anderson KM, Robinson A, Garon EB, Riess JW, Jain L, Mayawala K, Kang J, Ebbinghaus SW, Sinha V, de Alwis DP, Stone JA. ner, D., et al., Pembrolizumab exposure-response assessments challenged by association of cancer cachexia and catabolic clearance. *Clin Cancer Res*, 2018.
81. LeVasseur N, Stober C, Ibrahim M, et al. Perceptions of vascular access for intravenous systemic therapy and risk factors for lymphedema in breast cancer patients in early stage breast cancer – a patient survey. *Curr Oncol*. 2018 25(4)
82. Stone, C.J.L. Vaid HM, Selvam R, Ashworth A, Robinson A, Digby GC. , et al., Multidisciplinary Clinics in Lung Cancer Care: A Systematic Review. *Clin Lung Cancer*, 2018. **19**(4): p. 323-330.e3.
83. Robinson, A., et al., *Optimal vascular access strategies for patients receiving chemotherapy for early-stage breast cancer: a systematic review*. *Breast Cancer Res Treat*. 2018 Jul 42018.
84. Brahmer JR, Rodriguez-Abreu D, Robinson AG et al. Health related quality of life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (Keynote-024): a multicentre, international, randomized, open-label phase 3 trial. *Lancet Oncol*, 2017 Dec; 18(12):1600-1609.
85. Digby GC, Robinson A. Quality Improvement Initiatives to Optimize the Management of Chronic Obstructive Pulmonary Disease in Patients With Lung Cancer. *J Oncol Pract*. 2017; 13(11):e957-e965.
86. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Cssi T, Fp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR., Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer., 11-2016, *New England Journal of Medicine*, Vol. 375(19):1823-1833.

87. Robinson AG, Wei X, Mackillop WJ, Peng Y, Booth CM, Use of Palliative Chemotherapy for Advanced Bladder Cancer: Patterns of Care in Routine Clinical Practice., 3-2016, Journal of the National Comprehensive Cancer Network : JNCCN, Vol. 14(3):291-8
88. Hilton J, Mazzarello S, Fergusson D, Joy AA, Robinson A, Arnaout A, Hutton B, Vandermeer L, Clemons M, Novel Methodology for Comparing Standard-of-Care Interventions in Patients With Cancer., 12-2016, Journal of oncology practice, Vol. 12(12):e1016-e1024
89. Andrew G. Robinson , Xuejiao Wei, Francisco E. Vera-Badillo, William J. Mackillop, Christopher M. Booth, Palliative Chemotherapy for Bladder Cancer: Treatment Delivery and Outcomes in the General Population, -, Clinical Genitourinary Cancer. 2017 Aug;15(4):e535-e541.
90. Robinson AG, Young K, Balchin K, Owen T, Ashworth A. Causes of Death and Subsequent Treatment after Initial Radical or Palliative Therapy of Stage III Non-Small Cell Lung Cancer. . Curr Oncol. 2015 Dec;22(6):399-404
91. Robinson AG, Young K, Balchin K, Ashworth A, Owen T. Reasons for Palliative Treatments in Non-Small Cell Lung Cancer Stage III. What contribution is made by time-dependent changes in the tumour or patient status? Curr Oncol. 2015 Oct;22(5):333-40
92. Robinson AG, Booth CM, Eisenhauer EA. Progression-free survival as an endpoint in solid tumours – perspectives from clinical trials and clinical practice. Eur J Cancer. 2014; 50(13):2303-8.
93. Robinson AG, Booth CM, Eisenhauer EA. Disease Free Survival as an end-point in the treatment of solid tumours – perspectives from clinical trials and clinical practice. Robinson AG, Booth CM, Eisenhauer EA. Eur J Cancer. 2014; 50(13):2298-302.
94. Del Giudice ME, Young S-M, Vella ET, Ash M, Bansal P, Robinson A, Skrastins R, Ung Y, Zeldin R, Levitt C. Guideline for Referral of Patients with Suspected Lung Cancer by Family Physicians and Other Primary Care Providers. Canadian Family Physician. 2014; 60(8):711-6.
95. Del Giudice ME, Young S-M, Vella ET, Ash M, Bansal P, Robinson A, Skrastins R, Ung Y, Zeldin R, Levitt C. A Systematic Review of Guidelines for the Management of Suspicious Lung Cancer in Primary Care. Canadian Family Physician. 2014; 60(8):e395-404
96. Ung YC, Del Guidice, Young S, Vella E, Ash M, Bansal P, Robinson A, et al. Referral of Suspected Lung Cancer by Family Physicians and Other Primary Care Providers: A Clinical Practice Guideline. Internation Journal of Radiation Oncology Biology and Physics. Vol 84; 3(S603-S604), 2012 November

97. Del Guidice L, Young S, Vella E, Ash M, Bansal P, Robinson AG et al. Referral of suspected lung cancer by family physicians and other primary care providers. Program in Evidence Based Care (PEBC), Cancer Care Ontario. Report Date Aug 29, 2011.
98. Madarnas Y, Dent SF, Husain SF, Robinson A et al. Real-world experience with adjuvant FEC-D chemotherapy in four Ontario regional cancer centres. *Curr Oncol.* 2011; 18(3):119-25.
99. Sutherland LC, Wang K, Robinson AG. RBM5 as a putative tumor suppressor gene for lung cancer. *J Thorac Oncol.* 2010; 5(3):294-8.
100. Robinson AG, Clarke W. A Case Report of Gemcitabine Treatment for Duodenal Cancer: The Good (A Sustained Response) and The Bad (Life Threatening Refractory Thrombotic Thrombocytopenic Purpura). *J Gastroentero.* 2009; Dec 5
101. Ayeni M, Robinson AG. Hormone Replacement Therapy and Lung Cancer Outcomes in Women. *Curr Oncol.* 2009; 16(3):21-25.
102. Robinson AG. A review of the use of exemestane in early breast cancer. *Therapeutics and Clinical Risk Management.* 2009;5(91-98)
103. Giltane J, Molinaro A, Cheng H, Robinson A, Turbin D, Gelmon K, Huntsman D, Rimm DL. A comparison of quantitative immunofluorescence with conventional methods for HER2 testing with respect to response to trastuzumab therapy in metastatic breast cancer. *Arch Pathol Lab Med.* 2008; 1635-47.
104. Christopher B. Moeder, Jennifer M. Giltane, Malini Harigopal, Annette Molinaro, Andrew Robinson, Karen Gelmon, David Huntsman, Robert L. Camp and David L. Rimm. Quantitative Justification of the Change from 10% to 30% for HER-2 scoring in the ASCO-CAP guidelines: Tumor Heterogeneity in Breast Cancer and its Implications for Tissue Microarray-based Assessment of Outcome. *J Clin Oncol.* 2007; 25, 5418-5425.
105. Robinson AG, Speers C, Olivotto I, Chia S. Method of detection of new contralateral primary breast cancer in Younger versus older women. *Clin Breast Cancer.* 2007; 7 (9):705-709.
106. Robinson AG, Bainbridge T, Kollmannsberger C. A spermatocytic seminoma with rhabdomyosarcoma transformation and extensive metastases. *Am J Clin Oncol.* 2007 Aug;30(4):440-1
107. Robinson AG, Turbin T, Thomson T et al. Molecular predictive factors in patients receiving trastuzumab-based chemotherapy for metastatic disease. *Clin Breast Cancer.* 2006;7 (3):254-61.

Robinson CV

Jan 2, 2025

108. Brush biopsy for detection of nasopharyngeal cancer. Freeman JL, Robinson A, Irish J. J Otolaryngol. 2001
109. Valve Surgery in Octogenarians. Ralph-Edwards AC, Robinson AG, Gordon RS, Ivanov J. Can J Cardiol. 1999.
110. Increased Oxidative stress in patients with congestive heart failure. Keith M, Geranmayegan A, Sole MJ, Kurian R, Robinson A, Omran AS, Jeejeebhoy KN. J Am Coll Cardiol., 1998.

### **H index last five years – 24**

### **Conference Committees/Chairs**

- 2023** - Co-Chair, Ontario Thoracic Cancer Conference. Niagara-on the Lake
- 2016 – Co-Chair, Ontario Thoracic Cancer Conference. Niagara-on the Lake.
- 2012– Co-Chair, Ontario Thoracic Cancer Conference. Niagara-on the Lake
- 2012 – Chair, Initiator: Autumn Internal Medicine Update for Medical Oncologists.

### **Invited Talks 2018 to present**

**November 2023** – Canadian Cancer Research Conference - presentation

**September 2021** – World Lung Cancer Conference. Online. Invited Discussant – Real world data in lung cancer treatment.

**Feb 2020** – Canadian Lung Cancer Conference. Future of Lung Cancer in Canada. Invited speaker. Vancouver, BC.

**October 2019** – Best of Lung Cancer. Understanding complicated clinical trials. Toronto, Ontario.

**October 2019** – Maritime Immunotherapy Symposium. Invited speaker. Rationale for combinations with immunotherapy. Moncton, NB.

**March 2019** – Cancer Immunotherapy Symposium: Invited speaker. Several presentations and panels, including optimal first line treatment in lung cancer, controversies and clinical applicability, and case discussions. Sydney, Australia.

**October 2018** – Immune mediated toxicity management. Canadian ImmunoOncology Summit.

Robinson CV

Jan 2, 2025

**October 2018** - Updates in management of Lung Cancer with Immunotherapy. Health Sciences North Grand Rounds.

**September 2018** – Use of Immune therapies in patients with non-small cell lung cancer with immune related co-morbidity. International Association for the Study of Lung Cancer (IASLC) annual meeting. Invited speaker, Toronto. (Meet the expert session)

**April 2018** – Medical Assistance in Death in Thoracic Oncology Population. Ontario Thoracic Cancer Conference. McMaster University.

## **TEACHING**

---

**CANC440 – lecturer, lung cancer**

**Supervisory Committee – Path 830**

**Clinical Skills** – First year and second year medical students, Queens University. 2013- present (last done Fall 2022)

**Medical Oncology Resident Teaching** – Clinical supervision of Longitudinal Resident Clinics. Clinical supervision of residents in regular lung and breast clinics

**Resident Research Supervisor** – supervisor of resident research projects in medical oncology – generally 1-2 residents per year.

**Medical Oncology Half Day** – In addition to regular teaching for Breast and Lung Cancer, organized Lung Curriculum.

**Radiation Oncology Half-Day Teaching**

## **PAST MAJOR ADMINISTRATIVE/EDUCATION RESPONSIBILITIES**

---

**Chair of Breast Disease Site Group – 2014-2018**

**Chair of Department of Oncology Health Sciences North, Sudbury, Ontario – 2011-2013**

**Coordinator of 1<sup>st</sup> two years of medical education – Northern Ontario School of Medicine. 2009-2012**

**Chair of 1<sup>st</sup> two years of medical education (Phase 1) committee (2009-2012)**

## **PAST PROFESSIONAL APPOINTMENTS AND OTHER APPOINTMENTS**

---

**Locum Medical Oncologist – Prince Edward Island cancer Centre – 2018-Present**

Robinson CV  
Jan 2, 2025

**Locum Medical Oncologist** – Health sciences North, Sudbury Ontario. 2016-2018

**Attending Medical Oncologist** – Health sciences North, Sudbury Ontario. 2005-2013

**Locum Medical Oncologist** – Grand River Cancer Centre, Kitchener-Waterloo, Ontario. 2006 June.

**Chief Internal Medicine Resident** – St. Pauls Hospital, Vancouver BC. June 2013-December 2013.

**MIHAELA MATES MD FRCPC**

Department of Oncology, KHSC Cancer Centre of Southeastern Ontario  
25 King Street West, Kingston, Ontario K7L5P9  
Tel: 613-544 2631 x 4502  
Fax: 613-546 8209  
Email: [mihaela.mates@kingstonhsc.ca](mailto:mihaela.mates@kingstonhsc.ca)

---

**CURRENT APPOINTMENTS**

2009 - present      Associate Professor, Queen's University, Kingston  
Medical Oncologist, Department of Oncology, Cancer Centre of Southeastern Ontario (CCSEO) at  
Kingston Health Sciences Centre (KHSC)  
Cross-appointment, Department of Medicine, Queen's University, Kingston

**EDUCATION**

2006-2008      **Resident, Medical Oncology**, Queen's University, Kingston  
2004-2006      **Resident, General Internal Medicine**, Queen's University, Kingston  
2003-2004      **Clinical Fellow, Hematology**, University of Toronto  
2000-2001      **Clinical Fellow, Hematology (Attestation de Formation Spécialisée)** Université Claude Bernard  
Lyon 1, France  
1996-2000      **Resident, Hematology**, Institute of Oncology, Department of Hematology, Cluj-Napoca, Romania  
1989-1995      **Doctor of Medicine**, Faculty of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania

**CERTIFICATIONS**

2008      **Medical Oncology** – Royal College of Physicians and Surgeons of Canada  
2007      **Internal Medicine** – Royal College of Physicians and Surgeons of Canada  
2000      **Hematology** – Ministry of Health, Romania

**CONTINUING PROFESSIONAL EDUCATION**

Harvard T.H. Chan School of Public Health – Measurement, Design and Analysis for Methods for Health Outcomes Research  
(September 20-24, 2021)

**PROFESSIONAL QUALIFICATIONS AND AFFILIATIONS**

2014	Member, European Society of Medical Oncology (ESMO)
2008	Independent License – College of Physicians and Surgeons of Ontario
2008	Certificate of Special Competence, Medical Oncology, Royal College of Physicians and Surgeons of Canada
2008	Member, Ontario Medical Association (OMA)
2008	Member, Canadian Medical Association (CMA)
2007	Fellow of the Royal College of Physicians and Surgeons of Canada, FRCP(C)
2007	Member, American Society of Clinical Oncology (ASCO)
2007	Member, Canadian Association of Medical Oncologists (CAMO)
2004	Medical Council of Canada, Evaluating and Qualifying Examination, Part I, II

**COMMITTEE AND ADMINISTRATIVE INVOLVEMENT**

2023 – present	Regional Systemic Quality Lead
2023 – present	Deputy Division Head
2022 – present	Lung Drug Advisory Committee – Ontario Health
2021 – present	CADTH expert advisor
2021 – present	Member – Search Committee, Department of Surgery and Oncology
2021 – present	Member – Promotions Committee, Department of Oncology
2019 – present	Vice-Chair, Ontario Cancer Research Ethics Board (OCREB)
2016 – present	Member, Ontario Cancer Research Ethics Board (OCREB)
2013 – 2019	Oncology Discipline Lead – Undergraduate Medical Education, Queen’s University
2011 – present	Member, CCTG Audit and Monitoring Committee
2011 – present	Member, Systemic Therapy Programme, KHSC, Department of Oncology
2017 – 2023	Lung and Thoracic Cancer Disease Site Chair – Cancer Centre of Southeastern Ontario at KHSC
2010 – 2022	Member, Medical Oncology Training Committee, Queen’s University, Kingston
2010 – 2022	Billing Delegate, Medical Oncology Associates of Kingston
2010 – 2016	Member, Cancer Care Ontario Program in Evidence-based Care Breast Disease Site Group
2013 – 2016	Member, CCTG IND and Breast Cancer Committee
2013 – 2022	Breast Cancer Systemic Disease Site Lead – Cancer Centre of Southeastern Ontario at KHSC
2011 – 2013	Member, Pharmacology & Therapeutics Committee, KHSC
2010 – 2013	Co-Director, Adult Clinical Oncology Trials Group – CCSEO
2010 – 2013	Member, Program Council, Department of Oncology, CCSEO



## **GRANTS**

Cancer Nephrotoxin Stewardship—A Program to Reduce Acute Kidney Injury in Patients Receiving Cancer Therapy – QUICC in kind grant – Co-Investigator

Pfizer Lung Biomarker Quality Improvement Grant Application (2021) – Principal Investigator (\$100,000US over 18 months) – January 2022 – July 2023

Cancer Research Society (CRS) – Lung cancer immune-oncology grant (2021) – Co-applicant (\$120,000 over 2 years)

QCRI Translational Research Team Development Grant Biomarkers of response to immunotherapy in non-small cell lung cancers – Co-applicant (\$40,000 over 2 years) – 2018

Interdisciplinary Cancer Research Internal Grant Competition 2013–2015 Novel gene sequencing technique for molecular profiling of non-small cell lung cancer – Principal Investigator (\$40,000 over 2 years)

## **OTHER RESEARCH PROJECTS AND ACTIVITIES**

Co-investigator – Novel Tools to Assess and Predict the Risk of Cancer-Associated Thrombosis in Women Undergoing Chemotherapy for Breast and Gynecological Cancers – Thromboelastography project (2023 – ongoing)

Supervisor Medical Oncology Resident QI project – Outcomes of diagnostic mammograms in women younger than 50 (manuscript in progress)

Principal investigator – Patient Reported Outcomes in Breast Cancer Survivors: A Feasibility Pilot Project (2021 – now)

Co-investigator – Measuring variants in cell free DNA in lung cancer patients – (2016 – 2019)

Principal Investigator – Novel gene sequencing technique for molecular profiling of non-small cell lung cancer (2013 – 2015)

Supervisor Medical Oncology Fellow – Use of staging investigations in asymptomatic stage 1 and 2 breast cancer patients treated at the KGH Cancer Centre of Southeastern Ontario (completed 2016)

Supervisor – Medical Oncology Resident Quality Assurance Project - Patterns of EGFR/ALK mutation testing, management and outcomes in advanced non-small cell lung cancer at the Cancer Centre of Southeastern Ontario (completed 2014)

Supervisor- Internal Medicine Resident Research Project – Hospital admission after curative chemotherapy for breast cancer in the Southeastern Ontario LHIN (completed 2014)

Co-Investigator – Decision making by post-menopausal women with hormone receptor positive early-stage breast cancer considering adjuvant endocrine therapy (completed 2013)

Co-Investigator – Do novel strain and change in 3D volume parameters detect Trastuzumab-related cardiomyopathy earlier than a frank decline in left ventricular function (completed 2014)

## **CLINICAL TRIALS INVOLVEMENT**

Qualified Investigator: Protocol Number(s): 20060359, A5841023, BIANCO, BO28407, BR34, Breast-PRO, BREVITY, CLEE0A2404, CLEE011F2301, CRADY001YCA09, D08164000012, D3615C00001 (CAPItello-291), GDC490g, IND190, IND198, IND213, IND215, IND219, IND236, ISICA, MA17R, MA31, MA32/F/D, MA34, MA37, MA38 (PALLAS), MAC.4, MAC20, MAX.1, MK3475-495, MONALEESA-3, ONCOTYPE Dx, Real World Outcome, REaCT-Algorithm, REaCT-ZoL, MK7902-006, EFC15935 (AMEERA-5), IND239

Co-Investigator: Protocol Number(s): 20050136, A6181064, AD/MG1-MAGEA3, ALMERA, ATOM, AVERT, BI1200.125, BI18209 A/B, B9991023, B42, BO20603, BO20289, BO21003, BR26, BR28, BR29, BR31, CA209-153, CA209-568, CA209-76K, Concordance, D419AC00001 (MYSTIC), D910FC00001 (WAVE), D910LC00001 (MERMAID-1), E7389-G000-301, EGF105485, FACT, ILIAD, IND.211, IND.226, IND239, LY12, LUMINA, MA5, MA9, MA17, MA17R, MA21, MA27, MAC21, MK3475-024, MK3475-048, MK3475-189, MK3475-407, MK3475-604, MK3475-654, MO39196, OCTANE, PERFCT, REaCT-G, REaCT-VA, REaCT-G2, REaCT-BTA, REaCT-VA-ve, TORCH, Vascular Access Survey, W020697, W029522, PM1, MAC21, BRC7, MK3475-782, MK3475-867, MK7339-008, MK7902-008, ME13, CA209-490, Melanoma Database, CA209-73L, MK3475-587

## **TEACHING AND EDUCATION RESPONSABILITIES**

2020 – 2023	Academic Advisor, CBME, Queen's University
2013 – 2019	Oncology Undergraduate Discipline Lead – Queen's University Medical School
2012 – present	Supervisor, Resident Longitudinal Clinic
2011 – present	Tutor, First Patient Program, Queen's University Medical School
2010 – 2014	Tutor, Clinical Skills Term 3 and 4, Queen's University Medical School
2009 – present	Lecturer, Respiriology Case-based Series, Queen's University Medical School
2010 – present	Lecturer, Oncology Undergraduate Block, Queen's University, School of Medicine
2010 – present	Member, Medical Oncology Training Committee, Queen's University, Kingston
2009 – present	Lecturer, Oncology Academic Half-Day, Queen's University
2009 – present	Lecturer, Internal Medicine Academic Half-Day and Mid-Day Rounds, Queen's University

**UNDERGRADUTE MEDICAL EDUCATION – ONLINE TEACHING RESOURCES DEVELOPMENT**

Introduction to Clinical Oncology

[https://qshare.queensu.ca/Groups/School%20of%20Medicine/Assets/Public/Storyline/Clinical\\_Oncology/](https://qshare.queensu.ca/Groups/School%20of%20Medicine/Assets/Public/Storyline/Clinical_Oncology/)

Assessment of the Patient with a Suspected Cancer

[https://qshare.queensu.ca/Groups/School%20of%20Medicine/Assets/Public/Storyline/Clinical\\_Oncology\\_Assessment/](https://qshare.queensu.ca/Groups/School%20of%20Medicine/Assets/Public/Storyline/Clinical_Oncology_Assessment/)

Making a cancer diagnosis

[https://qshare.queensu.ca/Groups/School%20of%20Medicine/Assets/Public/Storyline/Oncology-Making\\_a\\_Cancer\\_Diagnosis/](https://qshare.queensu.ca/Groups/School%20of%20Medicine/Assets/Public/Storyline/Oncology-Making_a_Cancer_Diagnosis/)

Overview of cancer treatment

[https://qshare.queensu.ca/Groups/School%20of%20Medicine/Assets/Public/Storyline/Oncology-Overview\\_of\\_Cancer\\_Treatment/](https://qshare.queensu.ca/Groups/School%20of%20Medicine/Assets/Public/Storyline/Oncology-Overview_of_Cancer_Treatment/)

Prostate cancer

[https://qshare.queensu.ca/Groups/School%20of%20Medicine/Assets/Public/Storyline/Prostate\\_Cancer\\_Overview](https://qshare.queensu.ca/Groups/School%20of%20Medicine/Assets/Public/Storyline/Prostate_Cancer_Overview)

Respirology <https://qshare.queensu.ca/Groups/School%20of%20Medicine/Assets/Public/Storyline/Lung-Cancer-PartI/>

<https://qshare.queensu.ca/Groups/School%20of%20Medicine/Assets/Public/Storyline/Lung-Cancer-PartII/>

Breast cancer <https://meds.queensu.ca/central/events?id=82075>

Colon cancer [https://qshare.queensu.ca/Groups/School%20of%20Medicine/Assets/Public/Storyline/Colorectal-Cancer/story\\_html5.html](https://qshare.queensu.ca/Groups/School%20of%20Medicine/Assets/Public/Storyline/Colorectal-Cancer/story_html5.html)

Musculoskeletal tumours

[https://qshare.queensu.ca/Groups/School%20of%20Medicine/Assets/Public/Rise/Musculoskeletal-tumours/#/list/cj1jmc0rx000z3k6949dw65p0?\\_k=6fqgoy](https://qshare.queensu.ca/Groups/School%20of%20Medicine/Assets/Public/Rise/Musculoskeletal-tumours/#/list/cj1jmc0rx000z3k6949dw65p0?_k=6fqgoy)

Gynecological cancers

[https://qshare.queensu.ca/Groups/School%20of%20Medicine/Assets/Public/Storyline/IntroGyneCancers/story\\_html5.html](https://qshare.queensu.ca/Groups/School%20of%20Medicine/Assets/Public/Storyline/IntroGyneCancers/story_html5.html)

Abdominal distension and masses

[https://qshare.queensu.ca/Groups/School%20of%20Medicine/Assets/Public/Storyline/Abdominal-Distension-Masses/story\\_html5.html](https://qshare.queensu.ca/Groups/School%20of%20Medicine/Assets/Public/Storyline/Abdominal-Distension-Masses/story_html5.html)

## PUBLICATIONS

- 2024 Arif Ali Awan, Carol Stober, Gregory R Pond, Igor Machado, Lucas Clemons, Henry Conter, Demetrios Simos, Sukhbinder Dhesy-Thind, **Mihaela Mates**, Vikaash Kumar, John Hilton, Marie-France Savard, Dean Fergusson, Lisa Vandermeer, Mark Clemons. A randomised trial comparing 6-monthly adjuvant zoledronate with a single one-time dose in patients with early breast cancer. *Breast Cancer Research and Treatment* 2024 Jul 31. <https://doi.org/10.1007/s10549-024-07443-2>.
- 2024 Navdeep Dehar, Doris Jabs, Wilma Hopman, **Mihaela Mates**. A Retrospective Analysis of Diagnostic Breast Imaging Outcomes in Young Women at a Tertiary Care Center. *Curr Oncol*. 2024 Jul; 31(7): 3939–3948. doi: 10.3390/curroncol31070291
- 2024 Arif Ali Awan, Deanna Saunders, Gregory Pond, Caroline Hamm, Nadia Califaretti, **Mihaela Mates**, Vikaash Kumar, Mohammed Ibrahim, Ana-Alicia Beltran-Bless, Lisa Vandermeer, John Hilton, Mark Clemons. Does preemptive availability of PREDICT 2.1 results change ordering practices for Oncotype DX? A multi-center prospective cohort study. *Curr Oncol* 2024;31(3):1278-1290. doi: 10.3390/curroncol31030096.
- 2024 Yousra Tera, Yoon Jin Suh, Karina Fainchtein, Anita Agrawal, **Mihaela Mates**, Maha Othman. Assessing Hypercoagulability and VTE Risk Using Thromboelastography and Khorana Score in Women with Cancers Receiving Chemotherapy. *American Journal of Hematology* – accepted for publication.
- 2023 Laura J. Semenuk, Baskoro A. Kartolo, Harriet E. Feilotter, Shawna M. Lee, Colleen A. Savage, Alexander H. Boag, Geneviève C. Digby, **Mihaela Mates**. Implementing Next-Generation Sequencing Process Changes to Increase Capacity and Improve Timeliness of Molecular Biomarker Profiling for Lung Cancer Patients. *Journal of Applied Laboratory Medicine* 2023;00:1–11 <https://doi.org/10.1093/jalm/jfad105>
- 2023 Yeung C, Relke N, Good D, Satkunam N, **Mates M**. Antithymocyte globulin for aplastic anemia secondary to pembrolizumab: a case report and review of literature. *Immunotherapy*. Published online: 28 February 2023
- 2022 Leighl NB, Laurie SA, Goss GD, Hughes BGM, Stockler M, Tsao MS, Hwang DM, Joubert P, Kulkarni S, Blais N, Joy AA, **Mates M**, Rana P, Yadav SK, Underhill C, Lee C, Bradbury PA, Hiltz A, Dancey J, Ding K, Vera-Badillo F; Canadian Cancer Trials Group Lung Disease Site and the Australasian Lung Cancer Trials Group. CCTG BR34: A randomized phase II trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic non-small cell lung cancer. *J Thorac Oncol*. 2022 Mar;17(3):434-445. doi: 10.1016/j.jtho.2021.10.023.
- 2021 Mark Clemons, Michelle Liu , Carol Stober, Gregory Pond, Mashari Jemaan Alzahrani, Michael Ong, Scott Ernst, Christopher Booth, **Mihaela Mates**, Anil Abraham Joy, Olexiy Aseyev, Phillip Blanchette, Lisa Vandermeer, Megan Tu, Kednapa Thavorn, Dean Fergusson. Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer. *J Bone Oncol*. 2021 Sep 2;30:100388. doi: 10.1016/j.jbo.2021.100388. eCollection 2021 Oct.
- 2021 Dalia Kamel, Veronica Youssef, Wilma M Hopman, **Mihaela Mates**. Staging Investigations in Asymptomatic Early Breast Cancer Patients at the Cancer Centre of Southeastern Ontario. *Curr Oncol*. 2021 Jun 12;28(3):2190-2198. doi: 10.3390/curroncol28030203.
- 2021 Megan M Tu, Mark Clemons, Carol Stober, Ahwon Jeong, Lisa Vandermeer, **Mihaela Mates**, Phillip Blanchette, Anil Abraham Joy, Olexiy Aseyev, Gregory Pond, Dean Fergusson, Terry L Ng, Kednapa Thavorn. Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer. *Curr Oncol*. 2021 May 13;28(3):1847-1856. doi: 10.3390/curroncol28030171.
- 2021 Adi Kartolo, Tanveer Towheed, **Mihaela Mates**. A case of successful pembrolizumab rechallenge in a patient with non-small-cell lung cancer and grade 3 dermatomyositis. *Immunotherapy* (Epub ahead of print). 2021 Feb 25. doi: 10.2217/imt-2020-0309

**PUBLICATIONS (CONT'D)**

- 2020 Mark Clemons, Michael Ong, Carol Stober, Scott Ernst, Christopher Booth, Christina Canil, **Mihaela Mates**, Andrew Robinson, Phillip Blanchette, Anil Abraham Joy, John Hilton, Olexiy Aseyev, Gregory Pond, Ahwon Jeong, Brian Hutton, Sasha Mazzarello, Lisa Vandermeer, Igal Kushnir, Dean Fergusson. A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer. *European Journal of Cancer* Oct 3;S0959-8049(20)30470-6. doi: 10.1016/j.ejca.2020.08.019.
- 2020 M Clemons, D Fergusson, D Simos, **M Mates**, A Robinson, N Califaretti, L Zibdawi, M Bahl, J Raphael, M F K Ibrahim, R Fernandes, L Pitre, O Aseyev, C Stober, L Vandermeer, D Saunders, B Hutton, R Mallick, G R Pond, A Awan, J Hilton. A Multicentre, Randomised Trial Comparing Schedules of G-CSF (Filgrastim) Administration for Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia in Early Stage Breast Cancer. *Ann Oncol* 2020 Jul;31(7):951-957. doi: 10.1016/j.annonc.2020.04.005. Epub 2020 Apr 20.
- 2020 Isabel Pimentel, Bingshu E Chen, Ana Elisa Lohmann, Marguerite Ennis, Jennifer Ligibel , Lois Shepherd, Dawn L Hershman, Timothy Whelan, Vuk Stambolic , Ingrid Mayer, Timothy Hobday, Julie Lemieux, Alastair Thompson, Priya Rastogi, Karen Gelmon, Daniel Rea, Manuela Rabaglio, Susan Ellard, **Mihaela Mates**, Philippe Bedard, Lacey Pitre, Theodore Vandenberg, Ryan Jo Dowling, Wendy Parulekar, Pamela J Goodwin. The Effect of Metformin vs Placebo on Sex Hormones in CCTG MA.32. *J Natl Cancer Inst.* 2021 Feb 1;113(2):192-198. doi: 10.1093/jnci/djaa082.
- 2020 Juergens RA, Hao D, Ellis PM, Tu D, **Mates M**, Kollmannsberger C, Bradbury PA, Tehfe M, Wheatley-Price P, Robinson A, Bebb G, Laskin J, Goffin J, Hilton J, Tomiak A, Hotte S, Goss GD, Brown-Walker P, Sun X, Tsao MS, Cabanero M, Gauthier I, Song X, Dennis PA, Seymour LK, Smoragiewicz M, Laurie SA A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226 Lung Cancer:143: 1-11,2020 doi: 10.1016/j.lungcan.2020.02.016.
- 2019 Neal Ready, Matthew D. Hellmann, Mark M. Awad, Gregory A. Otterson, Martin Gutierrez, Justin F. Gainor, Hossein Borghaei, Jacques Jolivet, Leora Horn, **Mihaela Mates**, Julie Brahmer, Ian Rabinowitz, Pavan S. Reddy, Jason Chesney, James Orcutt, David R. Spigel, Martin Reck, Kenneth John O'Byrne, Luis Paz-Ares, MD, Wenhua Hu, Kim Zerba, Xuemei Li, Brian Lestini, MD, William J. Geese, Joseph D. Szustakowski, George Green, Han Chang, Suresh S. Ramalingam. First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. *J Clin Oncol* 2019 Apr 20; 37(12):992-1000. doi: 10.1200/JCO.18.01042.
- 2019 Stone CJL, Robinson A, Brown E, **Mates M**, Falkson CB, Owen T, Ashworth A, Parker CM, Mahmud A, Tomiak A, Thain SK, Gregg R, Reid KR, Chung W, Digby GC. Improving Timeliness of Oncology Assessment and Cancer Treatment Through Implementation of a Multidisciplinary Lung Cancer Clinic. *J Oncol Pract.* 2019 Jan 7;JOP1800214. Volume 15, Issue 2 e169 doi: 10.1200/JOP.18.00214.
- 2018 Goffin JR, Nicholas G, **Mates M**, Tu D, Chen E, Laurie SA, Juergens R, Robinson A, Goss G, Reaume M, Sun S, Christink K, Maize C, MacFarlan S, Sun X, Ritter H, Seymour L, Bradbury PA. Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens. *Invest New Drugs* 2019 Jun; 37(3):498-506. doi: 10.1007/s10637-018-0680-z.
- 2018 Bradbury PA, Morris DG, Nicholas G, Tu D, Tehfe M, Goffin JR, Shepherd FA, Gregg RW, Rothenstein J, Lee C, Kuruvilla S, Keith BD, Torri V, Blais N, Hao D, Korpany GJ, Goss G, Melosky BL, **Mates M**, Leighl N, Ayoub JP, Sederias J, Feilotter H, Seymour L, Laurie SA. Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy. *Lung Cancer.* 2018 Jun;120:142-148. doi: 10.1016/j.lungcan.2018.03.005. Epub 2018 Mar 9.

PUBLICATIONS (CONT'D)

- 2018 Ibrahim MFK, Hilton J, Mazzarello S, Fergusson D, Hutton B, Robinson A, Califaretti N, Hsu T, Gertler S, Mates M, Stober C, Vandermeer L, Mallick R, Clemons M. A multi-center pragmatic, randomized, feasibility trial comparing standard of care schedules of filgrastim administration for primary febrile neutropenia prophylaxis in early-stage breast cancer. *Breast Cancer Res Treat.* 2018 Apr;168(2):371-379. doi: 10.1007/s10549-017-4604-y. Epub 2017 Dec 6.
- 2018 Bernstein V, Ellard SL, Dent SF, Tu D, **Mates M**, Dhesy-Thind SK, Panasci L, Gelmon KA, Salim M, Song X, Clemons M, Ksienski D, Verma S, Simmons C, Lui H, Chi K, Feilotter H, Hagerman LJ, Seymour L A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213 *Breast Cancer Res Treat.* 2018 Jan;167(2):485-493. doi: 10.1007/s10549-017-4538-4. Epub 2017 Oct 13.
- 2017 Dhesy-Thind S, Fletcher G, Blanchette P, Clemons M, Dillmon M, Frank E, Gandhi S, Gupta S, **Mates M**, Moy B, Vandenberg T, and Van Poznak C. Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol* 2017 Jun 20; 35(18):2062-2081. doi: 10.1200/JCO.2016.70.7257.
- 2017 Chia S, Ellard S, **Mates M**; Welch S, Mihalciou C, Miller W, Gelmon K, Lohrisch C, Kumar V, Taylor S, Hagerman L, Goodwin R, Wang T, Sakashita S, Tsao M, Eisenhauer E, Bradbury P. A Phase 1 study of lapatinib in combination with foretinib, a c-MET, AXL and VEGFR inhibitor, in HER-2 positive metastatic breast cancer (MBC) – *Breast Cancer Research* (2017) 19:54-61 (DOI 10.1186/s13058-017-0836-3)
- 2016 Raphael M, Biagi J, Kong W, **Mates M**, Booth C, Mackillop W. The relationship between time to initiation of adjuvant chemotherapy and survival in breast cancer: A systematic review and meta-analysis. *Breast Cancer Res Treat.* 2016 Nov;160(1):17-28. doi: 10.1007/s10549-016-3960-3.
- 2015 Kamel D, Boag A, Bezjak A, **Mates M**. Prolonged progression free interval in a patient with locally recurrent small cell lung cancer presenting with cerebellar paraneoplastic syndrome. *Cancer Treatment Communications* 2015; 4:128-130
- 2015 Harrison L, Zhang-Salomons J, **Mates M**, Booth C, King W, MacKillop W. Comparing Effectiveness to Efficacy: Outcomes of Palliative Chemotherapy for Non-Small Cell Lung Cancer in Routine Practice – *Curr Oncol.* 2015 Jun;22(3):184-91
- 2015 Pittman N, Hopman W, **Mates M**. Emergency room visits and hospital admission rates after curative chemotherapy for breast cancer – *J Oncol Pract.* 2015 Mar;11(2):120-5
- 2015 **Mates M**, Fletcher GG, Freedman O, Eisen A, .Gandhi S, Trudeau M and Dent S. Systemic targeted therapy for HER2 positive early female breast cancer: A systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline – *Curr Oncol.* 2015 Mar;22 (Suppl 1):S114-22
- 2015 Gandhi S, Fletcher GG, Eisen A, **Mates M**, Freedman O, Dent S and Trudeau M. Adjuvant chemotherapy for early female breast cancer: A systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline – *Curr Oncol.* 2015 Mar;22 (Suppl 1):S82-94
- 2015 Freedman O, Fletcher GG, Gandhi S, **Mates M**, Dent S, Trudeau M and Eisen A. Adjuvant endocrine therapy for early breast cancer: A systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline *Curr Oncol.* 2015 Mar;22 (Suppl 1):S95-S113
- 2015 Eisen A, Fletcher GG, Gandhi S, **Mates M**, Freedman O, Dent S, Trudeau M and members of the Early Breast Cancer Systemic Therapy Consensus Panel. Optimal systemic therapy for early female breast cancer: A clinical practice guideline – *Curr Oncol.* 2015 Mar;22 (Suppl 1):S67-81
- 2014 Lawal S, Korenberg MJ, Pittman N, and **Mates M**. Predicting Neutropenia Risk in Breast Cancer Patients from Pre-Chemotherapy Characteristics – *The Open Bioinformatics Journal.* 2014; 8: 16-21

**PUBLICATIONS (CONT'D)**

- 2013 Feldman-Stewart D, Madarnas Y, Mates M, Tong C, Grunfeld E, Verma S, Carolan H, Brundage MD. Information for decision making by post-menopausal women with hormone receptor positive early-stage breast cancer considering adjuvant endocrine therapy. *Breast*. 2013 Oct;22(5):919-25
- 2013 Feldman-Stewart D, Madarnas Y, Mates M, Tong C, Grunfeld E, Verma S, Carolan H, Brundage MD. Information needs of post-menopausal women with hormone receptor positive early-stage breast cancer considering adjuvant endocrine therapy. *Patient Educ Couns*. 2013 Oct;93(1):114-21
- 2013 Altwaigi AK, Hopman WM, Mates M. Real-world impact of granulocyte-colony stimulating factor on febrile neutropenia. *Curr Oncol*. 2013 Jun; 20(3):e171-9
- 2011 Riolo G, Houlden R, **Mates M**. Adrenocorticotrophic Hormone-Secreting Small Cell Lung Cancer. *Canadian Journal of General Internal Medicine*. 2011;6(3):93-94.
- 2008 **Mates M**, Dudgeon D, Hookey L, Hurlbut D, Belliveau P, Booth C. Intractable Nausea in a Patient with Metastatic Colorectal Cancer Following Insertion of a Colonic Stent. *Journal of Pain and Symptom Management*. 2008; 36(1):e6-e10.
- 1999 Cucuianu A, Patiu M, Duma M, Basarab C, Soritau O, Bojan A, Vasilache A, **Mates M**, Petrov L. Hepatitis B and C Virus Infection in Romanian nonHodgkin's Lymphoma Patients. *British Journal of Hematology*. 1999;107(2):353-6.

POSTERS/ORAL PRESENTATIONS

- 2023 Igor Machado, Lucas Clemons, Carol Stober, Greg Pond, Arif Awan, Henry Conter, Demetrios Simos, Sukhbinder Dhesy-Thind, **Mihaela Mates**, Vikaash Kumar, John Hilton, Lisa Vandermeer, Mark Clemons; REaCT Investigators. A randomised trial comparing 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early breast cancer (REaCT-ZOL): Quality of life and toxicity outcomes. Poster presentation. San Antonio Breast Cancer Symposium December 2023.
- 2023 Catherine Doyle, Ana Elisa Lohmann, Nayyer Iqbal, Jan-Willem Henning, Swati Kulkarni, Nadia Califaretti, John Hilton, Cristiano Ferrario, Nathaniel Bouganim, **Mihaela Mates**, Stephanie Guillemette, Ricardo Leite, Stephen Chia. Impact of the introduction of CDK4/6 inhibitors on treatment duration in patients with HR+, HER2– advanced breast cancer: Final analysis of TreatER+ight, a Canadian prospective, real-world, observational study. Poster presentation. San Antonio Breast Cancer Symposium December 2023.
- 2022 Navdeep Dehar, Joseph Samuel, Wilma Hopman, **Mihaela Mates**. Outcomes Of Diagnostic Breast Imaging In Young Women (Less Than 50 Yearsold). Poster presentation. San Antonio Breast Cancer Symposium December 2022.
- 2022 Philippe Bedard, **Mihaela Mates**, John Hilton, Karen Gelmon, Amirrtha Srikanthan, Arif Awan, Xinni Song, Caroline A. Lohrisch, Andrew G. Robinson, Dongsheng Tu, David Cescon, Linda Hagerman, Siwei Zhang, Nancy Drummond-Ivars, Irene Li, Laleh Rastgou, Jackie Edwards, Mark Bray, Moira Rushton-Marovac and Pierre-Olivier Gaudreau. CCTG IND.236: A Phase 1b trial of combined CFI-402257 and weekly paclitaxel in patients with HER2-negative (HER2-) advanced breast cancer (aBC). Poster presentation. San Antonio Breast Cancer Symposium December 2022.
- 2021 **Mihaela Mates**, Philippe Bedard, John Hilton, Karen Gelmon, Amirrtha Srikanthan, Arif Awan, Xinni Song, Caroline A. Lohrisch, Andrew G. Robinson, Dongsheng Tu, David Cescon, Linda Hagerman, Siwei Zhang, Nancy Drummond-Ivars, Irene Li, Laleh Rastgou, Jackie Edwards, Mark Bray, Moira Rushton-Marovac and Pierre-Olivier Gaudreau. IND.236: A Canadian Cancer Trial Group (CCTG) Phase 1b trial of combined CFI-402257 and weekly paclitaxel (Px) in patients with HER2-negative (HER2-) advanced breast cancer (BC). Mini-oral presentation at ESMO TAT Virtual Congress March 2021.
- 2020 Natasha B. Leighl, Scott Andrew Laurie, Glenwood D. Goss, Brett Gordon Maxwell Hughes, Martin R. Stockler, Ming Sound Tsao, Swati Kulkarni, Normand Blais, Anil A. Joy, **Mihaela Mates**, Punam Rana, Sunil Yadav, Craig Underhill, Christopher W. Lee, Penelope Ann Bradbury, Andrea Hiltz, Janet Dancey, Keyue Ding, Francisco Emilio Vera Badillo. CCTG BR.34: A randomized trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic (Stage IV) squamous or non-squamous non-small cell lung cancer (NSCLC). Presented at the American Society of Clinical Oncology (ASCO) Annual Virtual Meeting June 2020
- 2020 Philippe L. Bedard, **Mihaela Mates**, Karen Gelmon, John Hilton, Dongsheng Tu, Irene Li, Laleh Rastgou, Nancy Drummond-Ivars, Jackie Edwards, David Warr, Caroline A. Lohrisch, Xinni Song, Amirrtha Srikanthan, Andrew Robinson, Linda Hagerman, Lesley Seymour, Moira Rushton, David Cescon. A Phase 1b trial of CFI-402257 in combination with weekly paclitaxel in patients with advanced HER2-negative breast cancer (CCTG IND.236). Presented at the ESMO TAT Virtual Conference March 2-4, 2020



POSTERS/ORAL PRESENTATIONS CONT'D

- 2019 Catherine Doyle, Nadia Califaretti, Cristiano Ferrario, Nayyer Iqbal, John Hilton, Ted Vandenberg, **Mihaela Mates**, Vivian Glenns, Swati Kulkarni, Puneet Bains, Sina Haftchenary, Sabrina R. Perri, Stephen Chia. Exploratory Analysis of TreatER+ight; A Canadian Prospective Real-World Observational Study in HR+ Advanced Breast Cancer. Poster Presentation SABCS 2019.
- 2019 R.A. Juergens, P.M. Ellis, D. Tu, D. Hao, S.A. Laurie, **M. Mates**, G. Goss, JR. Goffin, P. Bradbury, M. Tehfe, C. Kollmansberger, P. Brown-Walker, M. Smoragiewicz, M. Tsao, L. Seymour. Update on Platinum doublet + combination durvalumab +/- tremelimumab in advanced NSCLC: A CCTG phase IB study - IND.226 2019. Mini Oral Presentation at World Conference on Lung Cancer. Barcelona, Spain – September 2019.
- 2019 Mark Clemons, Carol Stober, **Mihaela Mates**, Anil Abraham Joy, Andrew Robinson, John Hilton, Phillip Blanchette, Olexiy Aseyev, Greg Pond, Dean Ferguson. A pragmatic, randomised, multicentre trial comparing 4-weekly versus 12-weekly administration of bone-targeted agents (denosumab, zoledronate or pamidronate) in patients with bone metastases. Poster Presentation at European Society of Medical Oncology (ESMO) Meeting, Barcelona, Spain – September 2019.
- 2019 Pharmacokinetic (PK) and updated survival data from the Canadian Cancer Trials Group IND.226 study of durvalumab ± tremelimumab in combination with platinum-doublet chemotherapy. Accepted as poster presentation (#4749) at ESMO 2019.
- 2019 R.A. Juergens, P.M. Ellis, D. Tu, D. Hao, S.A. Laurie, **M. Mates**, G. Goss, JR. Goffin, P. Bradbury, M. Tehfe, C. Kollmansberger, P. Brown-Walker, M. Smoragiewicz, M. Tsao, L. Seymour. Update on Platinum doublet + combination durvalumab +/- tremelimumab in advanced NSCLC: A CCTG phase IB study - IND.226 2019. Mini Oral Presentation at World Conference on Lung Cancer.
- 2019 Mark J. Clemons, Michael Ong, Carol Stober, D. Scott Ernst, Christopher M. Booth, Christina M. Canil, **Mihaela Mates**, Andrew George Robinson, Phillip S. Blanchette, Anil Abraham Joy, John Frederick Hilton, Olexiy Aseyev, Gregory Russell Pond, Brian Hutton, Sasha Mazzarello, Lisa Vandermeer, Dean Fergusson. A pragmatic, randomised, multicentre trial comparing 4-weekly versus 12-weekly administration of bone-targeted agents (denosumab, zoledronate or pamidronate) in patients with bone metastases from breast and prostate cancer. Abstract #11501 ASCO 2019 JCO 37, 2019 (suppl; abstr 11501)
- 2018 AA Joy, K Gelmon, **M Mates**, C Desbiens, M Clemons, S Taylor, J Lemieux, J Bartlett, T Whelan, JP Ayoub, D Cescon, L Bordeleau, Y Rahim, C Winch, BE Chen, WR Parulekar. Randomized Phase II Study Comparing Two Different Schedules of Palbociclib plus Second Line Endocrine Therapy in Women with Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer: CCTG MA38 (NCT02630693). Poster Presentation SABCS 2018.
- 2018 Catherine Doyle, Nadia Califaretti, Susan Dent, Nayyer Iqbal, **Mihaela Mates**, Swati Kulkarni, Puneet Bains, Vivian Glenns, Sabrina R Perri, Stephen Chia. Treat ER+ight Canadian Prospective Observational Study in HR+ Advanced Breast Cancer: 3rd Interim Analysis. Poster Presentation SABCS 2018 (P6-18-34).
- 2018 Neal Ready, Matthew D. Hellmann, Mark M. Awad, Gregory A. Otterson, Martin Gutierrez, Justin F. Gainor, Hossein Borghaei, Jacques Jolivet, Leora Horn, **Mihaela Mates**, Julie Brahmer, Ian Rabinowitz, Pavan S. Reddy, Jason Chesney, James Orcutt, David R. Spigel, Martin Reck, Kenneth John O'Byrne, Luis Paz-Ares, Wenhau Hu, Kim Zerba, Xuemei Li, Brian Lestini, William J. Geese, Joseph D. Szustakowski, George Green, Han Chang, Suresh S. Ramalingam. CheckMate 568: Efficacy and Safety of First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small Cell Lung Cancer and Assessment of Tumor Mutational Burden as a Biomarker. Presented at the American Association for Cancer Research Annual Meeting, Chicago, IL, April, 2018

POSTERS/ORAL PRESENTATIONS CONT'D

- 2018 Stone C, Robinson A, Brown E, **Mates M**, Falkson C, Owen T, Ashworth A, Mahmud A, Parker CM, Tomiak A, Thain SK, Greg R, Reid KR, Chung W, Digby GC. Assessing the Effects of a Multidisciplinary Lung Cancer Clinic on Timeliness of Lung Cancer Treatments and Staging Tests. Poster Presentation – International Forum on Quality & Safety in Healthcare, Amsterdam, Netherlands. May 2018.
- 2017 Nathalie Daaboul, Isabelle Gauthier, Dongsheng Tu, Pamela Brown-Walker, Xiaoqun Sun, Desiree Hao, Rosalyn A. Juergens, Penelope Ann Bradbury, **Mihaela Mates**, Mustapha Ali Tehfe, Christian K. Kollmannsberger, Peter Michael Ellis, Andrew George Robinson, Paul Wheatley-Price, Scott Andrew Laurie, Lesley Seymour. Immune related adverse events (irAE) with platinum chemotherapy (CT) with durvalumab (D) ± tremelimumab (T): CCTG IND226. Poster Presentation – 2017 ASCO Annual Meeting Jun 2 - 6, 2017 in Chicago, IL (J Clin Oncol 35, 2017 suppl; abstr 3058)
- 2017 Bernstein, V; Ellard, S; Dent, S; Gelmon, K; Dhesy-Thind, S; **Mates, M**; Salim, M; Panasci, L; Song, X; Clemons, M; Tu, D; Hagerman, L; Seymour, L. A randomized (RCT) phase II study of oncolytic reovirus (pelareorep ) plus standard weekly paclitaxel (P) as therapy for metastatic breast cancer (mBC). Poster Presentation – AACR Annual Meeting April 1-5, 2017 in Washington, DC (Abstract Number CT131)
- 2016 R.A. Juergens, D. Hao, S.A. Laurie, **M. Mates**, M. Tehfe, P. Bradbury, C. Kollmannsberger, P. Ellis, J. Hinton, P. Brown-Walker, L. Seymour. Cisplatin/Pemetrexed + Durvalumab +/- Tremelimumab in Pts with Advanced Non-Squamous NSCLC: A CCTG Phase IB Study - IND.226 *Mini Oral Presentation MA09.03* - 17th World Conference on Lung Cancer in Vienna, Austria, December 4-7, 2016
- 2016 D. Hao, R. Juergens, S. Laurie, **M. Mates**, M. Tehfe, P. Bradbury, C. Kollmannsberger, P. Ellis, J. Hilton, P. Brown-Walker, L. Seymour. A Canadian Cancer Trials Group phase IB study of durvalumab with or without tremelimumab + standard platinum-doublet chemotherapy in patients with advanced, incurable solid malignancies (IND.226). *Poster Presentation Abstract # 289* – 28th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, Munich, Germany, November 29 - Dec 2, 2016
- 2016 V. Lambert-Obry, A. Gouault-Laliberté, A. Castonguay, G.Zanotti, R. Banerjee, **M. Mates**, J. Lemieux, P. Chabot, C. Prady, F. Couture, J. Lachain. A real-world outcome research study on quality of life, work productivity and healthcare resource utilization in metastatic breast cancer for patients and caregivers. Presented at ISPOR 19th Annual European Congress, 29 October – 2 November, 2016, Austria Center Vienna, Vienna, Austria
- 2016 Kamel D, Hopman W, **Mates M**. Local practice and outcome of staging investigations in asymptomatic patients with early breast cancer. Poster and mini-oral presentation at the Canadian Medical Oncology (CAMO) meeting April 2016
- 2016 Shuo Xu, Alexander Boag, **Mihaela Mates**, Harriet Feilotter. Simultaneous Detection of Gene Rearrangements and Variants in Non-Small Cell Lung Cancer by Next-Generation Sequencing. Poster Presentation at the United States & Canadian Academy of Pathology's (USCAP) 105th Annual Meeting, March 2016 (Abstract #18245)
- 2016 Garth Andrew Nicholas, John R. Goffin, Scott Andrew Laurie, Andrew George Robinson, Glenwood D. Goss, M. Neil Reaume, **Mihaela Mates**, Paul Wheatley-Price, Peter Michael Ellis, Rosalyn A. Juergens, Anna T. Tomiak, Richard William Gregg, Barbara L. Melosky, Dongsheng Tu, Heather Ritter, Lesley Seymour, Penelope Ann Bradbury. A phase Ib study of selumetinib in patients (pts) with previously untreated metastatic NonSmall Cell Lung Cancer (NSCLC) receiving standard chemotherapy: NCIC Clinical Trials Group IND.215. NCT01783197. Poster Presentation ASCO 2015 (Abstract #150914)

**POSTERS/ORAL PRESENTATIONS CONT'D**

- 2016 Pitman N, Hopman W, Mates M. Emergency room visits and hospital admission rates after curative chemotherapy for breast cancer. A retrospective single centre experience. Poster Presentation at the San Antonio Breast Cancer Symposium December 2013.
- 2015 Chia S, Ellard S, **Mates M**, Welch S, Mihalciou CL, Miller WH, Gelmon KA, Lohrisch CA, Kumar V, Taylor SK, Hagerman L, Eisenhauer EA, Bradbury PA. A phase Ib study of an anti-HER2 inhibitor, lapatinib, in combination with a c-MET and VEGFR inhibitor, foretinib, in HER2-positive metastatic breast cancer (MBC): Results from NCIC CTG IND.198. Poster discussion session ASCO 2013.
- 2013 Al-Twaigi, A, Hopkins W, **Mates M**. Febrile neutropenia rate in patients with early breast cancer treated with modern adjuvant chemotherapy and primary granulocyte colony stimulating factor. Oral presentation at the Annual CAMO meeting, April 2012, Toronto.
- 2013 Feldman-Stewart D, Tong C, Madarnas Y, **Mates M**, TeBrake M, Brundage MD, Grunfeld E, Verma S. Decision support needs to be tailored to the individual patient: adjuvant endocrine therapy for post-menopausal women with receptor-positive early-stage breast cancer. Presented at 34th Annual meeting of the Society for Medical Decision Making, Oct 2012, Phoenix, Az.
- 2012 **Mates M**, Hopman W, Altwaigi A. Review of practice patterns of primary granulocyte-colony stimulating factor prophylaxis and impact on febrile neutropenia rate and chemotherapy delivery in patients with early breast cancer treated with modern adjuvant chemotherapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Abstracts. May 30, 2012:e19541
- 2011 A. Altwaigi, W. Hopman, **M. Mates**. Febrile neutropenia rate in patients with early breast cancer treated with modern adjuvant chemotherapy and primary granulocyte colony stimulating factor – Canadian Cancer Research Conference, Nov 2011.
- 2011 L. Harrison, J. Zhang-Salmons, **M. Mates**, W. J. Mackillop. Assessing the Effectiveness of Palliative Chemotherapy for Advanced Non-Small Cell Lung Cancer – Canadian Cancer Research Conference, Nov 2011.
- 2009 **Mates M**, Hopman W and Madarnas Y. Patterns of care and outcomes of locally advanced breast cancer at the Cancer Centre of Southeastern Ontario. Journal of Clinical Oncology, 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 27, No 15S (May 20 Supplement), 2009: e11614
- 2004 **Mates M**, Michalska H, Hasegawa W, Kiss T, Daly A, Loach D, Messner H, Lipton J. Once Daily Intravenous Busulfan as Part of a Busulfan / Cyclophosphamide Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation – Tandem Bone Marrow Transplant Meeting, Feb 2004 (Biology of Blood and Marrow Transplantation. 2004;10(2):36 Supplement 1)
- 2001 Michallet M, Le Q-H, **Mates M**, Berthaud P, Troncy J, Fiere D, Nicolini F. Impact of Interferon- $\alpha$  Therapy Duration and Chronic Myelogenous Leukemia (CML). History on Gleevec® (STI 571). Response in Interferon Resistant or Intolerant CML Patients in Chronic and Accelerated Phase. 43rd ASH Annual Meeting, Philadelphia

## GUIDELINE DEVELOPMENT

- 2016 Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline [www.asco.org/breast-cancer-adjuvant-bisphosphonates-guideline](http://www.asco.org/breast-cancer-adjuvant-bisphosphonates-guideline)
- 2015 Breast Cancer Pathway Map – Breast Cancer Well Follow-Up – Cancer Care Ontario <https://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=349003>
- 2014 Optimal Systemic Therapy for Early Female Breast Cancer - Cancer Care Ontario <https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=334827>
- 2011 Adjuvant Taxane Therapy for Women with Early-stage, Invasive Breast Cancer –Cancer Care Ontario <https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=34128>
- 2011 The role of Taxanes in Neoadjuvant Chemotherapy for Women with Non-metastatic Breast Cancer – Cancer Care Ontario <https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=13886>

## AWARDS

**Excellence in Teaching Award** – Department of Oncology, Queen’s University (2022)

**CCTG Phase 3 Program Team Award** – BRC.7 Team Cancer Centre of Southeastern Ontario (2021)

**Certificate of Merit** – Division of Medical Oncology. Outstanding CBME Supervisor Assessments (2020)

**Certificate of Recognition** University Hospitals Kingston Foundation – in recognition for making a difference in the care experienced at the Kingston Hospitals (2012, 2013, 2017, 2020, 2021, 2022, 2023, 2024)

**Excellence in Clinical Teaching Award** – Term 3 and 4, Queen’s University, Kingston (2011)

**TALEEN HADDAD, MD FRCPC**  
**Providence Care Hospital**  
**752 King Street West, Kingston, Ontario, K7L 4X3**  
**613 544 4900 ext. 53256**

**LANGUAGES:** Fluently trilingual in English, Arabic and Armenian  
Beginner level French, Spanish and Turkish

**EDUCATION:**

July 2018-June 2020 Geriatric Medicine Fellowship,  
University of Ottawa, Ottawa, Ontario, ON

July 2015-June 2018 Internal Medicine Core Residency,  
University of Ottawa, Ottawa, ON

Sep 2010-June 2015 MB BCh BAO,  
National University of Ireland, Galway, Ireland

Sep 2009-Apr 2010 MSc. in Human Kinetics,  
University of Ottawa, Ottawa, ON

Sep 2005-Jun 2009 Honours, Bachelor of Health Sciences,  
University of Ottawa, Ottawa, ON

**LISCENCING:**

September 2020 Royal College of Physicians and Surgeons of Canada Geriatric Medicine Exam

May 2019 Royal college of Physicians and Surgeons of Canada Internal Medicine Exam

May 2017 Medical Council of Canada Qualifying Exam Part 2

October 2015 Medical Council of Canada Qualifying Exam Part 1

September 2014 National Assessment Collaboration Examination

March 2014 Medical Council of Canada Evaluating Examination

**ACADEMIC APPOINTMENTS:**

**Providence Care Hospital**

July 2020-Present	Assistant Professor, Queen's University, Kingston, Ontario
Sept 2024-Present	Associate Researcher Appointment, PCH, Kingston, Ontario

**LEADERSHIP ROLES:**

July 2024-Present President MSA Providence Care Hospital

July 2021-June 2024 Vice President MSA Providence Care Hospital

**EDUCATION ROLES:**

September 2020-Present Academic Advisor, Internal Medicine Program

Sept 2022-Jan 2025 Geriatric Medicine Undergraduate Program Coordinator

July 2020-Present Academic Half Day Tutor, Postgraduate Medical Education

July 2020-Present Clinical skills and Consolidation Tutor, Undergraduate Medical Education

**COMMITTEES:**

Active Member, Physician Community for Equity & Inclusion, January 2021-Present

Non-voting Member, Medical Advisory Committee, July 2021-Present

**ORAL PRESENTATIONS:**

February 2025 Approach to Pain in Older Adults (brainXchange webinar)

October 2024 Approach to Pain in Older Adults (BSO learning day, Kingston)

September 2024 UHKF Talks With Docs: Brain Health (Bath, Ontario)

November 2023 St. Mark's Seniors Group: Guidance for Healthy Aging (East Kingston)

November 2023 UHKF Talks With Docs: Secrets to Healthy Aging (Amherstview, Ontario)

November 2023 Department of Medicine Morbidity and Mortality Rounds

October 2023 Circle of Care donor luncheon: The Golden Years (Central Kingston)

October 2023 Aging Well Together Series TV Interview on Vaccination and Polypharmacy

Jun 2022 Debunking Myths about Frailty  
2022 Annual CME DOM Day, Kingston, Ontario

Feb 2022 An approach to Geriatric Patient,  
Perioperative Medicine Rounds, Kingston, Ontario

Sept 2021 An Approach to Ortho-Geriatrics,  
Orthopedic Surgery Rounds, Kingston, Ontario

Sept 2021 Physiology of Aging,  
Geriatric Psychiatry Rounds, Kingston, Ontario

Sept 2020 Top 10 Landmark Articles in Geriatric Medicine,  
University of Ottawa's Geriatric Medicine Grand Rounds, Ottawa, Ontario

Oct 2020 An Approach to Cognition,  
University of Ottawa's Division of Geriatric Medicine Rounds, Division of  
Geriatric Medicine, Ottawa, Ontario

Dec 2018 The Role of ECT in the Treatment for Depression in the Elderly  
The Geriatric Grand Rounds, University of Ottawa

May 2018 Landmark Trials: Haldol Versus Placebo for Delirium Prevention  
University of Ottawa Internal Medicine Residency Program

Jan 2018 ID City Wide Rounds-A Case of IVDU and Infective Endocarditis  
The Ottawa Hospital, Division of Infectious Diseases

Feb 2018 ID City Wide Rounds-Finegoldia as A Pathogen in Prosthetic Joints  
The Ottawa Hospital, Division of Infectious Diseases

Apr 2017 Geriatrics Rotation Formal Oral Presentation, Falls in the Elderly  
University of Ottawa

Oct 2017 Reducing Post-Discharge Potentially Inappropriate Medications Amongst  
The Ottawa Hospital, The Ottawa Hospital Patient Safety Conference

Oct 2017 Morbidity and Mortality Rounds,  
The Ottawa Hospital

Jan 2016 Endocrinology Journal Club,  
The Ottawa Hospital

Nov 2015 Geriatrics Rotation Formal Oral Presentation, Dizziness in the Elderly

## **RESEARCH EXPERIENCE:**

Sept 2024-Present Co-Principal Investigator SWAY Music and Movement Program  
Queen's University, DAN school of Drama and Music

May 2023-Present Co-Principal Investigator Geriatric-Surgical Oncology Program  
KHSC, Kingston, Ontario

July 2023-July 2024 Co-Author of Frailty Assessments in Cardiac Surgery Book Chapter  
Dr. Habib Jabagi, Mount Sinai University & Valley Healthcare  
Dr. Louise Sun, Stanford University

March 2020-2022 Research collaborator, Frailty Focused Care at TOH-Development, evaluation and Implementation of an Online Frailty Assessment Module to Support Frailty Focused Care  
The Ottawa Hospital, Dr. Daniel McIssac

September 2016-2022 Research Assistant, Potentially Inappropriate Medications (PIMs) Hiding in plain sight? A Survey of learners and internists on CTU.  
University of Ottawa, Dr. K. Klair, Dr. A. Huang

September 2016-2022 Research Collaborator, Medsafer Project: Deprescribing in the elderly University of Ottawa, Dr. A. Forrester, Dr. A. Huang

Sep 2013-May 2015 Research Assistant, Breast Radiotherapy Department, Study Assessing the Feasibility of APBI in Early Breast Cancers,  
University College Hospital, Galway, Ireland, Dr. J. Martin

Jun 2013-Aug 2013 Research Assistant, CT Coronary Imaging Study,  
University of Ottawa Heart Institute Ottawa, ON, Dr. Benjamin Chow

Jun 2012-Jul 2012 Research Assistant, EnRich Resilience and High Risk Populations, University of Ottawa, Ottawa, ON, Dr. Tracey O'Sullivan

Jan 2010-Mar 2010 Research Assistant, Study: Environmental Scan and Analysis of Canadian and International Emergency Preparedness Programs for Vulnerable Groups,  
University of Ottawa, Ottawa, ON, Dr. Tracey O'Sullivan

May 2008-Sep 2010 Research Assistant, Study: Enhancing Quality of Life Following Stroke: Coping Strategies Utilized by Family Caregivers to Protect their Well-being,  
University of Ottawa, Ottawa, ON, Dr. Tracey O'Sullivan

Sep 2009-Apr 2010 Research Assistant, Study: Underlying CAD and Sudden Cardiac Events Among Male, Recreational Hockey Players.  
University of Ottawa's Heart Institute, Ottawa, ON, Dr. Robert Reid

May 2007-Aug 2007 Research Assistant, Cardiovascular Genetics Laboratory  
University of Ottawa's Heart Institute, Ottawa, ON, Dr. Michael Gollob

## **PUBLICATIONS:**

Jabagi, H., Sun, L., Haddad, T et al. Multidimensional Frailty Instruments for Cardiac Surgery. Recent Strategies in High Risk Surgery. E-book chapter pp. 629-649, July 2024.

Haddad, Taleen et al. Development and Evaluation of an Evidence-Based Theory-Grounded Online Clinical Frailty Scale Tutorial, February 2022 Age and Aging.

McDonald, Emily, Haddad, Taleen et al. The MedSafer Study: A Cluster Randomized Controlled Trial of Electronic Decision Support for Deprescribing in Hospitalized Older Adults. JAMA Internal Medicine, January 2022.

Geary, R., Haddad, T. et al. A Prospective feasibility Study of MammoSite Accelerated Partial Breast



Irradiation for Early Breast Cancer. Irish Journal of Medical Science, January 2020.

Molnar, F., Haddad, T., Dyks, D, Farrell, B. Problem-Based Deprescribing: A Practical Patient- Centered Approach to Promoting the Use of Existing Deprescribing Resources in Frontline Care. CGS Journal of CME, October 2018.

Huang, W, Haddad, T, Hasimja, D. A Perplexing Case of the Pituitary Apoplexy. Canadian Journal of General Internal Medicine. Volume 12, No. 4 (2018).

Premaratne, M, Mason, M, Hossain, A, Haddad, T, Chow, H. Chow, Benjamin. Canceled coronary computed tomography angiography: Downstream testing and outcomes. International Journal of Cardiology 227 (2017) 457–461.

Ng, B., MacPherson, P., Haddad, T. Heart Failure in HIV infection: focus on the role of atherosclerosis. Current Opinion in Cardiology, March 2014. 29(2), 174-179.

Sadek, M., Haddad, T., Haddad, H. The Role of Statins in Heart Failure. Current Opinion in Cardiology, March 2009. 24(2), 167-171.

#### **PEER-REVIEWED RESEARCH POSTERS:**

June 2017 Prescribing After Beers. How well are we doing? Haddad, Taleen, Huang, A. Annual Combined City Geriatric Resident Research Day, Ingersoll, ON  
*Oral and Poster Presentation*

June 2017 Prescribing After Beers. How well are we doing? Haddad, Taleen, Huang, A. University of Ottawa Annual Resident Research Day, Ottawa, ON

April 2017 Prescribing After Beers. How well are we doing? Haddad, Taleen, Huang, A. Canadian Geriatrics Society, Annual Meeting, Toronto, ON

Oct 2009 ‘Never thought of it as a job I’d do... Gender and Caregiving at Home After Stroke.’ University of Toronto Women’s Mental Health in Ontario Conference, Toronto,

Mar 2009 ‘Deadly Duo: Examining the Effects of Metabolic Syndrome on Coronary Heart Disease.’ University of Ottawa’s General Hospital, Ottawa, ON

May 2009 ‘Risky Business: Canadian Women and Heart Disease.’ University of Ottawa Women’s Health Research Day, Ottawa, ON

#### **CONTINUING MEDICAL EDUCATION:**

Mission Leadership Course September 2024-June 2025, Mississauga, Ontario

June 2024 Harvard University, Dementia Review Course, virtual attendee

October 2023 Dermatology full day Update and Procedural Skills

April 2022 Canadian Geriatric's Society Review Course, attended virtually

March 2020 Harvard University, Geriatrics Review Course, Boston, Massachusetts

January 2020 University of Ottawa Quality Improvement Research Day

May 2019 Geriatric Refresher Day, Ottawa, Ontario

Jan 2018, 2019 Internal Medicine Review Course, Toronto, Ontario

Apr 2017 & Apr 2018 Canadian Geriatric Society Annual Conference

Oct 2017 University of Ottawa, Patient Safety Conference

March 2016 McMaster University Review Course in Internal Medicine

Jun 2013 Primary Updates in Care, Ottawa, Ontario

May 2011 Best Practices in Diagnosis and Management of CHF, Carleton Place, ON

#### **AWARDS AND HONORS:**

December 2024: Nomination, DoM Young Clinician Award

Apr 2012-Apr 2015 National University of Ireland Presidential Award for Volunteering Certificate

**Christopher M. Booth MD FRCPC FCAHS**

Queen's University Cancer Research Institute  
Division of Cancer Care and Epidemiology  
10 Stuart Street, Kingston, Ontario, K7L 3N6  
Phone: 613-549-6666 x 4501  
Email: [booth@queensu.ca](mailto:booth@queensu.ca)

**CURRENT AND PAST APPOINTMENTS**

2022-Present Fellow, Canadian Academy of Health Sciences  
2021-Present Director, Division of Cancer Care and Epidemiology,  
Queen's Cancer Research Institute  
2021-Present Research Director, Queen's Global Oncology Program  
2020-Present Honorary Consultant (Research), Pallium India  
2017-Present Professor, Department of Oncology, Queen's University  
Cross-appointed to Departments of Medicine and Public Health Sciences  
2016-Present Special Advisor (Health Services Research), National Cancer Grid of India  
2014-Present Canada Research Chair in Population Cancer Care  
2008-Present Clinician-Scientist, Queen's University Cancer Research Institute  
2006-Present Attending Medical Oncologist, Kingston Health Sciences Centre  
2018-2021 Senior Adjunct Scientist, Institute for Clinical Evaluative Sciences  
2009-2018 Adjunct Scientist, Institute for Clinical Evaluative Sciences  
2013-2017 Associate Professor, Department of Oncology, Queen's University  
Cross-appointed to Departments of Medicine and Public Health Sciences  
2015-2016 Visiting Scientist, Regional Cancer Centre, Trivandrum, India  
2008-2013 Cancer Care Ontario Chair in Health Services Research  
2006-2013 Assistant Professor, Department of Oncology, Queen's University

**EDUCATION AND TRAINING**

2006-2008 Research Fellow, NCIC Clinical Trials Group, Queen's Cancer Research Institute  
2004-2006 Resident in Medical Oncology, University of Toronto  
2001-2004 Resident in Internal Medicine, University of Toronto  
1997-2001 Doctor of Medicine, Queen's University  
1994-1997 Bachelor of Science with Distinction (Biology), Queen's University

**PROFESSIONAL AND ADMINISTRATIVE ACTIVITIES**

**International**

2024-Present Lancet Oncology International Advisory Board  
2024-Present American Society of Clinical Oncology, Evidence-Based Medicine Committee  
2024-Present Association of American Cancer Institutes, Global Oncology Working Group

## Christopher Booth CV

2023-Present Journal of Clinical Oncology, Editorial Board

2023-Present Journal of the National Cancer Institute, Editorial Board

2022-Present World Health Organization, Drug Evaluation Panel, Expert Advisor

2021-Present eCancer, Editorial Board

2021-Present Queen's Global Oncology Masterclass in Critical Appraisal, Faculty and Lecturer

2020-Present National Cancer Grid of India, External Reviewer (Annual Operating Grant)

2020-Present Current Oncology, Editorial Board

2019-Present Indian Journal of Surgical Oncology, Editorial Board

2018-Present Nature Reviews Clinical Oncology, Editorial Board

2018-Present World Health Organization Essential Medicines List Cancer Medicines Working Group, Member

2017-Present CReDO Workshop (International Collaboration for Research Methods Development in Oncology Workshop), annual week-long course, Faculty Member, Mumbai, India.

2017-Present Journal of Cancer Policy, Editorial Board Member

2009-Present International Study Co-Chair, NCIC CTG CO21, A phase III study of the impact of a physical activity program on disease-free survival in patients with high risk stage II or stage III colon cancer.

2022-2024 European Society of Medical Oncology, Real World Data Working Group

2019-2024 Choosing Wisely Africa, Member of Steering Committee

2023 Tata Memorial Hospital (Mumbai) International Peer Review, Committee Member

2022 University of Sydney, Department of Epidemiology, External Examiner (PhD)

2022 University of Otago (New Zealand), External Reviewer, Promotions Committee

2021 University of Sydney, Department of Epidemiology, External Examiner (PhD)

2021-2022 New Zealand Cancer Control Agency, Cancer Medicine Availability Working Group

2021 Memorial Sloan Kettering Cancer Centre, External Reviewer, Promotion Committee

2021 Ministry of Science and Technology, India, External Reviewer (Operating Grant)

## Christopher Booth CV

2020-2022	Union for International Cancer Control (UICC), Cancer and COVID19, Global Taskforce Member
2017-2020	Choosing Wisely India, Co-Chair of Steering Committee
2019-2020	AACR India Regional Advisory Working Group, Member
2016-2020	International Cancer Benchmarking Partnership, Clinical Committee Member
2019	UK Medical Research Council (MRC), External Grant Reviewer
2019	University of Sydney, Department of Epidemiology, External Examiner (PhD)
2018	ACORD Workshop (Australia and Asia Pacific Clinical Oncology Research Development Initiative), Faculty Member, Sydney, Australia
2018	University of Wisconsin, Department of Medicine, Promotions External Reviewer
2018	UK Wellcome Trust India Alliance, External Grant Reviewer
2018	World Health Organization, Essential Cancer Medicines, Working Group Member and Speaker, Geneva, Switzerland
2018	University of Sydney, Department of Epidemiology, External Examiner (PhD)
2017	World Oncology Forum 2017 Panelist and Discussant, Lugano, Switzerland
2017	Tata Memorial Centre/King's College London Oncology Summer School, Visiting Faculty and Lecturer, Mumbai, India
2017	National Cancer Grid of India, External Reviewer (Operating Grant)
2016	ACORD Workshop (Australia and Asia Pacific Clinical Oncology Research Development Initiative), Faculty Member, Sydney, Australia
2016	Tata Memorial Cancer Hospital, External Review Panel Member, Mumbai, India
2010-Present	Ad Hoc Journal External Reviewer: Lancet JAMA British Medical Journal Lancet Oncology Journal of Clinical Oncology Journal of the National Cancer Institute Nature Reviews Clin Oncol Annals of Internal Medicine British Medical Journal Open

## Christopher Booth CV

European Journal of Cancer  
British Journal of Cancer  
British Journal of Surgery  
Annals of Oncology  
CMAJ  
JAMA Network Open  
Johns Hopkins University Press (Book Review)  
Journal of Oncology Practice  
Cancer Care Ontario Program in Evidence-Based Care  
PLOS ONE  
CMAJ Open  
Journal of the National Comprehensive Cancer Network (JNCCN)  
Mayo Clinic Proceedings  
Journal of Global Oncology  
ESMO Open  
Hepato-Pancreato-Biliary Journal (HPB)  
Current Oncology  
The Oncologist  
International Journal of Radiation Oncology, Biology, and Physics  
Clinical Trials  
International Journal of Cancer  
Cancer Treatment Reviews  
European Journal of Clinical Investigation  
Asia Pacific Journal of Cancer Prevention  
Journal of Pain & Symptom Management  
European Journal of Cancer Care  
Canadian Urological Association Journal  
Journal of the National Cancer Institute – Cancer Spectrum  
Medical Journal of Australia  
Health Affairs  
Journal of Cancer Policy  
Clinical Colorectal Cancer  
Clinical Oncology  
Cancer Epidemiology  
eClinical Medicine  
Clinical Advances in Hematology & Oncology  
Neurogastroenterology and Motility

- |      |  |
|------|--|
| 2015 | Dutch Cancer Society, External Reviewer (Operating Grant)  |
| 2015 | Global Task Force on Radiotherapy for Cancer Control Meeting, Panel member, Toronto, Canada.         |
| 2015 | National Health and Medical Research Council (NHMRC, Australia), External Reviewer (Operating Grant) |
| 2015 | University of Toronto, External Reviewer, Department of Medicine Promotions Committee                |

## Christopher Booth CV

2014-2016	American Society of Clinical Oncology Bladder Cancer Guideline, Expert Panel
2014	World Oncology Forum 2014 Task Force Member, Lugano, Switzerland
2009-2011	American Society of Clinical Oncology Cancer Education Committee

### **National**

2021-2024	Choosing Wisely Canada (Oncology), Co-Chair
2023	McGill University, Department of Oncology, External Grant Reviewer
2023	UBC, Department of Medicine Promotions, External Reviewer
2020	Canadian Global Oncology Workshop, Planning Committee
2017-2020	CIHR College of Reviewers
2019	Department of Medicine, Dalhousie University, External Reviewer (Promotions)
2019	CIHR, Health Research Training Award Peer Review Committee
2017	Health Quality Ontario Symposium, Panelist
2017	CIHR Early Career Investigator Award Peer Review Committee
2017	University of Toronto, MSc External Examiner, Institute of Medical Science
2017	Canadian Colorectal Cancer Sidedness Consensus Meeting, Invited Participant
2016	University of Toronto, External Reviewer, Department of Medicine Promotions Committee
2013-2015	pan-Canadian Oncology Drug Review, Clinical Guidance Panel
2013-2015	Choosing Wisely Canada Cancer Initiative, Advisory Panel
2014	Bladder Cancer Canada-Canadian Urological Association Bladder Cancer Quality of Care Consensus Meeting, Moderator, Montreal, Canada
2013-2014	Canadian Partnership Against Cancer, Diagnosis and Clinical Care Advisory Committee
2013-2014	Canadian Partnership Against Cancer, Chemotherapy Wait Times Clinical Advisory Panel

## Christopher Booth CV

2010-2011 CIHR Health Services Research Peer Review Committee

### **Provincial/Cancer Care Ontario**

2023-2024 Cancer Care Ontario Ontario GI Cancer Advisory Committee

2018-2020 Institute for Clinical Evaluative Sciences (ICES) Faculty Advisory Committee

2016-2019 Cancer Care Ontario Genitourinary Cancers Advisory Committee

2015-2016 Cancer Care Ontario Bladder Cancer Pathway, Working Group Member

2014-2015 Cancer Care Ontario Prostate Cancer Treatment Pathway Working Group

2014-2015 Cancer Care Ontario Systemic Treatment Funding Model Evaluation Subgroup

2013-2015 Cancer Care Ontario Program in Evidence-Based Care, Exercise in Cancer Working Group

2008-2012 Cancer Care Ontario Systemic Therapy Data Analysis Working Group

### **Queen's University**

2021-Present PhD Thesis Committee Member (Public Health Sciences), Matt Jalink

2018-Present Systemic Therapy Lead, Gastrointestinal Cancer Disease Site, Cancer Centre of Southeastern Ontario

2018-Present Department of Urology, Queen's University, Promotions Review Committee

2017-Present Chair, Queen's University Department of Oncology Research Advisory Committee

2011-Present Guest lecturer, Queen's University Department of Public Health Sciences (EPID 301 and 817, 2 seminars per year)

2010-Present External Examiner (1-2 MSc/year), Graduate Program in Epidemiology, Queen's University

2024 Principal's Advisory Committee, Selection of the Dean, Faculty of Health Sciences

2023-2024 Department of Oncology Headship Search Committee

2022 Queen's University Division of Medical Oncology, Search Committee

2022 Queen's Health Sciences CTAQ Chair in Health Policy and Economics, Search Committee

2022 Queen's University Division of Radiation Oncology, Search Committee



## Christopher Booth CV

2019-2020	Queen's University Department of Public Health Sciences, Headship Search Committee
2019-2020	Queen's University Faculty of Health Sciences, Global Health Advisory Committee
2019-2020	Queen's University, Division of Neurosurgery, Department of Surgery, Search Committee.
2021	Principal's Strategy (Global) Working Group, Committee, Queen's University
2020	Faculty of Health Sciences, Queen's University, Internal Research Competition, Grant Reviewer
2020	Faculty of Health Sciences, Queen's University, Internal Research Competition, Grant Reviewer
2020	Queen's University Office of Research, Catalyst Fund, Grant Reviewer
2019	Department of Public Health Sciences MSc (Epidemiology) Thesis Proposal Reviewer (Candidate Tori Barabash)
2019	Queen's University, Division of General Internal Medicine, Department of Medicine, Search Committee
2019	Queen's University Canada Research Chair Internal Review Committee
2018-2019	Queen's University Department of Surgery Research Advisory Committee
2013-2018	PhD Thesis Committee Member (Epidemiology), Lyndsay Harrison
2016-2018	Queen's University Department of Oncology Headship Search Committee
2013-2018	Systemic Therapy Lead, Genitourinary Cancer Disease Site, Cancer Centre of Southeastern Ontario
2018	Kingston Health Sciences Centre Research Grant Competition, Reviewer
2017	Queen's University SEAMO Innovation Fund Grant Review Committee
2012-2017	Member, Queen's University Department of Oncology Research Advisory Committee
2016	Queen's University Division of Nephrology, Search Committee
2016	Institute of Clinical Evaluative Sciences (ICES) Site Review, Panel Member
2014-2015	Queen's University Department of Surgery, Surgical Oncologist, Search Committee

## Christopher Booth CV

2012-2015	Queen's University SEAMO Innovation Fund Grant Review Committee
2014	Queen's Cancer Research Institute Director, Search Committee
2014	Queen's University Faculty of Health Sciences Task Force on Health Services, Policy and Population Health Research
2014	Queen's University Faculty of Health Sciences Research Grant Reviewer
2013	Interim Co-Director of Cancer Clinical Trials, Kingston General Hospital
2013	Queen's University Department of Medicine Research Grant Competition Panel
2011-2013	Kingston General Hospital Research Institute Steering Committee
2010-2012	MSc Thesis Co-supervisor (Epidemiology), David Wallace, Queen's University
2009-2013	Queen's Transdisciplinary Cancer Research Rounds Organizing Committee
2011-2012	Faculty Preceptor, Critical Enquiry MEDS 232 Course, Queen's University
2007-2009	Cancer Centre of Southeastern Ontario Oncology Drug Working Group
2007-2009	Queen's University Medical Oncology Training Program Committee

## HONOURS AND AWARDS

2022	Elected as Fellow of the Canadian Academy of Health Sciences
2022	Exceptional Healer Award, Kingston Health Sciences Centre (KHSC) Awarded annually to one physician at KHSC who embodies compassion, respect, and clinical excellence.
2021	Most widely cited paper Nature Reviews Clinical Oncology (impact factor 53) 2021 "Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic" 25K accesses, 190 citations, 280 Altmetric
2017	Nominated for Mentor of the Year Award Royal College of Physicians and Surgeons of Canada, Ottawa, ON
2016	Nominated for Ron Wigle Mentorship Award Faculty of Health Sciences, Queen's University, Kingston, ON
2016	Distinguished Preceptor Award (Excellence in Teaching) Department of Family Medicine, Queen's University, Kingston, ON

## Christopher Booth CV

- 2015 Nominated for Canadian Association for Medical Education Teaching Award  
Canadian Association for Medical Education, Toronto, ON
- 2015 Nominated for the PARO Excellence in Clinical Teaching Award,  
Professional Association of Residents of Ontario, Toronto, ON
- 2015 Nominated for the Dr. John T. Tweddell Award Clinical Teaching Award,  
Department of Family Medicine, Queen's University, Kingston, ON
- 2013 Mihran and Mary Basmajian Award for Excellence in Health Research,  
Faculty of Health Sciences, Queen's University, Kingston, ON
- 2012 Nominated for the Clinical Teaching Award in Undergraduate Education,  
Department of Medicine, Queen's University, Kingston, ON
- 2008 ASCO Merit Award, ASCO 2008, Chicago, IL
- 2007 ASCO Merit Award, ASCO 2007, Chicago, IL
- 2007 Novartis Oncology Young Canadian Investigator Award, ASCO 2007, Chicago, IL
- 2006 San Antonio Breast Cancer Symposium Scholars Award, San Antonio, TX
- 2006 Novartis Oncology Young Canadian Investigator Award, ASCO 2006, Atlanta, GA
- 2006 MASCC Symposium Young Investigator Award, Toronto, ON
- 2006 University of Toronto Medical Oncology Resident Research Award, Toronto, ON
- 2005 ASCO/AACR Vail Workshop in Clinical Trial Design Scholarship, Vail, CO
- 2005 AMGEN ASCO Fellows Alliance Scholarship, ASCO 2005, Orlando, FL
- 2004 Murray Muirhead House Staff Award (for academic excellence and humanity in the  
practice of medicine), St. Michael's Hospital, Toronto, ON
- 2003 Canadian Society for Clinical Investigation Resident Research Award, Halifax, NS
- 2003 Charles Hollenberg Research Competition Prize, Mt Sinai Hospital, Toronto, ON
- 2002 Murray Muirhead House Staff Award (for academic excellence and humanity in the  
practice of medicine), St. Michael's Hospital, Toronto, ON
- 2001 Canadian Association of Gastroenterology Student Scholarship, Banff, AB
- 2001 Virginia Parker Prize in Psychiatry, School of Medicine, Queen's University

2000	Margaret Pratt Berkeley Scholarship, School of Medicine, Queen's University
2000	Aesculapian Society Award of Merit, School of Medicine, Queen's University
1998	Dr. Isaac Sutton Prize, School of Medicine, Queen's University
1995-1999	Academic All-Canadian Varsity Athlete (Cross-Country Running & Track and Field)

## PUBLISHED PAPERS

**Total publications:** 404

**Total publications as first author:** 56

**Total publications as senior author:** 177

**Total citations (Google Scholar):** 21076

**h-index (Google Scholar):** 65

404. Galica J, Alsius A, Walker L, Stark D, Noor H, Kain D, **Booth C**, Wickenden A. Returning to work after cancer treatment: An exploratory sequential mixed method study guided by Transitions Theory. Cancer Nursing 2024: In Press.

403. Patel SV, McKechnie T, McClintock C, Kong W, Bankhead C, Merchant SJ, **Booth CM**, Heneghan C, Farooq A. An assessment of Cancer Centre Level Designation and guideline adherent care in those with rectal cancer: A population based retrospective cohort study. J Cancer Policy 2024; 42:100510.

402. Gupta A, Brundage MD, Galica J, Karim S, Koven R, Ng TL, O'Donnell J, tenHove J, Robinson A, **Booth CM**. Patients' considerations of time toxicity when assessing cancer treatments with marginal benefit. The Oncologist. 2024; 29(11):978-985.

401. Moraes FY, Gouveia AG, Bratti VF, Dee EC, Pavoni JF, Carson LM, de Sousa CFPM, Sullivan R, Hopman WM, **Booth CM**, Aggarwal A, Jemal A, Hanna TP, Wilson BE, Viani GA. Assessing Global LINAC Requirements: A Cross-sectional Population-Based Study and Personalized Country Recommendations. Lancet Oncology 2024: In Press.

400. Courneya KS, McNeely ML, **Booth CM**, Friedenreich CM. An Integrated Framework for the Study of Exercise Across the Postdiagnosis Cancer Continuum. Frontiers in Oncology 2024; 14:1432899.

399. Gupta A, Johnson WV, Henderosn NL, Ogunleye OO, Sekar P, George M, Breininger A, **Booth CM**, Hanna TP, Rocque GB, Parsons HM, Vogel RI, BVlaes AH. Patient, Caregiver & Clinician Perspectives on the Time Toxicity of Cancer Care: A Qualitative Analysis. JAMA Network Open 2024; 7(11):e2447649.

398. Banerjee S, **Booth CM**, Bruera E, Büchler MW, Drilon A, Fry TJ, Ghobrial IM, Gianni L, Jain RK, Kroemer G, Llovet JM, Long GV, Pantel K, Pritchard-Jones K, Scher HI, Tabernero J,

Weichselbaum RR, Weller M, Wu YL. Two decades of advances in clinical oncology - lessons learned and future directions. *Nat Rev Clin Oncol* 2024; 21(11):771-780.

397. Gyawali B, Eisenhauer EA, van der Graaf W, **Booth CM**, Cherny NI, Goodman AM, Koven R, Pe ML, Marini BL, Mohyuddin GR, Pond GR, Sengar M, Soto-Perez-de-Celis E, Trapani D, Tregear M, Wilson BE, and Tannock IF. Common Sense Oncology Principles for the Design, Analysis and Reporting of Phase III Randomised Clinical Trials. *Lancet Oncol*. 2024: In Press.

396. Wilson BE, Wright K, Koven R, **Booth CM**. Surveillance Imaging After Curative Intent Treatment for Cancer: Benefits, Harms, and Evidence. *J Clin Oncol* 2024; 42(19): 2245-2249.

395. Wilson BE, Eisenhauer EA, **Booth CM**. Study Participants, Future Patients, and Outcomes That Matter in Cancer Clinical Trials. *JAMA* 2024; 331(24): 2081-2083.

394. Panicker P, Iype T, Appireddy R, Ajithan A, Lijimal AS, Sasikumar A, Dileep R, Vijaya N, **Booth C**, Rajagopal MR. Palliative care needs of stroke patients at a tertiary care center in South India. *J Neurosciences in Rural Practice*. 2024; 15(2): 349-356.

393. Gupta A, O'Callaghan CJ, Zhu L, Jonker DJ, Wong RPW, Colwell B, Moore MJ, Karapetis CS, Tebbutt NC, Shapiro JD, Tu D, **Booth CM**. The Association of Healthcare Contact Days with Physical Function and Survival in CCTG/AGITG CO.17. *J National Cancer Institute* 2024; 116(8): 1313-1318.

392. Wilson BE, Sengar M, Tregear M, van der Graaf W, Battisti NML, Csaba DL, Soto-Perez de-Celis E, Gyawali B, **Booth CM**. Common Sense Oncology: Equity, Value, and Outcomes That Matter. *ASCO Educational Book* 2024; 44(3); e100039.

391. Dee EC, Pramesh CS, **Booth CM**, Rubagumya F, Mutebi M, Feliciano EJ, Eala MAB, Cerri GG, Ginsburg P, Gyawli B, Moraes F. Growing the Global Cancer Care System: success stories from around the world and lessons for the future. *J Natl Cancer Institute* 2024; 116(8): 1193-1197.

390. Iqbal J, Moineddin R, Fowler RA, Krzyzanowska MK, **Booth CM**, Downar J, Lau J, Le LW, Rodin G, Seow H, Tanuseputro P, Earle CC, Quinn KL, Hannon B, Zimmermann C. Socioeconomic Status, Palliative Care, and Death at Home Among Patients With Cancer Before and During COVID-19. *JAMA Netw Open*; 2024; 7(2):e240503.

389. Moffat GT, Kong W, MacKay HJ, McGee J, **Booth CM**, Ethier JL. Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian Cancer. *Gyne Oncol* 2024; 184:51-56.

388. Del Paggio JC, Naipaul R, Gavura S, Mercer R, Koven R, Gyawali B, Wilson BE, **Booth CM**. Cost and Value of Cancer Medicines Delivered in a Single-Payer Health System: A Cross-Sectional Study from Ontario, Canada. *Lancet Oncol* 2024; 25(4):431-438.

387. Kagalwalla S, Tsai AK, George M, Waldock A, Davis S, Jewett P, Vogel RI, Ganguli I, **Booth C**, Dusetzina SB, Rocque GB, Blaes AH, Gupta A. Consuming Patients' Days: Time Spent on Ambulatory Appointments by People with Cancer. *The Oncologist* 2024; 29(5): 400-406.

386. Sanford NN, Lievens Y, Aggarwal A, Hanna TP, Dawson LA, White J, Gyawali B, **Booth C**, de Moraes FY. Common Sense (Radiation) Oncology: Redefining targets in radiotherapy. *Radiother Oncol* 2024; 3:193:110118
385. Gupta A, Nguyen P, Kain D, Robinson AG, Kulkarni AA, Johnson DH, Presley CJ, Blaes AH, Rocque GB, Ganguli I, **Booth CM**, Hanna TP. Trajectories of Healthcare Contact Days for Patients With Stage IV Non-small Cell Lung Cancer. *JAMA Network Open* 2024; 1(7); e244278.
384. Ilerhunmwuwa NP, Abdul Khader AHS, Smith C, Cliff ERS, **Booth CM**, Rd EH, Aziz M, Lee-Smith W, Goodman A, Chakraborty R, Mohyuddin GR. Dietary interventions in cancer: a systematic review of all randomized controlled trials. *J Natl Cancer Inst* 2024; 116(7): 1026-1034.
383. Briercheck EL, Pyle D, Adams C, Atun F, **Booth C**, Dent J, Garcia P, Ilbawi A, Jazieh A, Kerr D, Knaul F, Kobayashi E, Lim C, Maza M, Milner D, Navarro M, O'Brien M, Rodroiguez C, Sullivan R, Torode J, Vokes E, Gralow J. Unification of Efforts to Improve Global Access to Cancer Therapeutics: Report from Access to Essential Cancer Medicines Stakeholder Summits. *JCO Global Onc* 2024; 10:e2300256.
382. Gouveia AG, Viani GA, Bratti VF, Marta GN, Hanna SA, Jacinto AA, Silva MS, Hamamura AC, Rosa AA, Castilho MS, Carson L, Hopman WM, Sullivan R, **Booth CM**, Aggarwal A, Hanna TP, Moraes FY. Challenges in Building Radiotherapy Capacity: A Longitudinal Study Evaluating Eight Years of the Brazilian Radiotherapy Expansion Plan. *J Cancer Policy* 2024; 39:100459.
381. Sanford N, Hall WA, **Booth CM**. Re-examining Trials of Radiotherapy Omission: When Less is Not Always More. *JCO Oncol Pract* 2024; 20(4): 460-462.
380. Matthews J, Merchant S, Galica J, Palmer M, O'Donnell J, Koven R, **Booth CM**, Brundage MD. Measuring prognostic awareness in patients with advanced cancer: a scoping review and interpretive synthesis of the impact of hope. *J Natl Cancer Inst* 2024; 116(4): 506-517.
379. Gupta A, Chant ED, Mohile S, Vogel RI, Parsons HM, Blaes AH, **Booth CM**, Rocque GB, Dusetzina SB, Ganguli I. Health Care Contact Days Among Older Cancer Survivors. *JCO Onc Prac* 2023; 20(7): 943-952.
378. McLeod M, Torode J, Leung K, Bhoo-Pathy N, **Booth C**, Chakowa J, Egamberdiev D, Gralow J, Ilbawi A, Jassam J, Mutebi M, Parks J, Pramesh CS, Sengar M, Tsunoda A, Unger K, Venderpuye V, Yusuf A, Sullivan R, Aggarwal A. Quality Indicators for Evaluating Cancer Care in Low- and Middle-Income Country Settings: A multinational modified Delphi study. *Lancet Oncol* 2024; 25(3): e63-72.
377. Wilson BE, Hanna TP, **Booth CM**. Efficacy-Effectiveness Gaps in Oncology: Looking beyond survival. *Cancer* 2024; 150(3): 335-338.
376. Gyawali B and **Booth CM**. Treatment of metastatic pancreatic cancer: 25 years of innovation with little progress for patients. *Lancet Oncol* 2024; 25(2): 167-170.

375. \*Rubagumya F, Wilson B, Shyirambere C, Manirakiza A, Mugenzi P, Chamberlin M, Hopman WM, **Booth C**. Assessing the Utilization of Cancer Medicines in Rwanda: An Analysis of Treatment Patterns. *eCancer* 2023; 17:1631. \*Trainee first author.
374. \*Rubagumya F, Wilson B, Manirakiza A, Mutabazi E, Ndoli DA, Rudakemwa E, Chamberlin MD, Hopman WM, **Booth CM**. Financial Toxicity: Unveiling the Burden of Cancer Care on Patients in Rwanda. *The Oncologist*; 2024; 29(3):e345-e350. \*Trainee first author.
373. Leung K, McLeod M, Torode J, Ilbawi A, Chakowa J, Bourbeau B, Sengar M, **Booth CM**, Gralow JR, Sullivan R, Aggarwal A. Quality indicators for systemic anticancer therapy services: a systematic review of metrics used to compare quality across healthcare facilities. *Eur J Cancer* 2023; 195:113389.
372. Castelo-Branco L, Pellat A, Martins-Branco D, Valachis A, Derksen JWG, Suijkerbuijk KPM, Dafni U, Dellaporta T, Vogel A, Prelaj A, Groenwold RHH, Martins H, Stahel R, Bliss J, Kather J, Ribelles N, Perrone F, Hall PS, Dienstmann R, **Booth CM**, Pentheroudakis G, Delaloge S, Koopman M. ESMO Guidance for Reporting Oncology real-World evidence (GROW). *Ann Oncol* 2023; 34(12):1097-1112.
371. Wilson BE, Sullivan R, Peto R, Abubakar B, **Booth C**, Werutsky G, Adams C, Saint-Raymond A, Fleming TR, Lyerly K, Gralow JR.. Global Cancer Drug Development-A Report From the 2022 Accelerating Anticancer Agent Development and Validation Meeting. *JCO Global Oncol* 2023; 9:e2300294.
370. Ikpeni O, Maraj D, Woods H, Workentin A, **Booth CM**, Persaud N. Essential cancer medicines and cancer outcomes: Cross-sectional study of 131 countries. *Cancer Medicine* 2023; 12(22):20745-20758.
369. Wilson BE, **Booth CM**, Patel S, Berry S, Kong W, Merchant S. First-line palliative chemotherapy for colorectal cancer: a population-based analysis of delivery and outcomes in a single-payer health system. *Clin Oncol* 2023; 13:S0936-6555(23)00460-0.
368. **Booth CM**, Sengar M, Goodman A, Wilson B, Aggarwal A, Berry S, Collingridge D, Denburg A, Eisenhauer EA, Ginsburg O, Goldstein D, Gunasekera S, Hammad N, Honda K, Jackson C, Karikios D, Knopf K, Koven R, Marini BL, Maskens D, Moraes FY, Mohyuddin GR, Poudyal BS, Pramesh CS, Roitberg F, Rubagumya F, Schott S, Sirohi B, Soto-Perez-de-Celis E, Sullivan R, Tannock IF, Trapani D, Tregear M, van der Graaf W, Vanderpuye V, Gyawali B. Common Sense Oncology: Outcomes that matter. *Lancet Oncology* 2023; 24(8): 833-835.
367. Chamberlin M, **Booth C**, Brooks GA, Manirakiza A, Rubagumya F, Vanderpuye V. More Drugs Versus More Data: The Tug of War on Cancer in Low- and Middle-Income Countries. *Hematol Oncol Clin North Am* 2024; 38(1):229-238.
366. Frank C, Gyawali B, **Booth CM**. Common sense cancer care for older adults: Outcomes that matter. *J Am Geriatr Soc* 2023; 71(12):3977-3980.

365. Dee EC, Eala MAB, Robredo JPG, Ramiah D, Hubbard A, Ho FDV, Sullivan R, Aggarwal A, **Booth C**, Legaspi GD, Nguyen PL, Pramesh CS, Grover S. Leveraging national and global political determinants of health to promote equity in cancer care. *J Nat Cancer Inst* 2023; 115(10):1157-1163.
364. **Booth CM**, Eisenhauer EA, Gyawali B, Tannock IF. Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs. *J Clin Oncol* 2023; 41(32):4968-4972.
363. Brundage MD, **Booth CM**, Eisenhauer EA, Galica J, Kankesan J, Karim S, Koven R, McDonald V, Ng T, O'Donnell J, tenHove J, Robinson A. Patients' attitudes and preferences toward delayed disease progression in the absence of improved survival. *J Natl Cancer Inst* 2023; 115(12):1526-1534.
362. Karim S, Doll CM, Dingley B, Merchant S, Moraes FY, **Booth CM**. Choosing Wisely Oncology Canada Cancer List: An Update. *J Cancer Policy* 2023; 37:100431.
361. Patel VR, Ramesh V, Tsai AK, Sedhom R, Westanmo AD, Blaes AH, Vogel RI, Parsons HM, Hanna TP, Ganguli I, Dusetzina SB, Rocque GB, **Booth CM**, Gupta A. Health Care Contact Days Experienced by Decedents With Advanced GI Cancer. *JCO Oncol Pract* 2023; 19(11):1031-1038.
360. Zimmermann C, Pope A, Hannon B, Bedard PL, Rodin G, Dhani N, Li M, Herx L, Krzyzanowska MK, Howell D, Knox JJ, Leighl NB, Sridhar S, Oza AM, Lheureux S, **Booth CM**, Liu G, Castro JA, Swami N, Sue-A-Quan R, Rydall A, Le LW. Symptom screening with Targeted Early Palliative care (STEP) versus usual care for patients with advanced cancer: a mixed methods study. *Support Care Cancer* 2023; 31(7): 404.
359. Martínez N, García MDP, Brundage M, Hanna TP, Soares C, Aggarwal I, Uribe M, Sullivan R, **Booth C**, Murillo R. Stress, Resilience, Moral Distress, and Depression-Anxiety among Oncology Care Providers in Colombia during the COVID-19 Pandemic. *Revista Colombiana de Psiquitria* 2023; In Press.
358. Manirakiza AVC, Rubagumya F, Mushonga M, Mutebi M, Lasebikan N, Kochbati L, Gyawali B, **Booth CM**, Stefan DC. The current status of National Cancer Control Plans in Africa: Data from 32 countries. *J Cancer Policy* 2023; 37:100430.
357. **Booth CM**, Ross JS, Detsky AS. The Changing Medical Publishing Industry: Economics, Expansion, and Equity. *J Gen Intern Med* 2023; 38(14):3242-3246.
356. Ranawka S, Gunarathna S, Gunasekera S, **Booth CM**, Jalink M, Carson LM, Berry S, Gyawali B, Seneviratne S, Wijeratne DT. Breast cancer-related financial toxicity in Sri Lanka insights from a lower-middle income country with free universal public healthcare. *The Oncologist* 2023; 29(2):e259-e265.
355. Wilson BE, Nadler M, Desnoyers A, **Booth CM**, Amir E. Meta-analysis of sex and racial subgroup participation rates and differential treatment effects for trials in solid tumors malignancies leading to FDA registration between 2010-2021. *Cancer* 2024; 130(2):276-286.



354. Wilson BE and **Booth CM**. Real world data and regulatory approval. eClinicalMedicine 2023; In Press.
353. Ouchveridze E, **Booth C**, Mohyuddin GR. Subgroups and precision in myeloma. J Cancer Policy 2023; 35: 100407.
352. Thanabalasingam SJ, Ranawaka SS, Gunarathna SSC, Yathev B, **Booth CM**, Seneviratne S, Gunasekera S, Wijeratne DT. Patient Satisfaction With Breast Cancer Care Delivery at the National Cancer Institute of Sri Lanka: Does Language Play a Role? J Global Oncol 2023; 9: e2200306.
351. Karim S, Doll CM, Dingley B, Merchant S, de Moraes FY, **Booth CM**. Are the Choosing Wisely Canada Cancer recommendations relevant and up to date with the current evidence? J Cancer Policy 2023; 35: 100406.
350. Sharma N, Wayant C, Neupane K, Lenka J, Berger K, Goodman AM, **Booth CM**, Prasad V, Mohyuddin GR. Quality of content reporting on two major oncology media websites: OncLive and Targeted Oncology. J Cancer Policy 2023; 36:100411.
349. Johnson WV, Blaes AH, **Booth CM**, Ganguli I, Gupta A. The unequal time burden of time toxicity. Trends in Cancer 2023; 5: 373-375.
348. \*Rubagumya F, Galica J, Rugengamanzi E, Niyibizi BA, Aggarwal A, Sullivan R, **Booth CM**. Media coverage of cancer therapeutics: A review of literature. J Cancer Policy 2023; 36:100418.  
**\*Trainee first author**
347. Saesen R, Van Hemelrijck M, Bogaerts J, **Booth CM**, Cornelissen JJ, Dekker A, Eisenhauer EA, Freitas A, Gronchi A, Hernán MA, Hulstaert F, Ost P, Szturz P, Verkooijen HM, Weller M, Wilson R, Lacombe D, van der Graaf WT. Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of Cancer. Eur J Cancer 2023; 186: 52-61.
346. Wilson B, Desnoyers A, Amir E, **Booth CM**. Differential treatment effect between younger and older adults for new cancer therapies in solid tumours supporting FDA approval between 2010-2021. Cancer 2023; 129(2): 3318-3325.
345. \*Rubagumya F, Fundytus A, Keith-Brown S, Hopman W, Gyawali B, Mukerjee D, Hammad N, Pramesh CS, Aggarwal A, Eniu A, Sengar M, Riechelmann R, Sullivan R, **Booth CM**. Allocation of authorship and patient enrollment among global clinical trials in oncology. Cancer 2023; 129(18): 2856-2863. **\*Trainee first author**
344. Richters A, Yildirim H, **Booth CM**, Vera Badillo FE, Kiemeny LA, Aben KK. Changes to primary endpoints in randomized clinical trials on immune checkpoint inhibitors in urologic and lung cancer are common and untransparent. JAMA Oncol 2023; 9(8): 1144-1147.
343. Ethier JL, Kong W, MacKay HJ, McGee J, **Booth CM**. Real-world outcomes associated with use of front-line bevacizumab in ovarian cancer. J Cancer Policy 2023; 36:100421.

342. \*Rubagumya F, Mushonga M, Abdihamid O, Nyagambona S, Hopman W, Nwamaka L, Ndlovu M, **Booth C**, Aggarwal A, Vanderpuye V, Brundage M, Moraes FY. Status of peer review in radiation oncology: a survey of cancer centers in Sub-Saharan Africa. *Int J Rad Oncol Bio Physics* 2023; 116(5): 984-991. **\*Trainee first author**
341. Gupta A, Hay AE, Crump M, Djurfeldt MS, Zhu L, Cheung MC, Shepherd LE, Chen BE, **Booth CM**. Contact Days Associated With Cancer Treatments in the CCTG LY.12 Trial. *Oncologist* 2023; 28(9): 799-803.
340. Lythgoe MP, Lewison G, Aggarwal A, **Booth C**, Lawler M, Trapani D, Sengar M, Sullivan R. The rise of immuno-oncology in China: a challenge to western dominance? *Lancet Oncol* 2023; 24(5): 439-441.
339. Wilson BE, **Booth CM**, Sullivan R, Aggarwal A, Sengar M, Jacob S, Bray F, Barton MB, Pearson SA. Global application of National Comprehensive Cancer Network resource-stratified guidelines for systemic treatment of colon cancer: a population-based, customisable model for cost, demand, and procurement. *Lancet Oncol* 2023; 24(6): 682-690.
338. Sengar M, Hopman W, Mohyuddin GR, Goodman AR, Gyawali B, Mukherji D, Hammad N, Pramesh CS, Aggarwal A, Sullivan R, **Booth CM**. Randomized controlled trials in hematological cancer: an overview of global research activity. *eCancer* 2023; 17:1558.
337. Gupta A, O'Callaghan CO, Zhu L, Jonker DJ, Wong RPW, Colwell B, Moore MJ, Karapetis CS, Tebbutt NC, Shapiro JD, Tu D, **Booth CM**. Evaluating the Time Toxicity of Cancer Treatment in the CCTG CO.17 Trial. *JCO Oncology Practice* 2023; 19(6): e859-e866.
336. Etteldorf A, Sedhom R, Rotolo S, Vogel R, **Booth C**, Blaes A, Virnig B, Dusetzina S, Gupta A. The least costly pharmacy for cancer supportive care medications over time: the logistic toxicity of playing catch up. *Support Care Cancer* 2022; 31(1):3.
335. \*Rubagumya F, Carson L, Mushonga M, Manirakiza A, Murenzi G, Abdihamid O, Athman A, Mungo C, **Booth C**, Hamamd N. An analysis of the African cancer research ecosystem: Tackling disparities. *BMJ Global Health* 2023; 8(2): e011338. **\*Trainee first author**
334. Etekal T, Koehn K, Sborov DW, McClune B, Prasad V, Haslam A, Berger K, **Booth C**, Goodman A, Mohyuddin GR. Time to Event Surrogate Endpoints in Multiple Myeloma Randomized Trials from 2005-2019: A Systematic Review and Surrogacy Analysis. *Br J Hematology* 2023; 200(5): 587-594.
333. Sachdev A, Sharpe I, Bowman M, **Booth CM**, Gyawali B. Objective response rate of placebo in randomized controlled trials of anticancer medicines. *EClinicalMedicine* 2022; 55:101753.
332. Boyle JM, van der Meulen J, Kuryba A, Cowling TE, **Booth C**, Fearnhead NS, Braun MS, Walker K, Aggarwal A. Measuring variation in the quality of systemic anti-cancer therapy delivery across hospitals: A national population-based evaluation. *Eur J Cancer* 2022; 178: 191-204.

331. \*Rubagumya F, Mutebi M, Manirakiza A, Hamid O, Vanderpuye V, Hammad N, **Booth CM**. Pharmaceutical industry relationships with oncologists in Sub-Saharan Africa. *Lancet Oncology* 2023; 24(2): e96-101. **\*Trainee first author**
330. Mutebi M, Lewison G, Aggarwal A, Alatis OI, **Booth C**, Cira M, Grover S, Ginsburg O, Gralow J, Gueye S, Kithaka B, Kingham TP, Kochbati L, Moodley J, Mohammed SI, Mutombo A, Ndlovu N, Ntuzimira C, Parham GP, Walter F, Parkes J, Shamely D, Hammad N, Seeley J, Torode J, Sullivan R, Vanderpuye V. Cancer research across Africa: a comparative bibliometric analysis. *BMJ Global Health* 2022; 7(11): e009849.
329. Jenei K, Aziz Z, **Booth C**, Capello B, Ceppi F, de Vries EGE, Fojo A, Gyawali B, Ilbawi A, Lombe D, Sengar M, Sullivan R, Trapani D, Huttner BD, Moja L. Cancer medicines on the WHO Model List of Essential Medicines: processes, challenges, and a way forward. *Lancet Global Health* 2022; 10(12): e1860-1866.
328. Gupta A, Antonarakis ES, Blaes AH, **Booth CM**, Dusetzina SB. Evaluation of Medicare Coverage and Estimated Out-of-Pocket Costs for Generic Abiraterone Products. *JAMA Netw Open* 2022; 5(9): e2231475.
327. Haque W, Chencheri S, Virnig BA, Blaes AH, **Booth CM**, Dusetzina SB, Gupta A. Price Comparison of Human and Veterinary Formulations of Common Medications. *JAMA Int Med* 2022; 182(11): 1216-1218.
326. Webber C, Brundage M, Hanna TP, **Booth CM**, Kennedy E, Kong W, Peng Y, Whitehead M, Groome PA. Explaining regional variations in colon cancer survival in Ontario, Canada: A population-based retrospective cohort study. *BMJ Open* 2022; 12(9): e059597.
325. Gouveia AG, Viani GA, Bratti VF, Pavoni JF, Sullivan PR, Rosa AA, **Booth CM**, Aggarwal A, Hanna TP, Moraes FY. System-Level Capacity of High-Dose Rate (HDR) Brachytherapy for Management of Cervical Cancer in an Upper-Middle Income Country: A Case Study From Brazil. *Int J Radiat Oncol Biol Phys* 2022; 114(3): 545-553.
324. \*Rubagumya F, Hopman WM, Gyawali B, Mukherji D, Hammad N, Pramesh CS, Zubaryev M, Eniu A, Tsunoda AT, Kutluk T, Aggarwal A, Sullivan R, **Booth CM**. Globalization of oncology clinical trials: Participation of lower- and upper-middle income countries in trials led by high income countries. *JAMA Network Open* 2022; 5(8): e2227252. **\*Trainee first author**
323. \*Rubaguyma F, Sengar M, Ka S, Hammad N, **Booth CM**, Karim S. Choosing Wisely – Barriers and solutions to Implementation in Low and Middle Income Countries. *Curr Oncol* 2022; 29(7): 5091-5096. **\*Trainee first author**
322. Gyawali B, **Booth CM**. Defining clinical significance of overall survival thresholds: lessons from quality of life. *Nat Rev Clin Oncol*; 19(10); 613-614.
321. Courneya KC, **Booth CM**. The Exercise as Cancer Treatment (EXACT) Framework: A Clinical Oncology Framework to Guide Exercise Oncology Research. *Frontiers in Oncology* 2022; 12:957135.

320. Moraes FY, Marta GN, Mitera G, Forte DN, Pinheiro RN, Vieira NF, Gadia R, Caleffi M, Kauer PC, Barros LH, Mathias C, Gondim K, Vasconcelos M, **Booth C**, Fernandes GDS. Choosing Wisely for oncology in Brazil: 10 recommendations to deliver evidence-based cancer care. *Nature Medicine* 2022; 28(9): 1738-1739.
319. \*Rubagumya F, Makori K, Borges H, Mwanzi S, Karim S, Msadabwe C, Dharsee N, Mutebi M, Hopman WM, Vanderpuye V, Ka S, Ndlovu N, Hammad N, **Booth CM**. Choosing Wisely Africa: insights from the front-lines of clinical care. *J Cancer Policy* 2022; 33:100348. **\*Trainee first author**
318. Samuel JN, **Booth CM**, Eisenhauer E, Brundage M, Berry SR, Gyawali B. Association of Quality-of-Life Outcomes in Cancer Drug Trials With Survival Outcomes and Drug Class. *JAMA Oncol* 2022; 8(6):879-886.
317. **Booth CM**, Aggarwal A, Sullivan R. Commercial determinants of cancer medicines. *EuroHealth* 2022; 28(2): 18-21.
316. Sullivan R, **Booth CM**, Aggarwal A. Non-pharmaceutical technologies in cancer care: for profit or for patients?. *EuroHealth* 2022; 28(2): 14-17.
315. Kitchlu A, Reid J, Jeyakumar N, Dixon SN, Munoz AM, Silver SA, **Booth CM**, Chan CTM, Garg AX, Amir E, Kim SJ, Wald R. Cancer Risk and Mortality in Patients With Kidney Disease: A Population-Based Cohort Study. *Am J Kidney Dis* 2022; 80(4):436-448.
314. \*Wright K, Meyers DE, Chisamore TM, McInnes MDF, Sismondo S, Gyawali B, Prasad V, **Booth CM**. Industry Relationships with Medical Oncologists: Who are the high-payment physicians? *JCO Oncology Practice* 2022; 18(7): e1164-e1169. **\*Trainee first author**
313. \*Wells JC, Fundytus A, Sharma S, Hopman WM, Del Paggio JC, Gyawali B, Mukherji D, Hammad N, Pramesh CS, Aggarwal A, Sullivan R, **Booth CM**. Randomized Controlled Trials in Lung, Gastrointestinal, and Breast. *Current Oncology* 2022; 29(4): 2530-2538. **\*Trainee first author**
312. Wijeratne DT, Gunasekara S, **Booth CM**, Berry S, Jalink M, Carson LM, Gyawali B, Promod H, Jayarajah U, Seneviratne S. Colorectal cancer treatment characteristics and concordance with guidelines in Sri Lanka; results from a hospital-based cancer registry. *JCO Global Oncology* 2022; 8:e2200004.
311. Hanna NM, Williams E, Kong W, Fundytus A, **Booth CM**, Patel SV, Caycedo-Marulanda A, Chung W, Nanji S, Merchant SJ. Incidence, Timing, and Outcomes of Venous Thromboembolism in Patients Undergoing Surgery for Esophagogastric Cancer: A Population-Based Cohort Study. *Annals Surg Oncol* 2022: ePub ahead of print March 12, 2022.
310. Denburg A, Fundytus A, Khan MS, Howard SC, Antillon-Klussmann F, Sengar M, Lombe D, Hopman W, Jalink M, Gyawali B, Trapani D, Roitberg F, De Vries EGE, Moja L, Ilbawi A, Sullivan R, **Booth CM**. Defining essential childhood cancer medicines to inform prioritization and access: results from an international, cross-sectional survey. *JCO Global Oncology* 2022; 8:e2200034.

309. **Booth CM**, Detsky AS. How Forced Dichotomization Hijacked Meaningful Debate During the COVID-19 Pandemic. *J Hospital Medicine* 2022; 17(7): 572-573.
308. Sengar M, Fundytus A, Hopman W, Pramesh CS, Radhakirshnan V, Ganesan P, Mathew A, Lombe D, Jalink M, Gyawali B, Trapani D, Roitberg F, De Vries EGE, Moja L, Ilbawi A, Sullivan R, **Booth CM**. Cancer medicines: what is essential and affordable in India? *JCO Global Oncology* 2022; 8:e2200060.
307. Patel S, McClintock C, **Booth CM**, Merchant S, Heneghan C, Bankhead C. Variations in Care and Real World Outcomes in those with Rectal Cancer: A protocol for the Ontario Rectal Cancer Cohort (OntaReCC). *JMIR Research Protocols* 2022; 11(8): e388874.
306. Viani GA, Gouveia AG, Bratti VF, Sullivan R, Hopman WH, **Booth CM**, Pavoni JF, Aggarwal A, Hanna TP, Moraes FY. Population-based study for prioritizing locations for radiotherapy equipment: a national study of Brazil and the development of the LINAC Shortage Index. *Lancet Oncol* 2022; 23(4): 531-539.
305. Gupta A, Eisenhauer EA, **Booth CM**. The "Time Toxicity" of Cancer Treatment. *J Clin Oncol* 2022; 40(15): 1611-1615.
304. Dodkins J, Hopman WM, Wells JC, Lievens Y, Malik RA, Pramesh CS, Gyawali B, Hammad N, Mukherji D, Sullivan R, Parkes J, **Booth CM**, Aggarwal A. Is Clinical Research Serving the Needs of the Global Cancer Burden? An analysis of contemporary global radiotherapy randomised controlled trials. *Int J Cancer Biol Phys* 2022; 113(3): 500-508.
303. Sengar M and **Booth CM**. Contemporary clinical trials in hematologic cancer have we forgotten where we came from? *Eur J Cancer* 2022; 167: 161-163.
302. Ames J, Djerboua M, Terrault NA, **Booth CM**, Flemming JA. Rising Healthcare Costs and Utilization in Young Adults with Cirrhosis in Ontario. *Canadian J Gastro Hepatol* 2022; 6175913.
301. Pramesh CS, Badwe RA, Bhoo-Pathy N, **Booth CM**, Chinnaswamy G, Dare AJ, de Andrade VP, Hunter DJ, Gopal S, Gospodarowicz M, Gunasekera S, Ilbawi A, Kapambwe S, Kingham P, Kutluk T, Lamichhane N, Mutebi M, Orem J, Parham GP, Ranganathan P, Sengar M, Sullivan R, Swaminathan S, Tannock I, Tomar V, Vanderpuye V, Varghese C, Weiderpass E. Priorities for cancer research in low- and middle-income countries – a global perspective. *Nature Medicine* 2022; 28(4): 649-657.
300. Mukherji D, Murillo RH, Van Hemelrijck M, Vanderpuye V, Shamieh O, Torode J, Pramesh CS, Yusuf A, **Booth CM**, Aggarwal A, Sullivan R. Global cancer research in the post-pandemic world. *Lancet Oncol* 2021; 22(12): 1652-1654.
299. Merchant S, Kong W, Mahmud A, **Booth CM**, Hanna TP. Palliative Radiotherapy for Esophageal and Gastric Cancer: Population-based Patterns of Utilization and Delivery in Ontario, Canada. *Journal of Pall Care* 2021; 19:8258597211072946.
298. Tannock IF, Pond G, **Booth CM**. Biased Evaluation in Cancer Drug Trials. *JAMA Oncol* 2022; 8(5): 679-680.

297. Gunasekera S, Jalink M, Seneviratne S, Joseph N, Ariyaratna Y, **Booth CM**, Wijeratne DT. Clinical oncology workload in Sri Lanka: infrastructure, supports, and delivery of clinical care. *J Global Oncol* 2021; 7:1703-1710.
296. Ngwa W, Addai BW, Adewole I, Ainsworth V, Alaro J, Alatisie OI, Ali Z, Anderson BO, Anorlu R, Avery S, Barango P, Bih N, **Booth CM**, Brawley OW, Dangou JM, Denny L, Dent J, Elmore SNC, Elzawawy A, Gashumba D, Geel J, Graef K, Gupta S, Gueye SM, Hammad N, Hessissen L, Ilbawi AM, Kambugu J, Kozlakidis Z, Manga S, Maree L, Mohammed SI, Msadabwe S, Mutebi M, Nakaganda A, Ndlovu N, Ndoh K, Ndumbalo J, Ngoma M, Ngoma T, Ntizimira C, Rebbeck TR, Renner L, Romanoff A, Rubagumya F, Sayed S, Sud S, Simonds H, Sullivan R, Swanson W, Vanderpuye V, Wiafe B, Kerr D. Lancet Oncology Commission report on Cancer in Sub-Saharan Africa: a call to urgent action. *Lancet Oncol* 2022; 23(6): e251-e312.
295. Gyawali B and **Booth CM**. Cancer treatments should benefit patients: a common sense revolution in oncology. *Nature Medicine* 2022; 28(4): 617-620.
294. Gyawali B, Eisenhauer EA, Tregear M, **Booth CM**. Progression-Free Survival: It is time for a new name. *Lancet Oncol* 2022; 23(3): 328-330.
293. Fox L, Beyer K, Rammant E, Morcom E, Van Hemelrijck M, Sullivan R, Vanderpuye V, Lombe D, Tsunoda AT, Kutluk T, Bhoo-Pathy N, Pramesh SC, Yusuf A, **Booth CM**, Shamieh O, Siesling S, Mukherji D. Impact of the COVID-19 Pandemic on Cancer Researchers in 2020: A Qualitative Study of Events to Inform Mitigation Strategies. *Front Public Health* 2021; 9:74223.
292. Hanna N, Brogly SB, Wei XS, **Booth CM**, Nanji S. Incidence and Risk Factors of Venous Thromboembolism Following Hepatectomy for Colorectal Metastases: A Population-Based Retrospective Cohort Study. *World J Surg* 2021; 46(1): 180-188.
291. Clemons M, Liu M, Stober C, Pond G, Jemaan Alzahrani M, Ong M, Ernst S, **Booth C**, Mates M, Abraham Joy A, Aseyev O, Blanchette P, Vandermeer L, Tu M, Thavorn K, Fergusson D. Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer. *J Bone Oncol* 2021; 30:100388.
290. Yusuf A, Sarfati D, **Booth CM**, Pramesh CS, Lombe D, Aggarwal A, Bhoo-Pathy N, Tsunoda A, Vanderpuye V, Kutluk T, Sullivan A, Mukherji D, Mutebi M, van Hemelrijck M, Sullivan R. Cancer and COVID-19 vaccines: a complex global picture. *Lancet Oncol* 2021; 22(6): 749-751.
289. Trapani D, Murthy S, Boniol M, **Booth CM**, Simensen VC, Kasumba M, Giuliani R, Curgliano G, Ilbawi A. Distribution of the Workforce Involved in Cancer Care: A Systematic Review of the Literature. *ESMO Open* 6(6):100292.
288. Wijeratne DT, Gunasekera S, **Booth CM**, Promod H, Jalink M, Jayarajah U, Seneviratne S. Demographic, tumour, and treatment characteristics of female patients with breast cancer in Sri Lanka; results from a hospital-based cancer registry. *BMC Cancer* 2021; 21(1): 1175.

287. Jaeger M, Hosier GW, McGregor T, Beiko D, Kasasni SM, **Booth CM**, Whitehead M, Siemens DR. The association of gender and persistent opioid use following an acute pain event: A retrospective population based study of renal colic. PLOS ONE 16(8): e025682.
286. Meyers D, Meyers B, Chisamore T, Wright K, Gyawali B, Prasad V, Sullivan R, **Booth CM**. Trends in drug revenue among the world's major pharmaceutical companies: a 2010-2019 cohort study. Cancer 2022; 128(2): 311-316.
285. **Booth CM** and Berry SR. Perioperative Chemotherapy for Resectable Liver Metastases in Colorectal Cancer: Do We Have a Blind Spot? J Clin Oncol 2021; 39(34): 3767-3769.
284. Fu M, Naci H, **Booth CM**, Gyawali B, Cosgrove A, Toh S, Xu Z, Guan X, Ross-Degnan D, Wagner AK. Real-world utilization of and spending on novel oral targeted cancer drugs in the US, 2011-2018. JAMA Internal Medicine 2021; 181(12): 1596-1604.
283. Gunasekera S, **Booth CM**, Seneviratne, Gyawali B, Jalink M, Soysa M, Abhayaratna S, Promod H, Wijesinghe P, Wijeratne DT. Healthcare delivery for Non-Communicable Diseases among Breast Cancer Survivors in Sri Lanka: Is there a missed opportunity? eCancer 2021; 15:1301.
282. Pramesh CS, Babu GR, Basu J, Bhusan I, **Booth CM**, Chinnaswamy G, Guleira R, Kalantri SP, Kang G, Mohan P, Mor N, Pai M, Prakash M, Rupali P, Sampathkumar P, Sengar M, Sullivan R, Ranganathan P. Choosing Wisely for COVID-19: Ten evidence-based recommendations on COVID-19 control and management. Nature Medicine 2021; 27(8): 1324-1327.
281. \*Fundytus A, Prasad VK, **Booth CM**. Too little of a good thing: Has the current oncology value paradigm forgotten patients' time? JAMA Onc 2021; 7(12): 1757-1758. **\*Trainee first author**
280. Rodin D, Dare AJ, Booker R, **Booth C**, Bryant H, Ginsburg O, Giuliani M, Gospodarowicz M, Gupta S, Hammad N, Rosberger Z, Sutcliffe S, Earle CC. Transforming Canada's Role in Global Cancer Control. Lancet Oncol 2021; 22(9): e400-409.
279. Van Hemelrijck M, Lewison G, Fox L, Vanderpuye V, Moreno R, **Booth CM**, Canfell K, Pramesh CS, Sullivan R, Mukherji D. Global cancer research in the era of COVID-19: a bibliometric analysis. eCancer 2021; 15:1264.
278. Boyle JM, Hegarty G, Frampton C, Harvey-Jones E, Dodkins J, Beyer K, George G, Sullivan R, **Booth CM**, Aggarwal A (CB and AA are joint final authors). Real world outcomes associated with new cancer medicines approved by the Food and Drug Administration and European Medicines Agency: a retrospective cohort study. Eur J Cancer 2021; 155:1361-44.
277. \*Fundytus A, Wells JC, Sharma S, Hopman W, Del Paggio JC, Gyawali B, Mukherji D, Hamamd N, Pramesh CS, Aggarwal A, Sullivan R, **Booth CM**. Industry Funding of Oncology Randomized Controlled Trials: Implications for Design, Results, and Interpretation. Clin Oncol 2021; 34(1): 28-35. **\*Trainee first author**
276. **Booth CM**, Goodman A. Practicing on the Edge of Oncology: When Standard of Care Feels Uncomfortable. Nat Rev Clin Oncol 2021; 18(11): 673-674.

275. \*Fundytus A, Sengar M, Lombe D, Hopman W, Jalink M, Gyawali B, Trapani D, Roitberg F, De Vries EGE, Moja L, Ilbawi A, Sullivan R, **Booth CM**. Access to cancer medicines deemed essential by oncologists in 82 countries: results from an international, cross-sectional survey. *Lancet Oncol* 2021; 22(10): 1367-1377. **\*Trainee first author**
274. Srivastava A, Jalink M, Moraes F, **Booth CM**, Berry SR, Rubagumya F, Roitberg F, Sengar M, Hammad N. Tracking the Workforce 2020-2030: Making the Case for a Cancer Workforce Registry. *JCO Global Oncol* 2021; 7 925-933.
273. Sudhakaran S, George PS, Krishna J, **Booth C**, Mathew A. Worldwide trends in incidence of thyroid cancer by age, gender and histology over four decades. *Indian J Cancer* 2021: In Press.
272. Lusty A, Doiron RC, **Booth CM**, Whitehead M, Siemens DR. No outcome differences after cystectomy between patients with de novo muscle-invasive bladder cancer compared to progressors: a retrospective population-based study. *J Urology* 2021; 206(2): 260-269.
271. Flemming JA, Djerboua M, Groome PA, **Booth CM**, Terrault NA. NAFLD and Alcohol-related Liver Disease Will Be Responsible for Almost All New Diagnoses of Cirrhosis in Canada by 2040. *Hepatology* 2021; 74(6): 3330-3344.
270. Ranganathan P, Chinnaswamy G, Sengar M, Gadgil, Thigarajan S, Bhargava B, **Booth CM**, Buyse M, Chopra S, Frampton C, Gopal S, Grant N, Krailo M, Langley R, Mathur P, Paoletti X, Parmar M, Purushotham A, Pyle D, Rajaraman P, Stockler MR, Sullivan R, Swaminathan S, Tannock I, Trimble E, Badwe R, Pramesh CS. The International Collaboration for Research methods Development in Oncology (CReDO) workshops – Shaping the future of global oncology research. *Lancet Oncol* 2021; 22(8): e369-376.
269. Gyawali B, Griffiths R, Robinson AG, McInnes MDF, Bedard PL, **Booth CM**. Utilization of imaging for active surveillance in testicular cancer: Is real-world practice concordant with guidelines? *Can Urol Assoc J* 2022; 16(2): 26-33.
268. Del Paggio JC, Berry JS, Hopman WM, Eisenhauer EA, Prasad V, Gyawali B, **Booth CM**. Evolution of the Randomized Controlled Trial in the Era of Precision Oncology. *JAMA Oncol* 2021; 7(5): 728-734.
267. Lombe D, Sullivan R, Caduff C, Ali Z, Bhoo-Pathy N, Cleary J, Jalink M, Matsuda T, Mukherji D, Sarfati D, Vanderpuye V, Yusuf A, **Booth C**. Silver Linings: A qualitative study of desirable changes to cancer care during the COVID-19 pandemic. *eCancer* 2021; 15:1202.
266. Zimmermann C, Pope A, Hannon B, Krzyzanowska M, Rodin G, Li M, Howell D, Knox J, Leighl NB, Sridhar S, Oza A, Prince R, Lheureux S, Hansen A, Rydall A, Chow B, Herx L, **Booth CM**, Dudgeon D, Dhani N, Liu G, Bedard PL, Mathews J, Swami N, Le LW. Phase II trial of Symptom screening with Targeted Early Palliative care (STEP) for patients with advanced cancer. *J Natl Comp Cancer Network* 2021; 7:1-10.
265. Sharma S, **Booth CM**, Eisenhauer EA, Gyawali B. Do editorialists with industry-related conflicts of interest write unduly favorable editorials for cancer drugs in top journals? *J Natl Cancer Comp Network* 2021; ePub ahead of print July 29, 2021.



264. Kwon D, **Booth CM**, Prasad V. Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib? *Eur Urol* 2021; 79(6): 710-712.
263. \*Raphael MJ, Griffiths R, Peng Y, Gupta S, Siemens DR, Soares C, **Booth CM**. Mental Health Resource Use Among Patients Undergoing Curative Intent Treatment for Bladder Cancer. *J Natl Cancer Inst* 2021; 113(9): 1238-1245. **\*Trainee first author**
262. Ethier JL, Desautels D, Robinson A, Amir E, Kong W, **Booth CM**. Practice patterns and outcomes of novel targeted agents for the treatment of HER-2 positive metastatic breast cancer: a population-based study. *JAMA Oncol* 2021; 7(9): e212140.
261. \*Sharma S, Wells JC, Hopman WM, Del Paggio JC, Gyawali B, Hammad N, Hay AE, **Booth CM**. Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials. *Curr Oncol* 2021; 28(2): 1518-1527. **\*Trainee first author**
260. \*Meyers DE, Chisamore TM, McInnes MDF, Gyawali B, Prasad V, **Booth CM**. Industry Payments to US Physicians for Cancer Therapeutics: An Analysis of the 2016-2018 Open Payments Datasets. *J Cancer Policy* 2021; 28:100283. **\*Trainee first author**
259. Del Paggio JC, Fundytus AM, Hopman WA, Pater JL, Chen BE, Brundage MD, Hay AE, **Booth CM**. Application of Value Frameworks to the Design of Clinical Trials: The Canadian Cancer Trials Group Experience. *J Nat Cancer Inst* 2021; 113(10): 1422-1428.
258. \*Fundytus A, **Booth CM**, Tannock IF. How Low Can You Go? PD-L1 Expression as a Biomarker in Trials of Cancer Immunotherapy. *Ann Oncol* 2021; 32(7): 833-836. **\*Trainee first author**
257. Yusuf A, Sarfati D, **Booth CM**, Pramesh CS, Lombe D, Aggarwal A, Bhoo-Pathy N, Tsunoda A, Vanderpuye V, Kutluk T, Sullivan A, Mukherji D, Mutebi M, van Hemelrijck M, Sullivan R. Cancer and COVID-19 vaccines. A complex global picture. *Lancet Oncol* 2021; 22(6): 749-751.
256. Robinson AG, O'Donnell J, **Booth C**, Koven R, Eisenhauer E, Brundage M. Patient Perspectives of Value of Delayed Disease Progression on Imaging (imaging PFS). A Treatment Trade-off Experiment. *J Cancer Policy* 2021; 30:100301.
255. \*Wells JC, Sharma S, Del Paggio JC, Hopman WM, Gyawali B, Mukherji D, Hammad N, Pramesh CS, Aggarwal A, Sullivan R, **Booth CM**. An Analysis of Contemporary Worldwide Randomized Controlled Trials. *JAMA Oncol* 2021; 7(3): 379-385. **\*Trainee first author**
254. Hanna TP, Aggarwal A, **Booth CM**, Sullivan R. Counting the Invisible Costs of COVID: The Cancer Pandemic. *BMJ* 2020; published online November 5, 2020.
253. Hanna TP, King W, Thibodeau S, Jalink M, Paulin GA, Harvey-Jones E, O'Sullivan DE, **Booth CM**, Sullivan R, Aggarwal A. Mortality due to cancer treatment delay: A systematic review and meta-analysis. *BMJ* 2020; 371:m4087.

252. \*Fundytus A, Sullivan R, **Booth CM**. Towards Affordable Cancer Drugs: Do we need firmer price negotiation, me-too drugs, or a biosimilar silver bullet? *Semin Oncol* 2020; 47(6): 353-354.

**\*Trainee first author**

251. Merchant S and **Booth CM**. Palliative chemotherapy for upper GI cancer: balancing hope, reality, survival, and symptoms. *Ann Surg Oncol* 2021; 28(1): 88-89.

250. Merchant S, Kong W, Brundage M, **Booth CM**. Symptom evolution in patients with esophageal and gastric cancer receiving palliative chemotherapy: a population-based study. *Ann Surg Oncol* 2021; 28(1): 79-87.

249. Merchant S, Kong W, Gyawali B, Hanna TP, Chung W, Nanji S, Patel SV, **Booth CM**. First-line palliative chemotherapy for esophageal and gastric cancer: practice patterns and outcomes in the general population. *JCO Oncol Practice* 2021; 17(10): e1537-1550.

248. Galica J, Liu Z, Kain D, Merchant S, **Booth C**, Koven R, Brundage M, Haase K. Coping during COVID-19: A mixed methods study of older cancer survivors. *Supp Care in Cancer* 2021; 29(6): 3389-3398.

247. Haase K, Kain D, Merchant S, **Booth C**, Koven R, Brundage M, Galica J. Older cancer survivors' reflections on the COVID-19 pandemic and recommendations for future care. *J Geriatric Oncol* 2021; 12(3): 461-466.

246. Hosier, G, McGregor T, Beiko D, Tasian G, **Booth C**, Whitehead M, Siemens DR. Increased Risk of New Persistent Opioid Use in Pediatric and Young Adult Patients with Kidney Stones. *Can Urol Assoc J* 2020; 14(8): 237-244.

245. \*Raphael MJ, Gupta S, Wei X, Peng Y, Soares CN, Bedard PL, Siemens DR, Robinson AG, **Booth CM**. Long-term mental health service utilization among survivors of testicular cancer: a population-based cohort study. *J Clin Oncol* 2021; 39(7): 779-786. **\*Trainee first author**

244. Jiang DM, North S, Canil C, Kolinsky M, Wood L, Gray S, Eigl BJ, Basappa N, Blais N, Winquist E, Mukherjee SD, **Booth C**, Alimohammed N, Czaykowski P, Kulkarni GS, Black PC, Chung P, Kassouf W, Kwast TVD, Sridhar SS. Management of Muscle-Invasive Bladder Cancer: Consensus Statement from the Genitourinary Medical Oncologists of Canada (GUMOC). *Bladder Cancer* 2020; 6(3): 363-392.

243. Nason GJ, Chung P, Warde P, Huddart R, Albers P, Kollmannsberger C, **Booth CM**, Hansen AR, Bedard PL, Einhorn L, Nichols C, Rendon R, Wood L, Jewett MAS, Hamilton RJ. Controversies in the management of clinical stage 1 testis cancer. *Can Urol Assoc J* 2020; 14(11): E537-E542.

242. Merchant S, Kong W, Gyawali B, Hanna T, Chung W, Patel SV, **Booth CM**. Effectiveness of Trastuzumab in Routine Clinical Practice: A Population-based Study of Patients with HER-2+ Esophageal, Gastroesophageal and Gastric Cancer. *Clin Oncol* 2021; 33(3): 202-207.

241. Wijeratne DT, Gunasekara S, **Booth CM**, Promod H, Seneviratne S. Patterns of cancer care in Sri Lanka: Assessing care provision and unmet needs through an electronic database. *J Cancer Policy* 2020; 25(2): 100243.
240. Gyawali B, Sharma S, Shilpakar R, Dulal S, Pariyar J, **Booth CM**, Poudyal B. An Overview of Delivery of Cancer Care in Nepal: Current Status and Future Priorities. *J Global Onc*. 2020; 6:1211-1217.
239. Rubagumya F, Mitera G, Ka S, Manirakiza A, Decuir P, Msadabwe SC, Adani Ifè S, Nwachukwu E, Ohene Oti N, Borges H, Mutebi M, Abuidris D, Vanderpuye V, **Booth CM**, Hammad N. Choosing Wisely Africa: Ten low-value or harmful practices that should be avoided in cancer care. *J Global Oncol*. 2020; 6:1192-1199.
238. Sridhar SS, Blais N, Tran B, Beaume MN, North SA, Stockler MR, Chi KN, Flshner NE, Liu G, Robinson JW, Mukherjee S, Rahim Y, Winquist E, **Booth CM**, Nguyen NT, Beardsley EK, Alimihamad NS, McDonald GT, Ding K, Parulekar WR. Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL12 Randomized Clinical Trial. *JAMA Oncol* 2020; 6(11): 1-8.
237. Rubagumya F, Costas-Chavarri A, Manirakiza A, Murenzi G, Uwinkindi F, Ntuzimira C, Rukundo I, Mugenzi P, Rugwizangoga B, Shyirambere C, Urusaro S, Pace L, Buswell L, Ntirenganya F, Rudakemwa E, Fadelu T, Mpunga T, Shulman LN, **Booth CM**. State of Cancer Control in Rwanda: Past, Present, and Future Opportunities. *J Global Oncol*. 2020; 6: 1171-1177.
236. Nanji S, Mir ZM, Karim S, Brennan KE, Patel SV, Merchant SJ, **Booth CM**. Perioperative blood transfusion and resection of colorectal cancer liver metastases: outcomes in routine clinical practice. *HPB* 2020; S1365-182X (20) 31104-7.
235. \*Raphael MJ, Loughheed MD, Wei X, Karim S, Robinson AG, Bedard PL, **Booth CM**. A Population-based Study of Pulmonary Monitoring and Toxicity for Patients with Testicular Cancer Treated with Bleomycin. *Curr Oncol* 2020; 27(6): 291-298. **\*Trainee first author**
234. \*Dyer T, Siemens DR, Nippak P, Meyer J, **Booth CM**. Histology at TURBT and Radical Cystectomy for Bladder Cancer: Insights from Population-Based Data: Histology at TURBT and Cystectomy. *Can Urol Assoc J* 2021; 15(4): 138-140. **\*Trainee first author**
233. Khalid S, Basulaiman BM, Emack J, **Booth CM**, Hernandez-Barajas, Duran I, Smoragiewicz, Amir E, Vera-Badillo FE. Fibroblast Growth Factor Receptor 3 Mutation as a Prognostic Indicator in Patients with Urothelial Carcinoma: A Systematic Review and Meta-analysis. *Eur Urol Open Science* 2020; 21: 61-68.
232. Clemons M, Ong M, Stober C, Ernst S, **Booth C**, Canil C, Mates M, Robinson A, Blanchette P, Joy AA, Hilton J, Aseyev O, Pond G, Jeong A, Hutton B, Mazzarello S, Vandermeer L, Kushnir L, Ferguson D. A randomised trial comparing 4-weekly versus 12-weekly administration of bone-targeted agents (denosumab, zoledronate or pamidronate) in patients with bone metastases from either breast or castration-resistant prostate cancer. *Eur J Cancer* 2021; 142: 132-140.

231. Jalan D, Rubagumya DF, Hopman WM, Vanderpuye V, Lopes G, Seruga B, **Booth CM**, Berry S, Hammad Z. Training of oncologists: results of a global survey. *eCancer* 2020; 14:1074.
230. Mathew A, George PS, Ramadas K, Mathew BC, Kumar A, Roshni S, **Booth CM**. Educational Status, Cancer Stage, and Survival in South India. *J Global Oncol* 2020; 6: 1704-1711.
229. Robinson AG, Wei X, Karim S, Raphael MJ, Bedard PL, **Booth CM**. Venous Thromboembolism During Chemotherapy for Testicular Cancer: A Population-Based Study. *Clin Oncol.* 2020; 32(10): e188-e193.
228. Nishikawa G, **Booth CM**, Prasad V. Olaparib for BRCA Mutant Pancreas Cancer: Should the POLO trial change clinical practice? *Cancer* 2020; 126(18): 4087-4088.
227. Liu Z, Zhang Y, Wang X, Zhang D, Diao D, Chandramohan K, **Booth CM**. Recommendations for Surgery During the Novel Coronavirus (COVID-19) Epidemic. *Indian J Surgery.* 2020; 11:1-5.
226. Hanna TP, Evans GA, **Booth CM**. Cancer, COVID-19, and the precautionary principle: Prioritizing cancer treatments during the global pandemic. *Nat Rev Clin Oncol* 2020; 17(5): 268-270.
225. Mah JM, Djerboua M, Groome PA, **Booth CM**, Flemming JA. Transjugular Intrahepatic Portosystemic Shunt for the Treatment of Refractory Ascites: A Population-based Study. *Can Liver Journal* 2020; 3(4): 334-347.
224. Winkvist E and **Booth CM**. Trimodality Therapy for Muscle-Invasive Bladder Cancer: Concurrent Chemotherapy is Not Enough. *J Clin Oncol.* 2020; 38(24): 2709-2711.
223. Lijimol AS, Krishnan A, Rajagopal MR, Gopal BK, **Booth CM**. Improving Access and Quality of Palliative Care in Kerala: A Cross-Sectional Study of Providers in Routine Practice. *Indian J Pall Care* 2020; 26(4): 500-505.
222. \*Raphael MJ, Gyawali B, **Booth CM**. Real world evidence and regulatory drug approval. *Nat Rev Clin Oncol.* 2020; 17(5): 271-272. **\*Trainee first author**
221. **Booth CM** and Hammad N. Childhood cancer care: closing equity gaps on the ground. *Lancet Oncol* 2020; 21(4): 485-487.
220. \*Raphael MJ, Siemens DR, Peng Y, VeraBadillo FE, **Booth CM**. Volume of Systemic Cancer Therapy Delivery and Outcomes of Patients with Solid Tumors: A Systematic Review and Methodologic Evaluation of the Literature. *J Cancer Policy* 2020; 23: 100215. **\*Trainee first author**
219. Merchant SJ, Nair CM, **Booth CM**. Leveraging high quality research to define the gastric cancer landscape in India. *Ind J Surg Oncol* 2020; 11(3) 334-336.
218. \*Raphael MJ, Ko G, **Booth CM**, Brogly SB, Li W, Kalyvas M, Hanna TP, Patel SV. Interruption and non-completion among patients with squamous cell anal carcinoma in routine practice: a population-based study. *JAMA Oncol.* 2020; 6(6): 881-887. **\*Trainee first author**

217. Templeton A, **Booth CM**, Tannock IF. Informing Patients about Expected Outcomes: The Efficacy-Effectiveness Gap. *J Clin Oncol*. 2020; 38(15): 1651-1654.
216. Prasad V and **Booth CM**. Multiplicity in Oncology RCTs: A Threat to Medical Evidence? *Lancet Oncol* 2019; 20(12): 1638-1640.
215. Cyriac S and **Booth CM**. Delivery of cancer care in India and Canada: Opportunities for Bi-Directional Learning. *J Global Oncol* 2019; 5:1-5.
214. Patel SV, Ko G, Raphael MJ, **Booth CM**, Brogly SB, Lajkosz, Kalyvas M, Hanna T. Salvage APR for anal squamous cell carcinoma: utilization, risk factors, and outcomes in a Canadian population. *Disease Colon Rectum* 2020; 63(6); 748-757.
213. Gyawali B, Sharma S, **Booth CM**. Is the number of cancer drug approvals a surrogate for regulatory success? *J Cancer Policy* 2019; 22: 100202.
212. Pramesh CS, Chaturvedi H, Reddy VA, Saikia T, Ghoshal S, Pandit M, Babu G, Ganpathy KV, Savant D, Mitera G, Sullivan R, **Booth CM**. “Choosing Wisely” for Cancer Care in India. *Indian J Med Paed Oncol* 2020; 41(4): 567-569.
211. Pramesh CS, Chaturvedi H, Reddy VA, Saikia T, Ghoshal S, Pandit M, Babu G, Ganpathy KV, Savant D, Mitera G, Sullivan R, **Booth CM**. “Choosing Wisely” for Cancer Care in India. *Indian Journal of Surgery* 2020; 82(1): 6-8.
210. Pramesh CS, Chaturvedi H, Reddy VA, Saikia T, Ghoshal S, Pandit M, Babu G, Ganpathy KV, Savant D, Mitera G, Sullivan R, **Booth CM**. “Choosing Wisely” for Cancer Care in India. *Journal of Cancer Research and Therapeutics* 2020; 16(4): 955-956.
209. Pramesh CS, Chaturvedi H, Reddy VA, Saikia T, Ghoshal S, Pandit M, Babu G, Ganpathy KV, Savant D, Mitera G, Sullivan R, **Booth CM**. “Choosing Wisely” for Cancer Care in India. *Indian J Surg Oncol*. 2020; 11(1): 4-6.
208. \*Karim S, **Booth CM**, Brennan K, Peng Y, Siemens DR, Krzyzanowska M, Mackillop WJ. Estimating the Optimal Rate of Adjuvant Chemotherapy Utilization for Stage III Colon Cancer. *Cancer Medicine* 2019; 8(14): 5590-5599. **\*Trainee first author**
207. \*Karim S, Mackillop WJ, Brennan K, Peng Y, Siemens DR, Krzyzanowska M, **Booth CM**. Estimating the Optimal Perioperative Chemotherapy Utilization Rate for Muscle Invasive Bladder Cancer. *Cancer Medicine* 2019; 8(12): 6258-6271. **\*Trainee first author**
206. Hosier G, McGregor T, Beiko D, Jaeger M, **Booth C**, Whitehead M, Siemens DR. Persistent Opioid Use Among Patients with Urolithiasis: A Population based Study. *Eur Urol Focus*. 2020; 6(4): 745-751.
205. Mannathazhathu AS, George PS, Sudhakaran S, Vasudevan D, Krishna KM, **Booth C**, Mathew A. Factors and Thyroid Cancer Risk: A Meta-analysis. *Head & Neck* 2019; 41(12): 4199-4208.

204. Patel SV, Zhang L, Wei X, Merchant SB, Nanji S, James P, **Booth CM**. A population-based cohort study of VTE rates following surgery and during adjuvant chemotherapy in patients with colon cancer. *Dis Colon Rectum* 2020; 63(3): 336-345.
203. Gyawali B, Hwang TJ, Vokinger KN, **Booth CM**, Amir E, Tibau A. Patient-Centered Cancer Drug Development: Clinical Trials, Regulatory Approval, and Value Assessment. *Am Soc Clin Oncol Educ Book* 2019; 39:374-387.
202. Seruga B, Sullivan R, Fundytus A, Hopman WA, Ocana A, Joffe J, Bodoky G, Le Tourneau C, Vanderpuye V, Lopes G, Hammad N, Sengar M, Brundage MD, **Booth CM**. Medical Oncology Workload in Europe: One continent, several worlds. *Clin Oncol* 2020; 32(1): e19-26.
201. Caduff C, **Booth CM**, Pramesh CS, Sullivan R. India's New Health Scheme: What Does It Mean for Cancer Care? *Lancet Oncol* 2019; 20(6): 757-758.
200. \*Raphael MJ, Robinson A, **Booth CM**, O'Donnell J, Palmer M, Eisenhauer EA, Brundage MD. The Value of Progression-Free Survival as a Treatment End Point Among Patients With Advanced Cancer: A systematic review and qualitative assessment of the literature . *JAMA Oncol* 2019; 5(12): 1779-1789. **\*Trainee first author**
199. \*Raphael MJ, Siemens DR, **Booth CM**. Would regionalization of systemic cancer therapy improve the quality of cancer care? *J Oncol Pract* 2019; 15(7): 349-356. **\*Trainee first author**
198. Naci H, Davis C, Savovic J, Higgins JPT, Sterne JAC, Gyawali B, Romo-Sandoval X, Handley N, **Booth CM**. Design characteristics, risk of bias, and reporting of randomised controlled trials supporting European Medicines Agency approvals of cancer drugs, 2014-2016: Cross-sectional analysis. *BMJ* 2019; 18(366): l5221.
197. Ghate K, Amir E, Kuksis M, Hernandez-Barajas D, Rodriguez-Romo L, **Booth CM**, Vera-Badillo FE. PD-L1 Expression and Clinical Outcomes in Patients with Advanced Urothelial Carcinoma Treated with Checkpoint Inhibitors: A Meta-Analysis. *Cancer Treat Rev* 2019; 76:51-56
196. Merchant SJ, Brogly SB, **Booth CM**, Goldie C, Peng P, Nanji S, Patel SV, Lajkosz K, Baxter NN. Management of Cancer-Associated Intestinal Obstruction in the Final Year of Life. *J Palliat Care* 2020; 35(2): 84-92.
195. Saleh RR, Majeed H, Tibau A, **Booth CM**, Amir E. Undisclosed Financial Conflicts of Interest among Authors in the American Society of Clinical Oncology Clinical Practice Guidelines. *Cancer* 2019; 125(22): 4069-4075.
194. Siemens DR, Visram K, Wei X, **Booth CM**. Effect of centralization on complex surgical care: a population-based case study of radical cystectomy. *Can Urol Assoc J* 2020; 14(4): 91-96.
193. Vijaykumar DK, Arun S, Abraham AG, Hopman W, Robinson AG, **Booth CM**. Breast Cancer Care in South India: Is Practice Concordant With National Guidelines? *J Global Oncol* 2019; 5: 1-7.
192. Vera-Badillo FE, Tannock IF, **Booth CM**. Immunotherapy for Urothelial Cancer: Where are the Randomized Trials? *J Clin Oncol* 2019; 37(29): 2587-2591.

191. Warren M, Kolinsky M, Canil CM, Czaykowski P, Sridhar SS, Black PC, **Booth CM**, Kassouf W, Eapen L, Mukherjee SD, Blais N, Eigl BJ, Winquist E, Basappa NS, North SA. Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma. *Can Urol Assoc J* 2019; 26: 318-327.
190. **Booth CM** and Detsky AS. Changing Your Disclosure Slide From None To Some: Advice To Physicians At the Start Of Their Careers. *BMJ* 2019; 365:11939.
189. Mir ZM, Yu D, Merchant SJ, **Booth CM**, Patel SV. Management of Rectal Cancer in Canada: An Evidence-Based Comparison of Clinical Practice Guidelines. *Can J Surg* 2020; 63(1): E27-E34.
188. Jiang D, Chan K, Jang R, **Booth CM**, Liu G, Amir E, Mason R, Everest L, Elimova E. Anti-Cancer Drugs Approved by the Food and Drug Administration (FDA) for Gastrointestinal Malignancies: Clinical Benefit and Price Considerations. *Cancer Medicine* 2019; 8(4): 1584-1593.
187. Pramesh CS, Chaturvedi H, Reddy VA, Saikia T, Ghoshal S, Pandit M, Babu KG, Ganpathy KV, Savant D, Mitera G, Sullivan R, **Booth CM**. Choosing Wisely India: ten low-value or harmful practices that should be avoided in cancer care. *Lancet Oncology* 2019; 20(4): e218 - e223.
186. Mah JM, Dewitt Y, Groome P, Djerboua M, **Booth CM**, Flemming JA. Early hospital readmission and survival in patients with cirrhosis: A population-based study. *Canadian Liver Journal* 2019; 2(3): 109-120.
185. Ko G, Sarkaria A, Merchant SJ, **Booth CM**, Patel SV. A systematic review of outcomes after salvage abdominoperineal resection for persistent or recurrent anal squamous cell cancer. *Colorectal Disease* 2019; 21(6):632-650.
184. French SD, Green ME, Bhatia RS, Peng Y, Hayden JA, Hartvigsen J, Ivers NM, Grimshaw JM, **Booth CM**, Rühland L, Norman KE. Imaging use for low back pain by Ontario primary care clinicians: protocol for a mixed methods study - The Back ON study. *BMC Musculoskeletal Disorders* 2019; 20(1): 50.
183. Hall, SF, Webber, C, Groome, PA, **Booth, CM**, Nguyen, P, DeWit, Y. Do doctors who order more routine medical tests diagnose more cancers? A population-based study from Ontario Canada. *Cancer Med.* 2019; 8: 850-859.
182. Mah JM, DeWit Y, Djerboua M, Menard A, **Booth CM**, Flemming JA. Association Between Institutional Factors and Long-Term Survival Following Transjugular Intrahepatic Portosystemic Shunt. *Hepatology Communications* 2019; 3(6): 838-846.
- 181.\*Karim S, **Booth CM**. Effectiveness in the Absence of Efficacy: Cautionary Tales From Real-World Evidence. *Journal of Clinical Oncology* 2019; 37(13): 1047-1050. **\*Trainee first author**

180. \*Raphael MJ, Wei X, Karim S, Robinson AG, Bedard PL, **Booth CM**. Neurotoxicity Among Survivors of Testicular Cancer: A Population-Based Study. *Clinical Oncology* 2019; 31(9): 653-658. **\*Trainee first author**
179. Vanderpuye V, Hammad N, Martei Y, Hopman WM, Fundytus A, Sullivan R, Seruga B, Lopes G, Sengar M, Brundage MD, **Booth CM**. Cancer Care Workforce in Africa: Perspectives from a Global Survey. *Infectious Agents and Cancer* 2019. 14:11.
178. Merchant SJ, Brogly SB, **Booth CM**. Goldie C, Nanji S, Patel S. Palliative Care and Symptom Burden in the Last Year of Life: A Population-Based Study of Patients with Gastrointestinal Cancer. *Ann Surg Oncol* 2019; 26(8): 2336-2345.
177. Karp I, Sivaswamy A, **Booth C**. Does the use of incretin-based medications increase the risk of cancer in patients with type-2 diabetes mellitus? *Pharmacoepidemiology and Drug Safety* 2019; 28(4): 489-499.
176. Gunasekera S, Seneviratne S, Wijeratne T, **Booth CM**. Delivery of Cancer Care in Sri Lanka. *J Cancer Policy* 2018; 18: 20-24.
175. \*Raphael MR, **Booth CM**. Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Underutilized Across the 49th Parallel. *Can Urol Assoc J* 2018; 13(2): 29-31. **\*Trainee first author.**
174. \*Raphael MR, Fundytus A, Hopman W, Vanderpuye V, Seruga B, Lopes G, Hammad N, Sengar M, Brundage MD, Sullivan R, **Booth CM**. Medical Oncology Job Satisfaction: Results of a Global Survey. *Seminars in Oncology* 2018; 46(1): 73-82. **\*Trainee first author.**
173. McGee SF, AlGhareeb W, Ahmad CH, Armstrong D, Babak S, Berry S, Biagi J, **Booth C**, Bossé D, Champion P, Colwell B, Finn N, Goel R, Gray S, Green J, Harb M, Hyde A, Jeyakumar A, Jonker D, Kanagaratnam S, Kavan P, MacMillan A, Muinuddin A, Patil N, Porter G, Powell E, Ramjeeasingh R, Raza M, Rorke S, Seal M, Servidio-Italiano F, Siddiqui J, Simms J, Smithson L, Snow S, St-Hilaire E, Stuckless T, Tate A, Tehfe M, Thirlwell M, Tsvetkova E, Valdes M, Vickers M, Virik K, Welch S, Marginean C, Asmis T. Eastern Canadian Colorectal Cancer Consensus Conference 2017. *Curr Oncol* 2018; 25(4): 262-274.
172. Brennan K, Karim S, Doiron RC, Siemens DR, **Booth CM**. Venous Thromboembolism and Peri-Operative Chemotherapy for Muscle-Invasive Bladder Cancer: A Population-based Study. *Bladder Cancer* 2018; 4(4): 419-428.
171. \*Del Paggio JC, Cheng S, **Booth CM**, Cheung MC, Chan KKW. Reliability of Oncology Value Framework Outputs: Concordance Between Independent Research Groups. *J Nat Cancer Inst Spectrum* 2018; 2(3): pky050. **\*Trainee first author.**
170. Flemming JA, Dewit Y, Mah JM, Saperis J, Groome PA, **Booth CM**. Incidence of Cirrhosis in Young Birth Cohorts in Canada from 1997-2016: A Population-based Study. *Lancet Gastro & Hepatol* 2018; 4(3): 217-226.



169. Mathew A, George PS, Ramadas K, Mathew B, Kumar A, Rishni S, Jayakumar KI, **Booth CM**. Socio-demographic Factors and Stage of Cancer at Diagnosis: A Population-Based Study in South India. *J Global Oncol* 2018; 5: 1-10.
168. **Booth CM**, Karim S, Mackillop WJ. Real World Data: Towards Achieving the Achievable in Cancer Care. *Nat Rev Clin Oncol* 2018; 16(5):312-325.
167. \*Karim S, Wei X, Leveridge MJ, Siemens DR, Robinson AG, Bedard PL, **Booth CM**. Delivery of Chemotherapy for Testicular Cancer in Routine Practice: A Population-Based Study. *Urol Oncol* 2018; 37(3):183.e17-183.e24. **\*Trainee first author.**
166. Rodriguez L, Brennan K, Karim S, Nanji S, Patel SV, **Booth CM**. Characteristics, Clinical Management, and Outcomes of Young Patients with Colon Cancer: A Population-Based Study. *Clin Colorectal Cancer* 2018; 18: 30168-3.
165. \*Karim S, Harle I, O'Donnell J, Li S, **Booth CM**. Documenting Goals of Care Among Patients With Advanced Cancer: Results of a Quality Improvement Initiative. *J Oncol Prac* 2018; 14(9): e557-e565. **\*Trainee first author.**
164. Sengar M, Fundytus A, Hopman WM, Malhotra H, Gupta S, Pramesh CS, Hammad N, Sullivan R, Vanderpuye V, Seruga B, Lopes G, Brundage MD, **Booth CM**. Medical Oncology in India: Workload, Infrastructure, and Delivery of Care. *Indian J Med Ped Oncol* 2018; 40(1): 121.
163. Tibau A, Molto C, Borrell M, Del Paggio JC, Barnadas M, **Booth CM**, Amir E. Magnitude of Clinical Benefit of Cancer Drugs Approved Based on Single-Arm Trials by the US Food and Drug Administration. *JAMA Oncol* 2018; 4(11): 1610-1611.
162. Wei X, Siemens DR, **Booth CM**. Use of radiotherapy for bladder cancer: A population-based study of evolving referral and practice patterns. *Can Urol Assoc J* 2018; 13(4): 92–101.
161. **Booth CM**, Detsky AS. Why Patients Receive Treatments That Are Minimally Effective. *Nat Rev Clin Oncol* 2019; 16(1): 3-4.
160. Kitchlu A, McArthur E, Amir E, **Booth CM**, Sutradhar R, Majeed H, Silver S, Nash D, Garg A, Chan C, Kim J, Wald R. Acute Kidney Injury in Patients Receiving Systemic Treatment for Cancer: A Population-based Cohort Study. *J Nat Cancer Inst* 2019; 111(7): 727-736.
159. Rodriguez L, Olaya Vargas A, Gupta S, Shalkow-Klincovstein J, Vega-Vega L, Reyes A, Cicero-Oneto C, Mejia-Arangure J, Gonzalez-Ramella O, Pineiro-Retif R, Lopez-Facundo A, del Campo A, Tejocote I, Brennan K, **Booth CM**. Delivery of Pediatric Cancer Care in Mexico: A National Survey. *J Global Oncol* 2018; 4:1-12.
158. Gandhi N, Krishna S, **Booth CM**, Breau RH, Flood TA, Morgan SC, Schieda N, Salameh JP, McGrath TA, McInnes M. Diagnostic accuracy of MRI for tumor staging of bladder cancer: Systematic review and Meta-Analysis. *BJU Int* 2018; 122(5): 744-753.

157. Hanna TP, Nguyen P, Baetz T, Parmar A, **Booth CM**, Eisenhauer EA. A population-based study of survival impact of new targeted and immune based therapies for metastatic or unresectable melanoma. Clin Oncol 2018; 30(10): 609-617.
156. Gregg RW, Vera-Badillo FE, **Booth CM**, Mahmud A, Leveridge MJ, Brundage MD, Hanna TP. Perioperative Chemotherapy for Urothelial Carcinoma of the Upper Urinary Tract: A Systematic Review and Meta-Analysis. Crit Rev Onc Heme 2018; 128:58-64.
155. Lemke M, DeWit Y, Nanji S, **Booth C**, Flemming J. The Role of Sex in the Outcomes of Patients with Biliary Tract Cancers in Ontario: A Population-Based Study. Am J Surgery 2018; 216(6): 1118-1121.
154. \*Fundytus A, Hopman WM, Hammad N, Biagi JJ, Sullivan R, Vanderpuye V, Seruga B, Lopes G, Sengar M, Brundage MD, **Booth CM**. Medical Oncology Workload in Canada: Infrastructure, Supports, and Delivery of Clinical Care. Curr Oncol 2018; 25(3): 206-212. **\*Trainee first author.**
153. Merchant S, Brogly S, Goldie, **Booth CM**, Nanji S, Patel S, Lajkosh, Baxter NN. Palliative Care is Associated with Reduced Aggressive End of Life Care in Patients with Gastrointestinal Cancer. Ann Surg Oncol 2018; 25(6): 1478-1487.
152. Nanji S, Karim S, Tang E, Brennan K, McGuie A, Pramesh CS, **Booth CM**. Pulmonary metastasectomy for colorectal cancer: predictors of survival in routine surgical practice. Annals of Thoracic Surgery 2018; 105(6): 1605-1612.
151. Leveridge M, Siemens DR, Brenna K, Izard J, Karim S, An H, Mackillop WJ, **Booth CM**. Temporal Trends in Management and Outcomes of Testicular Cancer: A Population-Based Study. Cancer 2018; 124(13): 2724-2732.
150. Gyawali B, Sullivan R, **Booth CM**. Cancer Groundshot: Going Global Before Going To The Moon. Lancet Oncology 2018; 19(3): 288-290.
149. Eigl B, Chi K, Tu D, Hotte S, Winquist E, **Booth CM**, et al. A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209. Oncotarget 2018; 9(8): 8155-8164.
148. Krishnan A, Rajagopal MR, Karim S, Sullivan R, **Booth CM**. Palliative Care Program Development in a Low-Middle Income Country: Delivery of Care by a Non-Governmental Organization in India. J Global Oncol 2018; 4:1-8.
147. Koven RL, Nelson P, **Booth CM**. What Really Matters in the Setting of Terminal Cancer: Perspectives from a Patient, a Family Member, and an Oncologist. Can Medical Assoc J 2018; 190: E473-475.
146. \*Ghate K, Brennan K, Karim S, Siemens DR, Mackillop WJ, **Booth CM**. Concurrent Chemoradiotherapy for Bladder Cancer: Practice Patterns and Outcomes in the General Population Radiotherapy and Oncology. Radiotherapy & Oncology 2018; 127(1): 136-142. **\*Trainee first author.**

145. Enright K, Desai T, Sutradhar, Gonzalez A, Powis M, Taback N, **Booth CM**, Trudeau ME, Krzyzanowska MK. Factors associated with imaging in early breast cancer patients following initial treatment. *Curr Oncol* 2017; 25(2): 126-132.
144. \*Karim S, Zhang-Salomons J, Biagi JJ, Asmis T, **Booth CM**. Uptake and Effectiveness of FOLFIRINOX for Advanced Pancreatic Cancer: A Population-based Study. *Clin Oncol* 2018; 30(1): e16-e21. **\*Trainee first author.**
143. \*Del Paggio JC, Sullivan R, **Booth CM**. Targeting the value of targeted therapy. *Oncotarget* 2017; 8(53): 90612-90613. **\*Trainee first author.**
142. Tibau A, Molto C, Ocana A, Templeton AJ, Del Carpio LP, Del Paggio JC, Barnadas A, **Booth CM**, Amir E. Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration. *J Natl Cancer Inst* 2017; 110(5): 486-492.
141. Merchant SJ, Lajkosz K, Brogly SB, **Booth CM**, Nanji S, Patel SV, Baxter NN. The Final 30 Days of Life: A Study of Patients With Gastrointestinal Cancer in Ontario, Canada. *J Palliat Care* 2017; 32(3-4): 92-100.
140. Patel SV, Brennan KE, Nanji S, Karim S, Merchant S, **Booth CM**. Peri-operative Blood Transfusion for Resected Colon Cancer: Practice Patterns and Outcomes in a Population-Based Study. *Cancer Epidemiol* 2017; 51:35-50.
139. **Booth CM**, Karim S, Peng Y, Siemens DR, Brennan K, Mackillop WJ. Radical Treatment of the Primary Tumour in Metastatic Bladder Cancer: Potentially Dangerous Findings from Observational Data? *J Clin Oncol* 2018; 36(6): 533-535.
138. \*Fundytus A, Sullivan R, Vanderpuye V, Seruga B, Lopes G, Hammad N, Sengar M, Hopman WM, Brundage MD, **Booth CM**. Delivery of Global Cancer Care: An International Study of Medical Oncology Workload. *J Global Oncol* 2017; (4):1-11. **\*Trainee first author.**
137. Hanna TP, Baetz T, Xu J, Miao Q, Earle C, Peng Y, **Booth CM**, Petrealla T, McKay D, Nguyen P, Langley H, Eisenhauer EA. Mental health services use by melanoma patients receiving adjuvant interferon: association of pre-treatment mental health care with early discontinuation. *Current Oncology* 2017; 24(6): e503-3512.
136. \*Walker M, Doiron RC, French SD, Brennan K, Feldman-Stewart D, Siemens DR, Mackillop WJ, **Booth CM**. Peri-Operative Chemotherapy for Bladder Cancer: A Survey of Providers to Determine Barriers and Enablers. *Bladder Cancer* 2018; 4(1): 49-65. **\*Trainee first author.**
135. **Booth CM**, Karim S, Brennan K, Siemens DR, Peng Y, Mackillop WJ. Peri-operative Chemotherapy for Bladder Cancer in the General Population: Are Practice Patterns Finally Changing? *Urol Oncol* 2018; 36(3): e13-19.
134. Siemens DR and **Booth CM**. Benchmarking Our Urological Care: It's Just the Beginning. *Can Urol Assoc J* 2017; 11(8): 223-224.

133. \*Walker M, French SD, Doiron RC, Brennan K, Feldman-Stewart D, Siemens DR, Mackillop WJ, **Booth CM**. Bladder-Sparing Radiotherapy for Muscle-Invasive Bladder Cancer: A Survey of Providers to Determine Barriers and Enablers. *Radiotherapy & Oncology* 2017; 125(2): 351-356. **\*Trainee first author.**
132. \*Walker M, Doiron RC, French SD, Feldman-Stewart D, Siemens DR, Mackillop WJ, **Booth CM**. Bladder-Sparing Radiotherapy for Muscle-Invasive Bladder Cancer: A Qualitative Study to identify Barriers and Enablers. *Clin Oncol* 2017; 29(12): 818-826. **\*Trainee first author.**
131. Sullivan R, Pramesh CS, **Booth CM**. Seeing Beyond Technology in Global Cancer Care. *Nature* 2017; 549(7672): 325-328.
130. Khare SR, Aprikian A, Black P, Blais N, **Booth C**, Brimo F, Chin J, Chung P, Drachenberg D, Eapen L, Fairey A, Fleshner N, Fradet Y, Gotto G, Izawa J, Jewett M, Kulkarni G, Lacombe L, Moore R, Morash C, North S, Rendon R, Saad F, Shayegan B, Siemens R, So A, Sridhar SS, Traboulsi SL, Kassouf W. Quality Indicators in the Management of Bladder Cancer. A Modified Delphi Study. *Urol Oncol* 2017; 35(6): 328-334.
129. Harle I, Karim S, Raskin W, Hopman W, **Booth CM**. Towards Improved Goals of Care Documentation in Advanced Cancer: Report on the Development of a Quality Improvement Initiative. *Curr Oncol* 2017; 24(6): 383-389.
128. Grossmann N, Del Paggio JC, Wolf S, Sullivan R, **Booth CM**, Rosian K, Emprechtinger, Wild C. Five years of EMA-approved systemic cancer therapies for solid tumours – a comparison of two thresholds for meaningful clinical benefit. *Eur J Cancer* 2017; 82: 66-71.
127. \*Walker M, Doiron RC, French SD, Feldman-Stewart D, Siemens DR, Mackillop WJ, **Booth CM**. Peri-Operative Chemotherapy for Bladder Cancer: A Qualitative Study of Physician Knowledge, Attitudes and Behaviour. *Can Urol Assoc J* 2018; 12(4): E182-E190. **\*Trainee first author.**
126. Powis ML, Sutradhar R, Gonzalez A, Enright K, Taback N, **Booth CM**, Trudeau ME, Krzyzanowska MK. Establishing Achievable Benchmarks for Quality Improvement in Systemic Therapy for Early Stage Breast Cancer. *Cancer* 2017; 123(18): 3772-3780.
125. Enright K, Yun L, Gonzalez A, Powis M, Taback N, **Booth CM**, Trudeau ME, Krzyznowska MK. Setting quality improvement priorities for women receiving systemic therapy (ST) for early stage breast cancer (EBC) using population level administrative data. *J Clin Oncol* 2017; 35(28): 3207-3214.
124. Dabbikeh A, Peng Y, Mackillop WJ, **Booth CM**, Zhang-Salomons J. Temporal Trends In The Association Between Socioeconomic Status And Cancer Survival: A Population-Based Retrospective Study on All Cancers Diagnosed in Ontario. *CMAJ Open* 2017; 5(3): E682-E689.
123. Del Paggio JC, Sullivan R, Schrag D, Hopman WA, Azariah B, Pramesh CS, Tannock IF, **Booth CM**. Delivery of Meaningful Cancer Care: A Retrospective Cohort Study Evaluating Cost and Benefit Using ASCO and ESMO Frameworks. *Lancet Oncol* 2017; 18(7): 887-894. **\*Trainee first author.**

122. Flemming JA, Nanji S, Wei X, Webber C, Groome P, **Booth CM**. Time From Diagnostic Endoscopy to Curative Resection in Patients With Colon Cancer: A Population-Based Study. *Eur J Surg Oncol* 2017; 43(8): 1447-1455.

121. Vardy J, Stouten-Kemperman M, Pond G, **Booth C**, Rourke S, Dhillon H, Dodd A, Crawley A, Tannock IF. A mechanistic cohort study evaluating cognitive impairment in women treated for breast cancer. *Brain Imaging Behav* 2017; 13(1):15-26.

120. **Booth CM** and \*Del Paggio JC. Approvals in 2016: questioning the clinical benefit of anticancer therapies. *Nature Reviews Clin Oncol* 2017; 14(3): 135-136. **\*Trainee second author.**

119. \*Del Paggio JC, Peng Y, Wei X, Nanji S, Macdonald PH, Nair CK, **Booth CM**. Re-evaluating the Optimal Threshold for Lymph Node Harvest in Colon Cancer: Insights from a Population-Based Study. *British J Surgery* 2017; 104(8): 1087-1096. **\*Trainee first author.**

118. Leveridge MJ, Siemens DR, Izard J, Wei X, **Booth CM**. Partial Cystectomy for Urothelial Carcinoma of the Bladder: Practice Patterns and Outcomes in the General Population. *Can Urol Assoc J* 2017; 11(12): 412-418.

117. \*Karim S, Nanji S, Brennan K, Pramesh CS, **Booth CM**. Chemotherapy for Resected Colorectal Cancer Pulmonary Metastases: Utilization and Outcomes in Routine Clinical Practice. *Eur J Surg Oncol* 2017; 43(8): 1481-1487. **\*Trainee first author.**

116. \*Karim S, Brennan K, Nanji S, Berry SR, **Booth CM**. Prognostic Impact of Tumour Laterality in Early-Stage Colon Cancer: A Population-Based Study. *JAMA Oncology* 2017; 3(10): 1386-1392. **Trainee first author.**

115. Merchant S, Nanji S, Brennan K, Karim S, Patel S, Biagi JJ, **Booth CM**. Management of Stage III Colon Cancer in the Elderly: Practice Patterns and Outcomes in the General Population. *Cancer* 2017; 123(15): 2840-2849.

114. Raphael MR, Fischer HD, Fung K, Austin PC, Anderson GM, **Booth CM**, Singh S. Neurotoxicity outcomes in a population-based cohort of elderly patients treated with adjuvant oxaliplatin for colorectal cancer. *Clin Colorectal Cancer* 2017; 16(4): 397-404.

113. McInnes MDF, Nanji S, Mackillop WJ, Flemming JA, Wei X, Macdonald DB, Schieda N, **Booth CM**. Utilization of pre-operative imaging for colon cancer: a population-based study. *J Surg Oncol* 2017; 115(2): 202-207.

112. Jaeger MT, Siemens DR, Wei X, Peng P, **Booth CM**. Association Between of Anesthesiology Volumes and Early and Late Outcomes after Cystectomy for Bladder Cancer: A Population-Based Study. *Anesthesia & Analgesia* 2017; 125(1): 147-155.

111. Siemens DR, Jaeger MT, Wei X, Vera-Badillo F, **Booth CM**. Validation of Peri-operative Blood Transfusion as a Surgical Quality Indicator of Radical Cystectomy for Urothelial Bladder Cancer. *World J Urol* 2017; 35(9): 1435-1442.

110. Robinson AG, Wei X, Vera-Badillo F, Mackillop WJ, **Booth CM**. Palliative Chemotherapy for Bladder Cancer: Treatment Delivery and Outcomes in the General Population. Clin Genitourinary Cancer 2017; 15(4): 3535-541.
109. Rajagopal MR, \*Karim S, **Booth CM**. Oral Morphine Utilization in South India: A Population-Based Study. J Global Oncol 2017; 3(6): 720-727. **\*Trainee second author.**
108. \*Quirt JS, Siemens DR, Zaza K, Mackillop WJ, **Booth CM**. Patterns of Referral to Radiation Oncology Among Patients who Undergo Cystectomy for Bladder Cancer: A Population-Based Study. Clin Oncol 2017; 29(3): 171-179. **\*Trainee first author.**
107. \*Del Paggio JC, Azariah B, Sullivan R, Hopman W, James FV, Rishni S, Tannock IF, **Booth CM**. Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical Benefit? Ann Oncol 2017; 28(1): 157-162. **\*Trainee first author.**
106. \*Quirt JS, Nanji S, Wei X, Flemming JA, **Booth CM**. Is there a Gender Effect in Colon Cancer? Disease Characteristics, Management, and Outcomes in Routine Clinical Practice. Curr Oncol 2017; 24(1): e15-e23. **\*Trainee first author.**
105. Nanji S, Tsang ME, Wei X, **Booth CM**. Regional lymph node involvement in patients undergoing liver resection for colorectal cancer metastases. Eur J Surg Oncol 2017; 43(2): 322-329.
104. Nanji S, Mackillop WJ, Wei X, **Booth CM**. Simultaneous resection of primary colorectal cancer and synchronous liver metastases: A population-based study. Can J Surg 2017; 60(2): 122-128.
103. \*Krishnamurthy A, Kankesan J, Wei X, Nanji S, Biagi JJ, **Booth CM**. Chemotherapy Delivery for Resected Colorectal Cancer Liver Metastases: Management and Outcomes in Routine Clinical Practice. Eur J Surg Oncol 2017; 43(2): 364-371. **\*Trainee first author.**
102. \*Satkunam S, Wei X, Biagi JJ, Nanji S, **Booth CM**. Delivery of Adjuvant Oxaliplatin for Colon Cancer: Insights from Routine Clinical Practice. J Natl Compr Canc Netw 2016; 14(12): 1548-1554. **\*Trainee first author.**
101. \*Karim S, Del Paggio JC, Berry SR, **Booth CM**. Cancer Care in South India: Perspectives from Visiting Canadian Oncologists. Curr Oncol 2016; 23(6): e527-e529. **\*Trainee first author.**
100. \*Raphael MJ, Biagi JJ, Kong W, Mates M, **Booth CM**, Mackillop WJ. The relationship between time to initiation of adjuvant chemotherapy and survival in breast cancer: A systematic review and meta-analysis. Breast Cancer Res Treat 2016; 160(1): 17-28. **\*Trainee first author.**
99. Mackillop WJ and **Booth CM**. Stage III NSCLC – Is it time to centralize care? Nature Reviews Clin Oncol 2016; 13(11): 657-658.
98. Tannock IF, Amir E, **Booth CM**, Niraula S, Ocana A, Seruga B, Templeton AJ, Vera-Badillo F. The relevance of randomized controlled trials to clinical practice. Lancet Oncol 2016; 17(12): e560-567.

97. Nanji S, Tsang ME, Wei X, **Booth CM**. Outcomes following repeat hepatic resection for recurrent metastatic colorectal cancer: A population-based study. *Am J Surg* 2017; 213(6): 1053-1059.
96. Flemming J, Zhang-Salomons J, Nanji S, **Booth CM**. Increased Incidence But Improved Median Overall Survival for Biliary Tract Cancers in Ontario From 1994-2012: A Population-Based Study. *Cancer* 2016; 122(16): 2534-2543.
95. **Booth CM**. First of all, I feel very loved: Humanism and Cancer Care in South India. *J Global Oncol* 2016; 2(6): 353-355.
94. **Booth CM**, Nanji S, Wei X, Peng Y, Biagi JJ, Hanna TP, Krzyzanowska MK, Mackillop WJ. Adjuvant Chemotherapy for Stage II Colon Cancer: Practice Patterns and Effectiveness in the General Population. *Clin Oncol* 2017; 29(1): e29-e38.
93. \*Doiron RC, Jaeger M, **Booth CM**, Wei X, Siemens DR. Is There a Measurable Association of Epidural Use at Cystectomy and Post-operative Outcomes? A Population Based Study. *Can Urol Assoc J* 2016; 10(9-10): 321-327. **\*Trainee first author.**
92. \*Del Paggio JC, Nanji S, Wei X, MacDonald PH, **Booth CM**. Lymph Node Harvest for Colon Cancer in Routine Clinical Practice: A Population-Based Study. *Curr Oncol* 2017; 24(1): e35-e43. **\*Trainee first author.**
91. Robinson AG, Wei X, Mackillop WJ, Peng Y, **Booth CM**. Use of Palliative Chemotherapy for Advanced Bladder Cancer: Patterns of Care in Routine Clinical Practice. *J Natl Compr Canc Netw* 2016; 14(3): 291-298.
90. \*Chandhoke G, Wei X, Nanji S, Biagi J, Peng P, Krzyzanowska M, Mackillop WJ, **Booth CM**. Patterns of Referral for Adjuvant Chemotherapy for Stage II and III Colon Cancer: A Population-Based Study. *Ann Surg Oncol* 2016; 23(8): 2529-2538. **\*Trainee first author.**
89. **Booth CM**. Perioperative chemotherapy for muscle-invasive bladder cancer: Closing the gap between evidence and practice. *Can Urol Assoc J* 2016; 10(1-2): 31-32.
88. \*Doiron RC, **Booth CM**, Wei X, Siemens DR. Risk factors and timing of venous thromboembolism after radical cystectomy in routine clinical practice: a population-based study. *BJU Int* 2016; 118(5): 714-722. **\*Trainee first author.**
87. Kassouf W, Aprikian A, Black P, Kulkarni G, Izawa J, Eapen L, Fairey A, So A, North S, Rendon R, Sridhar SS, Alam T, Brimo F, Blais N, **Booth C**, Chin J, Chung P, Drachenberg D, Fradet Y, Jewett M, Moore R, Morash C, Shayegan B, Gotto G, Fleshner N, Saad F, Siemens DR. Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015. *Can Urol Assoc J* 2016; 10(1-2): e46-80.

86. Goodwin RA, Jamal R, **Booth CM**, Goss PE, Eisenhauer EA, Tu D, Shepherd LE. Prognostic and predictive effects of diabetes, hypertension, and coronary artery disease among women on extended adjuvant letrozole: NCIC CTG MA.17. *Eur J Cancer* 2016; 58: 97-103.
85. Milowsky MI, Rumble RB, **Booth CM**, Gilligan T, Eapen LJ, Hauke RJ, Boumansour P, Lee CT. Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. *J Clin Oncol* 2016; 34(16): 1945-1952.
84. Di Valentin T, Asmis T, Asselah J, Aubin F, Aucoin N, Berry S, Biagi J, **Booth CM**, Burkes R, Coburn N, Colwell B, Cripps C, Dawson LA, Dorreen M, Frechette D, Goel R, Gray S, Hammad N, Jonker D, Kavan P, Maroun J, Nanji S, Roberge D, Samson B, Seal M, Shabana W, Simunovic M, Snow S, Tehfe M, Thirlwell M, Tsvetkova E, Vickers M, Vuong T, Goodwin R. Eastern Canadian Colorectal Cancer Consensus Conference 2013: emerging therapies in the treatment of pancreatic, rectal, and colorectal cancers. *Curr Oncol* 2016; 23(1): 52-55.
83. Courneya KS, Vardy JL, O'Callaghan CJ, Friedenreich CM, Campbell KL, Prapavessis H, Crawford JJ, O'Brien P, Dhillon HM, Jonker DJ, Chua NS, Lupichuk S, Sanatani MS, Gill S, Meyer RM, Begbie S, Bonaventura T, Burge ME, Turner J, Tu D, **Booth CM**. Effects of a structured exercise program on physical activity and fitness in colon cancer survivors: One year feasibility results from the CHALLENGE Trial. *Cancer Epidemiology, Biomarkers and Prevention* 2016; 25(6): 969-977.
82. **Booth CM**, Nanji S, Wei X, Peng Y, Biagi JJ, Hanna TP, Krzyzanowska MK, Mackillop WJ. Utilization and Effectiveness of Adjuvant Chemotherapy for Stage III Colon Cancer: A Population-Based Study. *J Natl Compr Canc Netw* 2016; 14(1): 47-56.
81. \*Patafio F, Brooks SC, Wei X, Peng Y, Biagi J, **Booth CM**. Cancer mortality and published research output: Is there any relationship? *Curr Oncol* 2015; 23(2): 75-80. **\*Trainee first author.**
80. **Booth CM**, Nanji S, Wei X, Mackillop WJ. The Outcome of Resected Colorectal Cancer Lung Metastases in Routine Clinical Practice: A Population-Based Study. *Ann Surg Oncol* 2016; 23(4): 1057-1063.
79. \*Raskin W, Harle I, Hopman W, **Booth CM**. Prognosis, treatment benefit, and goals of care: what do oncologists discuss with patients who have terminal cancer? *Clin Oncol* 2016; 28(3): 209-214. **\*Trainee first author.**
78. **Booth CM**, Nanji S, Wei X, Biagi J, Krzyzanowska M, Mackillop WJ. Surgical Resection and Peri-Operative Chemotherapy for Colorectal Cancer Liver Metastases: A Population-Based Study. *Eur J Surg Oncol* 2016; 42(2): 281-287.
77. **Booth CM**, Nanji S, Wei X, Mackillop WJ. Management and Outcome of Colorectal Cancer Liver Metastases in the Elderly: A Population-Based Study. *JAMA Oncology* 2015; 1(8): 1111-1119.
76. Simos D, Catley C, van Walraven C, Arnaout A, **Booth CM**, McInnes M, Fergusson D, Dent S, Clemons M. Imaging for distant metastases in women with early stage breast cancer: A population-based, cohort study. *CMAJ* 2015; 187(12): E387-397.



75. \*Patafio FM, Siemens DR, Wei X, **Booth CM**. Is there a Gender Effect in Bladder Cancer? A Population-Based Study of Practice and Outcomes. *Can Urol Assoc J* 2015; 9(7-8): 269-274.

**\*Trainee first author.**

74. Izard JP, Siemens DR, Mackillop WJ, Wei X, Leveridge MJ, Berman DM, Peng Y, **Booth CM**. Outcomes of Squamous Histology in Bladder Cancer: A Population-Based Study Urologic Oncology: Seminars and Original Investigations. *Urol Oncol* 2015; 33(10): e7-14.

73. Arnout A, Catley C, **Booth CM**, McInnes M, Graham I, Kumar V, Simos D, vanWalraven C, Clemons M. Utilization of Preoperative MRI for Breast Cancer: A Canadian Population-based Study. *JAMA Oncology* 2015; 1(9): 1238-1250.

72. Awad S, Parker C, Harrison M, **Booth CM**, Gregg R. Testicular choriocarcinoma presenting with massive hemoptysis and endobronchial metastases. *Am J Cancer Care Rep* 2015; 3(2): 1-7.

71. Siemens DR, Mackillop WJ, Peng Y, Wei X, Berman D, **Booth CM**. Lymph Node Counts are Valid Indicators of the Quality of Surgical Care in Bladder Cancer: A Population-Based Study. *Urol Oncol* 2015; 33(10): e15-23.

70. Robinson AG, Izard J, **Booth CM**. The Role of Population-Based Observational Research in Bladder Cancer. *Bladder Cancer* 2015; 1(2): 123-131.

69. Emmenegger U, **Booth CM**, Berry SR, Sridhar SS, Winquist E, Bendali N, Chow A, Lee CR, Xu P, Man S, Kerbel RS, Ko YK. Temsirolimus Maintenance Therapy After Docetaxel Induction in Castration-Resistant Prostate Cancer. *The Oncologist* 2015; 20(12): 1351-1352,

68. **Booth CM** and Tannock IF. Adjuvant Chemotherapy for Bladder Cancer Provides Benefit to Patients: Convergence of Evidence Despite Lack of Level 1 Data. *JAMA Oncology* 2015; 1(6): 727-728.

67. Mitera G, Bezjak A, **Booth CM**, Delouya G, Desbiens C, Earle C, Laing KE, Latosinsky S, Camuso N, Agent-Katwala M, Porter G. The Choosing Wisely Canada Cancer List: Ten Low Value or Harmful Practices That Should Be Avoided In Cancer Care. *J Oncol Prac* 2015; 11(3): e296-303.

66. Harrison L, Zhang-Salmons J, Mates M, **Booth CM**, King WD, Mackillop WJ. Comparing Effectiveness to Efficacy: Outcomes of Palliative Chemotherapy for Non-Small Cell Lung Cancer in Routine Practice. *Curr Oncol* 2015; 22(3): 184-191.

65. Cunningham MS, Skrastins E, Fitzpatrick R, Jindal P, Onoko O, Yeates K, **Booth CM**, Carpenter J, Aronson KJ. Cervical cancer screening and HPV vaccine acceptability among rural and urban women in Kilimanjaro Region, Tanzania. *BMJ Open* 2015; 5(3): e005828.

64. McInnes MDF, Siemens DR, Mackillop WJ, Peng Y, Wei S, Schieda N, **Booth CM**. Utilization of pre-operative imaging for muscle-invasive bladder cancer: a population-based study. *BJU Int* 2016; 117(3): 430-438.

63. Leveridge MJ, Siemens DR, Mackillop WJ, Tannock IF, Berman DM, **Booth CM**. Radical Cystectomy and Adjuvant Chemotherapy for Bladder Cancer in the Elderly: A Population-Based Study. *Urology* 2014; 85(4): 791-798.
62. **Booth CM** and Siemens DR. Delivering High-Quality Care to Patients with Muscle-Invasive Bladder Cancer: Insights from Routine Practice in Ontario. *Can Urol Assoc J* 2014; 8 (9-10) E755-E757.
61. \*Walker M, French, SD, Feldman-Stewart D, Siemens DR, Mackillop WJ, **Booth CM**. A Call for Theory-Informed Approaches to Knowledge Translation Studies: A Case Study of Chemotherapy for Bladder Cancer. *Curr Oncol* 2014; 22(3): 178-181. **\*Trainee first author.**
60. **Booth CM**, Siemens DR, Wei X, Peng Y, Berman DM, Mackillop WJ. Pathologic factors associated with survival benefit from adjuvant chemotherapy: a population-based study of bladder cancer. *BJU Int* 2015; 116(3): 373-381.
59. Berman DM, Kawashima A, Peng Y, Mackillop WJ, Siemens DR, **Booth CM**. Reporting trends and prognostic significance of lymphovascular invasion in muscle-invasive urothelial carcinoma: a population-based study. *Int J Urol* 2015; 22(2): 163-170.
58. Siemens DR, Mackillop WJ, Peng Y, Berman D, Elharram A, Rhee J, **Booth CM**. Processes of care and the impact of surgical volumes on cancer-specific survival: a population-based study in bladder cancer. *Urology* 2014; 84(5): 1049-1057.
57. Sridhar SS, Joshua AM, Gregg R, **Booth CM**, Murray N, Golubovic J, Wang L, Harris P, Chi KN. A phase II study of GW786034 (Pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer. *Clin Genitourin Cancer* 2015; 13(2): 124-129.
56. **Booth CM**, Siemens DR, Peng Y, Tannock IF, Mackillop WJ. Delivery of Peri-Operative Chemotherapy for Bladder Cancer in Routine Clinical Practice. *Ann Oncol* 2014; 25(9): 1783-1788.
55. **Booth CM**, Siemens DR, Peng Y, Mackillop WJ. Patterns of Referral for Peri-Operative Chemotherapy Among Patients with Muscle-Invasive Bladder Cancer: A Population-Based Study. *Urol Oncol* 2014; 32(8): 1200-1208.
54. Wasserman DW, Moulos M, Hopman WM, **Booth CM**, Goodwin R, Biagi JJ. Reasons for delay in time to initiation of adjuvant chemotherapy for colon cancer. *J Oncol Pract* 2014: Epub ahead of print August 19, 2014.
53. Robinson AG, **Booth CM**, Eisenhauer EA. Progression-Free Survival as an Endpoint in Solid Tumours - Perspectives from Clinical Trials and Clinical Practice. *Eur J Cancer* 2014; 50(13): 2303-2308.
52. Robinson AG, **Booth CM**, Eisenhauer EA. Disease-Free Survival as an Endpoint in the Treatment of Solid Tumors - Perspectives from Clinical Trials and Clinical Practice. *Eur J Cancer* 2014; 50(13): 2298-2302.

51. Courneya KS, Vardy J, Gill S, Jonker D, O'Brien P, Friedenreich CM, Dhillon H, Wong RKS, Meyer RM, Crawford JJ, Campbell KL, Prapavessis H, O'Callaghan C, Turner J, Spencer LM, van der Ploeg HP, Tu D, **Booth CM**. Update on the Colon Health and Life-Long Exercise Change (CHALLENGE) Trial: A Phase III Study of the Impact of an Exercise Program on Disease-Free Survival in Colon Cancer Survivors. *Current Colorectal Cancer Reports* 2014; 10(3): 321-328.
50. **Booth CM**, Siemens DR, Li G, Peng Y, Kong W, Berman DM, Mackillop WJ. Curative therapy for bladder cancer in routine clinical practice: a population-based outcomes study. *Clin Oncol* 2014; 26(8): 506-514.
49. **Booth CM**, Siemens DR, Li G, Peng Y, Tannock IF, Kong W, Berman DM, Mackillop WJ. Perioperative chemotherapy for muscle-invasive bladder cancer: a population-based outcomes study. *Cancer* 2014; 120(11): 1630-1638.
48. \*Patafio FM, Mackillop WJ, Feldman-Stewart D, Siemens DR, **Booth CM**. Why is perioperative chemotherapy for bladder cancer underutilized? *Urol Oncol* 2014; 32(4): 391-395. **\*Trainee first author.**
47. Gupta S, Kong W, **Booth CM**, Mackillop WJ. Impact of concomitant chemotherapy on outcomes of radiation therapy for head-and-neck cancer: a population-based study. *Int J Radiat Oncol Biol Phys* 2014; 88(1): 115-121.
46. **Booth CM**. Optimizing care and outcomes of patients with muscle-invasive bladder cancer. *Can Urol Assoc J* 2013; 7 (9-10) e625-627.
45. **Booth CM** and Tannock IF. Randomized control trials and population-based observational research: partners in the evolution of medical evidence. *Br J Cancer* 2014; 110(3); 551-555.
44. \*Fralick M, Ray M, Fung C, **Booth CM**, Mallick R, Clemons M. Bevacizumab for advanced breast cancer: hope, hype, and hundreds of headlines. *The Oncologist* 2013; 18(11): 1174-1179. **\*Trainee first author.**
43. \*Pak Ho Chan B, **Booth CM**, Manduch M, Touma N. Spontaneous Regression of Metastatic Pulmonary Renal Cell Carcinoma in the Setting of Sarcomatoid Differentiation of the Primary Tumour. *Can Urol Assoc J* 2013; 7(9-10): E587-589. **\*Trainee first author.**
42. Djulbegovic B, Kumar A, Miladinovic B, Reljic T, Galeb S, Mhaskar A, Mhaskar R, Hozo I, Tu D, Stanton HA, **Booth CM**, Meyer RM. Treatment success in cancer: industry compared to publicly sponsored randomized controlled trials. *PLoS One* 2013; 8(3): e58711.
41. \*Ramjeesingh R, Meyer RM, Brouwers MC, **Booth CM**. Translation of evidence into funding policy: An overview of guidelines from the Cancer Care Ontario's Program in Evidence-Based Care. *Curr Oncol* 2013; 20(1): e21-33. **\*Trainee first author.**
40. \*Kankesan J, Shepherd FA, Peng Y, Darling G, Li G, Kong W, Mackillop WJ, **Booth CM**. Factors Associated with Referral to Medical Oncology and Subsequent Use of Adjuvant Chemotherapy for Non-Small Cell Lung Cancer (NSCLC): A Population-Based Study. *Curr Oncol* 2013; 20(1): 30-37. **\*Trainee first author.**

39. **Booth CM** and Mackillop WJ. Achieving the achievable in muscle-invasive bladder cancer. *Can Urol Assoc J* 2012; 6(4): 251-252.
38. **Booth CM**, Shepherd FA, Peng Y, Darling G, Li G, Kong W, Biagi JJ, Mackillop WJ. Time to Adjuvant Chemotherapy and Survival in Non-Small Cell Lung Cancer: A Population-Based Study. *Cancer* 2013; 119(6): 1243-1250.
37. Di Valentin T, Alam Y, Ali Alsharm A, Arif S, Aubin F, Biagi J, **Booth CM**, et al. Eastern Canadian Colorectal Cancer Consensus Conference: application of new modalities of staging and treatment of gastrointestinal cancers. *Curr Oncol* 2012; 19(3): 169-174.
36. \*Altwairqi AK, **Booth CM**, Hopman W, Baetz TD. Discordance Between Conclusions Stated in the Abstract and Conclusions in the Article: Analysis of Published Randomized Controlled Trials of Systemic Therapy in Lung Cancer. *J Clin Oncol* 2012; 30 (28): 3552-3557. **\*Trainee first author.**
35. **Booth CM** and Eisenhauer EA. Progression Free Survival: Meaningful or Simply Measurable? *J Clin Oncol* 2012; 30(10):1030-1033.
34. Cuffe S, **Booth CM**, Peng Y, Darling G, Li G, Kong W, Mackillop WJ, Shepherd FA. Adjuvant Chemotherapy for Non-Small Cell Lung Cancer in the Elderly: A Population-Based Study in Ontario, Canada. *J Clin Oncol* 2012; 30(15): 1813-1821.
33. **Booth CM**, Shepherd FA, Peng Y, Darling G, Li G, Kong W, Mackillop WJ. Adjuvant Chemotherapy for Non-Small Cell Lung Cancer: Practice Patterns and Outcomes in the General Population of Ontario, Canada. *J Thorac Oncol* 2012; 7(3):559-566.
32. \*Kay A, Higgins J, Day A, Meyer RM, **Booth CM**. Randomized Controlled Trials in the Era of Molecular Oncology: Methodology, Biomarkers, and Endpoints. *Annals Oncol* 2012; 23(6): 1646-1651. **\*Trainee first author.**
31. Biagi JJ, \*Raphael MJ, Mackillop WJ, Kong W, King WD, **Booth CM**. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. *JAMA* 2011; 305(22): 2335-2342. **\*Trainee second author.**
30. **Booth CM** and Rapoport B. Uptake of novel medical therapies in the general population. *Curr Oncol* 2011; 18(3):105-108.
29. **Booth CM**, \*Ohorodnyk P, Zhu L, Tu D, Meyer RM. Randomized Controlled Trials in Oncology Closed Early for Benefit: Trends in Methodology, Results, and Interpretation. *Eur J Cancer* 2011; 47(6): 854-863. **\*Trainee second author.**
28. **Booth CM**. Evaluating patient-centered outcomes in the randomized controlled trial and beyond: informing the future with lessons from the past. *Clin Cancer Res* 2010; 16(24): 5963-5971.
27. **Booth CM**, Shepherd FA, Peng Y, Darling G, Li G, Kong W, Mackillop WJ. Adoption of Adjuvant Chemotherapy for Non-Small Cell Lung Cancer: A Population-Based Outcomes Study. *J Clin Oncol* 2010; 28(21): 3472-3478.

26. **Booth CM**, Li G, Zhang-Salomons J, Mackillop WJ. The Impact of Socioeconomic Status on Stage of Cancer at Diagnosis and Survival: A Population-based Study in Ontario, Canada. *Cancer* 2010; 116 (17): 4160-4167.
25. Seruga B, Hertz PC, Wang L, **Booth CM**, Cescon DW, Krzyzanowska M, Tannock IF. Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer. *Ann Oncol* 2010; 21(7): 1411-1418.
24. Chakrabarti S, **Booth CM**, Detsky AS, Gold W. Elements of Confusion. *Journal of Hospital Medicine* 2010; 5(9): 560-564.
23. **Booth CM**, Le Maître A, Ding K, Farn K, Fralick M, Phillips C, Cescon DW, Meyer RM. Presentation of non-final results of randomized controlled trials (RCTs) at major oncology meetings. *J Clin Oncol* 2009; 27(24): 3938-3944.
22. \*Ohorodnyk P, Eisenhauer EA, **Booth CM**. Clinical Benefit in Oncology Trials: Is this a patient-centered or tumor-centered endpoint? *Eur J Cancer* 2009; 45(13): 2249-2252. **\*Trainee first author.**
21. **Booth CM** and Mackillop WJ. Translating New Medical Therapies into Societal Benefit: The Role of Population-Based Outcome Studies. *JAMA* 2008; 300(18): 2177-2179.
20. **Booth CM**, Cescon DW, Wang L, Tannock IF, Krzyzanowska MK. Evolution of The Randomized Controlled Trial (RCT) in Oncology Over Three Decades. *J Clin Oncol* 2008; 26(33): 5458-5464.
19. **Booth CM** and Tannock IF. Reflections on Medical Oncology. Twenty-five Years of Clinical Trials in Oncology: Where Have We Come and Where Are We Going? *J Clin Oncol* 2008; 26(1):6-8.
18. Courneya KS, **Booth CM**, Gill S et al. The Colon Health and Life-Long Exercise Change trial: a randomized trial of the National Cancer Institute of Canada Clinical Trials Group. *Curr Oncol* 2008; 15(6):271-278.
17. **Booth CM**, Calvert AH, Giaccone G, Lobbezoo MW, Eisenhauer EA, Seymour LK. Design and Conduct of Phase II Studies of Targeted Anticancer Therapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies (MDICT). *Eur J Cancer* 2008; 44(1):25-29.
16. **Booth CM**, Calvert AH, Giaccone G, Lobbezoo MW, Seymour LK, Eisenhauer EA. Endpoints and Other Considerations in Phase I Studies of Targeted Anticancer Therapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies (MDICT). *Eur J Cancer* 2008; 44(1):19-24.
15. \*Mates M, Dudgeon D, Hookey LC, Hurlbut DJ, Belliveau P, **Booth CM**. Intractable nausea in a patient with metastatic colorectal cancer following insertion of a colonic stent. *J Pain Symptom Manage* 2008; 36(1): e6-e10. **\*Trainee first author.**

14. **Booth CM**, Clemons M, Dranitsaris G, et al. Chemotherapy induced nausea and vomiting in breast cancer patients: a prospective observational study. *J Support Oncol* 2007; 5(8):374-380.
13. **Booth CM**, Dranitsaris G, Gainford C, Berry S, Fralick M, Fralick J, Sue J, Clemons M. External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer. *BMC Cancer* 2007; 7:110.
12. **Booth CM**, Shepherd FA. Adjuvant chemotherapy for resected non-small cell lung cancer. *J Thoracic Oncol.* 2006; 1(2):180-187.
11. Detsky ME, McDonald DR, Tomlinson GA, McCrory DC, Simel DL, **Booth CM**. The Rational Clinical Examination: Does this patient with headache have a migraine or need neuroimaging? *JAMA.* 2006; 296(10):1274-1283.
10. Myckan KM, **Booth CM**, Mocarski E. *Pasturella multocida* bacteremia and tubovarian abscess. *Obstet Gynecol.* 2005; 106:1220-1222.
9. **Booth CM**, Stewart TE. SARS and critical care medicine: The Toronto experience. *Crit Care Med.* 2005; 33(1):S53-60.
8. Zimmermann C, Seccarrecia D, **Booth CM**, Cottrell W. Rotation to methadone after dose escalation of hydromorphone. *J Pain Palliat Care Pharmacother.* 2005; 19(2):25-31
7. **Booth CM**, Boone RH, Tomlinson GA, Detsky AS. The Rational Clinical Examination. Is this patient dead, vegetative, or severely neurologically impaired? Assessing outcome in comatose survivors of cardiac arrest. *JAMA.* 2004; 291(7):870-879.
6. **Booth CM**, Stewart TE. SARS and critical care medicine. *Yearbook of Intensive Care and Emergency Medicine.* Ed: J.-L. Vincent. Springer. 2004:333-342.
5. **Booth CM**, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. *JAMA.* 2003; 289(21):2801-2809.
4. **Booth CM**, Stewart TE. Communication in the Toronto critical care community: important lessons learned during SARS. *Critical Care.* 2003; 7(6):405-406.
3. **Booth CM**, Heyland DK, Paterson WP. Gastrointestinal promotility agents in the critical care setting: A systematic review of the evidence. *Crit Care Med.* 2002; 30(7):1429-1435.
2. **Booth CM**, Katz K, Brunton J. Clinical Vignette: Fever and a Rat Bite. *Can J Inf Dis.* 2002; 13:269-272.
1. **Booth CM**, MacLean JD. Knowledge, treatment-seeking patterns and socioeconomic impact of malaria on the Essequibo Coast of Guyana. *McGill Journal of Medicine.* 2001; 6(1): 17-25.

## PUBLISHED LETTERS

15. Tannock IF, **Booth CM**, Gyawali B, Joshua A. The ACIS Trial for Prostate Cancer: An Appeal for Transparent Reporting. *Lancet Oncol* 2021; 23(1): e4.
14. Del Paggio J, Eisenhauer E, **Booth CM**. Randomized Clinical Trials in the Era of Precision Oncology—The Role of End Points, Industry Funding, and Medical Writing Integrity—Reply. *JAMA Oncology* 2021; 7(10): 1579-1580.
13. Robinson AG, Gyawali B, **Booth CM**. Are patients with Lung Cancer at a higher risk of SARS COV-2 acquisition or of SARS COV-2 diagnosis. *JAMA Oncology* 2020; 6(9): 1471-1472.
12. Prasad V and **Booth CM**. Reply: Statistical significance and clinical evidence - Authors' reply. *Lancet Oncol* 2020; 21(3): e119.
11. Vera-Badillo F, Robinson A, Berman D, **Booth CM**. Value of biomarker expression for randomized clinical trial design: one (more) missed opportunity. *J Clin Oncol* 2020; 38(6):649-651.
10. Pramesh CS, Sullivan R, **Booth CM**. Choosing Wisely India: Ten Low Value or Harmful Practices That Should Be Avoided In Cancer Care. Reply to Letter. *Lancet Oncology* 2019; 20(5):e241.
9. Narod S, **Booth CM**, Foulkes WD. Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer. *N Engl J Med* 2017; 377(18): 1792.
8. Del Paggio JC, Sullivan R, Hopman WM, **Booth CM**. Re-Aligning the ASCO and ESMO Clinical Benefit Frameworks for Modern Cancer Therapies. *Ann Oncol* 2017: ePub ahead of print November 3, 2017.
7. Berman DM, Kawashima A, Peng Y, Mackillop WJ, Siemens DR, **Booth CM**. Response to editorial comments to Reporting trends and prognostic significance of lymphovascular invasion in muscle-invasive urothelial carcinoma: a population-based study. *Int J Urol* 2015; 22(2): 172.
6. Siemens DR and **Booth CM**. Reply to comments on Processes of care and the impact of surgical volumes on cancer-specific survival: a population-based study in bladder cancer. *Urology* 2014; 84(5):1056-1057.
5. **Booth CM** and Tannock IF. Evaluation of treatment benefit: randomized controlled trials and population-based observational research? (Letter) *J Clin Oncol* 2013; 31(26): 3298-3299.
4. Biagi JJ, King WD, **Booth CM**. Time to Initiation of Adjuvant Chemotherapy and Survival in Colorectal Cancer—Reply. *JAMA* 2011; 306(11): 1199-1200.
3. **Booth CM**, Ohorodnyk P, Eisenhauer EA. Call for Clarity in the Reporting of Benefit Associated with Anticancer Therapies (Letter), *J Clin Oncol* 2009; 27(33): e213-214.
2. **Booth CM**. Bevacizumab in Metastatic Colorectal Cancer: A Challenge to the Current Paradigm (Letter). *J Clin Oncol* 2008; 26(12):4693-4694.

1. **Booth CM**, Pater JL, Goss PE. Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant tamoxifen (Letter). *Cancer*. 2007; 109(9):1927-8.

## BOOK CHAPTERS

**Booth CM** and Simel DL. Outcome for comatose survivors of cardiac arrest. In: *The Rational Clinical Examination: Evidence-Based Clinical Diagnosis*. Eds. Simel DL, Rennie D. Pub JAMAevidence McGraw-Hill, New York, USA. pp. 215-226, 2009.

## OTHER REPORTS

**Booth CM**. Temporal Trends in Clinical Trials and the Benefit of New Cancer Therapies: Identifying High Value Treatment for Patients. A Technical Report Commissioned by the World Health Organization. October 2018.

Merchant SJ and **Booth CM**. Understanding patient, family and provider perceptions of palliative care. Commissioned by the ASCO Daily Post October 2018.

## PUBLISHED ABSTRACTS

**As of January 2020 I no longer add abstracts to my CV as I do not believe they represent meaningful scholarship in their own right. Any abstracts I do submit to major meetings are done for the career development of my trainees and will ultimately appear on my CV as fully published papers in peer-reviewed journals.**

**Total published abstracts: 132**

**Total published abstracts as first author: 21**

**Total published abstracts as senior author: 55**

132. Khalid S, Basulaiman BM, Emack J, **Booth CM**, Hernandez-Barajas D, Duran I, Smoragiewicz M, Amir E, Vera-Badillo F. FGFR3 mutation as a prognostic indicator in patients with urothelial carcinoma: A systematic review and meta-analysis. 2019 Genitourinary Cancers Symposium. *J Clin Oncol* 37, 2019 (suppl 7S; abstr 411)

131. Zimmermann C, Hannon B, Krzyzanowska MK, Li M, Rodin G, Pope A, Swami N, Giruparajah M, Howell D, Oza AM, Warr D, Knox JJ, Leighl NB, Sridhar SS, Prince RM, Lheureux S, Hansen AR, **Booth CM**, Dudgeon DJ, Le LW, STEP Trial Group. Phase 2 trial of Symptom screening with Targeted Early Palliative care (STEP) for patients with advanced cancer. 2019 ASCO Annual Meeting. *J Clin Oncol* 37, 2019 (suppl; abstr 11604)

130. Jalan D, Rubagumya F, Hopman WM, Vanderpuye VD, Lopes G, Seruga B, **Booth CM**, Berry SR, Hammad N. Training of oncologists: Results of a global survey. 2019 ASCO Annual Meeting. *J Clin Oncol* 37, 2019 (suppl; abstr 10526)



129. Clemons MJ, Ong M, Stober C, Ernst DS, **Booth CM**, Canil CM, Mates M, Robinson AG, Blanchette PS, Joy AA, Hilton JF, Aseyev O, Pond GR, Hutton B, Jeong A, Vandermeer L, Fergusson D. A randomized trial comparing four-weekly versus 12-weekly administration of bone-targeted agents (denosumab, zoledronate, or pamidronate) in patients with bone metastases from either breast or castration-resistant prostate cancer. 2019 ASCO Annual Meeting. J Clin Oncol 37, 2019 (suppl; abstr 11501)
128. **Booth CM**, Raphael MJ, Wei X, Soares C, Bedard PL, Leveridge M, Siemens DR, Robinson AG. Utilization of mental health services among survivors of testicular cancer: A population-based study. 2019 ASCO Annual Meeting. J Clin Oncol 37, 2019 (suppl; abstr e16062).
127. **Booth CM**, Raphael MJ, Wei X, Robinson AG, Bedard PL, Karim S, Loughheed MD. Delivery of bleomycin among patients with testicular cancer: A population-based study of pulmonary monitoring and toxicity. 2019 ASCO Annual Meeting. J Clin Oncol 2019; 37(15S): e16056.
126. Molto Valiente C, Borrell M, Ocana Fernandez A, Templeton AJ, del Crpio LP, Del Paggio J, Baradas A, **Booth CM**, Tibau A, Amir E. Magnitude of Clinical Benefit of Cancer Drugs Approved Based on Single-Arm Trials (SAT) by the US Food and Drug Administration (FDA). 2018 ESMO Annual Meeting. Ann Oncol 2018; 29(8S): viii562-viii575.
125. Brundage MD, Groome P, Hanna T, **Booth CM**, Kong W, Dyer, T, Carter B, Mackillop WJ. Cancer survival outcomes in Ontario, Canada: Significant unexplained variation. 2018 ASCO Quality of Care Symposium. J Clin Oncol 2018 ; 36 (30S): 36.
124. O'Donnell J, Robinson AR, **Booth CM**, Koven R, Eisenhauer EA, Brundage MD. Imaging progression-free survival: How much does it matter to patients? 2018 ASCO Quality of Care Symposium. J Clin Oncol 2018; 36 (30S): 99.
123. Sridhar SS, Blais N, Tran B, Reaume N, North SA, Stockler MR, Chi KN, Flshner NE, Liu G, Robinson JW, Mukherjee S, Rahim Y, Winquist E, **Booth CM**, Nguyen N, Beardsley EK, Alimohamed NS, McDonald GT, Ding K, Parulekar WR. CCTG BL12: Randomized phase II trial comparing nab-paclitaxel (Nab-P) to paclitaxel (P) in patients (pts) with advanced urothelial cancer progressing on or after a platinum containing regimen (NCT02033993). 2018 ASCO Annual Meeting. J Clin Oncol; 36 (S): 4505.
122. \*Del Paggio JC, Fundytus AM, Hopman WM, Pater JL, Chen BE, Brundage MD, Hay AE, **Booth CM**. A value framework analysis of the Canadian Cancer Trials Group. 2018 ASCO Annual Meeting. J Clin Oncol; 36 (S): 6614. **\*Trainee first author.**
121. Molto Valiente C, Amir E, Ocana A, Templeton A, Carpio Huerta L, Del Paggio J, Barnadas A, **Booth C**, Tibau C. Magnitude of Clinical Benefit of Randomized Controlled Trials Supporting US Food and Drug Administration Approval of Drugs for Solid Tumours. 2017 ESMO Annual Meeting. Ann Oncol; 28(5S): 1441.
120. Harle I, Karim S, **Booth CM**. Goals of care documentation in advanced cancer. 2017 ASCO Palliative and Supportive Care in Oncology Symposium. J Clin Oncol; 35 (31S), 58.

119. Krzyzanowska MK, Powis ML, Taback N, Diong C, Enright K, **Booth CM**, Trudeau M. Reliability of Administrative Data for Evaluating Quality of Systemic Cancer Treatment. 2017 ASCO Annual Meeting, J Clin Oncol; 35(15S), e18269.
118. \*Fundytus A, Sullivan R, Vanderpuye V, Seruga B, Lopes G, Hammad N, Sengar M, Hopman WM, Brundage MD, **Booth CM**. Delivering Global Cancer Care: An International Study of Medical Oncology Workload. 2017 ASCO Annual Meeting, J Clin Oncol; 35(15S), e18080. **\*Trainee first author.**
117. \*Ghate K, Brennan K, Karim S, Mackillop WJ, **Booth CM**. Concurrent Chemoradiotherapy for Bladder Cancer: Practice Patterns and Outcomes in the General Population. 2017 ASCO Annual Meeting, J Clin Oncol; 35(15S), e16025. **\*Trainee first author.**
116. \*Karim S, Brennan K, Nanji S, Berry SR, **Booth CM**. Prognostic Impact of Tumour Laterality in Early-Stage Colon Cancer: A Population-Based Study. 2017 ASCO Annual Meeting, J Clin Oncol; 35(15S), e15148. **\*Trainee first author.**
115. \*Del Paggio JC, Sullivan R, Scrag D, Hopman W, Azariah B, Pramesh CS, Tannock I, **Booth CM**. Delivery of Meaningful Cancer Care: Evaluating Benefit and Cost of Cancer Therapies Using ASCO and ESMO Frameworks. 2017 ASCO Annual Meeting, J Clin Oncol; 35(15S), 6609. **\*Trainee first author.**
114. \*Karim S, Brennan K, Peng Y, Mackillop WJ, **Booth CM**. Estimating the Optimal Rate of Adjuvant Chemotherapy in Stage III Colon Cancer. 2017 ASCO Annual Meeting, J Clin Oncol; 35(15S), 6591. **\*Trainee first author.**
113. Eigel BJ, Winkvist E, Tu D, Hotte SJ, Canil CM, Gregg RW, Zulfiqar M, North SA, Ellard S, Ruether JD, Le LH, Kakumanu AS, Theis A, **Booth CM**, Potvin KR, Chi KN, Seymour L. A randomized phase II study of pelareorep (REO) plus docetaxel vs. docetaxel alone in patients with metastatic castration resistant prostate cancer (mCRPC): Canadian Cancer Trials Group study IND 209. 2017 ASCO Annual Meeting, J Clin Oncol; 35(15S), 5021.
112. **Booth CM**, Karim S, Brennan K, Siemens DR, Mackillop W. Peri-operative chemotherapy for bladder cancer in the general population: Are practice patterns finally changing? 2017 European Cancer Congress, Eur J Cancer; 72(S1), 191.
111. \*Karim S, Zhang-Salomons J, Biagi JJ, Asmis T, **Booth CM**. Uptake and effectiveness of FOLFIRINOX for advanced pancreas cancer: A population-based study. 2017 ASCO Quality Care Symposium, J Clin Oncol; 35(8S), 245. **\*Trainee first author.**
110. \*Karim S, Nanji S, Brennan K, Pramesh CS, **Booth CM**. Chemotherapy for resected colorectal cancer pulmonary metastases: Utilization and outcomes in routine clinical practice. 2017 ASCO Quality Care Symposium, J Clin Oncol; 35(8S), 236. **\*Trainee first author.**
109. Hanna TP, Baetz TD, Xu J, Miao Q, Earle C, Peng Y, **Booth CM**, Petrella TM, McKay D, Nguyen P, Langley H, Eisenhauer EA. Toxicity of high-dose interferon for high-risk melanoma in Ontario: A population-based study of health services use. 2017 ASCO Quality Care Symposium, J Clin Oncol; 35(8S), 31.

108. Powis ML, Taback N, Diong C, Enright K, **Booth CM**, Trudeau ME, Krzyzanowska MK. Reliability of administrative data for evaluating the quality of systemic therapy for cancer. 2017 ASCO Quality Care Symposium, J Clin Oncol; 35(8S), 208.
107. \*Del Paggio JC, Azariah B, Sullivan R, Hopman W, James FV, Roshni S, Tannock IF, **Booth CM**. Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical Benefit? 2017 European Society of Medical Oncology Annual Meeting, Ann Oncol; 27(S6), 1365PD. **\*Trainee first author.**
106. Nanji S, Del Paggio JC, Peng P, Wei X, Macdonald PH, Nair CK, **Booth CM**. Re-evaluating the optimal threshold for lymph node (LN) harvest in colon cancer: Insights from a population-based study. 2016 Canadian Association of General Surgeons Annual Meeting, Can J Surg; 59 (4S1), S140.
105. Nanji S, Biagi J, Mackillop W, Wei X, Peng Y, Hanna T, Krzyzanowska M, **Booth CM**. Utilization and effectiveness of adjuvant chemotherapy (ACT) for colon cancer (CC) in the general population. 2016 Canadian Association of General Surgeons Annual Meeting, Can J Surg; 59 (4S1), S140.
104. Siemens DR, Jaeger M, Wei X, Vera-Badillo F, **Booth C**. Validation of Peri-operative Blood Transfusion as a Surgical Quality Indicator of Cystectomy: A Population-Based Study. 2016 American Urological Association Annual Meeting, J Urol; 195(4S), MP6315.
103. Siemens DR, Jaeger M, Wei X, **Booth C**. Impact of Anesthesiology Volumes on Early and Late Outcomes after Cystectomy: A Population-Based Study. 2016 American Urological Association Annual Meeting, J Urol; 195(4S), MP0604.
102. Enright K, Desai T, Sutradhar R, Gonzalez A, Powis ML, Taback N, **Booth CM**, Trudeau ME, Krzyzanowska MK. Identifying opportunities to improve quality of cancer care: An evaluation of the use of diagnostic imaging in women curatively treated for early breast cancer (EBC). 2016 ASCO Annual Meeting, J Clin Oncol; 34(15S), 6603.
101. Powis ML, Sutradhar R, Gonzalez A, Enright K, Taback N, **Booth CM**, Trudeau ME, Krzyzanowska MK. Establishing achievable benchmarks for quality improvement in systemic therapy for early stage breast cancer. 2016 ASCO Annual Meeting, J Clin Oncol; 34(15S), 6591.
100. Courneya KS, Vardy JL, O'Callaghan CJ, Friedenreich C, Campbell KL, Prapavessis H, Crawford JJ, O'Brien P, Dhillon HM, Jonker DJ, Chua NS, Lupichuk SM, Sanatani MS, Gill S, Meyer RM, Begbie S, Bonaventura A, Burge ME, Tu D, **Booth CM**. Effects of a structured exercise program on physical activity and health-related fitness in colon cancer survivors: One year feasibility results from the NCIC CTG CO.21 (CHALLENGE) trial. 2016 ASCO Annual Meeting, J Clin Oncol; 34(15S), 3621.
99. Ghate K, Burkes RL, Brezden C, Zbuk KM, Meyers BM, Levine O, Spadafora S, Welch S, Ko YJ, Davdani S, Hopman WM, **Booth CM**, Goodwin RA, Biagi JJ. Reasons for delay in time to initiation of adjuvant chemotherapy (TTAC) for colon cancer (CC): Analysis from six academic centers in Ontario, Canada. 2016 ASCO Annual Meeting, J Clin Oncol; 34(15S), 6541.

98. \*Krishnamurthy A, Kankesan J, Wei X, Nanji S, Biagi JJ, **Booth CM**. Chemotherapy delivery for resected colorectal cancer liver metastases: Management and outcomes in routine clinical practice. 2016 ASCO Annual Meeting, J Clin Oncol; 34(15S), 18089. **\*Trainee first author.**
97. \*Satkunam N, Wei X, Biagi J, Nanji S, **Booth CM**. Delivery of adjuvant FOLFOX for colon cancer: Insights from routine clinical practice. 2016 ASCO Annual Meeting, J Clin Oncol; 34(15S), 15110. **\*Trainee first author.**
96. \*Del Paggio JC, Peng Y, Nanji S, Macdonald PH, Nair CK, **Booth CM**. Re-evaluating the optimal threshold for lymph node (LN) harvest in colon cancer: Insights from a population-based study. 2016 ASCO Annual Meeting, J Clin Oncol; 34(15S), 3610. **\*Trainee first author.**
95. Raphael MJ, Fischer H, Fung K, Austin P, Anderson G, **Booth CM**, Singh S. Oxaliplatin associated neurotoxicity outcomes among older adults with colorectal cancer: a population-based study. 2016 ASCO Annual Meeting, J Clin Oncol; 34(15S), 18034.
94. Vardy JL, Stouten-Kemperman M, Pond GR, **Booth CM**, Rourke S, Dhillon HM, Dodd A, Crawley A, Tannock IF. Do women who self-report cognitive symptoms after breast cancer treatment have more cognitive impairment than those who do not report symptoms? A mechanistic cohort study with functional brain MRI. 2016 ASCO Annual Meeting, J Clin Oncol; 34(15S), 10097.
93. **Booth CM**, Nanji S, Wei X, Peng Y, Biagi JJ, Hanna TP, Krzyzanowska MK, Mackillop WJ. Adjuvant chemotherapy for stage II colon cancer: Practice patterns and effectiveness in the general population. 2016 ASCO Annual Meeting, J Clin Oncol; 34(15S), 6569.
92. Powis M, Gonzalez A, Sutradhar R, Enright K, Taback N, **Booth CM**, Trudeau ME, Krzyznowska MK. Establishing achievable benchmarks for quality improvement in systemic therapy for early-stage breast cancer. 2016 ASCO Quality Care Symposium, J Clin Oncol; 34(7S), 263.
91. Enright K, Yun L, Gonzalez A, Powis M, Taback N, **Booth CM**, Trudeau ME, Krzyznowska MK. Setting quality improvement priorities for women receiving systemic therapy (ST) for early stage breast cancer (EBC) using population level administrative data. 2016 ASCO Quality Care Symposium, J Clin Oncol; 34(7S), 299.
90. Raphael MJ, Fischer, H, Fung K, Austin P, **Booth CM**, Anderson G, Singh S. Oxaliplatin associated neurotoxicity outcomes among older adults with colorectal cancer: A population-based study. 2016 ASCO Gastrointestinal Cancer Symposium, J Clin Oncol; 34(4S), 601.
89. O'Callaghan CJ, Courneya KS, Vardy JL, Friedenreich C, Campbell KL, Prapavessis H, Crawford JJ, O'Brien P, Dhillon HM, Jonker DJ, Chua NS, Lupichuk SM, Sanatani MS, Gill S, Meyer RM, Begbie S, Bonaventura A, Burge ME, Tu D, **Booth CM**. Effects of a structured exercise program on physical activity and health-related fitness in colon cancer survivors: One year feasibility results from the NCIC CTG CO.21 (CHALLENGE) trial. 2016 ASCO Gastrointestinal Cancer Symposium, J Clin Oncol; 34(4S), 648.

88. Biagi JJ, Mackillop WJ, Nanji S, Wei X, Peng Y, Hanna TP, Krzyzanowska MK, **Booth CM**. Utilization and effectiveness of adjuvant chemotherapy (ACT) for colon cancer (CC) in the general population. 2016 ASCO Gastrointestinal Cancer Symposium, J Clin Oncol; 34(4S), 702.
87. Nanji S, Tsang M, Wei X, **Booth C**. Regional lymph node involvement in patients undergoing resection of colorectal cancer liver metastases: a population-based study. 2015 Canadian Association of General Surgeons Annual Meeting. Canadian Journal of Surgery 2015; 58(4) Suppl 2, S209.
86. Nanji S, MacKillop W, Wei X, **Booth C**. Management and Outcome of Colorectal Cancer (CRC) Liver Metastases in the Elderly: A Population-Based Study. 2015 Canadian Association of General Surgeons Annual Meeting. Canadian Journal of Surgery 2015; 58(4) Suppl 2, S208.
85. Nanji S, MacKillop W, Wei X, **Booth C**. Surgical Resection and Peri-Operative Chemotherapy for Colorectal Cancer Liver Metastases: A Population-Based Study. 2015 Canadian Association of General Surgeons Annual Meeting. Canadian Journal of Surgery 2015; 58(4) Suppl 2, S207.
84. Nanji S, Tsang M, Wei X, **Booth C**. Outcomes following repeat hepatic resection for recurrent metastatic colorectal cancer: A population-based study. 2015 Canadian Association of General Surgeons Annual Meeting. Canadian Journal of Surgery 2015;58(4 suppl 2): S208.
83. \*Patafio F, Brooks SC, Wei X, Peng Y, Biagi J, **Booth CM**. Cancer mortality and published research output: Is there any relationship? 2015 ASCO Annual Meeting. J Clin Oncol 2015; 33(15S), 6596. **\*Trainee first author.**
82. \*del Paggio JC, Nanji S, Wei X, **Booth CM**. Trends in lymph node (LN) harvest for colon cancer in routine clinical practice: Does node count matter in the real world? Trends in lymph node (LN) harvest for colon cancer in routine clinical practice: Does node count matter in the real world? 2015 ASCO Annual Meeting. J Clin Oncol 2015; 33(15S), e14635. **\*Trainee first author.**
81. \*Patafio F, Mackillop WJ, Siemens DR, Wei X, **Booth CM**. Is there a gender effect in bladder cancer? A population-based study. 2015 ASCO Annual Meeting. J Clin Oncol 2015; 33(15S), e15541. **\*Trainee first author.**
80. \*Raskin W, Harle I, Hopman W, **Booth CM**. Prognosis, treatment benefit, and goals of care: what do oncologists discuss with patients who have terminal cancer? 2015 ASCO Annual Meeting. J Clin Oncol 2015; 33(15S), e20509. **\*Trainee first author.**
79. Robinson AG, Wei X, Mackillop WJ, **Booth CM**. Utilization of palliative chemotherapy for advanced bladder cancer: Patterns of care in routine clinical practice. 2015 ASCO Annual Meeting. J Clin Oncol 2015; 33(15S), 6525.
78. **Booth CM**, Vardy J, O'Callaghan C, et al. A phase III study of the impact of a physical activity program on disease-free survival in patients with high-risk stage II or stage III colon cancer: A randomized controlled trial (NCIC CTG CO.21). 2015 ASCO Annual Meeting. J Clin Oncol 2015; 33(15S), TPS3620.

77. Harle I, Raskin W, Hopman W, **Booth CM**. Prognosis, treatment benefit, and goals of care: what do oncologists discuss with patients who have terminal cancer? 2015 Multinational Association of Supportive Care in Cancer Annual Meeting. *Supp Care in Cancer* 2015; 23(1S), 17-31-P.
76. Leveridge M, Siemens DR, Izard J, Wei X, Mackillop W, Berman D, **Booth C**. Partial Cystectomy for Urothelial Carcinoma of the Bladder: Practice Patterns and Outcomes in the General Population. 2015 American Urological Association Annual Meeting. *J Urol* 2015; 193(4), e45.
75. Nanji S, Mackillop WJ, Wei X, **Booth CM**. Management and outcome of colorectal cancer liver metastases in the elderly: a population-based study. 2015 AHPBA Meeting. *HPB* 2015; 17(S1), LO-E.04.
74. Nanji S, Mackillop WJ, Wei X, **Booth CM**. Simultaneous resection of primary colorectal cancer and synchronous liver metastases: a population-based study. 2015 AHPBA Meeting. *HPB* 2015; 17(S1), OP-I.33.
73. Nanji S, Mackillop WJ, Wei X, **Booth CM**. Temporal trends in surgical resection and peri-operative chemotherapy for colorectal cancer liver metastases in routine clinical practice. 2015 AHPBA Meeting. *HPB* 2015; 17(S1), OP-I.23.
72. Owen T, Zaza K, Kong W, **Booth C**, Mackillop W. Volume of practice and outcomes after radiotherapy for head and neck cancer. 2014 CARO Meeting. *Radiother Oncol* 2014; 112(S1), 98.
71. Nanji S, Biagi J, Chen J, Mackillop W, **Booth C**. Simultaneous resection of primary colorectal cancer and synchronous liver metastases: A population-based study. 2014 Canadian Association of General Surgeons Annual Meeting. *Canadian Journal of Surgery* 2014; 57(4) Suppl 1, S124.
70. Zaza K, **Booth C**, Siemens DR, Peng Y, Berman D, Wei X, Kong W, Mackillop WJ. Patterns of referral to radiation oncology among patients who undergo cystectomy for invasive bladder cancer in Ontario: A population-based study. 2014 CARO Meeting. *Radiother Oncol* 2014; 112(S1), 44.
69. Mackillop WJ, Siemens R, Zaza K, Li G, Peng Y, Kong W, Berman D, **Booth C**. The outcomes of radiotherapy and surgery for bladder cancer: A population-based outcomes study. 2014 CARO Meeting. *Radiother Oncol* 2014; 112(S1), 192.
68. Mackillop WJ, Siemens R, Zaza K, Kong W, Peng P, Berman D, **Booth C**. The outcomes of radiation therapy and surgery for bladder cancer: a population-based study. 2014 ASTRO Meeting. *Int J Radiat Oncol Biol Phys* 2014; 90(1S), S466.
67. Zaza K, **Booth C**, Siemens R, Peng P, Berman D, Wei X, Kong W, Mackillop WJ. Patterns of referral to radiation oncology among patients who undergo cystectomy for invasive bladder cancer in Ontario: a population-based study. 2014 ASTRO Meeting. *Int J Radiat Oncol Biol Phys* 2014; 90(1S), S463.
66. Mackillop W, Kong W, Zaza K, Owen T, **Booth C**. Volume of practice and the outcomes of radiation therapy for head and neck cancer. 2014 ASTRO Meeting. *Int J Radiat Oncol Biol Phys* 2014; 90(1S), S139.

65. Biagi J, Burkes R, Brezden-Masley C, Zbuk K, Meyers B, Levine O, Spadafora S, Welch S, Davdani S, Hopman W, **Booth CM**, Goodwin R. Reasons for delay in the time to initiation of adjuvant chemotherapy for colon cancer: a multi-institution study. 2014 ESMO Congress. Ann Oncol 2014; 26(1), 577.
64. Izard J, Siemens R, Leveridge M, Berman D, Peng P, Wei X, Mackillop W, **Booth C**. A Population-based Analysis of Squamous Histology in Bladder Cancer. 2014 Canadian Urological Association Annual Meeting. Can Urol Assoc J 2014; 8(5-6), S72.
63. Izard J, Siemens R, Leveridge M, Berman D, Peng P, Wei X, Mackillop W, **Booth C**. A Population-based Analysis of Adenocarcinoma of the Bladder. 2014 Canadian Urological Association Annual Meeting. Can Urol Assoc J 2014; 8(5-6), S72.
62. Leveridge M, Siemens R, Izard J, Wei X, Mackillop W, Berman D, **Booth C**. Partial Cystectomy for Urothelial Carcinoma of the Bladder: Practice Patterns and Outcomes in the General Population. 2014 Canadian Urological Association Annual Meeting. Can Urol Assoc J 2014; 8(5-6), S69.
61. Siemens R, Peng Y, Mackillop W, **Booth C**, Leveridge M. Population-based Patterns of Referral for Perioperative Chemotherapy among Patients with Muscle-invasive Bladder Cancer. 2014 Canadian Urological Association Annual Meeting. Can Urol Assoc J 2014; 8(5-6), S69.
60. Mitera G, Bezjak A, **Booth CM**, Delouya G, Desbiens C, Earle C, Laing KE, Latosinsky S, Camuso N, Agent-Katwala M, Porter G. The Choosing Wisely Canada cancer initiative. 2014 ASCO Quality of Care Symposium. J Clin Oncol 2014; 32(30s), 5.
59. **Booth CM**, Siemens DR, Peng, Y, Tannock I, Mackillop WJ. Delivery of peri-operative chemotherapy for muscle-invasive bladder cancer (MIBC) in routine clinical practice: Does regimen and timing matter? 2014 ASCO Annual Meeting Proceedings. J Clin Oncol 2014; 32:5s, 4537.
58. **Booth CM**, Siemens DR, Peng Y, Mackillop WJ. Patterns of referral for peri-operative chemotherapy among patients with muscle-invasive bladder cancer (MIBC): A population-based study. 2014 ASCO Annual Meeting Proceedings. J Clin Oncol 2014; 32:5s, e15507.
57. \*Kankesan J, Nanji S, Biagi JJ, Krzyzanowska MK, Mackillop WJ, **Booth CM**. Chemotherapy utilization in patients with resected colorectal cancer liver metastases (CRC LM): Does clinical practice follow the evidence? 2014 ASCO Annual Meeting Proceedings. J Clin Oncol 2014; 32:5s, e14522. **\*Trainee first author.**
56. Biagi JJ, Burkes RL, Brezden CB, Zbuk KM, Meyers BM, Levine OH, Spadafora S, Welch S, Davdani S, Hopman W, **Booth CM**, Goodwin RA. Reasons for delay in time to initiation of adjuvant chemotherapy for colon cancer: A multi-institution study. 2014 ASCO Annual Meeting Proceedings. J Clin Oncol 2014; 32:5s, e14504.
55. **Booth CM**, Vardy J, Gill S, et al. A phase III study of the impact of a physical activity program on disease-free survival in patients with high risk stage II or stage III colon cancer: a randomized controlled trial (NCIC CTG CO21). 2014 ASCO Annual Meeting Proceedings. J Clin Oncol 2014; 32:5s, TPS3663.

54. Kawashima A, Berman D, Peng Y, Mackillop W, Siemens W, **Booth C**. Reporting and Prognostic Significance of Lymphovascular Invasion in Muscle-Invasive Bladder Cancer: A Population-Based Study. 2014 American Urological Association Annual Meeting. J Urol 2014; 191:4S, PD18-02.
53. Izard J, Siemens R, Leveridge M, Berman D, Peng P, Wei X, Mackillop W, **Booth C**. A population-based analysis of squamous histology in bladder cancer. 2014 American Urological Association Annual Meeting. J Urol 2014; 191:4S, MP50-08.
52. Leveridge M, Siemens R, Mackillop W, Peng Y, Berman D, **Booth C**. Radical Cystectomy and Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer in the Elderly: A Population-Based Study. 2014 American Urological Association Annual Meeting. J Urol 2014; 191:4S, MP2-03.
51. Enright K, Ghannam, Yun L, Taback N, **Booth CM**, Trudeau M, Krzyzanowska MK. Identifying opportunities to improve quality of cancer care: an evaluation of the use of routine surveillance imaging scans in women with early breast cancer treated in Ontario, Canada. 2013 American Society of Clinical oncology Quality Care Symposium. J Clin Oncol 2013; 31(31S), 115.
50. Leveridge M, **Booth C**, Mackillop W, Li G, Berman D, Peng P, Siemens R. Radical cystectomy and the use of adjuvant chemotherapy in the elderly: a population-based outcomes analysis. 2013 Congress of the Société Internationale D'Urologie. Urology 2013; 82(3), s18.
49. Skrastins E, Cunningham M, Jindal P, Fitzpatrick R, Onoko O, Carpenter J, **Booth C**, Yeates K, Aronson K. Knowledge, attitude, and practices of cervical cancer screening among rural and urban women in Kilimanjaro, Tanzania. 2013 Canadian Society for Epidemiology and Biostatistics National Student Conference. Am J Epidemiol 2013; 178(10), 1588-1590.
48. Siemens R, Li G, **Booth C**, Mackillop W, Kong W, Elharram A, Rhee J. Utilization and impact of perioperative chemotherapy for muscle-invasive bladder cancer: are we achieving the achievable? 2013 Canadian Urological Association Annual Meeting. Can Urol Assoc J 2013; 7 (5-6S), S31.
47. Siemens R, Mackillop W, Peng Y, Berman D, Li G, **Booth C**. Process of care variables explaining influence of surgical volumes in bladder cancer outcomes. 2013 Canadian Urological Association Annual Meeting. Can Urol Assoc J 2013; 7 (5-6S), S33.
46. **Booth CM**, Courneya K, Vardy J, et al. A phase III study of the impact of a physical activity program on disease-free survival in patients with high risk stage II or stage III colon cancer: a randomized controlled trial (NCIC CTG CO21). 2013 ASCO Annual Meeting Proceedings. J Clin Oncol 2013; 31:15s, TPS3647.
45. Enright K, Ghannam M, Yun L, Taback N, **Booth CM**, Trudeau ME, Krzyzanowska MK. The use of routine surveillance imaging scans in women with early breast cancer (EBC) treated in Ontario, Canada. 2013 ASCO Annual Meeting Proceedings. J Clin Oncol 2013; 31:15s, 6628.
44. \*Wasserman DW, Boulos M, **Booth CM**, Hopman W, Goodwin RA, Biagi JJ. Reasons for delay in time to initiation of adjuvant chemotherapy (AC) for colon cancer (CC). 2013 ASCO Annual Meeting Proceedings. J Clin Oncol 2013; 31:15s, e14553. **\*Trainee first author.**



43. \*Fralick M, Fung C, Ray M, **Booth CM**, Mallick R, Burke M, Clemons M. Bevacizumab for advanced breast cancer: hope, hype, and hundreds of headlines. 2013 ASCO Annual Meeting Proceedings. J Clin Oncol 2013; 31:15s, e11597. **\*Trainee first author.**
42. Siemens D, Li G, Peng P, Tannock I, Elharram A, Kong W, Mackillop W, **Booth C**. Utilization and impact of peri-operative chemotherapy for muscle-invasive bladder cancer: a population-based outcomes study. 2013 American Urological Association Annual Meeting. J Urol 2013; 189(4) e766.
41. Siemens D, Mackillop W, Peng P, Berman D, Rhee J, Li G, **Booth C**. Process of Care Variables Explaining the Influence of Surgical Volumes in Bladder Cancer Outcomes: A Population-Based Study. 2013 American Urological Association Annual Meeting. J Urol 2013; 189(4), e21-e22.
40. Pal RS, **Booth C**, Yun L, Enright K, Krzyzanowska. Cardiotoxicity associated with chemotherapy for breast cancer. 2013 American College of Cardiology Scientific Session. J Am Coll Cardiol 2013; 61(10S).
39. \*Wasserman DW, **Booth CM**, Hopman W, Al Sharm A, Biagi JJ. Reasons for delay in time to initiation of adjuvant chemotherapy (AC) for colon cancer (CC). 2013 ASCO Gastrointestinal Cancers Symposium. J Clin Oncol 2013; 31(4S), 548. **\*Trainee first author.**
38. \*Wallace D, Zhang-Salomons J, **Booth CM**, Mackillop WJ. A multicenter, phase IV study of the effectiveness of palliative gemcitabine in patients with advanced pancreatic cancer. 2012 ASCO Quality of Care Symposium. J Clin Oncol 2012; 30:34S, 46. **\*Trainee first author.**
37. **Booth CM**, Siemens DR, Li G, Peng Y, Tannock I, Berman DM, Kong W, Mackillop WJ. Neoadjuvant (NACT) and adjuvant (ACT) chemotherapy for muscle-invasive bladder cancer: a population-based outcomes study. 2012 ESMO Congress. Ann Oncol 2012; 23:9s, 7880.
36. Siemens DR, Rhee J, Peng P, Li G, Mackillop W, **Booth C**. Peri-operative Chemotherapy for Bladder Cancer in Ontario: A population based study 2012 Northeast Section of the American Urological Association Meeting. CUAJ 2012; 6:4, P12.
35. **Booth CM**, Li G, Biagi JJ, Krzyzanoskwa MK, Mackillop WJ, Nanji S. Surgical resection and peri-operative chemotherapy for colorectal cancer (CRC) liver metastases in routine clinical practice: A population-based outcomes study. 2012 ASCO Annual Meeting Proceedings. J Clin Oncol 2012; 30:15s, 3632.
34. Emmenegger U, **Booth CM**, Berry SR, Sridhar SS, Winquist E, Bendali N, Chow A, Lee CR, Xu P, Man S, Kerbel RS, Ko YK. Temsirolimus (TEM) maintenance therapy after response of castration-resistant prostate cancer (CRPC) to docetaxel (TAX). 2012 ASCO Annual Meeting Proceedings. J Clin Oncol 2012; 30:15s, e15177.
33. Jang RWJ, Enright K, **Booth CM**, Chan KK, Yun L, Krzyzanowska MK. Serious adverse events among a population-based cohort of patients receiving first-line chemotherapy for metastatic

colorectal cancer (mCRC). 2012 ASCO Annual Meeting Proceedings. J Clin Oncol 2012; 30:15s, e14003.

32. \*Kankesan J, Shepherd FA, Peng Y, Darling G, Li G, Kong W, Mackillop WJ, **Booth CM**. Factors Associated with Referral to Medical Oncology (MO) and Subsequent Use of Adjuvant Chemotherapy (ACT) for Non-Small Cell Lung Cancer (NSCLC): A Population-Based Study. 2012 ASCO Annual Meeting Proceedings. J Clin Oncol 2012; 30:15s, 1583. **\*Trainee first author.**

31. Djulbegovic D, Kumar A, Miladinovic B, Mhaskar A, Reljic T, Galeb S, Mhaskar R, Iztok H, Tu D, Stanton H, **Booth CM**, Meyer RM. Success in Meeting the Primary Endpoint in Phase III Trials: A Comparison of Industry and Cooperative Group Trials. 2011 American Society of Hematology Annual Meeting. Blood 2011; 118, abstract 508.

30. Cuffe S, **Booth CM**, Peng Y, Darling G, Li G, Kong W, Mackillop WJ, Shepherd FA. Adoption of adjuvant chemotherapy (ACT) for non-small cell lung cancer (NSCLC) in the elderly: A population-based outcomes study. 2011 World Conference on Lung Cancer. J Thor Oncol 2011; 6:2s, S39-902.

29. \*Raphael M, Biagi JJ, King WD, Kong W, Mackillop WJ, **Booth CM**. The impact of time to adjuvant chemotherapy (AC) on survival in colorectal cancer (CRC): A systematic review and meta-analysis. 2011 ASCO Annual Meeting Proceedings. J Clin Oncol 2011; 29:15s, 6125. **\*Trainee first author.**

28. Cuffe S, **Booth CM**, Peng Y, Darling G, Li G, Kong W, Mackillop WJ, Shepherd FA. Adoption of adjuvant chemotherapy (ACT) for non-small cell lung cancer (NSCLC) in the elderly: A population-based outcomes study. 2011 ASCO Annual Meeting Proceedings. J Clin Oncol 2011; 29:15s, 7012.

27. Emmenegger U, Berry SR, **Booth CM**, Sridhar SS, Winkquist E, Bandali N, Chow A, Kerbel R, Ko Y. A phase II study of maintenance therapy with temsirolimus (TEM) after response to first-line docetaxel (TAX) chemotherapy in castration-resistant prostate cancer (CRPC). 2011 ASCO Annual Meeting Proceedings. J Clin Oncol 2011; 29:15s, e15152.

26. \*Ramjeesingh R, Meyer RM, Brouwers MC, **Booth CM**. Translation of evidence into funding policy: An overview of guidelines from the Cancer Care Ontario's Program in Evidence-Based Care (PEBC). 2011 ASCO Annual Meeting Proceedings. J Clin Oncol 2011; 29:15s, e16513. **\*Trainee first author.**

25. Biagi JJ, Raphael M, King WD, Kong W, **Booth CM**, Mackillop WJ. The effect of delay in time to adjuvant chemotherapy (TAC) on survival in breast cancer (BC): A systematic review and meta-analysis. 2011 ASCO Annual Meeting Proceedings. J Clin Oncol 2011; 29:15s, 1128.

24. **Booth CM**, Siemens DR, Tannock I, Peng Y, Li G, Mackillop WJ. Adoption of neoadjuvant (NACT) and adjuvant chemotherapy (ACT) for bladder cancer: A population-based study. 2011 ASCO Annual Meeting Proceedings. J Clin Oncol 2011; 29:15s, 4644.

23. \*Altairaqi AK, **Booth C**, Hopman W, Baetz TD. Discordance between conclusions in the abstract and conclusions stated in the body of the article: An analysis of randomized controlled trials (RCTs) of lung cancer. 2011 ASCO Annual Meeting Proceedings. J Clin Oncol 2011; 29:15s, 6046. **\*Trainee first author.**
22. Krzyzanowska MK, **Booth CM**, Chan KK, Enright K, Trudeau ME. Defining indicators for measuring the quality of systemic cancer therapy using administrative data. 2011 ASCO Annual Meeting Proceedings. J Clin Oncol 2011; 29:15s, 6055.
21. Biagi JJ, \*Raphael M, King WD, Kong W, Mackillop WJ, **Booth CM**. The impact of time to adjuvant chemotherapy (AC) on survival in colorectal cancer (CRC): A systematic review and meta-analysis. ASCO 2011 Gastrointestinal Cancers Symposium. J Clin Oncol 2011; 29:4s, 364.
20. Emmenegger U, Sridhar SS, **Booth CM**, Kerbel R, Berry SR, Ko Y. A phase II study of maintenance therapy with temsirolimus (TEM) after response to first-line docetaxel (TAX) chemotherapy in castration-resistant prostate cancer (CRPC). ASCO 2011 Genitourinary Cancers Symposium. J Clin Oncol 2011; 29:7s, 160.
19. Goodwin RA, Jamal R, **Booth CM**, Goss PE, Eisenhauer EA, Tu D, Shepherd LE. Effects of Diabetes (DM), Hypertension (HTN) and Coronary Artery Disease (CAD) on Prognosis after 5 Years of Adjuvant Tamoxifen (TAM) and on Treatment Outcomes with the Use of Extended Letrozole (LET): NCIC CTG MA.17. Abstracts of the 33rd San Antonio Breast Cancer Symposium. Breast Cancer Res Treat 2010; PD03-04.
18. Bass BH, Gregg R, **Booth C**, Brundage M. The value of quality of life information to hormone refractory prostate cancer patients facing treatment decisions. 2010 Meeting of the International Society for Quality of Life Research Proceedings.
17. **Booth CM**, Shepherd FA, Peng Y, Darling G, Li G, Kong W, Mackillop WJ. Adoption of Adjuvant Chemotherapy for Non-Small Cell Lung Cancer: A Population-Based Outcomes Study. 2010 ASCO Annual Meeting Proceedings. J Clin Oncol 2010; 28:15s, 7018.
16. Emmenegger U, Sridhar SS, **Booth CM**, Kerbel R, Berry SR, Ko Y. A phase II study of maintenance therapy with temsirolimus (TEM) after response to first-line docetaxel (TAX) chemotherapy in castration-resistant prostate cancer (CRPC). 2010 ASCO Annual Meeting Proceedings. J Clin Oncol 2010; 28:15s, TPS246.
15. Biagi JJ, Raphael M, **Booth CM**. The impact of time to adjuvant chemotherapy on outcomes in breast and colorectal cancer: A systematic review. 2010 ASCO Annual Meeting Proceedings. J Clin Oncol 2010; 28:15s, e16537.
14. **Booth CM**, Li G, Mackillop WJ. The impact of socioeconomic status (SES) on stage of cancer at time of diagnosis: a population-based study in Ontario, Canada. 2009 ASCO Annual Meeting Proceedings. J Clin Oncol 2009; 27:15s, 6505.
13. \*Ohorodnyk P, Eisenhauer EA, **Booth CM**. Clinical Benefit in Oncology Trials: Is this a patient-centered or tumor-centered endpoint? 2009 ASCO Annual Meeting Proceedings. J Clin Oncol 2009; 27:15s, 6564. **\*Trainee first author.**

12. Seruga B, Hertz PC, Wang L, **Booth CM**, Krzyzanowska M, Cescon DW, Tannock, IF. Absolute benefits of experimental medical therapies in phase III randomized clinical trials (RCTs) in breast and colorectal cancer. 2009 ASCO Annual Meeting Proceedings. J Clin Oncol 2009; 27:15s, 6513.
11. **Booth CM**, Le Maître A, Ding K, Farn K, Fralick M, Phillips C, Cescon DW, Meyer RM. Presentation of non-final results of randomized controlled trials (RCTs) at major oncology meetings. 2008 ASCO Annual Meeting Proceedings. J Clin Oncol 2008; 26:15s, 6550.
10. Vardy JL, Xu X, **Booth CM**, Park A, Dodd A, Rourke S, Dhillon H, Clarke SJ, Wagner L, Tannock IF. Relation between perceived cognitive function and neuropsychological performance in survivors of breast and colorectal cancer. 2008 ASCO Annual Meeting Proceedings. J Clin Oncol 2008; 26:15s, 9520.
9. **Booth CM**, Cescon DW, Wang L, Tannock IF, Krzyzanowska MK. Evolution of The Randomized Controlled Trial (RCT) in Oncology Over Three Decades. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 2007; 26:15s, 6515.
8. Cescon DW, **Booth CM**, Wang L, Tannock IF, Krzyzanowska MK. Trends in quality of abstract reporting in published oncology randomized controlled trials from 1975-2004. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 2007; 26:15s, 6541.
7. Vardy JL, **Booth C**, Pond GR, Zhang H, Galica J, Dhillon H, Clarke SJ, Tannock IF. G. R. Pond, H. Zhang, J. Galica, H. Dhillon, S. J. Clarke, I. F. Tannock. Cytokine levels in patients (pts) with colorectal cancer and breast cancer and their relationship to fatigue and cognitive function. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 2007; 26:15s, 9070.
6. **Booth CM**, Vardy J, Crawley A, Rourke S, Pond G, Wagner L, Tannock IF. Cognitive impairment associated with chemotherapy for breast cancer: A mechanistic cohort study. Abstracts of the 29th San Antonio Breast Cancer Symposium. Breast Cancer Res Treat 2006; 5074.
5. **Booth CM**, Clemons M, Dranitsaris G, Joy A, Young S, Callaghan W, Trudeau M, Petrella T. Chemotherapy induced nausea and vomiting in breast cancer patients: A prospective observational study. Abstracts of the 29th San Antonio Breast Cancer Symposium. Breast Cancer Res Treat 2006; 6085.
4. **Booth CM**, Vardy J, Crawley A, Rourke S, Pond G, Wagner L, Tannock IF. Cognitive impairment associated with chemotherapy for breast cancer: An exploratory case-control study. 2006 ASCO Annual Meeting Proceedings. J Clin Oncol 2006; 24:18s, 8501.
3. **Booth CM**, Vardy J, Crawley A, Rourke S, Pond G, Wagner L, Tannock IF. Cognitive impairment associated with chemotherapy for breast cancer: A mechanistic cohort study. Abstracts of the 18th International Symposium Supportive Care in Cancer. Supp Care Cancer 2006; 26, 189.
2. Detsky ME, McDonald DR, Tomlinson GA, McCrory DC, Simel DL, **Booth CM**. The Rational Clinical Examination: Does this patient with headache have a migraine or need neuroimaging? Abstracts of the 29th Annual SGIM Meeting. J Gen Intern Med 2006; 21:s4, 121.

1. **Booth CM**, Boone RH, Tomlinson GA, Detsky AS. The Rational Clinical Examination. Is this patient dead, vegetative, or severely neurologically impaired? Assessing outcome in comatose survivors of cardiac arrest. Abstracts of the 26th Annual SGIM Meeting. J Gen Intern Med 2003; S140.

## INVITED PRESENTATIONS

### International Lectures

111. eCancer India Choosing Wisely. Keynote lecture. “Choosing Wisely, Common Sense and Value in Cancer Care”. Raipur, India, September 2024.

110. eCancer India Choosing Wisely. Invited lecture. “Surveillance Imaging in Solid Tumour: Evidence, Risks, and Benefits”. Raipur, India, September 2024.

109. eCancer India Choosing Wisely. Invited lecture. “How to write a scientific paper”. Raipur, India, September 2024.

108. World Cancer Congress. Invited lecture. “The Cancer Value Crisis and Common Sense Oncology”. Geneva, Switzerland, September 2024.

107. World Cancer Congress. Invited lecture. “Common Sense Oncology: Meaningful Cancer Care”. Geneva, Switzerland, September 2024.

106. American Society of Clinical Oncology Annual meeting. Invited lecture. “Delivery of meaningful cancer care: why this matters”. Chicago, US, June 2024.

105. International Cancer Research Partnership Annual Meeting. Keynote lecture. “Global Oncology: Challenging the status quo”. Toronto, Canada, May 2024.

104. Alliance Clinical Trials Cooperative Group Annual Meeting. Keynote lecture. “Common Sense Oncology: The Value Crisis in Cancer”. Chicago, US, May 2024.

103. Common Sense Oncology Annual Meeting. Keynote lecture. “Common Sense Oncology: One Year Later”. Montreal, Canada, May 2024.

102. European Medicine Agency Cancer Medicines Forum. Invited lecture. “Cancer Drug Development as a Public Health Matter”. Amsterdam, Netherlands, April 2024.

101. Dutch Society for Medical Oncology Annual Meeting. Keynote speaker. “Common Sense Oncology: Outcomes That Matter.” Amsterdam, Netherlands, April 2024.

100. Netherlands Cancer Institute, Grand Rounds. “Common Sense Oncology: Outcomes That Matter.” Amsterdam, Netherlands, April 2024.

99. European Society of Oncology, Principles of Oncology Course. “Value in cancer care”. Online lecture, March 2024.
98. University of Pittsburgh Palliative Care Grand Rounds. “Time toxicity, value, and paradoxes of cancer care”. Online lecture, March 2024.
97. Collaboration for Research methods Development in Oncology (CReDO). Invited lecture. “Value in Cancer Care: Outcomes that matter”. Mumbai, India, March 2024.
96. Memorial Sloan Kettering Cancer Center (MSKCC), Department of Surgery Grand Rounds. Invited lecture. “Common Sense Oncology: equity, value, and outcomes. New York, US, December 2023.
95. University of Connecticut/Dartmouth University Global Oncology Series. Invited lecture. “Common Sense Oncology: health equity and value”. Online lecture, December 2023.
94. European Cancer Organization (ECO) Annual Meeting, Invited speaker and panellist. “Common Sense Oncology: outcomes that matter”. Online lecture, November 2023.
93. African Organization for Research and Training in Cancer (AORTIC) Bi-annual Meeting. Invited lecture. “Common Sense Oncology: value, equity, and outcomes”. Dakar, Senegal, November 2023.
92. eCancer Choosing Wisely Confernece, Invited lecture. “Common Sense Oncology: meaningful treatment and health equity”. Mumbai, November 2023.
91. Tata Memorial Hospital. Invited lecture. “Common Sense Oncology: getting back to what matters” Mumbai, India, November 2023.
90. Kathmandu Research Methods Workshop. Invited lecture. “How to write a scientific paper”. Kathmandu, Nepal, October 2023.
89. Switzerland Sarcoma Academy, invited lecture. “ Common Sense Oncology”. Online lecture, October 2023.
88. World Oncology Forum, Invited lecture. “Value in Cancer Care: Common Sense Oncology”. Ascona, Swtizerland, September 2023.
87. University of California San Diego, Invited lecture. “Common Sense Oncology: Outcomes that matter”. San Diego, July 2023.
86. Thoracic Oncology Group of Australasia, Keynote lecture. “Time toxicity in cancer treatment”. Online lecture, July 2023.
85. University of Connecticut, Global Health Seminar Series. “Essential cancer medicine: access and value”. Online lecture, March 2023.

84. Johns Hopkins, Division of Pediatric Palliative Care Seminars. "Time toxicity in cancer care". Online lecture, May 2023.

83. University College Cork Cancer Seminar Series Invited lecturer. "The Global Cancer Value Crisis". Online lecture, Cork Ireland, March 2023.

82. Australasian Gastro-Intestinal Cancer Trials Group (AGITG) annual scientific meeting. Invited keynote speaker. "Real world data and the value crisis in GI cancer". Online lecture, November 2022.

81. Dartmouth University Global Oncology Rounds. Invited speaker. "Searching for high-value cancer care globally". Online lecture, November 2022.

80. International Kidney Cancer Coalition Global Summit. Invited speaker. "Global access to essential cancer medicines". Online lecture, October 2022.

79. Choosing Wisely Nepal Symposium. Invited speaker. "Surrogate endpoints and the value crisis in cancer care". September 2022, Kathmandu, Nepal.

78. Choosing Wisely Nepal Symposium. Invited speaker. "How to write a academic paper". September 2022, Kathmandu, Nepal.

77. Choosing Wisely India Symposium. Invited speaker. "Time toxicity in cancer care". September 2022, Mumbai, India.

76. Choosing Wisely India Symposium. Invited speaker. "Surrogate endpoints in oncology clinical trials". September 2022, Mumbai, India.

75. The Lancet Summit on Oncology in Asia and Latin America. Invited speaker. "Searching for meaningful cancer care: from Canada to India and back again". Online lecture, July 2022.

74. European Organization for Research and Treatment on Cancer (EORTC) Workshop on Real World Data. Keynote speaker. "Promise and pitfalls of real world data: where does it fit into clinical cancer research?" Online lecture, June 2022.

73. Institute of Cancer Research (UK). Invited lecture. "Global Oncology: Perspectives from a medical oncologist". Online lecture, May 2022.

72. Consilium Seminar Series (UK). Invited lecture. "The Value Crisis in Cancer Care". Online lecture, April 2022.

71. University of Sydney Oncology Seminar. Invited lecture. "The Emperor Has No Clothes: Finding our way again in cancer care". Online lecture, March 2022.

70. Acute Leukemia Research and Care Network (US). Invited lecture. "The Emperor Has No Clothes: The Value Crisis in Cancer Care." Online lecture, December 2021.

69. African Organization for Research and Treatment in Cancer (AORTIC) annual meeting. Invited speaker. “Choosing Wisely Canada: Identifying low-value cancer care”. Online lecture, November 2021.
68. Brazilian Oncology Week. Invited lecture. “Treatment that matters to patients: what is high-value cancer care?”. Online lecture, November 2021.
67. World Ovarian Cancer Coalition. Panelist. “Access for high priority cancer medicines globally: an international perspective”. Online lecture, October 2021.
66. AAADV/FDA 2021 Annual Workshop. “Developing new cancer therapies – that actually help patients”. Online lecture. September 2021.
65. European Society of Medical Oncology and WHO Special Session. Invited lecture. “The Desert Island Project: Global Access to Essential Cancer Medicines”. Online lecture. September 2021.
64. European Society of Medical Oncology Annual Meeting. Invited lecture and session Chair. “Real world evidence and regulatory drug approval: where does it fit in clinical cancer research?”. Online lecture. September 2021.
63. Choosing Wisely India. Invited lecture. “Perspectives on high value care from Choosing Wisely Canada”. Online lecture, September 2021.
62. World Health Organization Essential Medicine List Open Session. Keynote lecture. The Desert Island Project: Global Access to Essential Cancer Medicines. Online lecture. June 2021.
61. King’s College London Cancer Control Workshop. Invited Lecture. “Cancer, COVID, and Canada: Will we now move towards high-value care?”. Online lecture, May 2021.
60. Kerala Association of Surgical Oncology. Invited Lecture. “Bias, spin, and hype in oncology RCTs”. Online lecture, May 2021.
59. National Breast Cancer Coalition. Invited Lecture. “Clinical Trials in Oncology: How to find the most effective treatments for patients worldwide?” Online lecture, May 2021.
58. World Health Organization Essential Medicines List Cancer Working Group. Invited Lecture. “Scenes from the Desert Island: Which cancer medicine are most essential?” Online lecture, May 2021.
57. Young Radiation Oncologists Club of India. “Population-based cancer research: how to optimize quality of cancer care.” Online lecture, January 2021.
56. Princess Margaret Cancer Centre Global Oncology Leadership Development Program. Keynote Lecture. “Developing a Program in Global Cancer Research: From Canada to India and Back Again.” Online lecture, November 2020.
55. National Breast Cancer Coalition. Invited Lecture. “The Promise and Pitfalls of Real World Data: Where does it fit in clinical cancer research?” Online lecture, October 2020.



54. ACORD Workshop (Australia and Asia Pacific Clinical Oncology Research Development Initiative). Invited Lecture. “Beyond Phase 3 Trials: What happens in the real world?” Online lecture, September 2020.
53. CReDO Methods Workshop. Invited Lecture. “Global Oncology Implementation Research”. Mumbai, India, March 2020.
52. ASCO GI Symposium. Invited Discussant Lecture. “Making the Most of Treatment Options for Advanced Colorectal Cancer: Is Less More?”. San Francisco, United States, January 2020.
51. National Cancer Institute of Sri Lanka, Grand Rounds. Invited Lecture. “Developing a Program in Global Cancer Research: From Canada to India to Sri Lanka.” Colombo, Sri Lanka, December 2019.
50. National Cancer Institute of Sri Lanka, Academic Seminar. Invited Lecture. “Management and Outcome of Colorectal Cancer: Insights from a Population-Based Research Program.” Colombo, Sri Lanka, December 2019.
49. Trivandrum Regional Cancer Centre, Global Oncology Workshop. Invited Lecture. “Interpreting and Reporting Medical Research.” Trivandrum, India, November 2019.
48. Trivandrum Regional Cancer Centre, Global Oncology Workshop. Invited Lecture. “Developing a Program in Global Cancer Research: From Canada to India and Back Again.” Trivandrum, India, November 2019.
47. Global Essential Medicines Workshop, Joint Symposium University of Toronto and World Health Organization. Invited Panelist. “Value in Essential Cancer Medicines: What is meaningful benefit?” Toronto, Canada, November 2019.
46. African Organization for Research and Training in Cancer (AORTIC), Biannual Congress. Keynote Lecture at AORTIC-ASCO Symposium on Value in Cancer Care. “Delivery of Meaningful Cancer Care: Achieving Real Benefits in the Real World.” Maputo, Mozambique, November 2019.
45. African Organization for Research and Training in Cancer (AORTIC), Biannual Congress. Invited Lecture. “Health Services Research in Urologic Cancer: Closing the gaps between evidence and practice.” Maputo, Mozambique, November 2019.
44. US Food and Drug Administration/AAADV Workshop. Invited Lecture. “Real World Data and the Search for Meaningful Cancer Care.” Bethesda, Maryland, May 2019.
43. Oregon Health and Science University, Division of Hematology Oncology. Grand Rounds. “Achieving the Achievable: Real World Data and the Search for Meaningful Cancer Care”. Portland, Oregon, May 2019.
42. CReDO Workshop (International Collaboration for Research Methods Development in Oncology Workshop), Faculty Member and Invited Speaker. “Health Services Research: Understanding the Gap between Evidence and Practice”. Mumbai, India, March 2019.

41. Canadian Testis Cancer Workshop. Panel Chair and Speaker. “Management and Outcomes of Testicular Cancer in the Real World”. Toronto, November 2018.
40. Canadian Testis Cancer Workshop. Invited Lecture. “Adoption of Surveillance for CSI Testicular Cancer: A Population-Based Study”. Toronto, November 2018.
39. ACORD Workshop (Australia and Asia Pacific Clinical Oncology Research Development Initiative). Invited Lecture. “Beyond Phase 3 Trials: What happens in the real world?” Sydney, Australia, September 2018.
38. American Society of Clinical Oncology Annual Meeting. Invited Speaker. “Improving Accessibility and Quality of Cancer Care in India”. Chicago, U.S., June 2018.
37. University of Edinburgh, Department of Oncology. Invited Lecture. “Cancer Health Services Research: Access, Quality of Care, and Outcomes in the Real World”. Edinburgh, Scotland, March 2018.
36. World Health Organization, Essential Medicines List (Cancer) Working Group, Invited Speaker. “Endpoints, Magnitude of Benefit, and Cost: Finding Value in Cancer Care”. Geneva, Switzerland, March 2018.
35. King’s College London, Workshop on Value of Cancer Care, Invited Speaker. “New Cancer Therapies: Which treatments really benefit our patients?”. London, U.K., March 2018
34. CReDO Workshop (International Collaboration for Research Methods Development in Oncology Workshop), Faculty Member and Invited Speaker. “How to Present your Research Findings”. Mumbai, India, March 2018.
33. CReDO Workshop (International Collaboration for Research Methods Development in Oncology Workshop), Faculty Member and Invited Speaker. “Health Services Research: From Canada to India and Back Again”. Mumbai, India, March 2018.
32. Mexican Association of Pediatric Oncology and Hematology Annual Meeting, Invited Speaker. “Cancer Health Services Research: From Canada to India to Mexico”. Leon, Mexico, June 2017.
31. National Cancer Grid of India Annual Meeting, Invited Speaker. “Achieving the Achievable for Patients with Cancer Across India”. Mumbai, India, May 2017.
30. Tata Memorial Centre, Grand Rounds, Invited Speaker. “Implementation Research: Closing the Efficacy to Effectiveness Gap”. Mumbai, India, May 2017.
29. Tata Memorial Centre/King’s College London Oncology Summer School, Guest Faculty. “Principles of Cancer Health Services Research”. Mumbai, India, May 2017.
28. European Cancer Congress (ECCO), Invited Speaker, Education Session. “Real World Data: How to explore large databases and correct for bias”. Amsterdam, Netherlands, January 2017.

27. European Cancer Congress (ECCO), Invited Speaker, Education Session. “How to plan and conduct a successful research study as a junior investigator”. Amsterdam, Netherlands, January 2017.
26. CReDO Workshop (International Collaboration for Research Methods Development in Oncology Workshop), Faculty Member and Invited Speaker. “Implementation Research: Closing the Gap between Evidence and Practice”. Mumbai, India, February 2017.
25. International Congress on Palliative Care, Invited Speaker. “The Politics of Program Development: Using population-level data to inform practice and policy”. Montreal, Canada, October 2016.
24. ACORD Workshop (Australia and Asia Pacific Clinical Oncology Research Development Initiative), Faculty Member and Invited Speaker. “Looking Beyond The RCT: Closing the Efficacy to Effectiveness Gap”. Sydney, Australia, September 2016.
23. University of Ottawa, BONUS (Bone and the Oncologist New Updates) Meeting, Invited Speaker. “Management of Bone Metastases in Routine Clinical Practice”. Ottawa, Canada, May 2016.
22. Trivandrum Regional Cancer Centre, Guest Lecture. “Challenges in the Interpretation and Reporting of RCTs: Limitations of the gold standard?” Trivandrum, Kerala, India, March 2016.
21. Trivandrum Oncology Club, Guest Faculty. “Management and Outcome of Colorectal Cancer in Canada: Insights from a population-based cancer registry.” Trivandrum, Kerala, India, February 2016.
20. Trivandrum Regional Cancer Centre, Guest Lecture. “Management of Bladder Cancer in Routine Practice: Is there a gap between evidence and practice?” Trivandrum, Kerala, India, March 2016.
19. Tata Memorial Cancer Centre Platinum Jubilee Conference, “RCTs and Health Outcomes Research” Mumbai, India, February 2016.
18. Trivandrum Regional Cancer Centre, Guest Lecture. “Cancer Care and Outcomes in the Real World: Are we achieving the achievable?” Trivandrum, Kerala, India, June 2015.
17. Chemotherapy Foundation Symposium, Invited Speaker. “Reducing the Risk of Colon Cancer Recurrence with Exercise: An emerging form of “adjuvant” therapy?” New York, New York, November 2014.
16. Mount Sinai School of Medicine Tisch Cancer Institute, Urology Grand Rounds. “Achieving the Achievable in Bladder Cancer: The Efficacy-Effectiveness Gap in Routine Clinical Practice”. New York, New York, November 2014.
15. World Oncology Forum, “Cancer Care and Outcomes in the Real World: Are we Achieving the Achievable?” Lugano, Switzerland, October 2014.

14. Princess Margaret Cancer Centre, Dr. Ian Tannock Symposium. "Observations of Clinical Trials and the Trials of Observational Data". Toronto, Canada, June 2014.
13. University of Ottawa, BONUS 9 (Bone and the Oncologist New Updates) Meeting, Invited Speaker. "Cancer Care and Outcomes in the Real World". Ottawa, Canada, April 2014.
12. Dartmouth University, Norris Cotton Cancer Center, Grand Rounds. "From Clinical Trials to Observational Data and Back Again: The Case for 'Adjuvant' Exercise in Colon Cancer." Lebanon, New Hampshire, September 2013.
11. Dartmouth University, Hematology-Oncology Fellows Academic Seminar. "Mentorship in Academic Medicine." Lebanon, New Hampshire, September 2013.
10. ESMO 37<sup>th</sup> Congress. "Neoadjuvant (NACT) and adjuvant (ACT) chemotherapy for muscle-invasive bladder cancer: a population-based outcomes study." Vienna, Austria, October 2012.
9. ASCO 46<sup>th</sup> Annual Meeting. Invited presentation (and session chair) at ASCO Educational Session. "Translating clinical trial results into societal benefit: the role of population-based outcome studies." Chicago, Illinois, June 2010.
8. ASCO 45<sup>th</sup> Annual Meeting. Invited presentation at ASCO Educational Session. "Evaluating cancer therapies in RCTs and beyond: What leads to real benefit in the real world?" Orlando, Florida, June 2009.
7. ASCO 45<sup>th</sup> Annual Meeting. "The impact of socioeconomic status (SES) on stage of cancer at time of diagnosis: a population-based study in Ontario, Canada." Orlando, Florida. June 2009.
6. ASCO 42<sup>nd</sup> Annual Meeting. "Cognitive impairment associated with chemotherapy for breast cancer: A mechanistic cohort study." Atlanta, Georgia, June 2006.
5. MASCC 18<sup>th</sup> International Symposium Supportive Care in Cancer. "Cognitive impairment associated with chemotherapy for breast cancer: A mechanistic cohort study." Toronto, Ontario, June 2006.
4. Department of Oncology Seminar, Christchurch, New Zealand. "The Toronto SARS Experience." Christchurch, New Zealand, February 2006.
3. Toronto Critical Care Medicine Symposium. "Assessing outcome in comatose survivors of cardiac arrest." Toronto, Ontario, October 2004.
2. Canadian Society for Clinical Investigation Annual Meeting. "Is this patient dead, vegetative, or severely neurologically impaired? Assessing outcome in comatose survivors of cardiac arrest." September 2003, Halifax, Nova Scotia.
1. Society of General Internal Medicine 26<sup>th</sup> Annual Meeting. "Is this patient dead, vegetative, or severely neurologically impaired? Assessing outcome in comatose survivors of cardiac arrest." May 2003, Vancouver, British Columbia.

## **National and Provincial Lectures**

48. Best of Oncology East. Invited lecture. “Common Sense Oncology: Outcomes, access, and equity”. Toronto, November 2024.
47. Nova Scotia Oncology Research Day. Keynote lecture: “Common Sense Oncology: Outcomes that matter”. Halifax, November 2024.
46. University of Toronto Otolaryngology Grand Rounds. “Common Sense Oncology: Outcomes that matter”. Virtual lecture, October 2024.
45. Canadian Association of Medical oncology (CAMO) Annual Meeting. Keynote lecture: “Access, Equity, Advocacy and Common Sense in Oncology”. Ottawa, October 2024.
44. Alberta Health Services Brain Tumour Conference. Invited lecture. “Common Sense Oncology and Outcomes that Matter”. Online lecture, September 2024.
43. Sudbury Cancer Centre Grand Rounds. Invited speaker. “Common Sense Oncology and Outcomes that Matter”. Online lecture, September 2024.
42. Cancer Care Ontario Research Rounds. Invited lecture. “Common Sense Oncology and Value Crisis”. Online lecture, June 2024.
41. University of Ottawa Oncology Grand Rounds. “Common Sense Oncology”. Ottawa, Canada, June 2024.
40. Canada’s Drug and Health Technology Agency (CADTH). “Common Sense Oncology: Outcomes that matter”. Online lecture, February 2024.
39. Princess Margaret Cancer Centre Grand Rounds. “Common Sense Oncology: moving back to outcomes that matter”. Toronto, September 2023.
38. Canadian Centre for Applied Research in Cancer Control (ARCC) annual meeting. Keynote lecture. “Common Sense Oncology: moving back to outcomes that matter”. Online lecture, September 2023.
37. Princess Margaret Cancer Centre Global Oncology Leadership Development Program. Keynote Lecture. “Developing a Program in Global Cancer Research: From Canada to India and Back Again.” Online lecture, January 2023.
36. McGill University, Seminars in Global Oncology (ONCO 645). Course lecturer. “Global Oncology: access, quality, and value”. Online lecture, March 2023.
35. McGill University Department of Oncology Annual Research Day. Keynote Speaker. “The Value Crisis in Cancer Care”. Montreal, June 2022.

34. Queen's University Alumni Lecture Series. Invited Speaker. "Finding our way again in cancer care". Online lecture, March 2022.
33. Princess Margaret Cancer Centre Global Oncology Leadership Development Program. Keynote Lecture. "Developing a Program in Global Cancer Research: From Canada to India and Back Again." November 2021, Online lecture, Toronto, Ontario.
32. University of British Columbia, Radiation Oncology Grand Rounds. "Using real world data to identify high-value care in routine practice." Online lecture, March 2021.
31. British Columbia Cancer Agency (Kelowna) Grand Rounds. "Delivery of Meaningful Cancer Care: Achieving Real Benefits in the Real World". Online lecture, February 2021.
30. University of Calgary Academic Half-Day. Invited Seminar. "Global Oncology and High-Value Care". Online lecture, February 2021.
29. University of British Columbia, Division of Medical Oncology Grand Rounds. "Delivery of Meaningful Cancer Care: Achieving Real Benefits in the Real World". Online lecture, February 2021.
28. University of Calgary Department of Oncology Grand Rounds. Invited Lecture. "Delivery of Meaningful Cancer Care: Achieving Real Benefits in the Real World". Online lecture, February 2021.
27. Canadian Global Oncology Conference. Invited Lecture. "Building a collaborative program in global cancer health services research". Online lecture, November 2020.
26. Canadian Cancer Trials Group (CCTG) Patient Representative Committee Webinar. Invited Speaker. "Real World Evidence: Care that Matters to Patients". June, 2020, Online Webinar.
25. CAMO/Oncology Education Webinar: COVID-19 - Implications for Canadian Cancer Care. Invited Speaker. "Cancer and COVID19: Treatment Priority-Setting During a Pandemic". April 2020, Online Webinar.
24. Princess Margaret Cancer Centre Global Oncology Leadership Development Program. Keynote Lecture. "Developing a Program in Global Cancer Research: From Canada to India and Back Again." November 2019, Toronto, Ontario.
23. University of Ottawa Medical Oncology Annual Retreat. Invited Speaker. "Developing a Program in Global Cancer Research: From India to Canada and Back Again". May 2018, Ottawa, Ontario.
22. Princess Margaret Cancer Centre Grand Rounds. "Global Oncology Research: From Canada to India". April 2018, Toronto, Ontario.
21. Canadian Cancer Trials Group Annual Meeting. Invited Speaker. "A Value Framework Analysis of the Canadian Cancer Trials Group". April 2018, Toronto, Ontario.

20. Health Quality Transformation. Invited Speaker. “From RCT to RWE: Using Real World Evidence to Strengthen Decision Making on Medical Tests and Treatments” October 2017, Toronto, Ontario.
19. Eastern Canadian Colorectal Cancer Consensus Conference. Invited Speaker. “Management and Outcomes of GI Cancer in the Real World” September 2017, St. John’s, Newfoundland.
18. Sunnybrook Odette Cancer Centre, Cancer Research Rounds. “Delivery of Global Cancer Care: From Ontario to India and Back Again” April 2017, Toronto, Ontario.
17. University of Ottawa, Department of Oncology Grand Rounds. “Global Cancer Care: Health Services Research in Ontario and South India” May 2016, Ottawa, Ontario.
16. McMaster University Department of Oncology Grand Rounds. “Cancer Care and Outcomes in the Real World: Are we Achieving the Achievable?” November 2015, Hamilton, Ontario.
15. McMaster University Department of Oncology Teaching Seminar. “Challenges in the interpretation and reporting of RCTs”. November 2015, Hamilton, Ontario.
14. University of Toronto, City-Wide Oncology Rounds. “Cancer Care and Outcomes in the Real World: Are we Achieving the Achievable?” April 2014, Toronto, Ontario.
13. Princess Margaret Cancer Centre, Genitourinary Rounds. “Curative Therapy for Bladder Cancer in Ontario: Patterns of Care and Outcomes in Routine Clinical Practice.” April 2014, Toronto, Ontario.
12. McGill University Medical Centre, Department of Oncology, Grand Rounds. “Do Cancer Treatments Work in the Real World? Insights from a Program in Population-Based Outcomes Research.” March 2013, Montreal, Quebec.
11. Cancer Care Ontario Hepato-Pancreatic-Biliary Cancer Community of Practice. Invited Speaker. “Surgical Resection and Peri-Operative Chemotherapy for Colorectal Cancer Liver Metastases in Routine Clinical Practice: A Population-Based Outcome Study.” March 2012, Toronto, Ontario.
10. Cancer Care Ontario Clinical Council. Invited Speaker. “Adjuvant Chemotherapy in Ontario: Perspectives From a Population-Based Research Program.” October 2011, Toronto, Ontario.
9. Eastern Canadian Colorectal Cancer Consensus Conference. Invited Speaker. “Exercise in colon cancer: an emerging adjuvant therapy?” October 2010, Ottawa, Ontario.
8. Grand River Regional Cancer Centre Oncology Grand Rounds. “Evaluating cancer therapies in RCTs and beyond: what leads to real benefit in the real world?” March 2010, Kitchener, Ontario.
7. Sunnybrook Odette Cancer Centre Gastrointestinal Oncology Rounds. “Exercise in colon cancer: an emerging adjuvant therapy?” March 2010, Toronto, Ontario.
6. Carlo Fidani Cancer Centre Journal Club. “Evaluating cancer therapies in RCTs and beyond: what leads to real benefit in the real world?” February 2010, Toronto, Ontario.

5. NCIC Clinical Trials Group New Investigators Course. Invited Speaker. “How to effectively present study results.” October 2009, Kingston, Ontario.
4. NCIC Clinical Trials Group Annual Meeting. Invited Speaker. “Issues in design of contemporary issues in early stage clinical trials of targeted anti-cancer agents.” May 2008, Toronto, Ontario.
3. Princess Margaret Hospital Breast Rounds. “Media coverage and time to funding for anti-cancer agents in Ontario.” September 2007, Toronto, Ontario.
2. Ontario Gastrointestinal Multidisciplinary Oncology Conference. Invited Speaker. “Intermittent chemotherapy in metastatic colorectal cancer.” November 2006, Toronto, Ontario.
1. Toronto Breast Cancer Conference. Invited Speaker. “Fatigue and cognitive impairment in patients with breast cancer.” June 2006, Toronto, Ontario.

### **Local Meetings and Seminars (stopped adding to this section in 2023)**

Queen’s GLPH 488. Global Oncology Course. Invited lecturer. “Access, quality, and outcomes of global cancer care”. January 2023, Kingston, Ontario.

QCARE Resident Education Day (Queen’s). Invited speaker. “Maintaining boundaries with the pharmaceutical industry in academic medicine”. November 2022, Kingston, Ontario.

Queen’s Department Medicine and Oncology Joint Grand Rounds. “A Return to Common Sense in Oncology”. October, 2022, Kingston, Ontario.

Queen’s Department of Family Medicine Grand Rounds. “Time toxicity and the value crisis in cancer care”. Online lecture, February, 2022.

Queen’s Department of Oncology Grand Rounds. “The Emperor Has No Clothes: The Value Crisis in Cancer Care”. Online lecture, November, 2021.

QCARE Resident Education Day (Queen’s). Invited speaker. “Maintaining boundaries with the pharmaceutical industry in academic medicine”. Online lecture. October 2021.

Queen’s University, Faculty of Health Sciences 5 à 7 event. Invited TED-style talk. “The Emperor has no Clothes: Finding our way again in cancer care”. October 2021, Kingston, Ontario.

QCARE Resident Education Day (Queen’s). Invited speaker. “Maintaining boundaries with the pharmaceutical industry in academic medicine”. Online lecture. February 2021.

Queen’s University, Department of Oncology Grand Rounds. “Real World Data and the Search for Meaningful Cancer Care.” January 2020, Kingston, Ontario.

Queen’s University Department of Oncology Research Day (Discussant). “Global Cancer Care in India: A Developing Program in Collaborative Research.” November 2018, Kingston, Ontario.



Queen's University, School of Medicine Academic Medicine Interest Group. "Global Cancer Research." February 2017, Kingston, Ontario.

Queen's University Department of Oncology Research Day (Discussant). "Projects that can Actually Make a Difference: Education and Global Oncology." November 2016, Kingston, Ontario.

Queen's University Faculty of Health Sciences Homecoming CPD. "Global Cancer Care: Health Services Research in Ontario and South India." October 2016, Kingston, Ontario.

Queen's University Departments of Medicine and Oncology Joint Grand Rounds. "Cancer Care in South India: Perspectives from Two Visiting Canadian Physicians." May 2016, Kingston, Ontario.

ICES Queen's Science Day, Invited Speaker, "Quality of Care and Outcomes of Bladder Cancer in Routine Clinical Practice." December 2015, Kingston, Ontario.

Queen's University Genitourinary Cancer Annual Retreat, Keynote Speaker, "Chemotherapy in New Metastatic Prostate Cancer: An Update." June 2015, Kingston, Ontario.

Queen's Cancer Research Institute and Canadian Cancer Society Open House, Keynote Speaker, "Understanding Physician Knowledge, Attitudes, and Behaviour: Towards Improving Utilization Rates of Peri-operative Chemotherapy for Bladder Cancer." June 2015, Kingston, Ontario.

Queen's Department of Public Health Sciences Annual Research Day, Keynote Speaker, "Do Cancer Treatments Actually Work in the Real World? Insights from Population-Based Outcomes Research." November 2014, Kingston, Ontario.

Basmajian Award Lecture, Faculty of Health Sciences, Queen's University. "Cancer Care and Outcomes and the Real World: Are we Achieving the Achievable?" November 2013, Kingston, Ontario.

Department of Medicine and Oncology Joint Grand Rounds, Queen's University. "Do Cancer Treatments Work in the Real World? Insights from a Program in Population-Based Outcomes Research." May 2013, Kingston, Ontario.

Queen's Department of Surgery Charles Sorbie Faculty Research Day, Keynote Speaker. "Do Cancer Treatments Work in the Real World? Insights from a Program in Population-Based Outcomes Research." April 2013, Kingston, Ontario.

Department of Epidemiology, Queen's University, Invited Lecture, "The role of population-based outcome studies." March 2013, Kingston, Ontario.

Queen's CME Therapeutics +, Invited Speaker, "Advances in Cancer Treatment." May 2012, Kingston, Ontario.

Queen's University Internal Medicine Resident Research Day, Keynote Speaker, "From tree-planting to South America to academic medicine: How I inadvertently became a clinician-investigator." May 2011, Kingston, Ontario.

Department of Epidemiology, Queen's University, Seminar Series. "Translating clinical trial results into societal benefit: the role of population-based outcome studies." October 2010, Kingston, Ontario.

Colorectal Cancer Association of Canada (Kingston Chapter). "Exercise in colon cancer: an emerging adjuvant therapy?" October 2010, Kingston, Ontario.

Urology Nurses of Canada (Kingston Chapter) Lecture. "Hormone refractory prostate cancer: a case-based approach." November 2009, Kingston, Ontario.

Transdisciplinary Cancer Research Rounds, Queen's University. "Moving genomic biomarkers into the clinic: translational research in prostate cancer." October 2009, Kingston, Ontario.

Regional Oncology Nurses Conference. "Metastatic prostate cancer – systemic therapy options." March 2008, Kingston, Ontario.

Queen's University Institute of Population and Public Health Research Day. "Chemotherapy for muscle invasive bladder cancer: a population-based study of practice patterns and outcomes in Ontario." January 2008, Kingston, Ontario.

Department of Oncology Grand Rounds, Queen's University. "The evolution of the randomized controlled trial in oncology: trends in methodology, results, and interpretation 1975-2004." May 2007, Kingston, Ontario.

Department of Oncology Grand Rounds, Queen's University. "Cognitive impairment associated with chemotherapy for breast cancer: a mechanistic cohort study." March 2007, Kingston, Ontario.

**Guest Lectures Queen's School of Medicine and Department of Epidemiology (stopped adding to this section in 2021)**

Postgraduate MSc Epidemiology, Invited Lecture, Foundations in Cancer Control (EPID 817). "Evaluating Efficacy of New Cancer Therapies." December 2021, Kingston, Ontario.

Undergraduate Medicine, Invited Lecture, Oncology Block (MEDS 126). "The Practice of Clinical Oncology." April 2021, Kingston, Ontario.

Undergraduate Medicine, Invited Lecture, Clinical Clerkship. "Conflicts of Interest in Medicine." November 2020, Kingston, Ontario.

Postgraduate MSc Epidemiology, Invited Lecture, Epid 837 Health Services Research Course. "Evaluating access and quality of cancer care using administrative health data sources". September 2020, Kingston, Ontario.

Undergraduate Medicine, Invited Lecture, Oncology Block (MEDS 126). "The Practice of Clinical Oncology." April 2020, Kingston, Ontario.

Postgraduate MSc Epidemiology, Invited Lecture, Foundations in Cancer Control (EPID 817).  
“Evaluating Efficacy of New Cancer Therapies.” November 2019, Kingston, Ontario.

Undergraduate Medicine, Invited Lecture, Critical Appraisal, Research, and Life long learning  
(MEDS 112). “Do Cancer Treatments Actually Work in the Real World? Insights from Population-  
Based Outcomes Research.” October 2019, Kingston, Ontario.

Postgraduate MSc Epidemiology, Invited Lecture, Epid 837 Health Services Research Course.  
“Evaluating access and quality of cancer care using administrative health data sources”. September  
2019, Kingston, Ontario.

Undergraduate Medicine, Invited Lecture, Oncology Block (MEDS 126). “The Practice of Clinical  
Oncology.” April 2019, Kingston, Ontario.

Postgraduate MSc Epidemiology, Invited Lecture, Cancer Epidemiology course. “Translating  
Evidence into Practice”. March 2019, Kingston, Ontario.

Undergraduate Medicine, Invited Lecture, Critical Appraisal, Research, and Life long learning  
(MEDS 112). “Do Cancer Treatments Actually Work in the Real World? Insights from Population-  
Based Outcomes Research.” October 2018, Kingston, Ontario.

Undergraduate Medicine, Invited Lecture, Oncology Block (MEDS 126). “The Practice of Clinical  
Oncology.” April 2018, Kingston, Ontario.

Undergraduate Medicine, Invited Lecture, Critical Appraisal, Research, and Life long learning  
(MEDS 112). “Do Cancer Treatments Actually Work in the Real World? Insights from Population-  
Based Outcomes Research.” October 2017, Kingston, Ontario.

Undergraduate Medicine, Invited Lecture, Oncology Block (MEDS 126). “The Practice of Clinical  
Oncology.” April 2017, Kingston, Ontario.

Postgraduate MSc Epidemiology, Invited Lecture, Foundations in Cancer Control (EPID 817).  
“Evaluating Efficacy of New Cancer Therapies.” November 2016, Kingston, Ontario.

Undergraduate Medicine, Invited Lecture, Critical Appraisal, Research, and Life long learning  
(MEDS 112). “Do Cancer Treatments Actually Work in the Real World? Insights from Population-  
Based Outcomes Research.” October 2016, Kingston, Ontario.

Undergraduate Medicine, Invited Lecture, Oncology Block (MEDS 126). “The Practice of Clinical  
Oncology.” April 2016, Kingston, Ontario.

Postgraduate MSc Epidemiology, Invited Lecture, Foundations in Cancer Control (EPID 817). “The  
role of population-based outcome studies.” November 2015, Kingston, Ontario.

Undergraduate Medicine, Invited Lecture, Critical Appraisal, Research, and Life long learning  
(MEDS 112). “Do Cancer Treatments Actually Work in the Real World? Insights from Population-  
Based Outcomes Research.” October 2015, Kingston, Ontario.

Undergraduate Medicine, Invited Lecture, Oncology Block (MEDS 126). “The Practice of Clinical Oncology: Negotiations and Love Songs.” April 2015, Kingston, Ontario.

Undergraduate BSc Epidemiology, Invited Lecture, Principles of Epidemiology (EPID 301). “Serendipity and Adventures in Clinical Epidemiologic Research” February 2015, Kingston, Ontario.

Undergraduate BSc Epidemiology, Invited Lecture, Principles of Epidemiology (EPID 301). “Exercise in Colon Cancer: An emerging adjuvant therapy?” March 2014, Kingston, Ontario.

Undergraduate Medicine, Invited Lecture, Critical Appraisal, Research, and Life long learning (MEDS 112). “Do Cancer Treatments Actually Work in the Real World? Insights from Population-Based Outcomes Research.” October 2014, Kingston, Ontario.

Postgraduate MSc Epidemiology, Invited Lecture, Foundations in Cancer Control (EPID 817). “The role of population-based outcome studies.” November 2013, Kingston, Ontario.

Undergraduate BSc Epidemiology, Invited Lecture, Principles of Epidemiology (EPID 301). “The role of population-based outcome studies.” March 2013, Kingston, Ontario.

Postgraduate MSc Epidemiology, Invited Lecture, Foundations in Cancer Control (EPID 817). “The role of population-based outcome studies.” March 2013, Kingston, Ontario.

Undergraduate BSc Epidemiology, Invited Lecture, Principles of Epidemiology (EPID 301). “Translating clinical trial results into societal benefit: the role of population-based outcome studies.” March 2012, Kingston, Ontario.

Undergraduate BSc Epidemiology, Invited Lecture, Principles of Epidemiology (EPID 301). “Exercise in Colon Cancer: An emerging adjuvant therapy?” March 2011, Kingston, Ontario.

## RESEARCH SUPERVISION

**Total trainees supervised: 37**

**Total trainee publications: 79**

**Total trainee first author publications: 69**

**Total trainee research awards: 20**

### Postgraduate Trainees

28. Sam Stevens (Medical Oncology Fellow and PhD student Clinical Epidemiology, University of Sydney), 2022-Present

Project #1: Time toxicity of palliative cancer medicines, 2022-Present. **Research Award Sydney Cancer Partners (\$105,000 CDN)**

27. Fidel Rubagumya (Global Oncology Research Fellow), 2021-2023

Project #1: Research parachutism in global oncology research. Trainee published four first author papers in JAMA Network Open, BMJ Global Health, Cancer, and Journal of Cancer Policy.

Project #2: Implementation of Choosing Wisely Africa (ongoing). **Research Award ASCO LiFE Grant (\$110,000 USD)**. Trainee published first author paper in Current Oncology.

Project #3: Media, Hype, and Low Value Cancer Care. Trainee published first author paper in J Cancer Policy.

Project #4: Industry conflict in Africa. Trainee published first author paper in Lancet Oncology.

Project #5: Delivery of cancer care in Rwanda. Trainee published 2 first author papers in The Oncologist and eCancer.

26. Matt Jalink (PhD student, Public Health Sciences), 2021-Present

25. Adam Fundytus (Medical Oncology Research Fellow), 2020-2021.

Project #1: Cancer drug policy. Trainee published first-author papers in Seminars in Oncology and Annals of Oncology.

Project #2: Value in Cancer Care. Trainee published one first author paper in JAMA Oncology.

Project #3: Industry and spin in oncology RCTs. Trainee published one first author paper in Clinical Oncology.

Project #4: WHO essential medicines for cancer: which ones are most “essential?”. Trainee published one first author paper in Lancet Oncology.

24. Kristin Wright (Internal Medicine Resident), 2020-2023. Financial Conflicts of Interest in Oncology (completed). **Research Award \$80,000 CAMO Fellowship Award**

Trainee published first-author paper in JCO Oncology Practice.

23. Connor Wells (Internal Medicine Resident), 2018-2021. Oncology RCTs from the Global Perspective. Trainee published first-author paper in JAMA Oncology, first-author paper in Current Oncology, second-author paper Current Oncology, presented ASCO Poster. National prize from Canadian Society for Clinical Investigation: “Best resident research project at Queen’s Medical School”.

22. Michael Raphael (Medical Oncology Research Fellow), 2018-2019.

Project #6: cancer drug policy. Trainee published first author paper in Nature Reviews Clinical Oncology.

Project #5: Patient perception of PFS. Trainee published first author paper in JAMA Oncology.

Project #4: Survivorship in testicular cancer. Trainee published 3 first-author papers in Journal of Clinical Oncology, Clinical Oncology and Current Oncology.

Project #3: Medical oncologist job satisfaction. Trainee published first author paper in Seminars in Oncology.

Project #2: Delivery of care for bladder cancer in routine practice. Trainee published first author papers in JNCI and Canadian Urological Association Journal.

Project #1: Volume-outcomes association for cancer systemic therapy. **Research award 2018:** \$50,000 fellowship award from Southeastern Ontario Academic Medical Organization (SEAMO).

**Research award 2018:** \$70,000 fellowship award from Canadian Association of Medical Oncologists. Trainee published first author paper in Journal of Oncology Practice. **Research award 2019:** Best Oral Presentation, Canadian Association of Medical Oncology annual meeting.

21. Ketan Ghate (Medical Oncology resident), 2016-2018. Concurrent chemoradiotherapy for bladder cancer: practice patterns and outcomes in the general population. Trainee published paper as first author in Radiotherapy & Oncology. One ASCO abstract.

20. Adam Fundytus (Internal Medicine resident), 2016-2018. Medical oncology workforce and delivery of global cancer care. Trainee published 2 papers as first author in Journal of Global Oncology and Current Oncology. Trainee published 3 papers as co-author. One ASCO abstract. **Research award 2017:** First Place Resident Research Competition, Queen's University Department of Medicine.

19. Safiya Karim (Medical Oncology Research Fellow), 2016-2017.

Project #8: Methodologic pitfalls in use of real world data. Trainee published first author paper in Journal of Clinical Oncology.

Project #7: Delivery of chemotherapy for testicular cancer in routine practice. Trainee published paper as first author in Urologic Oncology.

Project #6: Improving documentation of goals of care among patients with terminal cancer (Completed). Trainee published paper as first author in Journal of Oncology Practice.

Project #5: Uptake of FOLFIRINOX for pancreas cancer in routine practice. Trainee published paper as first author in Clinical Oncology. One ASCO QA abstract.

Project #4: Utilization of peri-operative chemotherapy for resected lung metastases. Trainee published paper as first author in Eur J Surg Oncol. One ASCO QA abstract.

Project #3: Exploring the prognostic role of laterality in colon cancer. Trainee published paper as first author in JAMA Oncology. One ASCO abstract.

Project #2: Morphine utilization in Kerala, India. Trainee published paper as second author in J Global Oncol.

Project #1: Benchmarking Appropriate Chemotherapy Utilization for Colon Cancer. Trainee published 2 first authors papers published in Cancer Medicine. One ASCO abstract. **Research award 2016:** \$50,000 fellowship award from Southeastern Ontario Academic Medical Organization (SEAMO). **Research award 2017:** \$50,000 fellowship award from Southeastern Ontario Academic Medical Organization (SEAMO).

18. Joseph Del Paggio (Internal medicine resident), 2014-2018.

Project #3: Clinical benefit and drug cost of new cancer therapies. Trainee published paper as first author in Lancet Oncology. Trainee published paper as first author in Oncotarget. Trainee published paper as second author in Nature Reviews Clin Oncol. Trainee published paper as first author in JNCI Specturm. One ASCO abstract. **Research award 2017:** Novartis Oncology Young Canadian Investigator Award. **Research award 2017:** ASCO Merit Award

Project #2: Magnitude of clinical benefit in published RCTs. Trainee published paper as first author in Ann Oncol. One ESMO abstract. **Research award 2016:** First Place Resident Research Competition, Queen's University Department of Medicine.

Project #1: Lymph node harvest in colon cancer surgery in Ontario: a population-based study. Trainee published two papers as first author in British Journal of Surgery and Curr Oncol. One ASCO abstract. **Research award 2015:** First Place Resident Research Poster Competition, Queen's University Department of Medicine.

17. Anu Krishnamurthy (Medical Oncology resident), 2015-2016. Chemotherapy delivery and outcomes for resected colorectal cancer liver metastases: a population-based study. Trainee published paper as first author in Eur J Surg Oncol. One ASCO abstract.

16. Natasha Satkunam (Internal Medicine resident), 2015-2016. Adjuvant chemotherapy for colon cancer: Delivery and outcomes in routine clinical practice. Trainee published paper as first author in J Nat Compr Canc Netw. One ASCO abstract.
15. Gursimran Chandhoke (Internal medicine resident), 2015-2016. Patterns of Referral for Adjuvant Chemotherapy for Stage II and III Colon Cancer: A population-based study. Trainee published paper as first author in Ann Surg Oncol.
14. Chris Doiron (Urology resident co-supervised with Dr. DR Siemens), 2014-2016.  
Project #2: Epidural anesthesia and outcomes of resected bladder cancer. Trainee published paper as first author in Can Urol Assoc J.  
Project #1: Risk factors and timing of venous thromboembolism after cystectomy in routine clinical practice: A population based study. Trainee published paper as first author in BJU Int. One CUA abstract. **Research award 2015:** Best Trainee Poster Canadian Urological Association Annual Meeting.
13. Senthuran Tharmalingam (MSc Epidemiology student co-supervisor), 2014-2016. Gallbladder cancer: A population-based analysis of surgical practice patterns and outcomes (MSc thesis completed).
12. Francis Patafio (Internal medicine resident), 2013-2015.  
Project #3: The impact of gender and socioeconomic status on treatment and outcome of bladder cancer. Trainee published as first author in Can Urol Assoc J. One ASCO abstract.  
Project #2: Public health burden, research funding, and scholarly output in cancer: is there a relationship? Trainee published paper as first author in Curr Oncol. One ASCO abstract. **Research award 2015:** First Place Resident Research Competition, Queen's University Department of Medicine.  
Project #1: Why is neoadjuvant chemotherapy for bladder cancer underutilized? Trainee published paper as first author in Urologic Oncology. **Research award 2013:** Best Resident Research Presentation, Queen's University Department of Medicine.
11. Melanie Walker (Post-doctoral fellow), 2014-2017. Understanding Physician Knowledge, Attitudes, and Behaviour: Towards Improving Utilization Rates of Peri-operative Chemotherapy for Bladder Cancer. Trainee published 5 papers as first author in: Curr Oncol, Can Urol Assoc J, Clin Oncol, Bladder Cancer and Radiotherapy&Oncology.
10. Willy Raskin (Internal medicine resident), 2014-2016. Goals of care in patients with advanced cancer: are medical oncologists having the conversation?. Trainee published as first author in Clin Oncol. One ASCO abstract. **Research award 2015:** First Place Resident Research Competition, Queen's University Department of Medicine.
9. Lyndsay Harrison (PhD Epidemiology student co-supervisor with Drs. W. Mackillop and W. King), 2013-2018. Patterns of care, symptom burden, and outcomes of men with advanced prostate cancer in the general population of Ontario (thesis abandoned).
8. David Wasserman (Medical oncology resident co-supervised with Dr. J. Biagi), 2012-2013. Time to adjuvant chemotherapy for colon cancer in southeastern Ontario. Trainee published as first author J Oncol Practice. Two ASCO abstracts.

7. Michael Fralick (Internal medicine resident co-supervised with Dr. M. Clemons), 2012-2013. Bevacizumab for advanced breast cancer: hope, hype, and hundreds of headlines. Trainee published paper as first author in The Oncologist. One ASCO abstract. **Research award 2013:** Best Poster Presentation 25th Annual Higgins Day, St. Michael's Hospital, Toronto, Canada.
6. David Wallace (MSc Epidemiology student co-supervisor with Dr. W. Mackillop), 2011-2012. Effectiveness of palliative Gemcitabine chemotherapy for advanced pancreas cancer in the general population (Thesis defended June 2012).
5. Jana Kankesan (Internal medicine resident), 2012. Referral patterns to medical oncology among patients with non-small cell lung cancer in Ontario. Trainee published paper as first author in Current Oncology. One ASCO abstract. **Research award 2011:** First Place Resident Research Competition, Queen's University Department of Medicine.
4. Ravi Ramjeesingh (Medical oncology resident), 2011. Concordance between cancer treatment guidelines and drug funding policy decisions in Ontario. Trainee published paper as first author in Current Oncology. One ASCO abstract.
3. Amin Kay (Internal medicine resident), 2010. Trends in oncology RCTs 2005-2009. Trainee published paper as first author in Annals of Oncology. One ASCO abstract.
2. Abdullah Altwaigi (Medical oncology resident co-supervised with Dr. T. Baetz), 2011-2012. Discordance between conclusions in abstract and conclusions in discussion section of published NSCLC RCT reports. Trainee published paper as first author in the Journal of Clinical Oncology. One ASCO abstract.
1. Mihaela Mates (Medical oncology resident), 2008. Case report of rare treatment complication in advanced colon cancer. Trainee published paper as first author in the Journal of Pain and Symptom Management.

### Undergraduate Trainees

10. Shubham Sharma (Medical student), 2020-2021. RCTs in Canada and the Global Perspective. Trainee published one paper as first author in Current Oncology, one paper as second author in JAMA Oncology.
9. Dan Meyers (Medical student), 2020-2021. Industry payments to physicians for cancer therapies (ongoing). Trainee published one paper as first author in Journal of Cancer Policy and one first author paper in Cancer.
8. Tina Dyer (BHA student), 2018. Waiting for Surgery: The Interval Between Diagnostic Biopsy and Cystectomy for Bladder Cancer. Trainee published as first author in CUAJ.
7. Jill Quirt (Medical student), 2016. Project #2: Patterns of referral to radiation oncology among patients with bladder cancer. Trainee published paper as first author in Clin Oncol.



Project #1: Is there a gender effect in colon cancer? Trainee published as first author in Current Oncology.

6. Priya Jindal and Ryan Fitzpatrick (Medical students co-supervised with Drs. K. Aronson, K. Yeates, J. Carpenter), 2012. Prevention of Cervical Cancer in the Kilimanjaro Region of Tanzania: A Survey of Knowledge, Attitudes and Barrier. Trainees published as co-authors BMJ Open.

5. Ryan Fitzpatrick (Medical student), 2011. Resection of colorectal cancer liver metastases in Ontario 1994-2008 (Project completed).

4. Mike Raphael (Medical student), 2010. Time to adjuvant chemotherapy for breast and colorectal cancer. Trainee published as second author JAMA paper and first author Breast Cancer Res Treat. Three ASCO abstracts.

3. Ahmed Elharram (BSc student), 2010. Utilization of peri-operative chemotherapy for resected bladder cancer in Ontario 1994-2008. Trainee published as co-author Urology paper. Two abstracts (CUA and AUA).

2. Pavlo Ohorodnyk (Medical student), 2009. RCTs in oncology closed early for benefit. Trainee published as first author Eur J Cancer paper and second author J Clin Oncol paper. One ASCO abstract.

1. Kristin Farn (Medical student), 2008. Presentation of non-final results of RCTs at major oncology meeting. Trainee published as middle author J Clin Oncol paper. One ASCO abstract.

## RESEARCH FUNDING HELD

**Total funding held as Principal Investigator:** \$3,752,423

**Total funding held as Co-Investigator:** \$14,668,278

2024-2026	Marathon of Hope Cancer Centres Network Disparities in access to precision oncology drugs across Canada Co-investigator (PI DR. Bishal Gyawali) \$180,000 (total)
2024-2026	Arnold Ventures Foundation Progression-free survival as a surrogate endpoint Principal Investigator \$530,494 (total)
2024-2025	University Hospitals Kingston Foundation Prognostic awareness among patients with advanced cancer. Co-investigator (Principal investigator Dr. Jean Mathews) \$25,000 (total)

## Christopher Booth CV

2024-2026	University Hospitals Kingston Foundation Common Sense Oncology Principal Investigator \$188,604 (total)
2024-2026	American Institute of Cancer Research Impact of aerobic exercise on adipose, muscle and sarcopenia in people with colon cancer Co-investigator (Principal investigator Dr. Kristin Campbell) \$200,000 (total)
2024-2026	Sydney Cancer Partners Evaluating the time toxicity of chemotherapy for metastatic colorectal cancer using patient survey data: a prospective feasibility study. Co-investigator (Principal investigator Dr. Sam Stevens) \$105,000 (total)
2023-2024	Canadian Institutes of Health Research Bridging a gap in global oncology research: Building capacity in research methods in Rwanda <b>Co-investigator</b> (Principal investigator Dr. Fidel Rubagumya) \$19,870 (total)
2023-2024	Canadian Institutes of Health Research Real world outcomes associated with PARP inhibitor maintenance therapy in ovarian cancer <b>Co-investigator</b> (Principal investigator Dr. Josee Ethier) \$100,000 (total)
2023	Clinical Teachers Association of Queen's Real-world outcomes associated with maintenance Olaparib in ovarian cancer. <b>Co-investigator</b> (Principal investigator Dr. Josee Ethier) \$25,000 (total)
2023	Queen's University, Clare Nelson Grant Assessing financial toxicity and evaluating its association with treatment outcomes among Canadian patients with cancer <b>Co-investigator</b> (Principal investigator Dr. Bishal Gyawali) \$20,000 (total)
2022-2023	World Health Organization Country-level barriers to accessing high priority cancer medicines <b>Principal Investigator</b> \$27,984 (total)

## Christopher Booth CV

- 2021-2025      UK Medical Research Council  
Access Cancer Care India: affordable, integrated multi-cancer early detection to improve equitable cancer outcomes  
**Co-investigator** (Principal investigator Dr. Richard Sullivan)  
\$3,026,412 (total)
- 2021-2027      Canadian Institutes of Health Research  
Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colorectal Cancer: A Multicentre Phase II/III Randomised Controlled Trial (DYNAMIC-III)  
**Co-investigator** (Principal investigator Dr. Jon Loree)  
\$1,426,724 (total)
- 2021-2023      Social Sciences and Humanities Research Council  
Using Transitions Theory to examine approaches for individuals who are returning to work.  
**Co-investigator** (Principal investigator Dr. Jacqueline Galica)  
\$68,415 (total)
- 2021-2022      Canadian Centre for Applied Research in Cancer Control  
Evaluation of the systemic cancer therapy volume-outcome association: a population-based study to inform the optimal provincial organization and delivery of systemic cancer therapy  
**Co-investigator** (Principal investigator Dr. Michael Raphael)  
\$50,000 (total)
- 2021-2022      Clinical Teachers Association of Queen's  
Choosing wisely Brazil: Facilitating the delivery of high-quality cancer care and promoting workload standardization in Brazil.  
**Co-investigator** (Principal investigator Dr. Fabio Moraes)  
\$17,130 (total)
- 2021-2024      Canadian Institutes of Health Research  
Palliative care at the end of life among patients with cancer before and during the COVID-19 pandemic  
**Co-investigator** (Principal investigator Dr. Camilla Zimmermann)  
\$423,045 (total)
- 2020-2021      Canadian Institutes of Health Research  
Disparities in the management and outcomes of patients with rectal cancer: a population based study.  
**Co-investigator** (Principal investigator Dr. Sunil Patel)  
\$95,500 (total)

## Christopher Booth CV

- 2020-2021 University of Toronto Alternative Funding Plan Innovation Grant  
Can we re-purpose existing medicines to improve cancer outcomes?  
**Co-investigator** (Principal investigator Dr. Michael Raphael)  
\$99,906 (total)
- 2019-2021 Canadian Institutes of Health Research  
Understanding how cancer patients value progression-free survival  
**Co-investigator** (Principal investigator Dr. Michael Brundage)  
\$175,000 (total)
- 2019-2023 National Health and Medical Research Council  
CHALLENGE clinical trial: Colon Health And Life Long Exercise ChaNGE  
**Co-investigator** (Principal investigator Dr. Janette Vardy)  
\$1,076,030 (total)
- 2019-2020 Clinical Teachers at Queen's (CTAQ)  
Barriers to optimal care of patients with rectal cancer in Ontario  
**Co-investigator** (Principal investigator Dr. Sunil Patel)  
\$20,000 (total)
- 2019-2020 Department of Surgery at Queen's University  
Barriers to optimal care of patients with rectal cancer in Ontario  
**Co-investigator** (Principal investigator Dr. Sunil Patel)  
\$15,000 (total)
- 2018-2023 Canadian Institutes of Health Research  
Symptom screening and early palliative care in patients with advanced cancer: a randomized trial  
**Co-investigator** (Principal investigator Dr. Camilla Zimmermann)  
\$1,022,150 (total)
- 2018-2023 Rio Arronte Foundation, Mexico  
Current Situation and Analysis of a Model of Comprehensive Care of Health Systems in Mexico, in Adolescent and Young Adults Patients with Diagnosis of Extracranial Germ Cell Tumors  
**Co-investigator** (Co-principal investigators Drs. Laura Rodriguez and Francisco Vera-Badillo).  
\$400,000 (total) (Funding declined)
- 2019-2020 Queen's University Southeastern Ontario Medical Organization  
Clinical Research Fellowship Funding  
**Co-investigator** (Principal investigator Dr. Bishal Gyawali)  
\$50,000 (total)
- 2019-2024 Canadian Institutes of Health Research  
Canada Research Chair in Population Cancer Care  
**Principal Investigator**  
\$500,000 (total)

## Christopher Booth CV

- 2019-2020      Cancer Care Ontario  
Understanding Differences in Colorectal Cancer Survival Outcomes in Ontario  
**Co-investigator** (Principal investigator Dr. Michael Brundage)  
\$100,000 (total)
- 2018-2019      Canadian Institutes of Health Research  
Real world outcomes of novel targeted agents for the treatment of metastatic HER-2  
positive breast cancer in Ontario: A population-based study  
**Co-investigator** (Principal investigator Dr. Josee-Lyne Ethier)  
\$97,999 (total)
- 2018-2019      Canadian Association of Medical Oncology Fellowship Award  
Clinical Research Fellowship Funding  
**Co-investigator** (Principal investigator Dr. Michael Raphael)  
\$70,000 (total)
- 2018-2019      Queen's University Southeastern Ontario Medical Organization  
Clinical Research Fellowship Funding  
**Co-investigator** (Principal investigator Dr. Michael Raphael)  
\$50,000 (total)
- 2018-2020      Queen's Cancer Research Institute Translational Team Grant  
Population-based precision cancer medicine for bladder cancer  
**Co-investigator** (Principal Investigator Dr. David Berman)  
\$40,000 (total)
- 2018-2020      Queen's University Interdisciplinary Cancer Research Grant  
Barriers to recommended care for rectal cancer patients in Ontario  
**Co-Principal Investigator** (Co-PI, Dr. Sunil Patel)  
\$38,900 (total)
- 2017-2020      Canadian Institutes of Health Research  
Imaging use for low back pain by primary care practitioners.  
**Co-investigator** (Principal Investigator Dr. Simon French)  
\$707,626 (total)
- 2017-2018      Queen's University Southeastern Ontario Medical Organization  
Clinical Research Fellowship Funding  
**Co-investigator** (Principal investigator Dr. Safiya Karim)  
\$50,000 (total)
- 2016-2018      Queen's University International Research Fund  
Cancer Health Services Research Collaboration at Regional Cancer Centre  
Thiruvananthapuram, Kerala, India.  
**Principal Investigator**  
\$20,000 (total)

## Christopher Booth CV

- 2015-2018 Canadian Institutes of Health Research  
Optimizing the Use of Adjuvant Chemotherapy for Colon Cancer:  
A Population-Based Study of Practice and Outcomes  
**Principal Investigator**  
\$218,101 (total)
- 2016-2018 Queen's University Southeastern Ontario Medical Organization  
Clinical Research Fellowship Funding  
**Co-investigator** (Principal investigator Dr. Safiya Karim)  
\$50,000 (total)
- 2015-2017 Canadian Cancer Society Research Institute  
Novel hypoglycemic agents and cancer risk  
**Co-investigator** (Principal Investigator Dr. Igor Karp)  
\$194,405 (total)
- 2015-2017 Queen's University Southeastern Ontario Medical Organization Innovation Fund  
Management and Outcomes of Testicular Cancer in Routine Clinical Practice: A  
Population-Based Outcomes Study  
**Co-investigator** (Principal Investigator Dr. Michael Leveridge)  
\$63,565 (total)
- 2014-2019 Canadian Institutes of Health Research  
Canada Research Chair in Population Cancer Care  
**Principal Investigator**  
\$500,000 (total)
- 2014-2016 Canadian Cancer Society Research Institute  
Understanding Physician Knowledge, Attitudes, and Behaviour: Towards Improving  
Utilization Rates of Peri-operative Chemotherapy for Bladder Cancer  
**Principal Investigator**  
\$99,344 (total)
- 2014-2017 Canadian Institutes of Health Research  
A Population Study of the Toxicity and Effectiveness of High-Dose Interferon for  
High-Risk Melanoma  
**Co-investigator** (Principal investigator Dr. Tim Hanna)  
\$360,993 (total)
- 2014 Kingston General Hospital Research Institute Clare Nelson Bequest Fund  
Towards Optimal Multidisciplinary Management of Bladder Cancer: Referral  
Patterns in the "Real World"  
**Principal Investigator**  
\$10,000 (total)

- 2013-2014 Queen's University Department of Surgery Research Competition  
Surgical Resection and Peri-Operative Chemotherapy for Colorectal Cancer Liver Metastases  
**Co-Principal Investigator** (co-PI Dr. Sulaiman Nanji)  
\$60,000 (total)
- 2013-2014 Queen's University Department of Oncology Research Competition  
Surgical Resection and Peri-Operative Chemotherapy for Colorectal Cancer Lung Metastases: A Population-Based Outcomes Study.  
**Co-Principal Investigator** (co-PI Dr. Sulaiman Nanji)  
\$40,000 (total)
- 2013-2014 Canada Foundation for Innovation, Infrastructure Operating Fund  
Translating New Anti-Cancer Treatments into Population Benefit  
**Principal Investigator**  
\$34,455 (total)
- 2013-2014 Queen's University Southeastern Ontario Medical Organization Innovation Fund  
Management and Outcomes of Testicular Cancer in Routine Clinical Practice: A Population-Based Outcomes Study  
**Co-investigator** (Principal Investigator Dr. Michael Leveridge)  
\$36,000 (total)
- 2011-2016 Cancer Care Ontario, Applied Cancer Research Unit Funding  
Cancer Care and Epidemiology  
**Co-investigator** (Principal Investigator Dr. Michael Brundage)  
\$1,182,500 (total)
- 2011-2014 Canadian Institutes of Health Research  
Understanding Diagnostic Episodes of Care in Patients with Early versus Late Cancers  
**Co-investigator** (Principal Investigator Dr. Patti Groome)  
\$413,621 (total)
- 2009-2013 Canadian Institutes of Health Research (CIHR-IC1 93466 & CIHR MOP 97767)  
Adoption of Adjuvant Chemotherapy for Non-Small Cell Lung Cancer in Ontario: A Population-Based Outcomes Study  
**Principal Investigator**  
\$357,109 (total)
- 2009-2013 Canada Foundation for Innovation/Ontario Research Fund  
Translating New Anti-Cancer Treatments into Population Benefit: A Provincial Chemotherapy and Outcomes Database  
**Principal Investigator**  
\$229,700 (total)

## Christopher Booth CV

- 2011-2014 Canadian Breast Cancer Foundation  
Measuring the quality of systemic therapy for breast cancer using population-level quality indicators  
**Co-investigator** (Principal Investigator Dr. Monika Krzyzanowska)  
\$242,352 (total)
- 2009-2010 Cancer Care Ontario  
Chemotherapy for muscle invasive bladder cancer: A population-based study of practice patterns and outcomes in Ontario  
**Principal Investigator**  
\$47,372 (total)
- 2009-2011 National Cancer Institute, National Institutes of Health  
Treatment Success and Ethical Principle of Equipoise  
**Co-investigator** (Principal Investigator Dr. Benjamin Djulbegovic)  
\$631,183 (USD) (total)
- 2009-2011 Ontario Institute for Cancer Research  
Development of systemic therapy quality indicators  
**Co-investigator** (Principal Investigator Dr. Monika Krzyzanowska)  
\$167,743 (total)
- 2008-2013 Cancer Care Ontario Chair in Health Services Research  
Patterns in Cancer Care  
**Principal Investigator**  
\$500,000 (total)
- 2008-2013 Ministry of Health and Long-Term Care Career Scientist  
Assessing Translation of Cancer Therapies into Benefit at the Population Level  
**Principal investigator**  
\$350,000 (total) declined as CCO Chair was accepted in lieu
- 2008-2014 Canadian Institutes of Health Research  
The Terry Fox Foundation Training Program in Transdisciplinary Cancer Research at CIHR  
**Co-investigator** (Principal investigator Dr. Lois Mulligan)  
\$1,650,000 (total)
- 2008-2009 Canadian Association of Radiation Oncology  
The Value of Quality of Life Information to Hormone-Refractory Metastatic Prostate Cancer Patients Facing Treatment Decisions  
**Co-investigator** (Principal investigator Dr. Michael Brundage)  
\$24,434 (total)



## Christopher Booth CV

2005-2006 Canadian Breast Cancer Research Alliance  
Cognitive Impairment Associated with Chemotherapy for Breast Cancer: An  
Exploratory Case Controlled Study  
**Co-investigator** (Principal investigator Dr. Ian Tannock)  
\$50,000 (total)

## **CURRICULUM VITAE**

**Shaila J. Merchant**

### **Personal Information**

Address: 76 Stuart Street, Burr 2, Kingston, Ontario, K7L 2V7

Citizenship: Canadian

### **Education and Professional Qualifications**

2000 Bachelor of Science (Biochemistry), University of British Columbia  
2003 Master of Science (Physiology, with Distinction), University of Alberta  
2007 Doctor of Medicine (with Honors), University of British Columbia  
2008 Licentiate of the Medical Council of Canada  
2010 Master of Health Science, University of British Columbia  
2013 Fundamentals of Laparoscopic Surgery  
2013 Royal College of Physicians and Surgeons of Canada, General Surgery  
2014 American Board of Surgery, General Surgery  
2015 Advanced Cardiac Life Support (ACLS)  
2015 Advanced Trauma Life Support (ATLS)  
2015 Royal College of Physicians and Surgeons of Canada, General Surgical Oncology  
2015 Fellow of the Royal College of Physicians and Surgeons of Canada  
2015 Independent Medical License, College of Physicians and Surgeons of Ontario  
2016 American Board of Surgery, Complex Surgical Oncology  
2016 Associate Fellow of the American College of Surgeons  
2023 Advancing Leadership Program, Queen's University

### **Awards**

1996 Outstanding Student Initiative Scholarship, University of British Columbia  
1997 Outstanding Student Initiative Scholarship, University of British Columbia  
1998 Outstanding Student Initiative Scholarship, University of British Columbia  
2002 Perinatal Research Centre Scholarship, University of Alberta  
2002 Province of Alberta Graduate Scholarship, University of Alberta  
2003 Mary Louise Imrie Graduate Student Award, University of Alberta  
2003 Perinatal Research Centre Graduate Student Award, University of Alberta  
2003 Government of Alberta Graduate Student Scholarship, Alberta Learning Achievement Scholarship Program  
2003 Girl Guides of Canada Scholarship, Girl Guides of Canada  
2003 Merit Award, Coast Capital Savings Education Awards  
2004 RX&D Studentship in Medicine, Canadian Institutes of Health Research

Dr. Shaila J. Merchant  
Curriculum Vitae

- 2004 Florence E. Heighway Summer Research Award, University of British Columbia
- 2004 John J. Mason Memorial Scholarship, University of British Columbia
- 2005 Florence E. Heighway Summer Research Award, University of British Columbia
- 2005 Faculty of Medicine Summer Research Award, University of British Columbia
- 2005 Connie and Sam Carlin Scholarship, University of British Columbia
- 2006 George W. Leroux Memorial Scholarship, University of British Columbia
- 2006 Gwynne-Vaughan Memorial Award in Medicine, University of British Columbia
- 2006 Wesbrook Scholar, University of British Columbia
- 2006 Harold B. and Nellie Boyes Memorial Scholarship, University of British Columbia
- 2006 Harry Logan Memorial Scholarship, University of British Columbia
- 2007 Wyeth Scientific Award for Best Podium Presentation, Canadian Association for Transplantation
- 2007 Dr. AM Agnew Memorial Prize, University of British Columbia
- 2007 Harcharan Kaur Mann Memorial Scholarship in Medicine, University of British Columbia
- 2009 Hoffmann-LaRoche Research Grant, Hoffmann-LaRoche Canada
- 2011 Surgical Oncology Network Travel Award, British Columbia Surgical Oncology Network
- 2013 Kristen Ann Carr Traveling Fellowship, Kirsten Ann Carr Fund
- 2015 City of Hope Graduate Medical Education Research Travel Award, City of Hope National Medical Center
- 2017 Canadian Society of Surgical Oncology Award for Best Scientific Paper, Canadian Association of General Surgeons/Canadian Society of Surgical Oncology
- 2019 Recipient of the Korean Society of Surgical Oncology Visiting Observership in Seoul, Korea
- 2019 Recipient of the Canadian Institutes of Health Research (CIHR) Early Career Researcher Observership
- 2023 Recipient of the Honor Your Caregiver Award, Kingston Health Sciences Centre
- 2024 Recipient of the Honor Your Caregiver Award, Kingston Health Sciences Centre

**Academic Appointments**

- |                        |   |
|------------------------|---|
| July 2015 to July 2021 | Assistant Professor, Department of Surgery and Oncology,<br>Queen's University, Kingston, Ontario |
| July 2021 to Present   | Associate Professor, Department of Surgery and Oncology,<br>Queen's University, Kingston, Ontario |

**Hospital Appointments**

- |                      |  |
|----------------------|--|
| July 2015 to Present | Attending Staff, Kingston Health Sciences Centre |
|----------------------|--|

### **Other Positions**

1. Lead, Interleukin-2 Injection Program for Melanoma (January 2017 – Present)
2. Fellow, Institute for Clinical Evaluative Sciences, Queen's Site (January 2017 – September 2019)
3. Clinician Scientist, Cancer Care and Epidemiology, Queen's Cancer Research Institute (June 2019 – Present)
4. Ontario Health Patient Reported Outcomes and Symptom Management Team (August 2021 – March 2022)

### **Professional Memberships**

2007 to Present	Canadian Association of General Surgeons
2007 to Present	Canadian Medical Association
2013 to Present	Royal College of Physicians and Surgeons of Canada
2013 to Present	American College of Surgeons
2013 to Present	Society of Surgical Oncology
2013 to Present	Canadian Society of Surgical Oncology
2015 to Present	Ontario Medical Association

### **Committees**

#### **International**

1. Branding Task Force Committee, Society of Surgical Oncology (March 2018 – November 2018)
2. Website User Experience Task Force, Society of Surgical Oncology (November 2018 – March 2019)
3. Scientific Program Committee, Society of Surgical Oncology (February 2019 – March 2021)
4. Member, Cancer and Aging Research Group (CARG) (October 2024 – Present)

#### **National**

1. Chair, Patient Education Committee, Canadian Gastric Cancer Association (February 2019 – Present)
2. Treasurer, Canadian Society of Surgical Oncology (May 2019 – April 2023)
3. Director of Education, Canadian Society of Surgical Oncology (April 2023 – September 2024)
4. Specialty Review Committee (Surgical Oncology), Royal College of Physicians and Surgeons of Canada (April 2020- Present)
5. Choosing Wisely Oncology Canada Working Group (August 2021 – Present)
6. Co-Chair, Scientific Program Planning, Canadian Surgical Forum (September 2024 – Present)
7. Member, Canadian Network on Aging and Cancer (CNAC) (October 2024 – Present)

### **Provincial**

1. Cancer Quality Council of Ontario (CQCO) (June 2024 – Present)

### **University**

1. Steering Committee, Breast and Colorectal Communities of Practice (January 2017 – January 2020)
2. Department of Surgery Research Committee (July 2022 – Present)
3. J. Farwaha Thesis Committee (MNSc candidate) (July 2023 – Present)
4. R. Howden Thesis Committee (MSc candidate) (September 2023 – Present)
5. First Patient Program Preceptor, Queen's University MD Program (September 2023 – Present)
6. Nominations and Governance Development Committee, Southeastern Ontario Academic Medical Organization (SEAMO) (June 2024 – Present)

### **Departmental**

1. Academic Advisor, General Surgery Residency Program, Queen's University (July 2017 – Present)
2. Member Competency Committee, General Surgery Residency Program, Queen's University (July 2021 – January 2022)
3. Chair, Breast Disease Site Group, Cancer Centre of Southeastern Ontario (September 2018 – December 2022)
4. Chief, Clinical Teaching Unit 3, Division of General Surgery and Surgical Oncology, Kingston Health Sciences Centre (December 2021 – Present)
5. Search Committee, Hepatobiliary Surgery (May-June 2021)
6. Search Committee, Plastic Surgery (July 2021)
7. Search Committee, Radiation Oncology (June 2022)
8. Search Committee, Acute Care General Surgery (May-June 2024)

**Research Grants and Funding**  
**Funded as Principal Investigator**

1. “A population-based analysis of end-of-life care in advanced gastrointestinal malignancies” (\$30,000). Granted by the Faculty of Health Sciences, Queen’s University, Kingston, Ontario (2016)
2. “Patterns of aggressive end-of-life care in gastrointestinal cancer - focus on palliative care referrals and ICU admissions” (\$13,855). Women’s Giving Circle, Kingston Health Sciences Centre, Kingston, Ontario (2018)
3. “Practice patterns, utilization and outcomes of multimodality therapies in the management of locally advanced/resectable and advanced unresectable/metastatic esophageal, gastroesophageal junction (GEJ) and gastric cancers in Ontario, Canada” (\$20,000). CTAQ Endowment Fund, Kingston, Ontario (2019)
4. “Practice patterns, utilization and outcomes of multimodality therapies in the management of locally advanced/resectable and advanced unresectable/metastatic esophageal, gastroesophageal junction (GEJ) and gastric cancers in Ontario, Canada” (\$25,000). University Hospitals Kingston Foundation, Kingston, Ontario (2019)
5. “Biopsy of gastric lesions to develop patient-derived cancer models” (\$2,500). Division of General Surgery Academic Excellence Fund, Kingston Health Sciences Centre, Kingston, Ontario (2019)
6. “Development and implementation of an opioid-sparing standardized multimodal analgesic protocol for patients undergoing outpatient breast surgery” (\$20,000) – CTAQ Endowment Fund, Kingston, Ontario (2020)
7. “Exploring palliative therapies, supportive care and symptom burden in patients with incurable large and small intestine cancers” (\$15,000) – Department of Surgery, Queen’s University, Kingston, Ontario (2021)
8. “Genetic Literacy in Oncology (GLiO): Understanding and bridging gaps in genetic knowledge in surgeons” (\$15,594) - CTAQ Endowment Fund, Kingston, Ontario (2021)
9. “Improving patient experiences and outcomes: A health services research program grounded in clinical practice” (\$50,000) – Department of Surgery, Queen’s University, Kingston, Ontario (2022)
10. “Building a clinical and research program dedicated to older adult cancer care at Kingston Health Sciences Centre” (\$180,000) – SEAMO Established Researcher Fund, Queen’s University, Kingston, Ontario (2024)

### **Funded as Co-Investigator**

1. “The psychosocial implications of COVID-19: How are cancer survivors coping?” (\$10,000). Queen’s SARS CoV-2/COVID-19 Rapid Response Funding (June – December 2020, Principal Investigator Dr. Jacqueline Galica)
2. “Disparities in the management and outcomes in patients with rectal cancer: A population based study” (\$95,500). Canadian Institutes of Health Research, Data Analysis Using Existing Databases and Cohorts (February 2020, Principal Investigator Dr. Sunil Patel).
3. “Establishing consensus on a competency-based surgical oncology fellowship curriculum for West Africa: a Delphi study” (\$15,000). Department of Surgery, Queen’s University (April 2020, Principal Investigator Dr. Faizal Haji)

### **Research Involvement**

### **Active Research as Principal Investigator**

1. “Genetic Literacy in Oncology”
  - Scoping review and needs assessment study
2. “Older Adult Cancer Care”
  - Health administrative database study and quality improvement initiative

### **Active Research as Collaborator**

1. “Image-guided breast surgery”
  - Translational research study (Principal investigators Dr. Parvin Mousavi, Dr. Gabor Fichtinger, Dr. John Rudan, Dr. Jay Engel)
2. “Development of a Surgical Oncology Curriculum for Surgeons in West Africa”
  - Delphi consensus methodology to develop curriculum content (Principal investigator Dr. Sulaiman Nanji)
3. “Cirrhosis and Surgery”
  - ICES database study (Principal investigator Dr. Jennifer Flemming)
4. “Male breast cancer outcomes”
  - ICES database study (Principal investigator Dr. Sean Bennett)
5. “The Treatment and Outcome of Merkel Cell Carcinoma: a Pan-Canadian Study”
  - Multi-center retrospective study (Principal Investigator Dr. Carolyn Nessim)
6. “Small Bowel Cancers”
  - Health administrative database linked to pathology reports (Principal Investigator Dr. Sean Bennett)
7. “Diagnosed with breast cancer in rural Canada: Utilizing an integrated knowledge translation approach to strategize advancements in cancer-related health equity (the DISTANCE study)”
  - Principal Investigator Dr. Jacqueline Galica
8. “Patient and diagnostic intervals in gastric cancer: measuring and addressing disparities for timely interventions”
  - Principal investigators: Dr. Alyson Mahar and Dr. Natalie Coburn



## Completed Research

1. “A Population-Based Analysis of End-of-Life Care in Advanced Gastrointestinal Malignancies”
  - Administrative database (ICES) study
  - Role: Principal investigator
2. “Occurrence and management of malignancy-associated intestinal obstruction near the end of life”
  - Administrative database (ICES) study
  - Role: Principal investigator
3. “Practice patterns, utilization and outcomes of multimodality therapies in the management of locally advanced/resectable and advanced unresectable/metastatic esophageal, gastroesophageal junction (GEJ) and gastric cancers in Ontario, Canada”
  - Administrative database study
  - Role: Principal investigator
4. “Incidence and outcomes of venous thromboembolism in esophagogastric cancer”
  - Administrative database study
  - Role: Principal investigator
5. “Management of post-operative breast pain in women with dependent children”
  - Quantitative and qualitative study
  - Role: Co-investigator (Principal investigator Dr. Susan Brogly)
6. “Implementation of the Begin Exploring Fertility Options, Risks and Expectations (BEFORE) decision aid – a stepped wedge cluster randomized trial and qualitative interviews with nurses and support staff”
  - Multi-center clinical trial
7. “BREAST-Q in Surgery”
  - Scoping review, prospective study (Principal investigator Dr. Glykeria Martou)
8. “Biopsy of Gastric Lesions to Develop Patient-Derived Cancer Models”
  - Translation research pilot study in conjunction with University of Kentucky, Lexington, KY, USA (Principal Investigator Dr. Joseph Kim)
9. “Development of an opioid-sparing standardized multimodal analgesic protocol for patients undergoing outpatient breast surgery “
  - Prospective pilot study, administrative database (ICES) study
10. “Exploring palliative therapies, supportive care and symptom burden in patients with incurable large and small intestine cancers”
  - Administrative database study

## **Publications**

### **Peer Reviewed Publications**

1. **Merchant SJ**, Narumiya H, Zhang Y, Guilbert LJ, and Davidge ST. The effects of preeclampsia and oxygen environment on endothelial release of matrix metalloproteinase-2. *Hypertens Pregnancy*, 2004, 23(1):47-60
2. **Merchant SJ**, Crocker IP, Baker PN, Davidge ST, and Guilbert LJ. Matrix metalloproteinase release from placental explants of pregnancies complicated by intrauterine growth restriction. *J Soc Gynecol Investig*, 2004, Feb; 11(2):97-103
3. **Merchant SJ** and Davidge ST. The role of matrix metalloproteinases in vascular function: implications for normal pregnancy and preeclampsia. *BJOG*, 2004, 111:1-9
4. Myers JE, **Merchant S**, Macleod M, Mires GJ, Baker PN, Davidge ST. MMP-2 levels are elevated in the plasma of women who subsequently develop preeclampsia. *Hypertens Pregnancy*, 2005, 24(2):103-15
5. **Merchant S**, Yoshida E, Lee T, Richardson P, Karlsbjerg K, Cheung E. Exploring the psychological effects of deceased organ donation on the families of the organ donors. *Clin Transplant*, 2008, May-Jun; 22(3):341-7
6. **Merchant SJ**, Cheung E, Yoshida EM Exploring the psychological effects of deceased organ donation on the families of the organ donors - a response. *Clin Transplant*, 2008 Sept; 22(5):687
7. **Merchant S**, Hameed M, Melck A. Pregnancy among residents enrolled in general surgery (PREGS): A survey of residents in a single Canadian training program. *Can J Surg*, Dec 2011, 54(6): 375–80
8. **Merchant S**, Cheifetz R, Knowling M, Khurshed F, McGahan C. Practice referrals patterns and outcomes in patients with primary retroperitoneal sarcoma in British Columbia. *Am J Surg*, May 2012, 203(5): 632–638
9. Johner AM, **Merchant S**, Aslani N, Planting A, Ball CG, Widder S, Pagliarello G, Parry NG, Klassen D, Hameed SM. Acute general surgery in Canada: a survey of current handover practices. *Can J Surg*, June 2013, 56(3): E24-8
10. **Merchant S**, Hameed M, Melck A. Pregnancy among residents enrolled in general surgery (PREGS): A nationwide survey of attitudes and experiences. *Am J Surg*, Oct 2013, 206(4):605-610
11. **Merchant SJ**, Li L, Kim J. Racial and ethnic disparities in gastric cancer outcomes: more important than surgical technique? *World J Gastroenterol*, Sept 2014; 20(33): 11546-11551

12. **Merchant SJ** and Chen SL. The exportability of the ACOSOG Z0011 criteria for omitting axillary lymph node dissection after positive sentinel lymph node biopsy findings: a multicenter study (Commentary). *Breast Diseases Quarterly*, May – June 2014, 25(1): 60-61
13. **Merchant SJ** and Chen SL. Prevention and management of lymphedema after breast cancer treatment. *The Breast J*, May 2015; 21(3): 276–284
14. **Merchant SJ**, Goldstein L, Kruper L. Patterns and trends in immediate post-mastectomy reconstruction in California: Complications and unscheduled readmissions. *Plast Reconstruct Surg*, July 2015; 136(1), 10e–19e
15. Sun V, Kim J, Kim J, Raz D, **Merchant SJ**, Chao J, Chung V, Jimenez T, Wittenberg-Lyles E, Grant M, Ferrell B. Dietary alterations and restrictions following surgery for upper gastrointestinal cancers: key components of a health-related quality of life intervention. *Eur J Oncol Nurs*, Aug 2015;19(4):343-8
16. Schoellhammer HF, Goldner B, **Merchant SJ**, Kessler J, Fong Y and Singh G. Colorectal Liver Metastases: Making the Unresectable Resectable Using Irreversible Electroporation for Microscopic Positive Margins – A Case Report. *BMC Cancer*, April 2015; 15: 271
17. Choi A, Hamner JB, **Merchant SJ**, Trisal V, Chow W, Garberoglio C, Kim J. Underreporting of gastrointestinal stromal tumors: is the true incidence being captured? *J Gastrointest Surg*, Sept 2015;19(9):1699-703
18. **Merchant SJ**, Ituarte P, Choi A, Sun V, Chao J, B Lee, Kim J. Hospital readmission following surgery for gastric cancer: frequency, timing, etiologies and survival. *J Gastrointest Surg*, Oct 2015; 19(10):1769-81
19. Choi AH, Nelson R, **Merchant SJ**, Kim JY, Chao J, Kim J. Rates of lymph node metastasis and survival in T1a gastric adenocarcinoma in Western populations. *Gastrointest Endosc*, June 2016;83(6):1184-1192
20. **Merchant SJ**, Nelson R, Choi AH, Sun V, Chao J, Kim J. A rising trend in the incidence of advanced gastric adenocarcinoma in young Hispanic men. *Gastric Cancer*, March 2017; 20(2): 226-234
21. Choi A, O’Leary MP, **Merchant SJ**, Sun V, Chao J, Raz DJ, Kim JY, Kim J. Complications of feeding jejunostomy tubes in patients with gastroesophageal cancer. *J Gastrointest Surg*, Feb 2017;21(2):259-265
22. **Merchant SJ**, Nanji S, Brennan K, Karim S, Patel SV, Biagi JJ, Booth CM. Management of stage III colon cancer in the elderly: practice patterns and outcomes in the general population. *Cancer*, Aug 2017;123(15):2840-2849

23. **Merchant SJ**, Lajkosz K, Brogly SB, Booth CM, Nanji S, Patel SV, Baxter NN. The final 30 days of life: a study of patients with gastrointestinal cancer in Ontario, Canada. *Journal of Palliative Care*, Dec 2017; Jul/Oct;32(3-4):92-100.
24. Patel SV, Brennan KE, Nanji S, Karim S, **Merchant S**, Booth CM. Peri-operative blood transfusion for resected colon cancer: Practice patterns and outcomes in a population-based study. *Cancer Epidemiology*, Dec 2017;51: 35-40
25. **Merchant SJ**, Brogly SB, Goldie C, Booth CM, Nanji S, Patel SV, Lajkosz K, Baxter NN. Palliative Care is Associated with Reduced Aggressive End of Life Care in Patients with Gastrointestinal Cancer. *Annals of Surgical Oncology*, Jun 2018;25(6):1478-1487.
26. Patel SV, Groome PA, **Merchant S**, Lajkosz K, Nanji S, Brogly SB. Timing of surgery and the risk of complications in patients with acute appendicitis: a population-level case-crossover study. *J Trauma Acute Care Surg*. 2018 May 4
27. **Merchant SJ**. Palliative Care and Aggressive End-of-Life Care – A Surgeon’s Reflections on Priorities for the Future. *Annals of Surgical Oncology*, Dec 2018; 25(Suppl 3):618-619.
28. Patel SV, Nanji S, Brogly SB, Lajkosz K, Groome PA, **Merchant S**. High complication rate among patients undergoing appendectomy in Ontario: a population-based retrospective cohort study, *Can J Surg*. 2018 Oct 1; 61(6): 11517.
29. Ko G, Sarkaria A, **Merchant SJ**, Booth CM, Patel SV. A systematic review of outcomes after salvage abdominoperineal resection for persistent or recurrent anal squamous cell cancer. *Colorectal Dis* June 2019;21(6):632-650.
30. **Merchant SJ**, Brogly SB, Booth CM, Goldie C, Nanji S, Patel SV, Lajkosz K, Baxter N. Palliative care and high symptom burden in the last year of life: a population-based study of patients with gastrointestinal cancer. *Annals of Surgical Oncology*, Aug 2019;26(8):2336-2345.
31. **Merchant SJ**. Managing symptoms at the end-of-life: some progress, many unanswered questions. *Annals of Surgical Oncology*, Aug 2019; 26(8):2346-2347.
32. **Merchant SJ**, Brogly SB, Booth CM, Goldie C, Peng Y, Nanji S, Patel SV, Lajkosz K, Baxter N. Management of Cancer-Associated Intestinal Obstruction in the Final Year of Life. *Journal of Palliative Care*. July 2019 (Epub ahead of print)
33. Gauvin G, Yeo CT, Ungi T, **Merchant S**, Lasso A, Jabs D, Vaughan T, Rudan J, Walker GR, Fichtinger G, Engel CJ. Real-time electromagnetic navigation in breast-conserving surgery using NaviKnife technology: a matched case-control study. *Breast Journal*. Sept 2019 (Epub ahead of print)
34. La J, **Merchant SJ**. Understanding survival disparities in gastric cancer. *Oncology & Hematology Review (US)* July 2019;15(2):78–82.

35. Mir ZM, Yu D, **Merchant SJ**, Booth CM, Patel SV. Management of rectal cancer in Canada: an evidence-based comparison of clinical practice guidelines. *Can J Surg*. 2020 Jan 22;63(1): E27-E34. doi: 10.1503/cjs.017518.
36. Patel SV, Zhang L, Wei XS, **Merchant SJ**, Nanji S, James PD, Booth CM. A Population-based cohort study of venous thromboembolism rates following surgery and during adjuvant chemotherapy in patients with colon cancer. *Dis Colon Rectum* 2020 Mar;63(3):336-345. doi: 10.1097/DCR.0000000000001557.
37. **Merchant SJ**, Nair CK, Booth CM. Leveraging high quality research to define the gastric cancer landscape in India. *Indian Journal of Surgical Oncology* 2020, March
38. Caycedo-Marulanda A, Patel S, **Merchant S**, Brown C. Introduction of new techniques and technologies in surgery: Where is transanal total mesorectal excision today? *World Journal of Surgery* 2020, May
39. **Merchant SJ**, Kong W, Gyawali B, Hanna T, Chung W, Nanji S, Patel SV, Booth CM. Effectiveness of Trastuzumab in Routine Clinical Practice: A Population-based Study of Patients with HER-2+ Esophageal, Gastroesophageal and Gastric Cancer. *Clinical Oncology*, July 2020.
40. **Merchant SJ**, Kong W, Gyawali B, Hanna T, Chung W, Nanji S, Patel SV, Booth CM. First-line palliative chemotherapy for esophageal and gastric cancer: practice patterns and outcomes in the general population. *Journal of Oncology Practice*, November 2020
41. Haase K, Kain D, **Merchant S**, Booth C, Koven R, Brundage M, Galica J. Older cancer survivors' reflections on the COVID-19 pandemic and recommendations for future care. *Journal of Geriatric Oncology*, December 2020:S1879-4068(20)30501-4.
42. Gerolami J, Wu V, Fauerbach PN, Jabs D, Engel CJ, Rudan J, **Merchant S**, Walker R, Anas EMA, Abolmaesumi P, Fichtinger G, Ungi T, Mousavi P. An End-to-End Solution for Automatic Contouring of Tumor Region in Intraoperative Images of Breast Lumpectomy. *Annu Int Conf IEEE Eng Med Biol Soc*. 2020 Jul; 2020: 2003-2006.
43. Nanji S, Mir Z, Karim S, Brennan KE, Patel SV, **Merchant SJ**, Booth CM. Perioperative blood transfusion and resection of colorectal cancer liver metastases: outcomes in routine clinical practice. *HPB (Oxford)* 2021 March
44. **Merchant SJ**, Kong W, Brundage M, Booth C. Symptom evolution in patients with esophageal and gastric cancer receiving palliative chemotherapy: a population-based study. *Annals of Surgical Oncology* 2021, 28:79-87
45. **Merchant SJ**, Booth CM. Palliative chemotherapy for upper GI cancer: balancing hope, reality, survival, and symptoms. *Annals of Surgical Oncology* 2021, 28: 88-89

46. Galica J, Liu Z, Kain D, **Merchant S**, Booth C, Koven R, Brundage M, Haase K. Coping during COVID-19: A mixed methods study of older cancer survivors. *Support Care Cancer*. 2021 Jan 6:1-10.
47. Yeo C, **Merchant SJ**. Considerations in the Management of Malignant Bowel Obstruction. *Surgical Oncology Clinics of North America*, 2021 June
48. Malcolm R, Pilkington M, **Merchant SJ**, Velez M, Brogly SB. Work-related factors and pregnancy outcomes in Canadian surgeons. *Annals of Surgery Open*, 2021 June
49. Hanna N, Mir Z, Williams E, **Merchant SJ**, Zevin B, Chung W. Laparoscopic ischemic conditioning of the gastric conduit prior to a hybrid McKeown esophagectomy does not decrease the risk of anastomotic leak (In press, Videosurgery and Other Miniinvasive Techniques)
50. Santilli AML, Jamzad A, Sedghi A, Kaufmann M, Logan K, Wallis J, Ren KYM, Janssen N, **Merchant S**, Engel J, McKay D, Varma S, Wang A, Fichtinger G, Rudan JF, Mousavi P. Domain adaptation and self-supervised learning for surgical margin detection. *Int J Comput Assist Radiol Surg*. 2021 May;16(5):861-869. Epub 2021 May 6.
51. Jamzad A, Santilli A, Akbarifar F, Kaufmann M, Logan K, Wallis J, Ren K, **Merchant S**, Engel J, Varma S, Fichtinger G, Rudan J, Mousavi P. Graph transformers for characterization and interpretation of surgical margins. *Medical Image Computing and Computer Assisted Intervention* 2021, September 21: 88-97.
52. **Merchant SJ**, Kong W, Mahmud A, Booth CM, Hanna TP. Palliative Radiotherapy for Esophageal and Gastric Cancer: Population-Based Patterns of Utilization and Outcomes in Ontario, Canada (*Journal of Palliative Care*, January 2022)
53. Hanna NM, Williams E, Kong W, Fundytus A, Booth C, Patel SV, Caycedo-Marulanda A, Chung W, Nanji S, **Merchant SJ**. Incidence, Timing and Outcomes of Venous Thromboembolism during Treatment of Esophagogastric Cancer: A Population-Based Cohort Study (*Annals of Surgical Oncology*, March 2022)
54. Hanna NM, **Merchant SJ**. ASO Author Reflections: Is it Time for a Tailored Approach to Venous Thromboembolism Prophylaxis in Patients with Esophagogastric Cancer? (*Annals of Surgical Oncology*, March 2022)
55. Patel SV, McClintock C, Booth CM, **Merchant SJ**, Heneghan C, Bankhead C. Variations in Care and Real World Outcomes in those with Rectal Cancer: Protocol for the Ontario Rectal Cancer Cohort (OntaReCC). *JMIR Research Protocols*, April 2022.
56. Patel SV, Wiseman V, Zhang L, MacDonald PH, **Merchant S**, Barnett KW, Caycedo-Marulanda A. The impact of robotic surgery on a tertiary care colorectal surgery program, an

- assessment of costs and short term outcomes: A Canadian perspective. *Surg Endosc.* 2022, August, 36(8).
57. La J, Alqaydi A, Wei X, Schellenberger J, Digby GC, Brogly SB, **Merchant SJ**. Variation in Opioid Filling after Same Day Breast Surgery in Ontario, Canada: A Population-Based Cohort Study. *CMAJ Open* 2023; March 7, 11(2).
58. Karim S, Doll C, Dingley B, **Merchant SJ**, Ynoe de Moraes, Booth CM. Are Choosing Wisely Canada cancer recommendations relevant and up to date with the current evidence? *Journal of Cancer Policy* 2023, March;35:100406.
59. Arora N, Lo M, Hanna N, Pereira J, Digby G, Bechara R, **Merchant SJ**, Hopman W, Nguyen R, Li S, Chung W. Influence of a patient navigation program on timeliness of care in patients with esophageal cancer. *Cancer Medicine* 2023; April 19.
60. **Merchant SJ**. Two Goodbyes. *CMAJ* May 2023
61. Arora N, Patel R, Sohi G, **Merchant SJ**, Martou G. A Scoping Review of the Application of Breast-Q in Surgical Research. *JPRAS Open* 2023, May 9
62. McDonald H, Harper M, Hill K, Gao A, Solomon A, Bailey C, Cavnar M, Mardini S, Pandalai P, Patel R, Kolesar J, Rueckert J, Hookey L, Ropeleski M, **Merchant SJ**, Kim J, Gao M. Creation of EGD-Derived Gastric Cancer Organoids to Predict Treatment Responses. *Cancers* 2023, 15(11), 3036.
63. Karim S, Doll C, Dingley B, **Merchant SJ**, Ynoe de Moraes F, Booth CM. Choosing Wisely Oncology Canada Cancer List: An Update. *Journal of Cancer Policy* 2023.
64. Syeda A, Fooladgar F, Jamzad A, Srikanthan D, Kaufmann M, Ren K, Engel J, Walker R, **Merchant S**, McKay D, Varma S, Fichtinger G, Rudan J, Mousavi P. Self-supervised learning and uncertainty estimation for surgical margin detection. *Medical Imaging 2023 Image-Guided Procedures, Robotic Interventions, and Modeling*. April, Volume 12466.
65. Sunil V Patel, Kelly Brennan, Lisa Zhang, Maya Djerboua, Sulaiman Nanji, **Shaila J Merchant**, Jennifer A. Flemming. Colorectal cancer in individuals with cirrhosis: a population-based study assessing practice patterns, outcomes and predictors of survival. *Current Oncology* 2023. Oct 30;30(11).
66. Wilson BE, Booth CM, Patel SV, Berry S, Kong W, **Merchant SJ**. First-line palliative chemotherapy for colorectal cancer: a population-based analysis of delivery and outcomes in a single-payer health system. *Clinical Oncology* 2024: Dec 13 36(4).
67. **Merchant SJ**, Shellenberger J, Sawhney M, La J, Brogly SB. Physician Characteristics Associated with Opioid Prescribing after Same Day Breast Surgery in Ontario, Canada: A Population-based Cohort Study. *Annals of Surgery Open*, 2023. Dec 4; 4(4).

68. Pan-Canadian Merkel Cell Cancer Collaborative. Survival of Patients With Head and Neck Merkel Cell Cancer: Findings From the Pan-Canadian Merkel Cell Cancer Collaborative JAMA Network Open 2023. Nov 1: 6(11).
69. Mathews J, **Merchant S**, Galica J, Palmer M, O'Donnell J, Koven R, Booth C, Brundage M. Measuring prognostic awareness in patients with advanced cancer: a scoping review and interpretive synthesis of the impact of hope. Journal of the National Cancer Institute 2-23. Dec 22.
70. Zhang L, Brennan K, Flemming J, Nanji S, Djerboua M, **Merchant S**, Caycedo-Marulanda A, Patel SV. Emergency colorectal surgery in patients with cirrhosis: A population-based study assessing practice patterns, outcomes and predictors of mortality. Journal of the Canadian Association of Gastroenterology 2023.
71. Mir ZM, Fei LY, Dinchong R, Rusnak A, Cofie N, Dalgarno N, McKeown S, Cheifetz R, **Merchant SJ**. Knowledge, perceptions, attitudes and barriers to genetic literacy in surgeons: a scoping review. Canadian Journal of Surgery 2024, 67(2), E118.
72. Caitlin Lees, Hsien Seow, Kelvin Kar-Wing Chan, Anastasia Gayowsky, **Shaila J. Merchant**, Aynharan Sinnarajah. Sex-based analysis of quality indicators of end-of-life care in gastrointestinal malignancies. Current Oncology 2024, 31 (3), 1170-1182.
73. Sunil V. Patel, Vanessa Wiseman, Lisa Zhang, **Shaila J. Merchant**, Antonio Caycedo-Marulanda, Kathleen Wattie Barnett, P. Hugh MacDonald. The impact of robotic rectal cancer surgery at a Canadian regional cancer centre. Canadian Journal of Surgery May 2024, 67(3), 206-213.
74. Sunil V. Patel, James Ahlin, Kelly Brennan, Sulaiman Nanji, **Shaila J. Merchant**, Katherine Laskosz, Susan B. Brogly, Patti A. Groome. The use of imaging studies and its association with surgical delays, costs and complications in patients with acute appendicitis: A population-based study in Ontario, Canada. Discover Public Health, October 2024, 24(157).
75. Sulaiman Nanji, Emanuel Ezeome, Olusegun Alitise, **Shaila Merchant**, Florence Dedey, Matthew Jalink, Sidy Ka, Klodiana Kolomitro, Clement Osime, Nazik Hammad, Nicholas Cofie, Faizal Haji, Serigne Magueye Gueye. A Novel Curriculum for Surgical Oncology Fellowship Training in West Africa. Annals of Surgical Oncology, November 2024.
76. Sulaiman Nanji, Olusegun Alitise, Serigne Magueye Gueye, **Shaila Merchant**, King-David Terna Yawe, Matthew Jalink, Temidayo O Ogundiran, Badejo Olawale, Klodiana Kolomitro, Sidy Ka, Scott Berry, Joe Nat Clegg-Lampsey, Nazik Hammad, Florence Dedey, Nicholas Cofie, Clement Osime, Ishmael Kyei, Faizal Haji, Emanuel Ezeome. Developing a Surgical Oncology Workforce in West Africa: A Needs Assessment and Environmental Scan. Annals of Surgical Oncology, November 2024.



77. Bennett S, Chen N, Kong W, Wilson B, Patel SV, Booth CM, **Merchant SJ**. Small bowel cancers: a population-based analysis of epidemiology, treatment and outcomes in Ontario, Canada from 2005-2020. *Surgical Oncology Insight*, December 2024, 1(4).
78. Jogendran M, Flemming JA, Djerboua M, Korzeniowski M, Wilson BE, **Merchant SJ**, Bennett S. The association between cirrhosis and outcomes among female patients undergoing surgery for breast cancer in Ontario: a population-based study (in press).

### **Under Review/Revisions Submitted**

1. Fei L, Messiha S, Mir Z, Dinchong R, Rusnak A, Cofie N, Dalgarno N, Cheifetz R, **Merchant SJ**. Genetic Literacy in Surgeons Who Manage Patients with Cancer: A National Survey of Knowledge, Perceptions, Attitudes, and Barriers.
2. Megan Delisle, Brittany Dingley, Sameer Apte, Anne Light, Ranjeeta Mallick, Trevor Hamilton, Heather Stuart, Martha Talbot, Gregory McKinnon, Evan Jost, Eve Thiboutot, Valerie Francescutti, Sal Samman, Alexandra Easson, Angela Schellenberg, **Shaila Merchant**, Julie La, Kaitlin Vanderbeck, Frances Wright, David Berger-Richardson, Pamela Hebbard, Olivia Hershorn, Rami Younan, Erica Patocskai, Samuel Rodriguez-Qizilbash, Ari Meguerditchian, Vanina Tchunte, Suzanne Kazadjian, Alex Mathieson, Farisa Hossain, Jessika Hetu, Stephanie Johnson-Obaseki, Carolyn Nessim. Management and outcomes of Merkel Cell Carcinoma in Canada between 2000 and 2018 from the Pan-Canadian Merkel Cell Collaborative.
3. Brittany Dingley, Megan Delisle, Anne Light, Sameer Apte, Ranjeeta Mallick, Trevor Hamilton, Heather Stuart, Martha Talbot, Gregory McKinnon, Evan Jost, Eva Thiboutot, Valerie Francescutti, Salsabila Samman, Alexandra M Easson, Angela Schellenberg, **Shaila Merchant**, Julie La, Kaitlin Vanderbeck, Frances C Wright, David Berger-Richardson, Pamela Hebbard, Olivia Hershorn, Rami Younan, Erica Patocskai, Samuel Rodriguez-Qizilbash, Ari Meguerditchian, Vanina Tchunte, Suzanne Kazandjian, Alex Mathieson, Farisa Hossain, Jessika Hetu, Stephanie Johnson-Obaseki and Carolyn Nessim. Survival Outcomes in the Canadian Merkel Cell Carcinoma Population between 2000-2018 and Descriptive Comparison with the UICC/AJCC TNM 8th Edition Staging System – A study from the Pan-Canadian Merkel Cell Collaborative.
4. Nair CK, Krishnamoorthy A, Jacob A, Thanda A, Merchant SJ, Booth CM, George P. Management and outcomes of gastric cancer at a multidisciplinary cancer centre in South India.

### Non-Peer-Reviewed Publications

1. **Merchant SJ**, Pyke O, Kim J. Robotic segmental gastrectomy for large gastrointestinal stromal tumors. Minimally Invasive Surgical Techniques for Cancers of the Gastrointestinal Tract: A Step-by-Step Approach. Editors: Kim J, Garcia-Aguilar J. Publisher: Springer.
2. **Merchant SJ** and Booth CM. Understanding patient, family and provider perceptions of palliative care. Invited Expert Editorial. Published in the American Society of Clinical Oncology Daily News (December 2018)  
<https://dailynews.ascopubs.org/doi/10.1200/adn.18.190006/full>
3. **Merchant SJ**. Gastric Cancer Patient Education Material (“Gastric cancer”)  
<https://khscnow.kingstonhsc.ca/cancer-ed/surgical-oncology>
4. **Merchant SJ**. Gastric Cancer Patient Education Material (“What to expect after surgery for gastric cancer”) <https://khscnow.kingstonhsc.ca/cancer-ed/surgical-oncology>
5. Ontario Health Patient Reported Outcomes and Symptom Management Working Group. Symptom Management Algorithm – Constipation in Adults with Cancer.  
<https://www.cancercareontario.ca/en/symptom-management/3146>
6. Ontario Health Patient Reported Outcomes and Symptom Management Working Group. Symptom Management Algorithm – Diarrhea in Adults with Cancer.  
<https://www.cancercareontario.ca/en/symptom-management/3151>
7. Jamzad, A. *et al.* (2023). Bridging Ex-Vivo Training and Intra-operative Deployment for Surgical Margin Assessment with Evidential Graph Transformer. In: Greenspan, H., *et al.* Medical Image Computing and Computer Assisted Intervention – MICCAI 2023. MICCAI 2023. Lecture Notes in Computer Science, vol 14226. Springer, Cham.  
[https://doi.org/10.1007/978-3-031-43990-2\\_53](https://doi.org/10.1007/978-3-031-43990-2_53)

## Abstracts Presented

1. Lopez de Menezes DE, **Merchant S**, Chi K, Dragowska W, Sartor J, Wallis A, Mayer LD. Combination of Bcl-2 antisense and liposomal doxorubicin can suppress the growth of human breast cancer xenografted in SCID mice (Presented at Bridging the Straits of Georgia: the Fifth Symposium on Cancer Research, September 1999)
2. **SJ Merchant**, LJ Guilbert and ST Davidge. Human umbilical vein endothelial cell production of matrix metalloproteinase-2 and matrix metalloproteinase-9: effects of vascular endothelial growth factor stimulation and varying oxygen conditions (Presented at the Canadian Physiological Society Annual Meeting, February 2002)
3. Tildesley H, Begg I, Singer J, **Merchant S**, Lavery MJ, Pottinger B, Johns K. The clinical utility of the use of a non-mydriatic camera in a diabetes teaching clinic (Presented at the American Diabetes Association Conference, June 2002)
4. **SJ Merchant**, LJ Guilbert and ST Davidge. Endothelial cells demonstrate a biphasic matrix metalloproteinase-2 release in response to varying oxygen tensions (Presented at the 50<sup>th</sup> Annual Scientific Meeting of the Society for Gynecologic Investigation, March 2003)
5. **SJ Merchant**, IP Crocker, PN Baker, LJ Guilbert, and ST Davidge. Decreased matrix metalloproteinase-2 release in placental explants from complicated pregnancies (Presented at the 11<sup>th</sup> Annual Western Perinatal Research Meeting, February 2003)
6. J Myers, **S Merchant**, M Macleod, G Mires, P Baker, and S Davidge. Elevated levels of MMP-2 and MMP-9 in the plasma of women who subsequently develop pre-eclampsia (Presented at the Blair Bell Scientific Meeting, United Kingdom, 2003)
7. **SJ Merchant**, SM Szabo, MJ Potter. Twelve month clinical outcomes following treatment of subfoveal choroidal neovascularization in pathologic myopia using photodynamic therapy with Verteporfin (Visudyne) (Presented at the UBC Multidisciplinary Undergraduate Research Conference, March 2004)
8. Veerareddy S, Hemmings DG, **Merchant SJ**, Baker PN, and Davidge ST. Maternal undernutrition affects modulation of myogenic reactivity in the uterine arteries in the pregnant offspring in the rat model (Presented at the Society for Gynecologic Investigation Annual Meeting, March 2004)
9. MJ Potter, **SJ Merchant**, SM Szabo. Twelve month clinical outcomes following treatment of subfoveal choroidal neovascularization in pathologic myopia using photodynamic therapy with Verteporfin (Visudyne) (Presented at the ARVO 2004 Annual General Meeting, April 2004)
10. MJ Potter, **SJ Merchant**, SM Szabo. Twelve month clinical outcomes following treatment of subfoveal choroidal neovascularization in pathologic myopia using photodynamic therapy

with Verteporfin (Visudyne) (Presented at the 20<sup>th</sup> Annual Ophthalmology Research Day, May 2004)

11. **SJ Merchant**, SM Szabo, MJ Potter. Twelve month clinical outcomes following treatment of subfoveal choroidal neovascularization in pathologic myopia using photodynamic therapy with Verteporfin (Visudyne) (Presented at the 1<sup>st</sup> Annual Medical Undergraduate Society Medical Student Research Forum, November 2004)
12. Khazaei M, Moien-Afshari F, **Merchant S**, Laher I. Exercise improves endothelial dysfunction in db/db mice model of type II diabetes (Presented at the 35<sup>th</sup> Annual Experimental Biology Meeting, April 2005)
13. Khazaei M, Moien-Afshari F, **Merchant S**, Laher I. Exercise improves endothelial dysfunction in db/db mouse model of type II diabetes. The FASEB Journal. 2005. March 4, 19(4): A631, 364.5
14. **Merchant S**, Yoshida E, Lee T, Richardson P, Cheung E. Exploring the effects of cadaveric organ donation on the families of the organ donors: learning how to make the transplant process better for British Columbia (Presented at the BC Transplant Research Institute, 10<sup>th</sup> Annual Transplantation Research Day, December 2006)
15. **Merchant S**, Yoshida E, Lee T, Richardson P, Karlsbjerg K, Cheung E. Exploring the psychological effects of deceased organ donation on the families of the organ donors (Presented at the Canadian Association for Transplantation Annual Meeting, Banff, AB, March 2007)
16. **Merchant S**, Hameed M, Melck A. Pregnancy among residents enrolled in general surgery (PREGS): A survey of residents in a single Canadian training program (Presented at the University of British Columbia Department of Surgery Resident Research Day 2010)
17. **Merchant S**, Hameed M, Melck A. Pregnancy among residents enrolled in general surgery (PREGS): A survey of residents in a single Canadian training program (Presented at the Canadian Surgery Forum, Quebec City, QC, September 2010)
18. **Merchant S**, Knowling M, Cheifetz R. Is there an association between timing of referral to a tertiary care centre and local recurrence in primary retroperitoneal sarcoma in British Columbia? (Presented at the BC Surgical Society Meeting, Parksville, BC, May 2011)
19. **Merchant S**, Knowling M, Cheifetz R. Practice Referral Patterns and Outcomes for Primary Retroperitoneal Sarcoma in British Columbia (Presented at the North Pacific Surgical Association Meeting, Vancouver, BC, November 2011)
20. **Merchant SJ**, Hameed SM, Melck AL. Pregnancy among residents enrolled in general surgery (PREGS): A nationwide survey of attitudes and experiences (Presented at the Association for Surgical Education Meeting, San Diego, CA, March 2012)

21. Johner A, Aslani N, **Merchant S**, Hameed M. Acute General Surgery in Canada: A Survey of Current Hand-Over Practices (Presented at the BC Surgical Society Meeting, Whistler, BC, May 2012)
22. Lam E, **Merchant S**, Knowling M, Lai A, McGahan C, Cheifetz R. Practice referral patterns and outcomes in patients with gastrointestinal stromal tumors in British Columbia (Presented at the Canadian Society of Surgical Oncology Meeting, Toronto, ON, April 2013)
23. **Merchant SJ**, Schoellhammer H, Kim J, Lai L, Kessler J, Park J, Singh G. Early experience with irreversible electroporation in the treatment of liver metastases (Presented at the 11<sup>th</sup> World Congress of the International Hepato-Pancreato-Biliary Association, Seoul, Korea March 2014)
24. **Merchant S**, Goldstein L, Vito C, Yim J, Chen S, Kruper L. Disparities in immediate reconstruction after mastectomy in California (Presented at the Canadian Society of Surgical Oncology Annual Meeting, Toronto, ON, May 2014)
25. **Merchant SJ**, Goldstein L, Kruper L. Complications and readmissions after immediate breast reconstruction: the California experience (Presented at the American College of Surgeons 2014 Clinical Congress, October 2014)
26. **Merchant SJ**, Nelson R, Choi A, Chao J, Lin J, Kim J, Kim J. An alarming trend in the incidence of advanced gastric adenocarcinoma in young Hispanic males (Presented at the Society of Surgical Oncology Annual Meeting, Houston, TX, March 2015)
27. Falor A, Choi A, **Merchant S**, Lew M, Lee B, Paz IB, Nelson R, Kim J. Outcomes Using Double-Stapled Technique for Esophagoenteric Anastomosis in Gastric Cancer (Presented at the 10<sup>th</sup> Annual Academic Surgical Congress, Las Vegas, NV, February 2015)
28. Choi AH, Hamner JB, **Merchant SJ**, Trisal V, Chow W, Garberoglio C, Kim J. Underreporting of Gastrointestinal Stromal Tumors to the National Cancer Registry: Is the True Incidence Being Captured? (Presented at the Society of Surgical Oncology Annual Meeting, Houston, TX, March 2015)
29. Kessler J, **Merchant SJ**, Singh G, Park J. Margin extension with irreversible electroporation: a novel, adjunctive approach to treating liver malignancies (Presented at the Society of Interventional Radiology 40<sup>th</sup> Annual Scientific Meeting, Atlanta, GA, March 2015)
30. Choi A, Nelson R, **Merchant SJ**, Kim JY, Chao J, Kim J. Endoscopic mucosal resection may not be appropriate for all T1a gastric cancers (Presented at Digestive Disease Week, Washington, DC, May 2015)
31. **Merchant SJ**, Ituarte P, Choi AH, Sun V, Chao J, Kim J. Hospital readmission following surgery for gastric cancer: frequency, timing, etiologies and survival (Presented at the Canadian Society of Surgical Oncology Annual Meeting, Toronto, ON, May 2015)

32. Gauvin G, Ungi T, Lasso A, Yeo CT, Fichtinger G, Jabs D, Walker R, **Merchant S**, Rudan JF, Engel CJ. Breast-conserving surgery using Naviknife technology: pilot study on non-palpable tumors (Presented at the Canadian Surgery Forum, Toronto, ON, September 2016)
33. **Merchant SJ**, Brennan K, Karim S, Patel S, Nanji S, Booth CM. Management of stage III colon cancer in the elderly: practice patterns and outcomes in the general population (Presented at the Society of Surgical Oncology Annual Cancer Symposium, Seattle, WA, March 2017)
34. **Merchant SJ**, Lajkosz K, Brogly S, Booth C, Nanji S, Patel S, Baxter NN. The last thirty days of life: Trends in aggressive end-of-life care in gastrointestinal malignancies (Presented at the Canadian Surgical Forum, Victoria, BC, September 2017)
35. **Merchant SJ**, Brogly SB, Goldie C, Booth CM, Nanji S, Patel SV, Lajkosz K, Baxter NN. Palliative Care is Associated with Reduced Aggressive End of Life Care in Patients with Gastrointestinal Cancer (Presented at the Society of Surgical Oncology Annual Cancer Symposium, Chicago, IL, March 2018)
36. **Merchant SJ**, Brogly SB, Goldie C, Booth CM, Nanji S, Patel SV, Lajkosz K, Baxter NN. Palliative Care is Associated with Reduced Aggressive End of Life Care in Patients with Gastrointestinal Cancer (Presented at the Canadian Society of Surgical Oncology Annual Meeting, Toronto, ON, April 2018)
37. **Merchant SJ**, Brogly S, Booth CM, Goldie C, Nanji S, Patel SV, Lajkosz K, Baxter NN. The Effect of Palliative Care on Symptom Burden in Patients with Gastrointestinal Cancer (Presented at the Society of Surgical Oncology Annual Cancer Symposium, San Diego, CA, March 2019).
38. **Merchant SJ**, Brogly S, Booth CM, Goldie C, Peng Y, Lajkosz K, Baxter NN. Cancer-Associated Intestinal Obstruction at the End of Life (Presented at the Society of Surgical Oncology Annual Cancer Symposium, San Diego, CA, March 2019).
39. **Merchant SJ**, Brogly S, Booth CM, Goldie C, Peng Y, Lajkosz K, Baxter NN. Cancer-Associated Intestinal Obstruction at the End of Life (Presented at the Canadian Surgical Forum, Montreal, Canada, September 2019).
40. **Merchant SJ**, Kong W, Gyawali B, Hanna T, Chung W, Nanji S, Patel SV, Booth CM. “First-line palliative chemotherapy for esophageal and gastric cancer: practice patterns and outcomes in the general population” (Presented at the Canadian Surgical Forum, Virtual Meeting, September 2021).
41. Megan E Delisle, Brittany Dingley, Sameer Apte, Ranjeeta Mallick, Trevor D Hamilton, Heather Stuart, Valerie Francescutti, Greg McKinnon, Evan Jost, Alexandra Easson, **Shaila J Merchant**, Pamela Hebbard, Frances Catriona Wright, David Berger Richardson, Rami Younan, Ari Meguerditchian, Alex Mathieson, Jessika Hetu, Stephanie Johnson, Carolyn Nessim. Pan-Canadian Merkel Cell Collaborative. “Sentinel lymph node biopsy in Merkel

cell carcinoma: A multi-institutional study from the Pan-Canadian Merkel Cell Collaborative.” *Journal of Clinical Oncology* 2022, Vol 40, Issue 16 supplement, page 9583 (Poster presentation).

42. **Pan-Canadian Merkel Cell Collaborative.** Survival among patients with Stage III and Stage IV Merkel Cell Carcinoma of known vs. unknown primary origin: A Multi-Institutional Study of the Pan-Canadian Merkel Cell Collaborative. Canadian Society of Surgical Oncology Annual Meeting, April 2022 (Podium presentation).
43. S Patel, A Caycedo-Marulanda, **S Merchant**, S Nanji, K Brennan, L Zhang, M Djerboua, JA Flemming. “Practice patterns and outcomes in cirrhotics with colorectal cancer: a population-based study”. *Diseases of the Colon and Rectum* 2022, Volume 65, Issue 5, pages 100-101 (Podium presentation).
44. S Patel, A Caycedo-Marulanda, **SJ Merchant**, C McClintock, CM Booth, C Bankhead, C Heneghan. “The impact of surgeon volume on quality of care and outcomes in individuals with rectal cancer: a population-based study”. *Diseases of the Colon and Rectum* 2022, Volume 65, Issue 5, pages 222-223 (Podium presentation).
45. V Wiseman, K Brennan, A Caycedo Marulanda, **SJ Merchant**, C McClintock, S Patel. “The association between hospital characteristics and minimally invasive rectal cancer surgery: a population-based study.” *Diseases of the Colon and Rectum* 2022, Volume 65, Issue 5, pages 223-223 (Podium presentation).
46. K Brennan, L Zhang, J Flemming, M Djerboua, S Nanji, A Caycedo, **S Merchant**, S Patel. “Outcomes after elective colorectal surgery in patients with cirrhosis: a population-based study”. *Diseases of the Colon and Rectum* 2022, Volume 65, Issue 5, pages 103-103 (Poster presentation).
47. Sunil Patel, Chad McClintock, **Shaila Merchant**, Christopher M Booth, Antonio Caycedo Marulanda, Carl Bankhead, Carl Heneghan. “Incomplete preoperative staging results in suboptimal treatment in rectal cancer patients: A population-based study.” *Journal of Clinical Oncology* 2022, Volume 40, Issue 4 supplement, Page 20 (Poster presentation).
48. **Merchant SJ**, Kauffman M, Rudan JF et al. “3D Navigated Mass Spectrometry for Intra-operative Margin Assessment During Breast Cancer Surgery” *Annals of Surgical Oncology* 2024, supplement (Podium presentation).
49. M Jogendran, JA Flemming, M Djerboua, **S Merchant**, S Bennett. “The association between cirrhosis and outcomes amongst female patients undergoing surgery for breast cancer in Ontario: a population-based study” *Annals of Surgical Oncology* 2024, supplement (Poster presentation)
50. S Bennett, G Nelson, N AlMarzooqi, M Jogendran, M Djerboua, BE Wilson, **SJ Merchant**, et al. “Epidemiology, treatment and outcomes of males diagnosed with breast cancer in

Ontario, 2007-2017: a population-based analysis” *Annals of Surgical Oncology* 2024, supplement (Poster presentation)

51. Sean Bennett, Brooke Wilson, Nan Chen, Weidong Kong, Sunil Patel, Christopher Booth, **Shaila Merchant**. Small Bowel Cancers: A Population-Based Analysis of Epidemiology, Treatment and Outcomes in Ontario, Canada from 2005-2020. Presented at the Canadian Surgical Forum September 2024, Winnipeg, Manitoba (ORAL)
52. Manisha Jogendran, Jennifer Flemming, Maya Djerboua, Martin Korzeniowski, Brooke Wilson, **Shaila Merchant**, Sean Bennett. The Association between Cirrhosis and Outcomes among Female Patients undergoing Surgery for Breast Cancer in Ontario: A Population-Based Study. Presented at the Canadian Surgical Forum September 2024, Winnipeg, Manitoba (ORAL)
53. Georgia Nelson, Nouf AlMarzooqi, **Shaila Merchant**, Sean Bennett. Axillary Lymph Node Management of Clinically N0 Male Breast Cancer: A Systematic Review. Presented at the Canadian Surgical Forum September 2024, Winnipeg, Manitoba (ORAL)
54. Sean Bennett, Georgia Nelson, Nouf AlMarzooqi, Manisha Jogendran, Maya Djerboua, Brooke Wilson, Jennifer Flemming, **Shaila Merchant**. The Epidemiology, Treatment and Outcomes of Males Diagnosed with Breast Cancer in Ontario, 2007-2017: A Population-Based Analysis. Presented at the Canadian Surgical Forum September 2024, Winnipeg, Manitoba (ORAL)



### **Presentations by Trainees**

1. La J, Alqaydi A, Digby G, **Merchant SJ**. A pilot study for evaluation of current post-operative pain medication prescribing practices, consumption and pain experience in patients undergoing outpatient breast surgery. Presented at the 39<sup>th</sup> Annual William Ersil Resident Research Day, November 2020 (ORAL)
2. Arora N, Nguyen R, Lo M, Pereira J, Digby G, Bechara R, **Merchant S**, Chung W. Impact of Patient Navigation on Esophageal Cancer Patient-Related Outcomes. Presented at the 39<sup>th</sup> Annual William Ersil Resident Research Day, November 2020 (ORAL)
3. Alqaydi A, La J, Digby G, **Merchant SJ**. Opioid prescription and consumption in patients undergoing outpatient breast surgery – baseline data for a quality improvement initiative. Presented at the Canadian Surgical Forum, Virtual Meeting, September 2021 (POSTER)
4. J. La, A. Alqaydi, X. Wei, G.C. Digby, S.B. Brogly, **S.J. Merchant**. Post-operative opioid prescribing practices for outpatient breast surgery in Ontario: a population-based study. Presented at the 40<sup>th</sup> Annual William Ersil Resident Research Day, November 2021 (ORAL)
5. Hanna N, Williams E, Kong W, Fundytus A, Booth C, Patel S, Caycedo-Marulanda A, Chung W, Nanji S, **Merchant SJ**. Incidence, Timing and Outcomes of Venous Thromboembolism during Treatment of Esophagogastric Cancer: A Population-Based Cohort Study. Presented at the 40<sup>th</sup> Annual William Ersil Resident Research Day, November 2021 (ORAL)
6. J. La, A. Alqaydi, X. Wei, G.C. Digby, S.B. Brogly, **S.J. Merchant**. Post-operative opioid prescribing practices for outpatient breast surgery in Ontario: a population-based study. Presented at the Society of Surgical Oncology Annual Cancer Symposium, Dallas, Texas, March 2022 (POSTER)
7. Hanna N, Williams E, Kong W, Fundytus A, Booth C, Patel S, Caycedo-Marulanda A, Chung W, Nanji S, **Merchant SJ**. Incidence, Timing and Outcomes of Venous Thromboembolism during Treatment of Esophagogastric Cancer: A Population-Based Cohort Study. Presented at the Society of Surgical Oncology Annual Cancer Symposium, Dallas, Texas, March 2022 (POSTER)
8. J. La, A. Alqaydi, X. Wei, G.C. Digby, S.B. Brogly, **S.J. Merchant**. Variation in opioid prescribing after outpatient breast surgery: time for a streamlined approach? Canadian Surgical Forum, Toronto, Ontario, September 2022 (ORAL)
9. Hanna N, Williams E, Kong W, Fundytus A, Booth C, Patel S, Caycedo-Marulanda A, Chung W, Nanji S, **Merchant SJ**. Incidence, Timing and Outcomes of Venous Thromboembolism during Treatment of Esophagogastric Cancer: A Population-Based Cohort Study. Canadian Surgical Forum, Toronto, Ontario, September 2022 (ORAL)

10. Fei L, Mir Z, **Merchant SJ**. Knowledge, Perceptions, Attitudes and Barriers to Genetic Literacy Among Surgeons: A Scoping Review. Presented at the 41st Annual William Ersil Resident Research Day, November 2022 (ORAL – 1<sup>st</sup> prize for best presentation)
11. Messiha S, Fei L, Mir Z, **Merchant SJ**. Genetic Literacy in Oncology: A Nationwide Needs Assessment of Practicing Surgical Oncologists, Colorectal and General Surgeons. Presented at the 41st Annual William Ersil Resident Research Day, November 2022 (ORAL)
12. Fei L, Mir Z, McKeown S, Dinchong R, Cofie N, Dalgarno N, Rusnak A, Cheifetz R, **Merchant SJ**. Knowledge, Perceptions, Attitudes and Barriers to Genetic Literacy among Surgeons: A Scoping Review. Presented at the Society of Surgical Oncology 2023 Annual Cancer Symposium, Boston, MA, March 2023 (POSTER)
13. Mir Z, Fei L, Messiha S, Cheifetz R, Dinchong R, Rusnak A, Cofie N, Dalgarno N, **Merchant SJ**. Knowledge, Perceptions, Attitudes, and Barriers to Genetic Literacy among Surgeons: A Scoping Review. Presented at the Canadian Surgical Forum, Vancouver, British Columbia, September 2023 (ORAL)
14. La J, Shellenberger J, Sawhney M, Brogly SB, **Merchant SJ**. Characteristics of opioid providers for patients undergoing same day breast surgery in Ontario, Canada. Presented at the Canadian Surgical Forum, Vancouver, British Columbia, September 2023 (ORAL)
15. Fei L, Mir Z, McKeown S, Dinchong R, Cofie N, Dalgarno N, Rusnak A, Cheifetz R, **Merchant SJ**. Knowledge, Perceptions, Attitudes and Barriers to Genetic Literacy among Surgeons: A Scoping Review. Presented at the 42<sup>nd</sup> Annual William Ersil Resident Research Day, November 2023 (ORAL)
16. Messiha S, Fei L, Mir Z, **Merchant SJ**. Genetic Literacy in Oncology: A Nationwide Needs Assessment of Practicing Surgical Oncologists, Colorectal and General Surgeons. Presented at the 42nd Annual William Ersil Resident Research Day, November 2023 (ORAL)
17. Messiha S, Fei L, Mir Z, Dinchong R, Rusnak A, Cofie N, Dalgarno N, Cheifetz R, **Merchant SJ**. Exploring Genetic Literacy in Surgeons Who Manage Patients with Cancer: A National Survey of Knowledge, Perceptions, Attitudes, and Barriers. Presented at the Canadian Surgical Forum September 2024, Winnipeg, Manitoba (ORAL)
18. Messiha S, Fei L, Mir Z, Dinchong R, Rusnak A, Cofie N, Dalgarno N, Cheifetz R, **Merchant SJ**. Exploring Genetic Literacy in Surgeons Who Manage Patients with Cancer: A National Survey of Knowledge, Perceptions, Attitudes, and Barriers. Presented at the 43<sup>rd</sup> Annual William Ersil Resident Research Day, November 2024 (ORAL)

## **Invited Presentations**

### **International**

1. “Pregnancy among residents enrolled in general surgery (PREGS): A nationwide survey of attitudes and experiences”, Association for Surgical Education Meeting, San Diego, CA, USA, March 2012 (ORAL)
2. “Early experience with irreversible electroporation in the treatment of liver metastases”, 11<sup>th</sup> World Congress of the International Hepato-Pancreato-Biliary Association, Seoul, Korea, March 2014 (POSTER)
3. “Disparities in immediate reconstruction after mastectomy in California”, Canadian Society of Surgical Oncology Annual Meeting, Toronto, ON, Canada, May 2014 (ORAL)
4. “Understanding readmissions following surgery for gastric cancer”, Canadian Society of Surgical Oncology Annual Meeting, Toronto, ON, Canada, May 2015 (ORAL)
5. “Management of stage III colon cancer in the elderly: practice patterns and outcomes in the general population”, Society of Surgical Oncology Annual Cancer Symposium, Seattle, WA, March 2017 (ORAL)
6. “Palliative Care is Associated with Reduced Aggressive End of Life Care in Patients with Gastrointestinal Cancer”, Society of Surgical Oncology Annual Cancer Symposium, Chicago, IL, March 2018 (ORAL)
7. “Disparities in Esophago-gastric cancers”, American Society of Clinical Oncology Gastrointestinal Cancer Symposium (ASCO-GI), San Francisco, CA, January 2019 (ORAL)
8. “The Effect of Palliative Care on Symptom Burden in Patients with Gastrointestinal Cancer”, Society of Surgical Oncology Annual Cancer Symposium, San Diego, CA, March 2019 (ORAL)
9. “Cancer-Associated Intestinal Obstruction at the End of Life”, Society of Surgical Oncology Annual Cancer Symposium, San Diego, CA, March 2019 (SELECTED AS TOP 25% POSTER)
10. “Gastric Cancer Disparities and Opportunities for Collaboration”, Trivandrum Oncology Club-Association of Surgeons of India (TOC-ASI) Joint Meeting, Trivandrum, March 2020 (ORAL)
11. “Non-Surgical Options for Malignant Bowel Obstruction – Crossing Disciplines and Bridging Gaps in Knowledge”, Society of Surgical Oncology Annual Cancer Symposium, Boston, MA, March 2020 (Invited faculty speaker but cancelled due to COVID 19)
12. “Surgical Considerations in the Management of Gastric Cancer”, Upper Gastrointestinal Cancer Management Updates, Ghana College of Physicians and Surgeons, December 2020 (ORAL)
13. “The Great Debates: Aggressive surgical resection should be performed for patients with gastric adenocarcinoma with positive peritoneal cytology that is subsequently cleared with chemotherapy”, Society of Surgical Oncology Annual Cancer Symposium, Virtual Meeting March 2021 (ORAL)
14. “Utilization of routinely collected health care data in surgical research”, Trivandrum Oncology Club-Association of Surgeons of India (TOC-ASI) Joint Meeting, May 2021 (ORAL)

15. “3D Navigated Mass Spectrometry for Intra-operative Margin Assessment During Breast Cancer Surgery” Society of Surgical Oncology Annual Cancer Symposium, Atlanta, GA, March 2024 (ORAL)
16. “Developing a Geriatric Oncology Program at Kingston Health Sciences Centre”, Cancer and Aging Research Group Implementation Core, Virtual, December 2024 (ORAL)

## **National**

1. “Exploring the psychological effects of deceased organ donation on the families of the organ donors”, Canadian Association for Transplantation Annual Meeting, Banff, AB, Canada, March 2007 (ORAL)
2. “Pregnancy among residents enrolled in general surgery (PREGS): A survey of residents in a single Canadian training program”, Canadian Surgery Forum, Quebec City, QC, Canada, September 2010 (POSTER)
3. “Complications and readmissions after immediate breast reconstruction: the California experience”, American College of Surgeons 2014 Clinical Congress, San Francisco, CA, USA, October 2014 (POSTER)
4. “An alarming trend in the incidence of advanced gastric adenocarcinoma in young Hispanic males”, Society of Surgical Oncology Annual Meeting, Houston, TX, March 2015 (POSTER)
5. “The last thirty days of life: Trends in aggressive end-of-life care in gastrointestinal malignancies”, Canadian Surgery Forum, Victoria, BC, Canada, September 2017 (ORAL)
6. “Palliative Care is Associated with Reduced Aggressive End of Life Care in Patients with Gastrointestinal Cancer”, Canadian Society of Surgical Oncology Annual Meeting, Toronto, Ontario, April 2018 (ORAL)
7. “Challenging cases in Surgical Oncology”, Canadian Society of Surgical Oncology Annual Meeting, Toronto, Ontario, April 2018 (ORAL)
8. “Potentially aggressive care, palliative care, and symptom burden at the end-of-life”, presented as part of “From Population Outcomes to Policy: A Discussion of Research and Possibilities for Implementation” to members of Cancer Care Ontario, Toronto, Ontario, June 2019 (ORAL).
9. “Cancer-Associated Intestinal Obstruction at the End-of-Life”, Canadian Surgical Forum, Montreal, Canada, September 2019 (POSTER)
10. “First-line palliative chemotherapy for esophageal and gastric cancer: practice patterns and outcomes in the general population”, Canadian Surgical Forum, Virtual Meeting, September 2021 (POSTER)
11. “Malignant Bowel Obstruction: An Old Problem, Some New Tricks”, Canadian Association of General Surgeons National Webinar, May 5, 2022 (ORAL)
12. “An approach to surgical decision-making for patients with malignant bowel obstruction”, Surgical Oncology/Acute Care Surgery Joint Symposium, Canadian Surgical Forum, Toronto, Ontario, September 2022 (ORAL)
13. “Palliative Surgery- Survival and Beyond”, BC Surgical Oncology Network Update, Vancouver, British Columbia, April 2023 (ORAL)
14. “Palliative Oncology and Geriatric Care”, BC Surgical Oncology Network Update, Vancouver, British Columbia, April 2023 (PANEL SPEAKER)

15. “Past Presidents’ Panel”, Canadian Society of Surgical Oncology Annual Spring Meeting, Toronto, Ontario, April 2023 (MODERATOR)
16. “Multidisciplinary Management of Benign and Malignant Breast Disease, Canadian Surgery Forum, Vancouver, BC, September 2023 (PRESENTER AND MODERATOR)
17. “Gastric Cancer Update and Video Session”, Canadian Surgery Forum, Vancouver, BC, September 2023 (PRESENTER AND MODERATOR)
18. “Breaking the Cycle: Rethinking Prolonged Use of Opioid Analgesia in Postoperative or Other Acute Pain Management”, Canadian Association of General Surgeons Webinar, April 2024 (ORAL)
19. “President’s Panel with Complex Surgical Oncology Cases”, Canadian Society of Surgical Oncology Annual Spring meeting, Toronto, ON, May 2024 (MODERATOR)
20. “ATM Variants and Breast Cancer – Implications for Management”, Presented at the Canadian Surgical Forum September 2024, Winnipeg, Manitoba (ORAL)
21. “Breast Cancer Tumor Board”, Canadian Surgical Forum September 2024, Winnipeg, Manitoba (PANEL SPEAKER)
22. “The Role of Genetic and Molecular Information in the Management of Gastrointestinal Cancers”, Canadian Surgical Forum September 2024, Winnipeg, Manitoba (MODERATOR)

## **Provincial**

1. “Human umbilical vein endothelial cell production of matrix metalloproteinase-2 and matrix metalloproteinase-9: effects of vascular endothelial growth factor stimulation and varying oxygen conditions”, Canadian Physiological Society Annual Meeting, Banff, AB, Canada, February 2002 (ORAL)
2. “Decreased matrix metalloproteinase-2 release in placental explants from complicated pregnancies”, 11<sup>th</sup> Annual Western Perinatal Research Meeting, Edmonton, AB, Canada, February 2003 (ORAL)
3. “Twelve-month clinical outcomes following treatment of subfoveal choroidal neovascularization in pathologic myopia using photodynamic therapy with Verteporfin (Visudyne)”, 20<sup>th</sup> Annual Ophthalmology Research Day, Vancouver, BC, Canada, May 2004 (ORAL)
4. “Exploring the effects of cadaveric organ donation on the families of the organ donors: learning how to make the transplant process better for British Columbia”, BC Transplant Research Institute, 10<sup>th</sup> Annual Transplantation Research Day, Vancouver, BC, Canada, December 2006 (ORAL)
5. “Pregnancy among residents enrolled in general surgery (PREGS): A survey of residents in a single Canadian training program”, University of British Columbia Department of Surgery Resident Research Day, Vancouver, BC, Canada, May 2010 (ORAL)
6. “Is there an association between timing of referral to a tertiary care centre and local recurrence in primary retroperitoneal sarcoma in British Columbia?”, BC Surgical Society Meeting, Parksville, BC, Canada, May 2011 (ORAL)
7. “Practice Referral Patterns and Outcomes for Primary Retroperitoneal Sarcoma in British Columbia” North Pacific Surgical Association Meeting, Vancouver, BC, Canada, November 2011 (ORAL)
8. “Surg Onc Talks: Trends in Provincial Gastric Cancer Surgery and Best Surgical Practices”. Provincial Webinar, May 11, 2022 (PANEL SPEAKER)

## **Continuing Medical Education**

1. "Management of pancreatic trauma", Vancouver General Hospital, Vancouver, BC, Canada, July 2010 (ORAL)
2. "Phyllodes tumors of the breast: evidence-based action", Mount St. Joseph Hospital, Vancouver, BC, Canada, February 2011 (ORAL)
3. "Breast abscesses", Mount St. Joseph Hospital, Vancouver, BC, Canada, March 2011 (ORAL)
4. "Role of completion axillary lymph node dissection for positive sentinel lymph nodes in T1 and T2 breast cancer", St. Paul's Hospital, Vancouver, BC, Canada, May 2011 (ORAL)
5. "Breast MRI – current indications and emerging evidence", Victoria General Hospital, Victoria, BC, Canada, January 2012 (ORAL)
6. "Enhanced recovery after colorectal surgery", University Hospital of Northern BC, Prince George, BC, Canada, February 2012 (ORAL)
7. "Cytoreductive surgery and intraperitoneal chemotherapy in gastric cancer – what's the evidence?", Foothills Hospital, Calgary, AB, Canada, April 2012 (ORAL)
8. "Cytoreductive surgery and intraperitoneal chemotherapy in colorectal cancer – worth it?", City of Hope National Medical Center, Duarte, CA, USA, August 2013 (ORAL)
9. "Intra-operative radiotherapy in breast cancer", City of Hope National Medical Center, Duarte, CA, USA, September 2013 (ORAL)
10. "Ductal Carcinoma In Situ: Risk Assessment and Management Strategies", City of Hope National Medical Center, Duarte, CA, USA, December 2013 (ORAL)
11. "The role of cytoreductive surgery and intraperitoneal chemotherapy in colorectal cancer", Queen's University, Kingston, ON, Canada, September 2014 (ORAL)
12. "Multidisciplinary management of resectable gastric cancer", City of Hope National Medical Center, Duarte, CA, USA, April 2015 (ORAL)
13. "Nipple Sparing Mastectomy: Considerations and Outcomes", Communities of Practice Retreat, Kingston, ON, Canada, October 2015 (ORAL)
14. "Surgical Management of Colorectal Cancer", Oncology Academic Day, Queen's University, Kingston, ON, Canada, October 2015 (ORAL)
15. "Small Bowel Neoplasms: the Good, the Bad, and the Ugly", Division of General Surgery, Queen's University, Kingston, ON, Canada, November 2015 (ORAL)
16. "Surgical Management of Esophageal and Gastric Cancers", Oncology Academic Day, Queen's University, Kingston, ON, Canada, February 2016 (ORAL)
17. "Contralateral Prophylactic Mastectomy – Indications and Outcomes", Communities of Practice Retreat, Kingston, ON, Canada, February 2016 (ORAL)
18. "Ductal Carcinoma in Situ – Risk Assessment, Radiation and Endocrine Therapy", Communities of Practice Retreat, Kingston, ON, Canada, June 2016 (ORAL)
19. "Multidisciplinary Management of Gastric Cancer", Division of General Surgery, Queen's University, Kingston, ON, Canada, June 2016 (ORAL)
20. "The Surgical Management of Breast Cancer", Breast Reconstruction Awareness Day, Kingston, ON, Canada, October 2016 (ORAL)
21. "Management of Incidental Pathology of the Appendix", Communities of Practice Retreat, Kingston, ON, Canada, November 2016 (ORAL)
22. "What happens in the final thirty days of life? An analysis of patients with gastrointestinal malignancies", Charles Sorbie Department of Surgery Research Day, Queen's University, Kingston, ON, Canada, March 2017 (ORAL)

23. “To resect or not to resect? Management of the asymptomatic primary in unresectable metastatic colorectal cancer”, Communities of Practice Retreat, Kingston, ON, Canada, June 2017 (ORAL)
24. “Multidisciplinary Management of Gastric Cancer”, Division of General Surgery, Queen’s University, Kingston, ON, Canada, August 2017 (ORAL)
25. “Primary and Secondary Small Bowel Neoplasms”, Division of General Surgery, Queen’s University, Kingston, ON, Canada, November 2017 (ORAL)
26. “Surgical Management of Esophageal and Gastric Cancers”, Oncology Academic Day, Queen’s University, Kingston, ON, Canada, November 2017 (ORAL)
27. “Multidisciplinary Management of Resectable Gastric Cancer”, Division of General Surgery, Queen’s University, Kingston, ON, Canada, July 2018 (ORAL)
28. “Omission of Axillary Surgery in Elderly Women with Breast Cancer”, Communities of Practice Retreat, Kingston, ON, Canada, December 2018 (ORAL)
29. “Considerations in the Management of Neuroendocrine Tumors”, Division of General Surgery, Queen’s University, Kingston, ON, Canada, May 2019 (ORAL)
30. “Omission of Axillary Surgery in Elderly Women with Breast Cancer – Review and Update”, Communities of Practice Retreat, Kingston, ON, Canada, June 2019 (ORAL)
31. “To clip or not to clip: retrieval of the metastatic lymph node at the time of sentinel node biopsy”, Communities of Practice Retreat, Kingston, ON, Canada, June 2019 (ORAL)
32. “Multidisciplinary Management of Resectable Gastric Cancer”, Division of General Surgery, Queen’s University, Kingston, ON, Canada, October 2019 (ORAL)
33. “Multidisciplinary Management of Resectable Gastric Cancer”, Division of General Surgery, Queen’s University, Kingston, ON, Canada, October 2020 (ORAL)
34. “What Does Incurable Disease Look Like? Evaluating the Spectrum of Experience in Patients with Cancer”, Charles Sorbie Department of Surgery Research Day, Queen’s University, Kingston, ON, Canada, April 2021 (ORAL)
35. “Surgical Management of Colorectal Cancer” Oncology Academic Day, Queen’s University, Kingston, ON, Canada, October 2021 (ORAL)
36. “Overview of Benign and Malignant Neoplasms of the Breast” Division of General Surgery, Queen’s University, Kingston, ON, Canada, March 2022 (ORAL)
37. “Technique of Axillary Lymph Node Dissection” Division of General Surgery, Queen’s University, Kingston, ON, Canada, April 2022 (ORAL)
38. “New Initiatives in Surgical Oncology – Focus on Pain Management and Genetics”, Charles Sorbie Department of Surgery Research Day, Queen’s University, Kingston, ON, Canada, April 2022 (ORAL)
39. “An Overview of Measuring Quality in Surgery”, Surgical Oncology Journal Club, Queen’s University, September 2022 (ORAL)
40. “Characteristics of Opioid Providers for Patients Undergoing Same Day Breast Surgery”, Charles Sorbie Department of Surgery Research Day, Queen’s University, Kingston, ON, Canada, April 2023 (ORAL)
41. “Research Metrics Update”, Department of Surgery, Queen’s University, Kingston, ON, Canada, June 2023 (ORAL)
42. “Primary and Secondary Small Bowel Neoplasms”, Division of General Surgery, Queen’s University, Kingston, ON, Canada, January 2024 (ORAL)
43. “Optimizing Older Adults for Cancer Treatment”, Charles Sorbie Department of Surgery Research Day, Queen’s University, Kingston, ON, Canada, April 2024 (ORAL)

### **Media Involvement**

1. Interview for [cancernetwork.com](https://www.cancernetwork.com/authors/shaila-merchant-md) on “using genetics to determine disparities in gastric cancer” (February 2019) <https://www.cancernetwork.com/authors/shaila-merchant-md>
2. Interview with Society of Surgical Oncology SURGONConnect regarding surgical observership experience in Seoul, Korea (March 2019)  
<https://sso.informz.net/informzdataservice/onlineversion/ind/bWFpbGluZ2luc3RhbmNlaWQ9NzY3JpYmVyaWQ9NzkyOTAwNjc>

### **Other Scholarly Activities**

1. Peer reviewer for journals “Medicine”, “Health Science Reports”, “Annals of Surgical Oncology”, “Lancet Gastroenterology & Hepatology”, “Surgical Endoscopy”, “Canadian Journal of Surgery”, “Current Oncology”, “Cancer Control”, “CMAJ”
2. Scientific judge for e-poster session, Canadian Society of Surgical Oncology, Canadian Surgical Forum
3. Scientific Abstract Reviewer, Canadian Surgical Forum



# Curriculum Vitae

## Personal information

**Haydee Cristina Verduzco-Aguirre, MD, MHPE**

Queen's University Sinclair Cancer Research Institute

Division of Cancer Care and Epidemiology

10 Stuart Street, Kingston, Ontario, K7L 3N6

e-mail: haydee.verduzcoaguirre@kingstonhsc.ca

## Education/training

### Medical school

- Universidad Autónoma de Nuevo León (2007-2014). Graduated with second-highest ranking (95.3/100)
- Academic international student exchange supported by the International Federation of Medical Students Associations (IFMSA) (General Surgery at Landeskrankenhaus Innsbruck, Austria. January 2012)
- Internship: Hospital Universitario "Dr. José Eleuterio González" – Monterrey, NL, Mexico (2010-2013)
- Social Service in Clinical Research – Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán"- Mexico City, Mexico (2013-2014)

### Residence and fellowship

- Internal Medicine Resident - Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán" – Mexico City, Mexico (2015-2017)
- Medical Oncology Fellow - Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán" (2017 – 2020)
  - Chief Medical Oncology Fellow (2019-2020)
- Research observership in Geriatric Oncology – University of Rochester (July 2019)
- Genitourinary Oncology Fellow - Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán" (March 2020 – February 2021)
- Clinical Fellow in Medical Oncology (Patricia A. Wood MD PhD/Baruch Spinoza Common Sense Oncology Fellowship) – Queen's University/Sinclair Cancer Research Institute – Kingston, Ontario (July 2024 - present)

### Other training

- Master's in Health Professions Education – Faculty of Medicine, National Autonomous University of Mexico – 2022-2024
- Implementation Sciences in Cancer – Continuing Education in Public Health and Epidemiology, Public Health School of Mexico – July 2022

### Languages spoken

- Spanish – Native speaker
- English – TOEFL ITP 663/667 points, December 3, 2021
- French - Diplôme d'études en langue française (DELFI) level B1, 92/100, December 15, 2010

### Employment

- Clinical Fellow in Medical Oncology (Patricia A. Wood MD PhD/Baruch Spinoza Common Sense Oncology Fellowship) – Queen’s University/Sinclair Cancer Research Institute – Kingston, Ontario (July 2024 - present)
- Attending Physician – Medical Oncology – Department of Hemato-Oncology, Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán” (2021 – present, on sabbatical leave since June 2024)
- Assistant Professor - Medical Oncology Fellowship program - Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (2021 – present, on sabbatical leave since June 2024)
- Invited Professor in the Family Medicine Residency course at the Family Medicine Unit No. 28 Gabriel Mancera Clinic of the National Institute of Social Security in Mexico City (2022 – 2024)
- Invited Professor (Geriatric Oncology) - Medical Oncology Fellowship program – National Cancer Institute, Mexico City (2024)

### Grants and awards

- Union for International Cancer Control - UICC Technical Fellowship in July 2019 (awarded for a 1-month stay at University of Rochester, NY, USA, for a research observership in geriatric oncology)
- Carlos Slim Foundation – Beca Impulso a la Investigación en Salud 2019 (1-year resident research award)
- Alianza Médica para la Salud – Uro-Oncology Open Medical Institute/Memorial Sloan-Kettering Cancer Center seminar, October 2019
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán – “José Antonio Martín Mora” Award (1st place in fellowship thesis work), February 2020
- Conquer Cancer, the ASCO Foundation - 2020 Global Oncology Young Investigator Award, May 2020
- Lynn Sage Breast Cancer Foundation - Lynn Sage Breast Cancer Symposium Chicago Sister Cities Medical Initiative Award, September 2022
- Consejo Nacional de Humanidades, Ciencias y Tecnologías - National Postgraduate Education Scholarship, August 2022
- Conquer Cancer, the ASCO Foundation – 2023 International Innovation Grant, February 2023
- Costs of Care Fellowship – 2023-2024 Oncology Fellow
- National Council for Humanities, Science and Technology (Mexico) – Level 1 National Researcher – January 2024-December 2028

### Other professional activities

ASCO Member since 2017

Volunteer activities within ASCO

- Global Oncology Community of Practice Leadership (2023-present)
- Grant application reviewer for 2024 Young Investigator Award in Geriatric Oncology
- Reviewer for JCO Global Oncology, JCO Oncology Advances, JCO Clinical Cancer Informatics
- Geriatric Assessment: ASCO Global Guideline Expert Panel Member

ESMO Member (2017)

SMeO (Mexican Society of Oncology) member (017)  
Life Member of the Association of UICC Fellows (2021)  
Member of the International Society of Geriatric Oncology (2021)  
Member of the Latin American Cooperative Oncology Group (2022)  
Member of Common Sense Oncology (2024)

Ad-hoc peer reviewer for: Mexican Journal of Oncology, Journal of Geriatric Oncology, JCO Global Oncology, BMJ Oncology, BMC Cancer

### **Publication list**

#### **Selected journal publications**

1.-The effect of a geriatric oncology clinic on treatment decisions in Mexican older adults with cancer.

*Haydee C Verduzco-Aguirre*, Ana P Navarrete-Reyes, Yanin Chavarri-Guerra, José A Ávila-Funes, Enrique Soto-Perez-de-Celis

J Am Geriatr Soc. 2019 Jan 14. <https://doi.org/10.1111/jgs.15753>

2.-Implementation of diagnostic resources for cancer in developing countries: a focus on PET/CT

*Haydeé C Verduzco-Aguirre*, Gilberto Lopes and Enrique Soto-Perez-De-Celis

Ecanermedicalscience on January 31, 2019. <https://doi.org/10.3332/ecancer.2019.ed87>

3.-Predicting Life Expectancy for Older Adults with Cancer in Clinical Practice: Implications for Shared Decision-making

*Haydeé C. Verduzco-Aguirre*, Carolina Gómez Moreno, Yanin Chavarri-Guerra, Enrique Soto Perez-de-Celis

Current Oncology Reports Curr Oncol Rep. 2019 Jun 25;21(8):68 <https://doi.org/10.1007/s11912-019-0821-3>

4.-Cáncer en el adulto mayor en Latinoamérica: cooperación interdisciplinaria entre oncología y geriatría (Cancer in the older adult in Latin America: interdisciplinary cooperation between oncology and geriatrics)

*Haydeé C. Verduzco Aguirre*, Ana P. Navarrete-Reyes, Juan P. Negrete Najar, Enrique Soto-Pérez-de-Celis

Salud Pública 2020;22(3):1-9. doi:10.15446/rsap.V22n3.84617

5.-Installing oncofertility programs for common cancers in limited resource settings (Repro-Can-OPEN Study): An extrapolation during the global crisis of Coronavirus (COVID-19) pandemic

Salama M, Ataman-Millhouse L, Braham M, Berjeb K, Khrouf M, Rodrigues JK, Reis FM, Silva TC, Sánchez F, Romero S, Smitz J, Vásquez L, Vega M, Sobral F, Terrado G, Lombardi MG, Scarella A, Bourlon MT, *Verduzco-Aguirre H*, Sánchez AM, Adiga SK, Tholeti P, Udupa KS, Mahajan N, Patil M, Dalvi R, Venter C, Demetriou G, Geel J, Quintana R, Rodriguez G, Quintana T, Viale L, Fruguglia M, Coirini M, Remolina-Bonilla YA, Noguera JAR, Velásquez JC, Suarez A, Arango GD, Pineda JID, Aldecoa MDC, Javed M, Al Sufyan H, Daniels N, Oranye BC, Ogunmokun AA, Onwuzurigbo KI, Okereke CJ, Whesu TC, Woodruff TK.

J Assist Reprod Genet. 2020 Jul;37(7):1567-1577. doi: 10.1007/s10815-020-01821-7

6.-Associations of uncertainty with psychological health and quality of life in older adults with advanced cancer

*Haydee C Verduzco-Aguirre*, Dilip Babu, Supriya Gupta Mohile, Javier Bautista, Huiwen Xu, Eva Culakova, Beverly Canin, Yingzi Zhang, Megan Wells, Ronald Epstein, Paul Duberstein, Colin McHugh, William Dale, Alison Conlin, James Bearden 3rd, Jeffrey Berenberg, Mohamedtaki Tejani, Kah Poh Loh

J Pain Symptom Manage. 2020 Aug 18;S0885-3924(20)30690-4. doi: 10.1016/j.jpainsymman.2020.08.012

7.-Geriatric Oncology in Mexico

Gomez-Moreno C, *Verduzco-Aguirre H*, Soto-Perez-de-Celis E

Ecanermedicalsience. 2020 Sep 15;14:1102. doi: 10.3332/ecancer.2020.1102

8.- Barriers and Facilitators for the Implementation of Geriatric Oncology Principles in Mexico: A Mixed-Methods Study.

*Verduzco-Aguirre HC*, Bolaño Guerra LM, Culakova E, Chargoy JM, Martínez-Said H, Quintero Beulo G, Mohile SG, Soto-Perez-De-Celis E.

JCO Glob Oncol. 2022 Mar;8:e2100390. doi:10.1200/GO.21.00390.

9.- Dosis bajas de dietilestilbestrol para cáncer de próstata metastásico resistente a la castración altamente pretratado [Low-dose diethylstilbestrol in highly pretreated castration-resistant metastatic prostate cancer]

*Verduzco-Aguirre, Haydeé C.*; Hinojosa-Fano, Juan; Gabilondo-Navarro, Fernando y Bourlon, María T.

Gac. mex. oncol. [online]. 2022, vol.21, n.1, pp.10-16. Epub 14-Mar-2022  
doi:10.24875/j.gamo.220000641.

10.- Addressing the Needs of Older Adults With Cancer in Low- and Middle-Income Settings.

Webb T, *Verduzco-Aguirre HC*, Rao AR, Ramaswamy A, Noronha V.

Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-10. doi: 10.1200/EDBK\_349829

11.- Patterns of Treatment and Outcomes in Older Men With Penile Cancer: A SEER Dataset Analysis

Bourlon MT, *Verduzco-Aguirre H*, Molina E, Meyer E, Kessler E, Kim SP, Spiess PE, Flaig T

Front Oncol 2022 Jun 29;12:926692. doi: 10.3389/fonc.2022.926692.

12.- Cost-effectiveness of the addition of CDK4/6 inhibitors to standard endocrine therapy in first-line treatment of women with advanced HR+/HER2- breast cancer in Mexico.

Molina-Jaimes M, Galindo-González A, *Verduzco-Aguirre HC*, Bautista-Arredondo S, Reyes-Terán G, Soto-Perez-de-Celis E.

Clin Transl Oncol. 2023 Jun 17. doi: 10.1007/s12094-023-03247-w

13.- Factors associated with the evaluation of geriatric assessment (GA) domains by oncology specialists in Mexico.

*Verduzco-Aguirre HC*, Bolaño-Guerra LM, Chargoy JM, Culakova E, Martinez-Said H, Beulo GQ, Mohile SG, Soto-Perez-de-Celis E.

Ecanermedicalsience. 2023 Aug 31;17:1597. doi: 10.3332/ecancer.2023.1597

14.- Low dose nivolumab in metastatic mucosal melanoma: a case report

Andrés Meraz-Brenez, Ana P. Navarrete-Reyes, Eleazar Ignacio-Álvarez, Georgina J. Ramírez-Anguiano, *Haydee C. Verduzco-Aguirre*  
Gac Mex Oncol. 2023;22(3):140-145. doi: 10.24875/j.gamo.23000030

15. Real-world data in patients with BRCA-mutated breast cancer treated with poly (ADP-ribose) polymerase inhibitors

Beas-Lozano EL, *Verduzco-Aguirre HC*, Gonzalez-Salazar R, Chavarri-Guerra Y.  
Ecancermedicalsecience. 2023;17:1633.

16. Differences in the expression of the phosphatase PTP-1B in patients with localized prostate cancer with and without adverse pathological features

Bourlon MT, Urbina-Ramirez S, Verduzco-Aguirre HC, Mora-Pineda M, Velazquez HE, Leon-Rodriguez E, et al..  
Front Oncol. 2024;14:1334845.

17. Geriatric Oncology: A 5-Year Strategic Plan

Diaz FC, Hamparsumian A, Loh KP, *Verduzco-Aguirre H*, Abdallah M, Williams GR, et al..  
Am Soc Clin Oncol Educ Book. 2024;44(3):e100044.

18. Guiding Principles for Community Building in Global Oncology.

Abuali I, Mathew A, Rugengamanzi E, Sainamthip P, *Verduzco-Aguirre H*, Parikh AR.  
Am Soc Clin Oncol Educ Book. 2024;44(3):e100045.

19. Development and Implementation of a Geriatric Oncology Interdisciplinary Case-Based Educational Intervention for Cancer Care Providers

*Verduzco-Aguirre HC*, Gomez-Moreno C, Navarrete-Reyes AP, Henriquez-Santos G, Monroy Chargoy J, Mateos-Soria A, Sánchez-Hernández JJ, Castelo-Loureiro A, Hamui-Sutton L, Sánchez-Mendiola M, Soto-Perez-de-Celis E  
JCO Glob Oncol. 2024 Oct;10:e2400258

20. Balancing clinical benefit and social value: challenges in HTA assessments.

*Verduzco-Aguirre H*, Wilson BE.  
Lancet Oncol. 2024 Dec;25(12):1518-1519.

#### Book chapters

1.- Global Disparities: Can the World Afford Cancer?

*Haydee Cristina Verduzco-Aguirre*, Enrique Soto-Perez-de-Celis, Yanin Chavarri-Guerra, Gilberto Lopes

Chapter in: Cancer and Society: A Multidisciplinary Assessment and Strategies for Action. Eric H. Bernicker (editor). Springer Nature Switzerland AG, 2019

2.- Cancer Screening

*Haydeé Cristina Verduzco-Aguirre*, Ana Patricia Navarrete-Reyes, Yanin Chavarri-Guerra, Enrique Soto-Perez-de-Celis

Chapter in: Encyclopedia of Gerontology and Population Aging. Springer Nature Switzerland AG 2020.